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ABSTRACT 
Lectins are carbohydrate-binding proteins that are widely spread in nature and crucially 
involved in a multitude of biological processes. This thesis addresses the design of 
glycomimetic antagonists for the human lectin DC-SIGN (chapter 2) and the bacterial lectin 
FimH (chapter 3), which are both involved in infectious diseases. 
Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) is a C-type lectin 
expressed on immature dendritic cells (DCs) prevalent in mucosal tissue. Besides its function 
as an adhesion molecule enabling the migration of DCs and binding to T cells, DC-SIGN is 
one of the major pathogen recognition receptors on DCs. In general, pathogen binding leads 
to phagocytosis, DC maturation, and migration to the lymph nodes, where antigenic 
fragments are presented to resting T cells which finally initiate a specific immune response. 
However, a variety of pathogens, such as viruses (e.g. HIV-1), bacteria (e.g. Mycobacterium 
tuberculosis), and parasites (e.g. Schistosoma mansoni), exploit this initial interaction with 
DC-SIGN to evade the immune system and, instead, efficiently infect the host. With its Ca2+-
dependent carbohydrate recognition domain (CRD), DC-SIGN binds oligomannosides or 
fucose-containing Lewis antigens such as Lewisx (Lex = Gal!(1-4)[Fuc"(1-3)]GlcNAc) 
present on the surface of microbial cells or on viral envelop proteins. Blocking the first 
interaction between the microorganisms and DC-SIGN by suitable antagonists is therefore a 
promising therapeutic approach towards the prevention of infectious diseases.  
The first part of this thesis addresses the development of fucose-based glycomimetic 
antagonists for DC-SIGN. To this end, the interaction of Lewis-type structures with 
DC-SIGN was elucidated. STD NMR experiments were conducted to determine the binding 
epitopes of Lewis trisaccharides bearing different aglycones. This study revealed a switch of 
the binding mode upon introduction of aromatic aglycones as a result of an additional 
hydrophobic interaction (chapter 2.2).  
A series of trisaccharide mimics of Lex was synthesized to elucidate the role of D-Gal and 
D-GlcNAc in Lewis-type structures for binding to DC-SIGN. For this purpose, the central 
D-GlcNAc was replaced with (1R,2R)-cyclohexane-1,2-diol based moieties and the D-Gal 
moiety was replaced with various deoxy analogues. Affinity data including thermodynamic 
binding parameters indicate that, first, D-Gal is not crucial for binding and, second, 
mimicking of one sugar moiety enhances binding affinity (chapters 2.3.1 and 2.3.2).  
Based on the preliminary results, further glycomimetics were developed to enable the 
interaction with the hydrophobic area in the binding site and tested for their potential as  
DC-SIGN antagonists (chapter 2.3.3). 
FimH is a bacterial, mannose-specific lectin expressed on the tip of filamentous surface 
organelles of uropathogenic Escherichia coli. The CRD of FimH interacts with 
glycoconjugates such as uroplakin Ia present on urothelial cells. This bacterial adhesion is the 
initial and most crucial step in the establishment of urinary tract infections (UTIs), since it 
prevents the bacteria from being washed out by the bulk flow of urine. UTIs are among the 
most common infectious diseases affecting millions of people every year. The treatment with 
antibiotics encounters increasing bacterial resistance and demands for alternative strategies to 
prevent and treat UTIs. The development of anti-adhesive agents that are able to inhibit the 
crucial interaction of FimH with the urothelial cells presents a promising, alternative 
therapeutic approach.  
Intestinal absorption and renal clearance are key issues for orally dosed FimH antagonists to 
reach the therapeutic target in the human bladder. Besides high affinity and selectivity for the 
target, a potent FimH antagonist thus must exhibit favourable pharmacokinetic (PK) 
properties. The second part of this thesis covers three studies that aim at improving these 
characteristics in mannose-based FimH antagonists.  
The first study was directed towards the replacement of a conserved water molecule within 
the CRD of FimH. For this purpose, an appropriately modified "-D-mannoside was 
synthesized and biologically evaluated. The unexpected loss in affinity towards FimH could 
be explained by detailed molecular dynamics studies (chapter 3.2.1).  
A Topliss-based structure-activity relationship study was conducted for the investigation of 
biphenyl mannosides as FimH antagonists. The #-# stacking of the aromatic aglycone with 
Tyr48 at the rim of the binding site was elucidated and a group of high-affinity antagonists 
with promising physico-pharmacological properties was identified (chapter 3.2.2).   
One of these compounds was further investigated as part of a bioisosteres study for its 
potential as orally available FimH antagonist. In addition to the optimal in vitro PK/PD 
profile, this antagonist showed an excellent PK profile in vivo (chapter 3.2.3).  
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Lectins are carbohydrate-binding proteins widely spread throughout nature. The term lectin 
originates from the latin word “legere” which means “to choose” and reflects the major 
characteristic of these proteins, namely their carbohydrate specificity.1 A second 
characteristic of lectins is their agglutinating effect on erythrocytes, which was first noted 
over 100 years ago.2  Early studies focused on plant-derived lectins. The research on 
mammalian lectins started to gain popularity only in the 1970’s, as their role in biological 
processes became gradually apparent and the first hepatic lectin was successfully isolated.3 It 
was early noted that the lectin-mediated agglutination of cells can be inhibited by 
carbohydrates or oligosaccharides.4 Consequently, lectins were initially classified according 
to their carbohydrate-specificity. Later, Drickamer suggested a more standardized 
classification based on the sequence homology in the carbohydrate recognition domain 
(CRD).5,6 According to this classification system, important members of mammalian lectins 
include the following: 
• C-type lectins which have a Ca2+-dependent CRD (e.g. selectins and DC-SIGN).5 
• S-lectins (galectins) which show specificity towards !-galactosides and have several 
conserved amino acid residues in their CRD.2 
• I-type lectins that are members of the immunoglobulin superfamily (e.g. the Siglec 
family of sialic acid-binding lectins).7  
Lectins are widely distributed in mammalian tissues and serve many different biological 
functions as they are involved in cell adhesion, cell recognition, cell signaling, and host 
immune response.8 Hence, a dysfunction of lectins can lead to serious diseases, such as 
infections, inflammatory diseases, and cancer, highlighting the potential of mammlian lectins 
as drug target. 
Microbial lectins are an important virulence factor of bacteria. They are located on bacterial 
fimbriae and mediate the initial adhesion to glycoproteins present on endo- and epithelial 
cells of a host. Lectins of the enterobacteriaceae family are among the best-characterized 
bacterial lectins and were shown to play a major role in urinary tract infections and infections 
of the kidney. Members of this family are for example FimH, PapG, and F17G.9 
This thesis focuses on the C-type lectin DC-SIGN (Chapter 2) and the microbial lectin FimH 
(Chapter 3). Both are involved in infectious diseases and therefore, constitute putative 
therapeutic targets for treatment and prevention. 
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Dendritic Cells and their Role in Immune Response 
Dendritic cells (DCs), termed due to their unusual tree-like shape (Greek, dendron, tree), 
were discovered in 1973 by Steinman and Cohn.1 DCs play a major role in initiation and 
modulation of an immune response operating at the interface of innate and adaptive 
immunity. They are present in tissues (skin, mucosa, inner-lining of nose, intestines etc.) and 
fluids (blood) and can be described as sentinels of the immune system patrolling the body for 
invaders.2  
There are two main types of DCs: myeloid DCs, also including Langerhans cells (LCs), and 
plasmacytoid DCs. Depending on their tissue location and differentiation state, DCs express 
various pattern recognition receptors (PRRs) on their surface, such as Toll-like receptors 
(TLRs)3 and C-type lectin receptors (CTLs).4 Immature DCs present the largest variety in 
CTLs. They are found in peripheral mucosal tissue and are among the first defense barrier to 
be encountered by invading pathogenic microorganisms.2 
Once the DC captures a pathogen via receptor-mediated phagocytosis, it starts to migrate to 
the lymphoid organs. Meanwhile, the DC matures, processes the antigen in lysosomal 
compartments, and expresses co-stimulatory molecules such as cytokines and receptors that 
can modulate the effector functions of responding T cells.5 At the lymph nodes, the DC 
presents the degraded antigenic fragments on its surface on major histocompatibility complex 
(MHC) class I and II molecules to resting T cells. This results in T cell activation and 
initiation of an adaptive immune response, i.e. interaction with B cells for antibody formation 
or macrophages for cytokine release. Hence, they are called professional antigen-presenting 
cells.2,6,7 
The PRRs on DCs recognize specific pathogen-associated molecular patterns (PAMPs) of the 
microorganisms, e.g. viral and bacterial nucleic acids or fungal and bacterial cell wall 
components, such as lipopolysaccharides (LPS). The recognition of PAMPs by PRRs triggers 
a specific signaling pathway which contributes to the adaptive immune response. In this way, 
distinct PAMPs on a certain pathogen induce a specific immune response via signal 
transduction and receptor cross talk, as described later in this chapter.8 
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Figure 1. Scheme of a DC with its pattern-recognition receptors, such as Toll-like receptors (TLRs) and C-type 
lectins (CTLs). Microorganisms recognized by CTLs are internalized into lysosomal compartments where they 
are processed to peptidic fragments and presented as major histo-compatibility complex (MHC) to resting 
T cells. Binding to TLRs leads to activation of a signaling cascade triggering upregulation of co-stimulators and 
cytokine production, which facilitates DC maturation, taken from Geijtenbeek and van Kooyk9. 
 
C-type Lectins 
CTLs represent an important group of PRRs on DCs besides TLRs and scavenger receptors.10 
The classification of lectins is based on primary structural homology of their carbohydrate 
recognition domain (CRD). The characteristic for CTLs is their Ca2+-dependent carbohydrate 
binding.11 However, the members of this lectin family differ in the type of carbohydrate 
structures they recognize with high affinity. The majority of CTLs are transmembrane 
proteins, though, soluble proteins exist as well, such as the collectins lung surfactant protein 
A (SP-A) and mannose binding protein (MBP).12 One can further distinguish between type I 
and type II transmembrane CTLs with two and more CRD-like domains or with only one 
CRD, respectively. Another difference is the location of the N-terminus; in type I 
transmembrane proteins it is located outside the cell, whereas in type II transmembrane 
proteins the N-terminus is pointing into the cytoplasm. 
By recognition of carbohydrate structures that are present on pathogens or self-antigens and 
by regulation of signaling pathways, CTLs are involved in many immune system functions. 
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Furthermore, they enable cell-cell adhesion and, in case of endocytic receptors, 
internalization of pathogens.13 The CTLs expressed on DCs are almost exclusively type II 
transmembrane proteins, such as DC-SIGN (CD209), the related DC-SIGNR (CD299)14, 
dectin-1, and Langerhans-cell-specific C-type lectin (Langerin, CD207).15 
 
DC-SIGN 
In 1992, Curtis et al. described a membrane associated PRR that has high affinity for the 
glycoprotein gp120 present on HIV-1.16 In 2000, the same receptor was discovered to 
mediate intercellular interactions with ICAM-3 on T cells by Geijtenbeek et al.17 They 
termed this transmembrane protein “dendritic cell-specific intercellular adhesion molecule 
(ICAM) 3-grabbing nonintegrin” (DC-SIGN). Up to now, DC-SIGN has gained more and 
more popularity, in particular because its crucial involvement in infections caused by HIV, 
Ebola virus, Mycobacterium tuberculosis (M. tuberculosis), SARS and many other 
microorganisms.18 DC-SIGN is one of the main receptors on DCs for recognition and uptake 
of various pathogens and therewith heavily involved in modulation of the immune 
response.19,20  
DC-SIGN is preferentially expressed on immature myeloid DCs and is found on dermal, 
interstitial, a subset of blood DCs, and on in vitro differentiated monocyte-derived DCs.21,22 
Due to its highly restricted expression, DC-SIGN is considered a DC-specific phenotypic 
marker acquired during DC differentiation.23 
Endogenous ligands of DC-SIGN are the glycoproteins intercellular adhesion molecule-2  
and -3 (ICAM-2 and ICAM-3). Besides its function as a cell-adhesion receptor for the control 
of DC migration via ICAM-2,22,24 DC-SIGN regulates the DC–T cell interactions via 
ICAM-3 that is present on the surface of T cells.18,25,26 It furthermore stabilizes the formation 
of synapses between the MHC class II molecules and the T cell receptor. 
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Figure 2. Schematic representation of the type II transmembrane protein DC-SIGN (taken from the dissertation 
of Meike Scharenberg, University of Basel27). DC-SIGN consists of three domains: The cytoplasmic domain, 
the transmembrane domain (TM), and the extracellular domain. The cytoplasmic domain contains a di-leucin 
motif, a tri-acidic internalization motif and a tyrosin residue. The extracellular domain neck region is formed by 
seven and a half repeats of a 23 amino acid motif and induces tetramerisation of DC-SIGN monomers stabilized 
by hydrophobic interactions. The Ca2+-dependent carbohydrate recognition domain (CRD) is located at the 
top.20 
 
The type II transmembrane protein DC-SIGN is part of the C-type lectin family. Figure 2 
displays a schematic representation of DC-SIGN. DC-SIGN can be divided into three 
domains:  the cytoplasmic region, the transmembrane domain and the extracellular domain. 
The CRD of DC-SIGN is located at the extracellular C-terminus on top of a seven and a half 
repeat unit of a 23 amino acid motif. This extended neck region is responsible for 
tetramerisation of the receptor. The "-helical structure of this extracellular unit stabilizes the 
tetramer via coiled-coil interactions.28 Furthermore this region functions as a spacer placing 
the CRD away from the cell-surface, reachable for glycan structures, and allowing for 
multivalent interactions. The neck domain also has the function of a pH sensor. Variations in 
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pH encountered in physiological surrounding affect the oligomerisation state and can in 
particular lead to ligand release and receptor recycling.29 The neck region passes on to the 
transmembrane region followed by a cytoplasmic tail that contains recycling and 
internalization motifs, such as a di-leucine based motif (Leu-Leu), a triacidic cluster (Glu-
Glu-Glu), and an incomplete immunoreceptor tyrosine-based activation motif (ITAM, Tyr-x-
x-Leu) which is an internalization loop associated with signaling.10,30  
Multimerization of the receptor enables recognition of multivalent epitope presentation, as it 
is the case for most pathogenic antigens. Besides increasing binding avidity, it promotes 
ligand specificity and is a determining factor for a specific immune response.31 It was shown 
that DC-SIGN tetramers further multimerize into so-called microdomains or lipid rafts within 
the membrane. This feature is associated with ligand recognition and specificity as well as 
internalization and signal transduction.32,33  
The CRD of DC-SIGN located at the top of the extracellular domain has a globular overall 
structure and is composed of 12 !-strands, two "-helices, and three disulfide-bridges.28 Two 
calcium binding sites are present: one Ca2+ ion is essential for the tertiary protein 
conformation, the other one is directly involved in ligand-binding.34 The CRD of DC-SIGN 
recognizes high D-mannose (D-Man) structures35 and L-fucose (L-Fuc) containing Lewis 
antigens (Le), i.e. Lea, Lex, and Ley present on viral envelope proteins or microbial 
membranes.36,37  
 
DC-SIGNR 
DC-SIGNR is termed according to its close relation to DC-SIGN and shares 77% sequence 
identity with the latter. However, it shows distinct tissue tropism. It is not expressed in DCs 
but is mainly found on endothelia of liver sinusoids, lymph node sinuses, and placental 
villi.38,39 DC-SIGN and DC-SIGNR have been shown to have markedly different ligand 
binding characteristics. Both receptors bind to N-linked high-mannose oligosaccharides, 
however, DC-SIGNR has a diminished binding affinity for L-Fuc-containing 
oligosaccharides.40 
 
Langerin 
Another protein related to DC-SIGN is Langerin, expressed exclusively on LCs.41 Langerin 
recognizes as well gp120 on HIV-1 but is much less susceptible to infection with the virus.42 
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Furthermore, there is no transmission of HIV-1 to T cells via Langerin.43 Internalization of 
virus into LCs leads to degradation of the virus and it was shown that inhibition of Langerin 
leads to infection of LCs. Therefore, Langerin is an important antiviral immune receptor, 
although signaling processes have not been elucidated yet.44 
 
Signaling and Involvement in Infection 
The normal immunoregulatory response of DCs following pathogen recognition includes 
pathogen uptake, degradation, and antigen presentation. The latter together with 
costimulation determines CD4+ T helper cell differentiation as well as cytokine excretion. 
T helper 1 cells (Th1) secrete Interferon-$ to activate macrophages to fight intracellular 
microbes. Activation of Th2 cells leads to excretion of cytokines for a humoral immune 
response. Th17 cells mobilize phagocytes for elimination of fungi or bacteria.45 However, 
some microorganisms circumvent the normal degradation mechanisms and instead exploit the 
binding to DC-SIGN to efficiently infect the host. Among these pathogens are viruses, such 
as HIV-118, Ebola virus46,47, Hepatitis C virus (HCV)48,49, Dengue virus50, Herpes simplex 
virus51 , and SARS corona virus52, bacteria, such as M. tuberculosis53,54 and H. pylori, fungi 
such as C. albicans55, and parasites, such as Leishmania36,56 and Schistosoma mansoni (S. 
mansoni)36.  They bind with Fuc-containing Lex epitope (H. pylori, S. mansoni egg 
antigen)36,57-59 or via high-Man structures (M. tuberculosis, HIV-1, and Candida 
ablicans)54,60,61 to the CRD of DC-SIGN. It was found that each of these epitope types 
triggers a specific immune responses.57 Elucidation of the exact mechanisms including 
signaling pathways downstream of CTLs has just begun and many details are still 
speculative.9,62 A simplified overview is given in Figure 3.  
For most of the mentioned pathogens the interaction with DC-SIGN leads to interference 
with the transcription factor nuclear factor %B (NF-%B). The activation of NF-%B is crucial 
for the development of an immune response.63 p65 is a transcriptional active subunit of the 
NF-%B familiy and is phosphorylated, i.e. activated, at Ser276 in DC-SIGN mediated 
signaling. Activation leads to translocation into the nucleus and to acetylation of p65 at a Lys 
residue. The latter is pivotal for p65 activity and modulates the transcription activity. In case 
of DC-SIGN mediated activation of p65, the gene transcription of the IL-10 promoter is 
prolonged which results in high levels of the immunosuppressive IL-10.19 Notably, DC-SIGN 
alone is not able to activate p65, however, it is instrumental in modulation of p65 activity.64 
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Activation of Raf-1 via TLRs appears to be the prerequisite for induction of an immune 
response.  
HIV-1 is one of the best-investigated examples of co-evolution to evade the eradication by 
host immune response. This virus targets CD4+ T cells by fusion to CD4 and chemokine 
receptors (CCR5 and CXCR4) on T cells. The envelope protein gp120 in HIV-1 interacts via 
its mannan structures with DC-SIGN in the mucosal tissue at the port of entry. It is then 
transported by DC-SIGN+ DCs to lymph nodes where the virus can efficiently infect CD4+ 
T cells via viral synapses.65 Efficient virus production is mediated by CD4+ T cells, however 
infection of the DC itself was noted as well.66 Internalization of the virus into the DC leads to 
triggering of endosomal TLR8 via viral ssRNA and results in activation of NF-%B and 
translocation into the nucleus. This initiates the transcription of short viral DNA. Binding of 
gp120 to DC-SIGN activates Raf-1. Phosphorylation and acetylation of p65 lead to 
transcription elongation of IL-10, which is crucial for synthesis of full-length HIV-1 
transcripts and therewith the production and dissemination of virions.57 
A modulation of the Th1/Th2 balance, i.e. a shift of the immune response towards Th2 
resulting in immune evasion, is regarded as another feature pathogens evolved to favor their 
persistence.9 Infection with M. tuberculosis presents one example where the infection reaches 
a latent chronic state. The bacterium presumably subverts the elimination by suppressing the 
cellular immune response through induction of a specific DC-SIGN mediated signaling.60 
Mannosylated lipoarabinomannan (ManLam) and bacterial cell-wall structures bind to DC-
SIGN and TLR, respectively. Binding of ManLAM to DC-SIGN does not induce an effective 
immune modulation. But simultaneous triggering of TLR4 and TLR2 induces the activation 
of p65 and its translocation into the nucleus where DC-SIGN signaling results in 
phosphorylation and acetylation. This leads to a modulation of transcription of the 
immunosuppressive IL-10 but also of pro-inflammatory cytokines such as IL-6, IL-12, and 
IL-12p70.57 Ultimately, this results in a disturbed Th1/Th2 balance, which might be the reason 
for persistence of M. tuberculosis. 57,60 
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Figure 3. Schematic representation of DC with DC-SIGN-mediated signaling induced by mycobacteria, viruses 
and fungi (taken from the dissertation of Meike Scharenberg, University of Basel27). Mannose-expressing 
pathogens such as M. tuberculosis, C. albicans and HIV-1 activates Raf-1 (activation of Ras leads to binding to 
Raf-1 and induces conformational changes that allow for subsequent phosphorylation of Raf-1 by Src and Pak 
kinases; Src kinases induce the phosphorylation of Raf-1 at residue Tyr340/341, whereas Rho GTPase-
dependent activation of Pak kinases results in phosphorylation of Raf-1 at Ser338). After translocation of NF-
"B by TLR-stimulation, DC-SIGN-induced Raf-1 activation mediates the phosphorylation of NF-"B subunit 
p65 at Ser276, which in turn leads to p65-acetylation. Acetylation of p65 prolongs and increases the IL-10 
transcription, resulting in increased IL-10 production.57  
 
In contrast to D-Man-induced signaling, immune responses induced by L-Fuc-containing 
ligands (e.g. H. pylori) are independent of Raf-1 activation, i.e. do not need TLR triggering 
and as a consequence upregulate IL-10 but downregulate IL-6 and IL-12.57 The reduction of 
IL-12 levels induced by ligands presenting Le antigens is associated with the shift of Th1 to 
Th2 immune response, which results in persistence (e.g. S. mansoni and H. pylori).67,68 
Binding of self-antigens such as ICAM-2 and ICAM-3 does not lead to DC maturation or 
cytokine production. Obviously, for the latter effect a secondary stimulation is necessary, 
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which is offered by the PAMPs of pathogens. This demonstrates the complex network and 
the fine tuning of these signaling cascades enabled by cross talk between different PRRs.20 
 
Co-crystallization Studies with DC-SIGN 
The CRD of DC-SIGN was co-crystallized with ligand bearing D-Man (Man2 (2IT6)69, 
Man6(2IT5)69, Man4 (1SL4)40, GlcNAc2Man3 (1K9I)34 or L-Fuc (LNFP III, 1SL5)40. These 
crystallographic data reveal a rather shallow binding site. The hallmark of sugars binding to 
DC-SIGN is the coordination of the Ca2+ in the primary binding site. Five protein residues 
(Glu347, Asn349, Glu354, Asn365 and Asp366) define the principal Ca2+ binding site and 
contribute five of the seven coordination sites (Figure 4).40 The coordination sphere is 
completed by two vicinal hydroxyl groups of the ligand, i.e. of a D-Man or a L-Fuc moiety. 
Analysis of different crystal structures shows that the CRD maintains almost the same 
geometry independent of the bound ligand. However, the distinct configuration of hydroxyl 
groups in D-Man and L-Fuc entails differences in Ca2+-coordination (Figure 4) influencing 
the orientation of the ligand in the binding site.  
 
 
 
Figure 4. Comparison of the Ca2+-coordination (magenta sphere) in equatorial-equatorial manner by D-Man 
(green carbons) and a equatorial-axial manner by L-Fuc (yellow carbons). L-Fuc is tipped (yellow carbons) 
compared to D-Man (left). Coordination of Ca2+ by the equatorial 3-OH and the axial 4-OHs of L-Fuc in LNFP 
III (right). (PDB 1SL540, modeled by Sameh Eid, Institute of Molecular Pharmacy, University of Basel). 
 
D-Man-bearing ligands coordinate the Ca2+ in an equatorial-equatorial manner via the 3- and 
4-OH group of a Manα1-3(Manα1-6)Manα-motif. DC-SIGN recognizes this trimannose 
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substructure only if the central D-Man is linked in the "-anomeric configuration.34 Figure 5 
depicts the binding mode of GlcNAc2Man3 in complex with DC-SIGN. 
 
 
Figure 5. Binding mode of the resolved part of GlcNAc2Man3 (green carbons). Dashed lines show Ca2+-
coordination by the 3-OH and the 4-OH of D-Man. D-GlcNAc and D-Man-3 are interacting with a secondary 
binding site lined by Phe313. (PDB 1K9I34, modeled by Sameh Eid, University of Basel). 
 
In Lex as part of lacto-N-fucopentaose III (LNFP III = Lex–D-Gal–D-Glc) the calcium is 
complexed by the terminal L-Fuc residue via the equatorial 3-OH and the axial 4-OH (PDB 
1SL5, Figure 6)40. Consequently, the L-Fuc is tipped and differently oriented compared to the 
D-Man moiety (Figure 4). This enables a van der Waals contact through C2 with Val351. The 
terminal D-Gal is involved in an H-bond network with Asp367 and Leu371 via its 6- and 4-
OH group respectively (not shown). The D-GlcNAc moiety with the D-Gal and (unresolved) 
D-Glc residues points towards the solvent without efficiently contributing to binding. Hence, 
L-Fuc-containing ligands elevate in an upright position from the binding site and point 
towards the solvent (Figure 6), whereas D-Man-bearing ligands lie rather flat on the protein 
surface (Figure 5). Furthermore, there are differences in occupation of the binding site. L-
Fuc-containing Lex solely interacts with the main binding site surrounding the principal Ca2+. 
Mannosides use an enlarged binding site adressing also a secondary binding site lined by 
Phe313. This amino acid residue contributes to both ligand selectivity as well as affinity.40 
The differences in binding site accomodation and occupation might also be a reason for the 
distinct effects on signaling cascades downstream of DC-SIGN and therewith, on immune 
modulation.57 
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Figure 6. DC-SIGN CRD in complex with LNFP III (PDB 1SL540, modeled by Sameh Eid, Institute of 
Molecular Pharmacy, University of Basel). L-Fuc coordinates the calcium via its 3-OH and 4-OH in an 
equatorial-axial manner. The terminal D-Gal establishes a water mediated H-bond with Glu358 via the 4-OH. 
The 6-OH of D-Gal exhibits a H-bond to Asp367, which is stabilized by an interaction with Lys373. The  
D-GlcNAc moiety points towards the solvent. 
 
DC-SIGN Antagonists 
DC-SIGN interacts with a broad variety of pathogens, which indicates its meaningful role as 
an immunomodulatory receptor. Development of anti-infective agents that block the first 
contact between DC-SIGN and the pathogens is a promising therapeutic approach towards 
prevention of infectious diseases.70-72 
Many efforts have been made to develop DC-SIGN antagonists and investigate their 
inhibitory potential by in vitro assays.47,73 In general, monovalent carbohydrate–lectin 
interactions are weak. Pathogens benefit from an avidity increase due to multivalent 
presentation of carbohydrate motifs. The design of DC-SIGN antagonists includes two main 
concepts: 1) monovalent glycomimetics and 2) multimeric presentation of oligosaccharides 
or respective glycomimetics.  
The majority of pathogens bear D-Man-containing structures, such as GlcNAc2Man9 (1, 
Figure 7). This epitope is found on glycoprotein gp120 and binds to DC-SIGN with 
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micromolar affinity.69,74 The development of oligomannose glycodendrons has been proven 
successful in blocking DC-SIGN in a glycan array with an improved binding affinity in the 
nanomolar range.75 Furthermore, gold-nanoparticles were functionalized with glycodendrons 
and were shown to efficiently prevent DC-SIGN-mediated trans-infection of T cells with 
HIV-1 at nanomolar concentrations.76 In fact, already a tetravalent presentation of the linear 
trimannose mimic 2 is able to inhibit trans-infection at low micromolar concentrations 
(Figure 7).73,77 Similarly, a ROMP-derived glycopolymer with multimeric presentation of a 
shikimic acid based glycomimetic exhibited IC50 values in the low micromolar range.78 
Furthermore, this demonstrated that shikimic acid is a suitable replacement for the D-Man 
moiety and hence, represents a non-carbohydrate based approach.  
In many studies an increased binding avidity due to multimeric presentation of the binding 
epitope was proven.37,75,79 The multivalent presentation of oligosaccharides and mimetics 
makes a systemic administration difficult. However, a topical administration at the site of 
infection, such as mucosal surfaces, presents a possible therapeutic approach.80 
 
 
Figure 7. DC-SIGN ligands and glycomimetic antagonists. Multimeric presentation of D-Man-based 
glycomimetic 273, monovalent ligand 381, and L-Fuc-based mimic 582 lead to affinities in the micro-molar range. 
 
Monosaccharides, such as D-Man and L-Fuc, have low affinities to DC-SIGN with KD values 
in the millimolar range.35 Due to their polarity carbohydrates show no ideal drug-like 
properties concerning pharmacokinetics. Therefore, the development of monovalent DC-
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SIGN antagonists is based on the design of glycomimetic compounds. In general, one 
monosaccharide anchor is chosen to establish the crucial Ca2+ coordination in the CRD of 
DC-SIGN and additional subsituents are attached to make use of areas in the binding site that 
are not or only partially addressed by the natural ligands. In this manner, Obermajer et al. 
reported a series of potent monovalent D-man-based antagonist with low micromolar 
affinities (3, Figure 7).81 These inhibitors interact via aromatic substituents with the 
hydrophobic region lined by Phe313. Moreover, D-Man-containing di- or trisaccharide 
mimics have been designed with a cyclohexadiol moiety replacing D-man, which improved 
affinity.73,83,84 
Binding affinities of L-Fuc-containing ligands have not been determined extensively in the 
past. Lewis antigen, such as Lex (4) and Ley are epitopes presented by pathogens (H. pylori) 
or endogeneous ligands of DC-SIGN (ICAM-2).24,58,85 Lex (1) in a monovalent manner was 
determined to bind in the millimolar range.82 Multivalent presentation, as in human milk, 
leads to higher affinities and was shown to efficiently inhibit HIV-1 trans-infection of CD4+ 
lymphocytes.37 In a glycan array Lea exhibited a slightly higher relative binding affinity to 
DC-SIGN than the Lex motif.74 Lewis antigens sulfated or sialylated at the 3-O-position of D-
Gal show no binding to DC-SIGN.74 Considering the crystal structures of DC-SIGN, these 
extensions seem to clash with Phe313.40 Recently, the development of L-Fuc-containing 
ligands has gained more interest. Bernardi et al. displaced the metabolically unstable  "-
glycosidic linkage of L-Fuc by a fucosylamide anchor.86,87 These ligands (e.g. 5) exhibited 
sightly improved affinities compared to Lex. 86,87,88 Lewis-type structures are especially 
advantageous regarding their specificity. Whereas D-Man-containing ligands might be 
recognized by various other lectins as well, the mentioned L-Fuc-containing mimics were 
shown not to inhibit Langerin which is eligible in case of HIV-1 infection.86 
Besides the carbohydrate-based approach also screening approaches of small molecule 
libraries have been undertaken. In a high-throughput fluorescence-based competition assay 
monovalent non-carbohydrate ligands were identified with affinities in the low-micromolar 
range.89 They proved to be effective in DC-SIGN dependent cell-adhesion assays, however, 
the precise binding mechanism was not being clarified and an allosteric binding cannot be 
excluded.71 
A major challenge in the design and development of DC-SIGN ligands is the unpredictable 
outcome. Up to now no integral assay has been developed that allows for clear identification 
of a ligand as antagonist or agonist. Understanding of signal transduction processes and 
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involvement of receptor cross-talk has just begun and many details are still to be elucidated. 
Although much can be learned from in vitro data, the elaboration of suitable assay formats to 
elucidate DC-SIGN-related processes is a serious future task. For this matter, the design and 
synthesis of new ligands with high affinity and selectivity is substantial and presents the 
prerequisite for the development of drug-like anti-infectives. 
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ABSTRACT  
Dendritic cells (DCs) are antigen presenting cells and are essential bridges between innate 
and adaptive immune system. In particular, they activate T-cells during the course of 
infection with various pathogens. DC-SIGN (DC-specific intercellular adhesion molecule-3-
grabbing non-integrin) is one of the major receptors on DCs involved in the uptake of 
pathogens and has gained increasing interest over the last decade. It is crucially involved in 
infections caused by HIV-1, Ebola virus, Mycobacterium tuberculosis, and a variety of other 
pathogens. High-mannosylated N-glycans or L-Fuc-containing trisaccharide motifs such as 
the Lewis (Le) blood group antigens Lea and Lex, which are surface components of these 
microorganisms, mediate binding to DC-SIGN. 
Crystallographic data for DC-SIGN in complex with a Lex-containing pentasaccharide 
suggest that the terminal sugar residues, L-Fuc and D-Gal, are predominantly involved in 
binding. We elucidated the interaction of DC-SIGN with Lea and Lex bearing two different 
aglycones. Binding assays together with STD NMR analysis, molecular modeling and 
mutagenesis studies revealed distinct binding modes dependent on the nature of the aglycone.  
Introduction of phenyl aglycones at the Le trisaccharides offers the establishment of an 
additional hydrophobic contact with Phe313 in the binding site of DC-SIGN, which entails a 
switch of the binding mode. Based on this information a new series of DC-SIGN antagonists 
can be designed. 
 
1. INTRODUCTION 
 
Immature dendritic cells (DCs), found in peripheral tissues throughout the body, play an 
essential role in triggering the immune response as they are antigen-presenting cells.1,2 DCs 
recognize and capture a broad variety of pathogens including viruses,3 bacteria,4 and yeasts5 
by pathogen recognition receptors (PRRs). Pathogen uptake by PRRs as well as inflammatory 
cytokines and chemokines (e.g. IL-4) trigger DC differentiation and migration to the 
lymphoid organs where the mature DCs present pathogenic peptides on the major 
histocompatibility complex (MHC) to resting T cells. 
Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) is 
one of the main receptors on DCs for recognition and uptake of pathogens. Since its first 
discovery by Geijtenbeek et al. in 20003 DC-SIGN gained popularity, particularly because a 
variety of pathogens exploit DC-SIGN to infect their host, including HIV, Ebola virus or 
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SARS.6,7,8 The fact that different pathogens have capitalized on this infection strategy makes 
DC-SIGN an interesting target for a new class of anti-infectives.9 In a study on the binding 
and transfer of HIV in human rectal mucosa cells, DC-SIGN+ cells accounted for more than 
90% of bound viruses although they represented only 1–5% of the total mucosal mononuclear 
cells. Furthermore, anti-DC-SIGN antibodies blocked more than 90% of HIV binding.10  
DC-SIGN is a type II transmembrane protein with a C-terminal carbohydrate recognition 
domain (CRD). It is part of the C-type lectin family and ligand binding is Ca2+-dependent. 
The majority of pathogens bind with N-linked high-mannose oligosaccharides to DC-
SIGN11,12, e.g. mannan structures on the gp120 envelope protein of HIV-1.6,13 Besides 
oligomannosides, L-Fuc-containing blood group antigens, such as Lewisx (Lex, Gal!(1-
4)[Fuc$(1-3)]GlcNAc) and Lewisa (Lea, Gal!(1-3)[Fuc$(1-4)]GlcNAc) that are also 
commonly found on pathogens, are recognized by DC-SIGN.14-17 Lex and Lea bind to 
DC-SIGN in the low millimolar range, with Lea exhibiting a slightly higher binding affinity 
than Lex.18,19 Since pathogens present these rather low-affinity sugar motives in a multimeric 
form to the DC-SIGN tetramers, high binding avidities are observed.20,21  
 
   
Figure 1. A) X-ray of LNFP III/CRD of DC-SIGN (PDB 1SL5).22 The equatorial 3-OH and the axial 4-OH of 
L-Fuc coordinate the calcium ion. The interaction of 4-OH with Glu358 is mediated by a water molecule. The 6-
OH of D-galactose forms a H-bond with Asp367 which on its part is stabilized by an interaction with Lys373. 
B) X-ray of Man4 {Man"(1-6)[Man"(1-3)]Man"(1-6)Man}/CRD of DC-SIGN (PDB 1SL4).11,22 The calcium 
ion is coordinated by the equatorial 3-OH and the equatorial 4-OH of the terminal "(1-3)-linked D-Man. In 
addition, a hydrophobic contact of the terminal "(1-6)-linked D-Man further stabilizes the interaction. 
 
DC-SIGN 2.2.1 – Manuscript 1 
 
32 
Crystallographic data (PDB: 1SL5)22 obtained from the CRD of DC-SIGN co-crystallized 
with lacto-N-fucopentaose III (LNFP III, Gal!(1-4)[Fuc$(1-3)]GlcNAc!(1-3)Gal!(1-4)Glc) 
suggest that the equatorial 3-OH and axial 4-OH of the L-Fuc moiety coordinate the calcium 
ion (Figure 1A). For the 4-OH of the D-Gal moiety a water-bridged H-bond with Glu358 is 
proposed. In addition, a H-bond of 6-OH of D-Gal to Lys373, bridged by Asp367 is 
assumed.22 For the CRD of DC-SIGN co-crystallized with oligomannosides (Man4 and 
GlcNAc2Man3) a comparable binding mode was obtained where the equatorial 3- and 4-OH 
of the "(1-3)-linked D-Man moiety complex the calcium ion (Figure 1B). In addition, Man4 
(PDB 1SL4) addresses a second binding site lined by Phe313, contributing to selectivity as 
well as affinity.11,22 Only recently, Bernardi et al. took advantage of this additional 
hydrophobic contact for their design of glycomimetic DC-SIGN antagonists.23,24 
In our program directed to the identification of high-affinity DC-SIGN antagonists, a large 
library of carbohydrates and mimetics thereof was screened. One interesting finding was the 
unexpectedly improved affinity discovered for Lex and Lea antigens with aromatic aglycones 
('3,4) compared to the corresponding methyl glycosides ('1,2). When these derivatives 
adopt a binding mode similar to LNFP III,22 the aglycones should point to the solvent and 
therefore not contribute directly to binding. To clarify whether a modified binding mode is 
responsible for the increased affinity, the binding epitopes of the Lea and Lex derivatives 1-4 
were analyzed by STD NMR and docking studies.  
 
2. RESULTS AND DISCUSSION 
 
2.1. Binding Affinities for Lewis Structures. For the determination of the affinities of 
methyl Lex (1), methyl Lea (2), phenyl Lex (3) and phenyl Lea (4) (Table 1) a cell-free 
competitive binding assay was developed. It is based on the competition of a biotinylated 
polyacrylamide glycopolymer (Gal!(1-3)[Fuc$(1-4)]GlcNAc!-polyacrylamide, Lea-PAA) 
and the ligand of interest for the CRD of DC-SIGN. A soluble recombinant protein consisting 
of the DC-SIGN CRD-Fc (amino acid residues 250-404) was expressed in CHO-K1 cells and 
purified by affinity chromatography (protein A- and L-Fuc-sepharose column). For the 
determination of IC50 values, a microtiter plate coated with DC-SIGN CRD-Fc was incubated 
with biotinylated Lea-PAA polymer conjugated to streptavidin-horseradish peroxidase and 
the DC-SIGN antagonist in a serial dilution. The assay was performed in duplicates and 
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repeated three times for each compound. To ensure comparability of different ligands, the 
reference compound L-Fuc was tested in parallel on each individual microtiter plate.  
L-Fuc and D-Man were used as reference compounds showing IC50 values of 7.6 mM and 9.1 
mM, respectively. These affinities correlate well with published data.20 Phenyl Lex (3) (IC50 
1.2 mM) and phenyl Lea (4) (IC50 0.9 mM) showed a two- to threefold increase in affinity 
compared to corresponding methyl derivatives [IC50 2.3 mM for methyl Lex (1) and 2.9 mM 
for methyl Lea (2)]. For phenyl Lea (4), the best antagonist in this series, we also performed 
isothermal titration calorimetry (ITC) experiments. The KD of 582 µM for phenyl Lea (4) 
confirms the results of the competitive binding assay (see experimental section) with affinity 
in the high micromolar range. As observed for the majority of carbohydrate–lectin 
interactions,25-27 the binding is enthalpy driven ((H = - 28.0 ±2.0  kJ/mol, T(S = - 9.5 ± 2.1 
kJ/mol).  
If the Lex- and Lea-motifs bind comparable to LNFP III,22 only the L-Fuc and D-Gal moiety 
participate in binding, whereas the D-GlcNAc moiety as well as the aglycone point to the 
solvent. Therefore, the observed beneficial effect of the aromatic aglycone was unexpected.  
 
Table 1. The cell-free competitive binding assay is based on the competition of a biotinylated Lea-PAA with the 
antagonist of interest for the CRD of DC-SIGN. The assay was performed in duplicates and repeated three times 
for each compound. To ensure comparability of different ligands, the reference compound L-Fuc was tested in 
parallel on each individual microtiter plate. ITC experiments were performed at 25 °C. Thermodynamic 
parameters were calculated according to the equation (G° = (H° - T(S° =  -RTlnKD; n.d. not determined. 
Ligand Competitive binding assay, IC50  
Isothermal titration 
calorimetry, KD  
D-Man 9.1 ± 1.3 mM n.d. 
L-Fuc 7.6 ± 2.6 mM n.d. 
Methyl Lex (methyl Gal!(1-4)[Fuc$(1-3)]!GlcNAc) (1) 2.3 ± 0.1 mM n.d. 
Methyl Lea (methyl Gal!(1-3)[Fuc$(1-4)]!GlcNAc) (2) 2.9 ± 0.5 mM n.d. 
Phenyl Lex (phenyl Gal!(1-4)[Fuc$(1-3)]!GlcNAc) (3) 1.2 ± 0.5 mM n.d. 
Phenyl Lea (phenyl Gal!(1-3)[Fuc$(1-4)]!GlcNAc) (4) 0.9 ± 0.3 mM  582 ± 40 µM 
%G°: -18.5 ± 1.0  kJ/mol 
%H°: -28.0 ± 2.0  kJ/mol 
T%S°: -9.5 ± 2.1 kJ/mol 
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2.2. Saturation Transfer Difference (STD) NMR Analysis. For the interpretation of the 
unexpected higher affinities correlated with the phenyl aglycone of antagonists 3 and 4, the 
binding epitopes of the Lea and Lex derivatives were characterized by STD NMR (Figure 
2A-D), which is particularly suited for epitope mapping of ligand receptor couples with weak 
interactions.28-31 STD NMR experiments are based on spin magnetization transfer from a 
macromolecule, the protein, to a smaller binding molecule, the ligand. The saturation transfer 
proceeds through space via dipolar coupling and is therewith dependent on the distance (r-6) 
of ligand hydrogens to the protein surface.  
 
 
Figure 2. Binding epitopes of the Lewis antigens 1 - 4 interacting with DC-SIGN CRD-Fc determined by STD 
NMR. The contribution of each hydrogen to the STD epitope is quantified by forming the ratio of the signal 
intensities in the STD to those in the reference spectrum. These values are normalized to H-6 of L-Fuc (in red, 
100%) to give the percentage epitope. STD values greater than 100% represent proximity to DC-SIGN CRD-Fc 
closer than that of the H-6 of L-Fuc. The letter size used for the hydrogens expresses the proximity to the 
protein, i.e. the relative amount of saturation transfer. The STD epitope for methyl Lex (1) is consistent with 
recently published data with respect to experimental accuracy.32 Further details regarding the percentage 
epitope, sample preparation and parameters for the STD NMR measurement are available in the experimental 
section. 
 
In the STD NMR analysis significantly higher STD values for the aromatic hydrogens (3 and 
4, Figure 2C&D) compared to the methyl groups (in 1 and 2, Figure 2A&B) were found. This 
data fits better to a model with spatial proximity of the aromatic aglycones to DC-SIGN. 
H
OO
O
NH
O
O
HO
OH
OH
OH
O
OH
HO
HO
OH
H3C O
H
H
H
H
O
H2C
O
O
NH
O
O
HO
OH
OH
O
OH
HO
HO OH
H3C
O
CH3
H
H
H
HH
H
HO
H
H
H
H
H
H
H
H
H
H
phenyl Lex (3)
phenyl Lea (4)
CH3
H    ! 45%
H   " 46-80%
H  " 81-125%
H  = 100%
H " 126-160%
H > 160%
H
OO
O
NH
O
O
HO OH
OH
OH
O
OH
HO
HO
HO
H3C
H
H
H
H
H
H
H
H
H
H
CH3
O
CH3
H
H
O
CH2
O
O
NH
O
O
HO
OH
OH
OH
O
OH
HO
HO OH
H3C
CH3
O
CH3
H H
H
H
H
H
H H
H
methyl Lex (1)
methyl Lea (2)
H
H
H
H
A
B
C
D
DC-SIGN 2.2.1 – Manuscript 1 
 
35 
However, a comparison of the binding epitopes reveals further differences going beyond 
aglycones. For the D-GlcNAc moieties of methyl Lex (1) and Lea (2) the maximal STD values 
for ring hydrogens are smaller than for H-6 of L-Fuc (up to 75%), whereas for the phenyl 
derivatives 3 and 4 the values reach up to 165%. Especially for phenyl Lea (4), and to a lesser 
extent for phenyl Lex (3), high STD values (80-220%) are equally distributed over the entire 
structure. In contrast, for methyl Lex (1), methyl Lea (2) high STD values are predominantly 
located on the L-Fuc moiety. The latter finding corresponds with X-ray data when the Lex-
containing LNFP III is co-crystallized with DC-SIGN,22 indicating the dominant role of the 
L-Fuc moiety in these binding epitopes.  
 
2.3. Molecular Modeling Studies. Overall, the correlation of increased affinity with the 
presence of aromatic aglycones as well as the STD NMR data suggest a spatial proximity of 
the phenyl substituent to DC-SIGN. This is in contrast to the structural information deduced 
from the co-crystallization of LNFP III with the CRD of DC-SIGN.22 For a possible solution 
of this riddle, docking studies were initiated. The crystal structure 1SL522 was used as 
starting point for the docking studies. The replacement of the internal D-Gal moiety in 
LNFP III by a methyl aglycone [LNFP III ' methyl Lex (1)] is not expected to have a 
significant influence on its binding mode as indicated by the small STD value of the aglycone 
in 1 (Figure 2A). In addition, the proximity of the N-acetyl of the D-GlcNAc moiety to 
Val351 as proposed by the crystal structure (inter-proton distance of 2.5 Å)22 is reflected by 
the increased STD value.  
Automated docking of methyl Lex (1) positions the Lex subunit in close agreement (RMSD 
0.7Å) with its orientation in the crystal structure22 as shown in Figure 3A. In the docking 
pose of methyl Lea (2), on the other hand, the D-GlcNAc residue is flipped along its C1-O5 
axis, thereby positioning L-Fuc moiety similar to the LNFP III crystal structure. Calcium 
coordination and H-bond network to L-Fuc are thus maintained (Figure 3B). In this new 
orientation D-Gal can establish the same characteristic H-bond to Asp367 as well. However, 
N-acetyl group of D-GlcNAc no longer forms a hydrophobic contact with Val351 but with 
Phe313 instead, with a much longer inter-proton distance of ~ 4.5 Å. This is in good 
agreement with the lower intensity of the STD NMR signal of the N-acetyl group of GlcNAc 
in methyl Lea (2, Figure 2B).  
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Figure 3. A) Docking modes of methyl Lex (1) and B) methyl Lea (2). Contacts between the N-acetyl groups 
and closest protein residues are highlighted with double-headed arrows. 
 
A binding mode for phenyl Lex (3) where the Lex subunit adopts an analogous orientation to 
LNFP III (Figure 1A) is inconsistent with the significant saturation transfer observed for the 
aromatic protons, since the aglycone would point to the solvent with no close contacts to the 
protein (Figure 4A). The top-ranked pose from Glide XP33 induced-fit docking presents an 
alternative pose where the ligand lies “flat” on the receptor and the phenyl aglycone makes a 
close contact with a hydrophobic cavity formed by the side chains of Phe313 and Leu371 
(Figure 4B). This docking pose perfectly explains the large STD values of the aromatic 
protons of phenyl Lex (3, Figure 2C), indicating a close proximity to DC-SIGN. 
 
 
 
DC-SIGN 2.2.1 – Manuscript 1 
 
37 
       
Figure 4. A) When phenyl Lex (3) binds to DC-SIGN in a manner comparable to methyl Lex (2) (Figure 3A) 
and LNFP III (Figure 1A), the phenyl aglycone points to the solvent (black arrow), not exhibiting an apparent 
protein contact. B) The induced-fit docking pose for phenyl Lex (3) shows an interaction of the phenyl aglycone 
with the hydrophobic cleft formed by Phe313 and Leu371, rationalizing the strong aromatic proton signals in 
STD NMR. 
 
Because of smaller overlaps of the resonances in the 1H-NMR spectrum of phenyl Lea (4), its 
STD NMR analysis is more detailed. The automated docking pose of phenyl Lea (Figure 5) is 
similar to phenyl Lex (3) where L-Fuc coordinates to Ca2+ via the two equatorial hydroxyl 
groups at the 2- and 3-position. In addition, H-bonds from 2-OH to both Glu354 and Asn365 
and between 3-OH and Glu347 are formed. The D-Gal moiety lies close to the primary 
binding site forming two H-bonds from 6-OH to Glu347 and from 2-OH to Ser360 (not 
shown). The phenyl aglycone occupies the same hydrophobic pocket (Phe313 and Leu371) as 
phenyl Lex (3) (Figure 4B), rationalizing the large STD values for the aromatic protons 
(Figure 2D). Moreover, D-GlcNAc also interacts via a H-bond between its 6-OH and Asp367, 
which in turn bridges this H-bond to Lys373. In the proposed orientation, the D-GlcNAc 
moiety of phenyl Lea (4) is in closer contact with the receptor compared to methyl Lea (2) 
(Figure 3B), which explains the observed larger STD values for the D-GlcNAc protons.  
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Figure 5. Binding mode of phenyl Lea (4) to DC-SIGN. Binding of the phenyl aglycone in the hydrophobic 
cleft formed by Phe313 and Leu371 and proximity of the D-GlcNAc moiety to protein surface coincides with the 
measured STD NMR values (Figure 2D). 
 
Dynamic stability of this novel binding mode was confirmed by molecular dynamics (MD) 
simulation. Analysis of MD trajectories revealed that the interactions of phenyl Lea (4) with 
key residues in the DC-SIGN binding site were maintained throughout the simulation (Figure 
6A). Particularly, the favorable interaction of phenyl Lea with Phe313 was stable during the 
simulated time span (Figure 6B). Despite the alteration in binding mode in comparison to the 
crystal structure of LNFP III, the Ca2+ coordination via Fuc-O2 and Fuc-O3 of phenyl Lea (4) 
is of comparable stability as reflected by the variation in the distance between Ca2+ and its 
two coordinating oxygens (Figure 6C&6D). Additionally, throughout the MD simulation all 
protons of the phenyl moiety of phenyl Lea exhibited one or more contacts with a proton from 
a nearby protein residue, consistent with the observed STD signals for these protons 
(Supporting Information, Figure S4). 
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Figure 6. Results of molecular dynamics simulations. A) average interaction energies between phenyl Lea (4) 
and some binding site residues during a 6 ns MD simulation, standard deviations are indicated by error bars. B) 
time evolution of interaction energy between phenyl Lea and Phe313 residue throughout the MD simulation. C) 
and D) time evolution of the distances between Ca2+ and L-Fuc oxygens (2O, 3O, 4O) along MD simulations 
starting from LNFP III (in 1SL5 crystal structure) and the docking mode of phenyl Lea, respectively. The third 
(non-Ca2+-coordinating) oxygen is shown for comparison. 
 
2.4. Mutagenesis Studies. To further confirm the proposed hydrophobic interaction between 
Phe313 and the aromatic aglycone, the previously described DC-SIGN CRD F313A22 was 
expressed and the binding affinities for methyl Lea (2) and phenyl Lea (4) were determined. 
Table 2 summarizes the results of the competitive binding assay with wild type and mutant 
DC-SIGN CRD. L-Fuc was included as reference compound. The F313A mutation should not 
have an impact on binding affinity of L-Fuc since the monosaccharide is assumed to bind 
exclusively in the primary binding site.22 However, L-Fuc showed a lower IC50 value for the 
mutant protein (IC50 3.9 mM) than for the wild type (IC50 7.6 mM). This can be explained by 
the lower affinity of Lea-PAA for the F313A mutant, reflected by the EC50 value (Table 2). 
For a better comparison we state relative IC50 values (rIC50) with L-Fuc as reference 
(Table 2). 
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Table 2. Results of the competitive binding assay for L-Fuc, methyl Lea (2), and phenyl Lea (4) with wild type 
and mutant DC-SIGN. The observed differences in the absolute inhibitory potencies between wild type and 
mutant are due to different binding affinities to Lea-PAA reflected by a higher EC50 value (half maximal 
effective concentration) in case of the mutant protein. The rIC50 values of methyl Lea (2) and phenyl Lea (4) 
with L-Fuc as reference were determined by dividing the respective IC50 values by the IC50 of L-Fuc; a value 
below 1 resembles higher affinity than L-Fuc. Detailed information on protein expression and competitive 
binding assay is given in the experimental section. 
Ligand DC-SIGN  wild type 
DC-SIGN  
F313A mutant 
EC50 Lea-PAA 66.9 ± 0.3 ng/ml 111.2 ± 0.2 ng/ml 
rIC50 L-Fuc 1 1 
rIC50 methyl Lea (2) 0.38 0.46 
rIC50 phenyl Lea (4) 0.12 0.43 
Factor of 2 to 4 3.2  1.1  
 
 
In Figure 7, inhibition curves for methyl Lea (2) and phenyl Lea (4) with wild type and 
mutant DC-SIGN CRD-Fc are shown. Graph A visualizes the aforementioned difference in 
binding affinity of methyl Lea (2) and phenyl Lea (4) to wild type DC-SIGN (factor 3.2). In 
contrast, both compounds exhibited near identical binding affinities (factor 1.1, Figure 6B) 
for the F131A mutant, which indicates the omission of the beneficial hydrophobic contact of 
Phe313 with the phenyl aglycone.  
 
 
 
Figure 7. Inhibition curves for methyl Lea (2) and phenyl Lea (4) obtained from the competitive binding assay, 
with (A) wild type DC-SIGN and (B) F313A mutant.  
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3. CONCLUSIONS 
 
STD NMR spectroscopy and molecular modeling supplemented with a protein mutation 
study were used to rationalize diverging binding modes of Lea and Lex antigens to DC-SIGN 
induced by the nature of the aglycone. The originally found improved binding affinity of 
phenyl Lex (3) and phenyl Lea (4) indicated a contribution of the phenyl aglycone to binding, 
presumably by a hydrophobic contact with the protein. Strong STD NMR values further 
confirmed this assumption. Docking and MD studies finally revealed a favorable interaction 
of the phenyl aglycone with a hydrophobic pocket formed by Phe313 and Leu371. With a 
single-point mutation of the DC-SIGN CRD the proposed interactions of the phenyl aglycone 
of 4 with Phe313 could be verified.  
Here, we report an interesting example, illustrating how flexible binding modes on shallow 
protein surfaces can be, especially when the starting affinity is low, a situation often present 
in carbohydrate-lectin interactions. Therefore, improved affinities induced by structural 
modifications should be carefully analyzed regarding possible reorientations of binding 
modes. STD NMR experiments28,29 represent an excellent tool for this endeavor.  
Based on the new binding mode of phenyl Lex (3) and phenyl Lea (4), the interaction within 
the hydrophobic pocket formed by Phe313 and Leu371 provides a promising rationale for the 
design of more potent DC-SIGN antagonists. Therewith, our findings support recent 
approaches from other researchers with the objective of using this interaction for the design 
of glycomimetic DC-SIGN ligands.24 
Our findings that introduction of a hydrophobic moiety at Lewis trisaccharides induces a 
switch in the binding mode in order to establish an additional contact with the protein 
demonstrates the value of this interaction. In fact, recently Bernardi et al. made use of this 
interaction for the design of glycomimetic DC-SIGN antagonists.24 
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4. EXPERIMENTAL SECTION 
 
4.1. Ligands. Methyl Lex (1) and methyl Lea (2) were purchased from Toronto Research 
Chemicals Inc. Phenyl Lex (3) was prepared according to ref 34 and phenyl Lea (4) was 
prepared as desribed in the supporting information. 
 
4.2. Cloning of DC-SIGN CRD-IgG(Fc). Plasmids containing the full-length cDNA of DC-
SIGN were kindly provided by Daniel A. Mitchell (Glycobiology Institute, Department of 
Biochemistry, University of Oxford). Standard molecular techniques35 were used for the 
cloning of the carbohydrate recognition domain of DC-SIGN (DC-SIGN CRD; aa residues 
250-404, GenBank accession no. M98457). The DC-SIGN CRD encoding insert was 
amplified by PCR using specific forward and reverse primers containing the restriction sites 
EcoRI and NcoI (New England BioLabs, Allschwil, Switzerland), respectively. The insert 
was ligated into the corresponding cloning site of the pFUSE-hIgG2-Fc2 expression vector 
(Invivogen, Toulouse, France). The construct was amplified in chemocompetent DH5! E. 
coli (Novagen, Lucerne, Switzerland). After plasmid minipreparation and restriction control, 
the construct correctness was confirmed by DNA sequencing. 
 
4.3. Expression and purification of DC-SIGN CRD-Fc. CHO-K1 cells (American Type 
Culture Collection No. CCL-61TM) were cultivated in Ham’s Nutrient Mixture F-12 
(Invitrogen, Paisley, UK) supplemented with 2 mM L-glutamate, 10% fetal calf serum (FCS, 
Invitrogen, Paisley, UK), 100 U/mL penicillin, and 100 &g/mL streptomycin (Sigma-Aldrich, 
Basel, Switzerland). The cells were cultivated as monolayers in tissue culture flasks (Nunc, 
Roskilde, Denmark). The CHO-K1 cells were transfected with the DC-SIGN CRD 
expression vector using the FuGENE® HD transfection reagent (Roche Applied Science, 
Rotkreuz, Switzerland) following to the instructions of the supplier. Stably transfected CHO-
K1 cells were selected by treatment with ZeocinTM (0.5 &g/ml, Invitrogen, Paisley, UK) and 
single clones were obtained by limiting dilution. For DC-SIGN CRD-Fc production the cells 
were cultivated as described above and the culture medium, containing the secreted DC-
SIGN CRD-Fc chimera was harvested weekly, adjusted to pH 7.6 and sterile filtrated 
(conditioned medium). 
The purification of the recombinant protein was achieved by applying conditioned medium 
on a protein A-sepharose column (BioVision, Mountain View, CA, USA) attached to a fast 
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protein liquid chromatography apparatus (BioLogic (FPLC) system, BioRad, Reinach BL, 
Switzerland), which was previously equilibrated with loading buffer I (20 mM Tris/HCl, pH 
7.6, 150 mM NaCl, 0.05% (v/v) Tween-20TM). The protein was eluted with elution buffer I 
(0.5 M acetic acid/ammonium acetate, pH 3.4). The collected protein was further purified on 
a L-Fuc-sepharose column (prepared in house) using loading buffer II (20 mM Tris/HCl, pH 
7.8, 0.5 M NaCl, 25 mM CaCl2) and elution buffer II (20 mM Tris/HCl, pH 7.8, 0.5 M NaCl, 
2 mM EDTA). For long-term storage, the protein was frozen at -80 °C.  
 
4.4. Cloning of the F313A DC-SIGN CRD mutant. The PCR overlap extension 
method36was used for the substitution of the codon TTC against CGC at cDNA bp 968-970, 
resulting in the mutation of phenyl alanine 313 to an alanine. In a first step, two overlapping 
DNA fragments were generated separately, both using wild type DC-SIGN cDNA as 
template (PCR 1: primer fw: 5` g gaa ttc cat atg gaa cgc ctg tgc cac ccc 3` and primer F313A 
rv: 5`tcc aga agt aac cgc gcg acc tgg atg gga 3`; PCR 2: primer F313A fw: 5`aag tcc cat cca 
ggt cgc gcg gtt act tct 3` and primer rv: 5` cgc gga tcc tta cta cgc agg agg ggg gtt tgg g 3`). 
The two internal primers contained a mismatch for the site-directed base substitution (bold). 
In a second step, both overlapping DNA fragments were elongated to the full-length gene, 
containing the single point mutation. The NdeI and BamHI (New England BioLabs, 
Allschwil, Switzerland) treated insert was ligated into the corresponding cloning site of the 
expression vector pET-3a. After E.coli DH5" transformation, plasmid minipreparation, the 
mutation was confirmed by DNA sequencing. Finally, for protein expression the construct 
was transformed into BL21 E.coli (Novagen, Lucerne, Switzerland).  
 
4.5. Expression and purification of F313A DC-SIGN CRD mutant. Protein expression 
was carried out in TB medium (terrific broth) containing 100 &g/mL ampicillin (Applichem, 
Darmstadt, Germany). The bacteria were cultured at 37 °C until an OD600 of 1.0 was reached. 
The expression was induced by the addition of isopropyl-!-D-thiogalactoside (IPTG, 
Applichem, Darmstadt, Germany) at the final concentration of 0.4 mM. The cells were 
further cultivated for 12 h, prior to harvesting by centrifugation at 4000 rpm for 20 min at 4 
°C. For bacterial lysis, the pellet was dissolved in 20 mM Tris-HCl buffer, pH 7.8, 0.5 M 
NaCl, containing 1 mg/mL lysozym (Sigma, Buchs, Switzerland) and incubated for 30 min at 
4 °C under shaking. The inclusion bodies were solubilized by addition of !-mercaptoethanol 
(0.01 % v/v), urea (8 M), and brief sonication followed by gentle rotation for 30 min at 4 °C. 
The mixture was centrifuged at 22000 rpm for 1 h at 4°C and the supernatant was diluted by 
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slow addition of the fivefold volume loading buffer II. The mixture was dialyzed against 6 
volumes of loading buffer II with 6 buffer exchanges. After dialysis, insoluble precipitate was 
removed by centrifugation at 22000 rpm for 1 h at 4°C. The protein was purified using a 
L-Fuc-sepharose column as described above. 
Protein purity was confirmed by standard SDS-PAGE analysis37 followed by Coomassie 
Brilliant Blue G-250 staining (Bio-Rad laboratories, Hercules, CA, USA). Protein 
concentration was determined either by the Bradford method (Bio-Rad laboratories, 
Hercules, CA, USA) or with HPLC38.  
 
4.6. Competitive binding assay. Biotinylated Lea-PAA polymer (20 &L, 1 mg/mL, 
GlycoTech, Gaithersburg, MD, USA) was mixed with 80 &L assay buffer (20 mM HEPES, 
150 mM NaCl, 10 mM CaCl2, pH 7.4), 20 &L FCS and 80 &L streptavidin-horseradish 
peroxidase-conjugate (500 U/mL, Roche, Mannheim, Germany) and incubated for 2 h at 37 
°C. The complex was stable for several weeks when stored at 4 °C. 
Flat-bottom 96-well microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 µL/well of 
a 2.5 µg/mL solution of DC-SIGN CRD-Fc protein in assay buffer overnight at 4 °C in a 
humidified chamber. The coating solution was discarded and the wells were blocked with 
200 µL/well of 3% bovine serum albumin (BSA, Sigma-Aldrich, Buchs, Germany) in assay 
buffer for 2 h at 4 °C. After three washing steps with assay buffer (150 µL/well), a serial 
dilution of the test compound (25 µL/well) in assay buffer and streptavidin-peroxidase 
coupled Lea-PAA (25 µL/well, 0.25 µg/mL final concentration) were added. Subsequent to an 
incubation of 3 h at room temperature and 350 rpm the plate was carefully washed four times 
with 200 µL/well assay buffer. Lea-PAA binding was detected by addition of 100 µL/well of 
ABTS-substrate (2,2’-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid, Invitrogen, Paisley, 
UK). The colorimetric reaction was allowed to develop for 2 min, then stopped by the 
addition of 2% aqueous oxalic acid before the optical density (OD) was measured at 415 nm 
on a microplate-reader (Spectramax 190, Molecular Devices, Ca, USA). The IC50-values 
were calculated using the Prism software (GraphPad Software, Inc, La Jolla, USA). The IC50 
(half maximal inhibitory concentration) defines the molar concentration of the test compound 
that reduces the maximal specific binding of carbohydrate-polymer to DC-SIGN-CRD-Fc by 
50%.  
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For EC50 determination (half maximal effective concentration) of the Lea-PAA, the assay was 
performed as described above with a serial dilution of Lea-PAA (0-3 &g/mL) in absence of 
antagonist. 
 
4.7. Isothermal titration calorimetry. ITC experiments were performed at 298 K and a 
reference power of 10 &cal/sec under constant stirring speed of 307 rpm using a MicroCal 
VP-ITC instrument (MicroCal, Northampton, MA). The concentration of DC-SIGN CRD-Fc 
was determined by HPLC-UV against a standard curve of BSA at 210 nm 38 after extensive 
dialysis against 10 mM HEPES, 150 mM NaCl, 10 mM CaCl2, pH 7.4. The ligand was 
diluted in the dialysat. Injections of 3-5 &l ligand solutions were added from a syringe at an 
interval of 5 min into the sample cell solution containing DC-SIGN CRD-Fc (cell volume 
1.4523 ml). Control experiments were performed, where identical ligand solutions were 
injected into buffer without protein, and showed insignificant heat of dilution. The 
experimental data were fitted to a theoretical titration curve (one site binding model) using 
Origin software (version 7, MicroCal). The quantity c=Mt(0)/KD with Mt(0) as initial 
macromolecule concentration, is of importance in titration microcalorimetry.39 The 
experiments were performed with c values below 1. The stoichiometry was fixed to 1 
(concentration expressed in terms of binding site) to allow reliable determination of KD and 
'H.40, 41 Thermodynamic parameters were calculated from the equation 1,  
  
! 
"G° = "H° # T"S° = #RTlnKA = RTlnKD  (eq. 1) 
where 'G°, 'H°, and 'S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively. T is the absolute temperature, and R = 8.314 J/mol/K. 
 
4.8. STD NMR. Experiments were performed on a Bruker 11.7 T spectrometer with an 
Avance III console at a temperature of 298 K. Shigemi NMR tubes with a sample volume of 
250 µL were used for the measurements. Each sample contained 20-30 µM DC-SIGN CRD-
Fc (dimer) and 1-2 mM ligand. A d-Tris buffer was used as solvent containing 20 mM d-
TRIS (98% Cambridge Isotope Libraries), 4 mM CaCl2 and 150 mM NaCl in D2O (99.8% 
Sigma-Aldrich) adjusted to a pH of 8.1 with HCl. 
Using a pulse sequence modified from Mayer and Meyer28 allows simultaneous saturation of 
the protein at two frequencies, which leads to a more intense STD epitope. The cosine 
modulated E-Burp-1 pulse42 for the on-resonance spectrum was centered at 1555 Hz and 
resulted in two sidebands at 0 and 3110 Hz with a power of 53 dB .43 The duration of each of 
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the 40 E-Burp-1 pulses used to saturate the protein was 50 ms with a 1 ms recovery between 
the pulses. 
Off-resonance excitation was set to 26000 Hz. STD NMR experiments were performed 
applying a Watergate solvent suppression. Specific parameters were determined via 
preliminary experiments including negative control experiments with only ligand-containing 
sample to avoid artifacts from direct excitation. Scaling each STD signal on an off-resonance 
reference spectrum resulted in a relative binding epitope (approximate values, see supporting 
information).30 Ligand resonances were assigned by using 2D NMR and 1D selective 
TOCSY experiments. Not all protons could be assigned doubtlessly, due to solvent 
suppression and partial signal overlap. 
Detailed conditions: STD NMR of methyl-bearing compounds: 2 mM ligand with 20 µM 
DC-SIGN CRD-Fc, STD NMR of phenyl Lea: 1 mM ligand with 20 µM DC-SIGN CRD-Fc, 
STD NMR of phenyl Lex: 1 mM with 30 µM DC-SIGN CRD-Fc; number of scans was 
typically 14k for on-resonance spectra and 512 for off-resonance spectra. 
Experiments with different saturation times were performed for phenyl Lea. These data 
indicate an overall consistent epitope at either saturation times of 0.7, 1, 2, and 3 s and 
exclude misinterpretation due to T1 bias for different proton species (see supporting 
information). 
 
4.9. Molecular Modeling. All ligands were manually built using Maestro, and optimized 
using standard procedures. Model for DC-SIGN in complex with LNFP III was downloaded 
from the Protein Data Bank (code: 1SL5). Hydrogens were added and water molecules were 
removed using Maestro Protein Preparation Wizard. Partial charges were calculated from 
OPLS2005 force field while protonation states and oxidation states for metals were assigned 
by Epik44 Orientation of added hydrogens was sampled for optimal H-bond formation and the 
model was then refined by minimization within RMSD of 0.3Å. 
GlideXP33 was used for docking of novel ligands to DC-SIGN. To account for the possibility 
of side chain re-organization upon ligand binding the Induced-Fit Docking (IFD) 
methodology was employed 45. The binding site was defined to include residues within 5 Å 
radius around the co-crystallized ligand LNFP III in the prepared complex. In the initial 
stages of IFD protocol amino acids within 5 Å radius around any found pose were considered 
as flexible, and their side chain conformations were optimized. Up to 50 poses were retained 
for each calculation within an energy window of 40 kcal/mol to allow for larger diversity in 
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output poses. Prioritization was done by Standard Precision (SP)46 scoring function in the 
initial soft-docking stage followed by more rigorous Extra Precision (XP)47 scoring in the 
redocking stage. Output poses were then visually inspected for agreement with STD NMR 
experiment, and those showing considerable discrepancy were disregarded. 
Stability of the proposed modes was assessed using molecular dynamics. Docking poses and 
crystal structure (PDB 1SL5) were used as a starting point for 6 ns MD simulations using 
Desmond package48 from D. E. Shaw Research lab. The protein-ligand complex was soaked 
in an orthorhombic TIP3P water box extending 10 Å away from the complex. Counter-ions 
were added to make it neutral and 0.15 M sodium and chloride ions were added to 
approximate physiological conditions. The complex was then minimized to a convergence 
threshold of 1.0 kcal/mol/Å. MD experiments were carried out using the OPLS2005 force 
field and the NPT ensemble (constant number of particles, pressure and temperature) at 300 
K with periodic boundary conditions. Default parameters were used and snapshots recorded 
every 1.2 ps. Output files were analyzed using component-interactions script in Maestro 
(Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011) to compute interaction 
energies between the ligand and individual amino acids defining the binding site as well as 
the conserved calcium along the MD simulations. Interaction energies were computed as the 
sum of OPLS2005 Van der Waals and electrostatic terms. 
 
 
ASSOCIATED CONTENT 
Detailed protocols concerning the synthesis of phenyl Lea (4), ITC experiments, STD NMR 
experiments, and molecular dynamics simulations are given in the “Supporting Information”. 
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1. Synthesis of phenyl Lea (4) 
 
 
Scheme S1. a) 4, NIS, TfOH, DCM, -20 °C, 4 h, 81%; b) Me3N.BH3, AlCl3, THF, rt, overnight, 77%; c) 10, Br2, Et4NBr, 
DCM/DMF (1:1), rt, overnight, 49%; d) i. NaOMe, MeOH, rt, 1 h, 90%, ii. Pd(OH)2, H2 (4 atm), NEt3, dioxane/water (4:1), 
12 h, iii. Pd(OH)2, H2 (4 atm), dioxane/water (4:1) 12 h, 92% over two steps. 
  
The phenyl Lea (4) was prepared from the known building block 5 in six steps. The 
glucosamine acceptor 5 was glycosylated with thiogalactoside 6 using NIS/TfOH in good 
yield. Regioselective opening of acetal 7 was performed with AlCl3/ Me3N.BH3 to afford 8 
ready for the fucosylation. The acceptor 8 was fucosylated using bromofucoside prepared 
from thiofucoside under in situ anomerization condition to give 9. Finally, removal of 
O-acetyl group by mild transesterification with catalytic NaOMe, reduction of 
trichloroacetamide group to N-Ac and removal of benzyl protecting groups under 
hydrogenolytic condition afforded the Ph-O-Lea 4 in very good yield. 
  
Experimental procedure 
General Methods 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
TOCSY). Chemical shifts are expressed in ppm using residual CHCl3, CHD2OD, and HDO 
as references. Optical rotations were measured using Perkin-Elmer polarimeter 341. Electron 
spray ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. 
LC/HRMS analysis was carried out using a Agilent 1100 LC equipped with a photodiode 
array detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter.  
Microanalyses were performed at the Department of Chemistry, University of Basel, 
Switzerland. Reactions were monitored by TLC using glass plates coated with silica gel 60 
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F254 (Merck) and visualized by using UV light and/or by heating to 140°C for 5 min with a 
molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography was 
performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep normal phase 
disposable flash columns (silica gel). Reversed phase chromatography was performed on 
LiChroprepRP-18 (Merck, 40-63 µm). LC-MS separation was done on a Waters system 
equipped with sample manager 2767, pump 2525, PDA 2525 and micromass ZQ. 
Commercially available reagents were purchased from Fluka, Aldrich, Merck, AKSci, ASDI, 
or Alfa Aesar. Methanol (MeOH) was dried by refluxing with sodium methoxide and 
distilled immediately before use. Toluene and dichloromethane were dried by filtration over 
Al2O3 (Fluka, type 5016 A basic). Tetrahydrofuran was dried by distillation from 
sodium/benzophenone. Molecular sieves 4Å were activated under vacuum at 500°C for 2 h 
immediately before use. 
 
Phenyl (2,3,4,6-tetra-O-acetyl-!-D-galactopyranosyl)-(1'3)-4,6-O-benzylidene-2-deoxy-
2-trichloroacetamido-!-D-glucopyranoside (7). A mixture of 5 (500 mg, 1.02 mmol), 6 
(602 mg, 1.53 mmol) and powdered molecular sieves 4Å in DCM (20 mL) was stirred at rt 
for 1 h. Then N-iodosuccinimide (690 mg, 3.07 mmol) was added, the solution was cooled to 
-20°C and treated with trifluoromethanesulfonic acid (27 µL, 0.31 mmol). After stirring for 
2 h at -20°C the reaction mixture was filtered, diluted with DCM (30 mL) and washed 
successively with aq. NaHCO3 (20 mL), aq. Na2S2O8 (20 mL) and brine (20 mL). The DCM 
layer was dried with Na2SO4 and concentrated under reduced pressure. The residue was 
purified by chromatography on silica (petrol ether/EtOAc, 4:1 to 2:1) to yield 7 (800 mg, 
81%). 
["]D20 -17.9 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.44-7.39 (m, 2H, Ar-H), 7.33-
7.28 (m, 3H, Ar-H), 7.27 (d, J = 7.6 Hz, 1H, NH), 7.21-7.17 (m, 2H, Ar-H), 6.98 (t, J = 7.4 
Hz, 1H, Ar-H), 6.92 (d, J = 8.7 Hz, 2H, Ar-H), 5.51 (d, J = 8.2 Hz, 1H, Glc-H1), 5.48 (s, 1H, 
CHPh), 5.25 (dd, J = 0.8, 3.5 Hz, 1H, Gal-H4), 5.14 (dd, J = 8.0, 10.4 Hz, 1H, Gal-H2), 4.87 
(dd, J = 3.4, 10.4 Hz, 1H, Gal-H3), 4.73 (d, J = 8.0 Hz, 1H, Gal-H1), 4.55 (t, J = 9.6 Hz, 1H, 
Glc-H3), 4.29 (dd, J = 4.9, 10.5 Hz, 1H, Glc-H6a), 4.05 (dd, J = 6.9, 11.3 Hz, 1H, Gal-H6a), 
3.91 (dd, J = 6.6, 11.2 Hz, 1H, Gal-H6b), 3.79-3.72 (m, 3H, Glc-H2, -H4, -H6b), 3.68 (t, J = 
7.1 Hz, 1H, Gal-H5), 3.56 (td, J = 4.9, 9.8 Hz, 1H, Glc-H5), 2.03, 1.93, 1.88, 1.82 (4 s, 12H, 
4 COCH3); 13C NMR (125 MHz, CDCl3): ! 170.3, 170.2, 170.1, 169.6 (4 COCH3), 162.2 
(COCCl3), 156.8, 136.9, 129.7, 129.3, 128.3, 126.2, 123.6, 117.3, (12C, 2 C6H5), 101.5 
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(CHPh), 99.3 (Glc-C1), 98.4 (Gal-C1), 92.4 (CCl3), 78.7 (Glc-C4), 75.9 (Glc-C3), 71.0 
(Gal-C3), 70.7 (Gal-C5), 68.9 (Gal-C2), 68.5 (Glc-C6), 66.9 (Gal-C4), 66.4 Glc-C5), 61.3 
(Gal-C6), 58.5 (Glc-C2), 20.7, 20.6, 20.6, 20.5 (4 COCH3); ESI-MS: m/z calcd for 
C35H38Cl3NO15 [M+Na]+: 840.12, found: 840.36; Anal. calcd: C, 51.33; H, 4.68; N, 1.71; 
found: C, 51.13; H, 4.68; N, 1.54. 
  
Phenyl (2,3,4,6-tetra-O-acetyl-!-D-galactopyranosyl)-(1'3)-6-O-benzyl-2-deoxy-2-tri-
chloroacetamido-!-D-glucopyranoside (8). To a solution of 7 (800 mg, 0.98 mmol) in dry 
THF (20 mL) were added successively borane-trimethylamine complex (285 mg, 3.90 mmol) 
and AlCl3 (780 mg, 5.85 mmol) at rt. After 15 h water (20 mL) was carefully added followed 
by 1 N HCl (10 mL). The mixture was extracted with EtOAc (3 ) 30 mL), and the combined 
organic layers were washed with water (20 mL) and brine (15 mL), dried with Na2SO4, and 
concentrated. Column chromatography of the residue on silica (petrol ether/EtOAc, 2:1) gave 
8 (615 mg, 77%). 
["]D20 -15.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.30-7.14 (m, 8H, Ar-H, NH), 
6.97-6.90 (m, 3H, Ar-H), 5.30 (s, 1H, Gal-H4), 5.25 (dd, J = 3.2, 8.2 Hz, 1H, Glc-H1), 5.19 
(dd, J = 8.8, 10.4, 1H, Gal-H2), 4.87 (dd, J = 3.4, 10.5 Hz, 1H, Gal-H3), 4.54 (d, J = 7.5 Hz, 
1H, Gal-H1), 4.51 (s, 2H, CH2Ph), 4.22 (m, 1H, Glc-H3), 4.04 (m, 1H, Glc-H6a), 3.94 (t,  
J = 6.5 Hz, 1H, Gal-H5), 3.85 (d, J = 10.3 Hz, 1H, Glc-H6a), 3.72 (m, 1H, Glc-H2), 3.66-
3.53 (m, 3H, Glc-H4, -H5, -H6b), 2.07, 2.02, 1.95, 1.89 (4 s, 12H, 4 COCH3); 13C NMR (125 
MHz, CDCl3): ! 170.5, 170.2, 170.1, 169.6 (4 COCH3), 162.3 (COCCl3), 157.1, 138.2, 
129.6, 128.3, 127.6, 127.5, 123.3, 117.2 (12C, 2 C6H5), 100.8 (Gal-C1), 97.9 (Glc-C1), 92.4 
(CCl3), 82.5 (Glc-C3), 75.7 (Glc-C5), 73.5 (CH2Ph), 71.1 (Gal-C5), 70.9 (Gal-C3), 69.4 
(Glc-C6), 69.3 (Glc-C4), 68.5 (Gal-C2), 66.9 (Gal-C4), 61.2 (Gal-C6), 57.8 (Glc-C2), 21.0, 
20.6, 20.6, 20.5 (4 COCH3); ESI-MS: m/z calcd for C35H40Cl3NO15 [M+Na]+: 842.14, found: 
842.28; Anal. calcd: C, 51.20; H, 4.91; N, 1.71; found: C, 51.13; H, 4.90; N, 1.51. 
  
Phenyl (2,3,4,6-tetra-O-acetyl-!-D-galactopyranosyl)-(1'3)-[(2,3,4-tri-O-benyl-6-deoxy-
"-L-galactopyranosyl-(1'4)]-6-O-benzyl-2-deoxy-2-trichloroacetamido-!-D-gluco-
pyranoside (9). To a solution of 10 (525 mg, 1.10 mmol) in DCM (5 mL) was added 
bromine (60 µL, 1.21 mmol) at 0°C under argon.  After 5 min, the cooling bath was removed 
and the reaction mixture was stirred for 30 min at rt. Then cyclohexene (100 µL) was added 
to destroy the excess bromine. The reaction mixture was added to a pre-stirred suspension 
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(2 h, rt) of 8 (300 mg, 0.37 mmol), Et4NBr (160 mg, 0.76 mmol) and powdered molecular 
sieves 4Å in DCM (2.5 mL) and DMF (10 mL). After stirring overnight, the reaction mixture 
was filtered, diluted with DCM (30 mL) and washed with aq. NaHCO3 (20 mL) and brine 
(20 mL). The organic layer was dried (Na2SO4), filtered, and evaporated to dryness. The 
residue was purified by chromatography on silica (petrol ether/EtOAc/MeOH, 8:1.8:0.2) to 
yield 9 (225 mg, 0.18 mmol, 49 %). 
["]D20 -29.6 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.32 (d, J = 7.2 Hz, 2H, Ar-H), 
7.30-7.11 (m, 20H, Ar-H), 7.07 (d, J = 8.2 Hz, 1H, NH), 6.96 (d, J = 7.4 Hz, 1H, Ar-H), 6.95-
6.90 (m, 2H, Ar-H), 5.30 (d, J = 3.1 Hz, 1H, Gal-H4), 5.21 (d, J = 6.1 Hz, 1H, Glc-H1), 5.13 
(dd, J = 8.1, 10.5 Hz, 1H, Gal-H2), 5.04 (d, J = 3.9 Hz, 1H, Fuc-H1), 4.93-4.86 (m, 2H, Gal-
H3, CH2Ph), 4.81 (d, J = 8.1 Hz, 1H, Gal-H1), 4.75-4.67 (m, 3H, 3H of CH2Ph), 4.63 (d, J = 
11.8 Hz, 1H, CH2Ph), 4.57 (d, J = 11.4 Hz, 1H, CH2Ph), 4.34 (s, 2H, CH2Ph), 4.25 (q, J = 6.3 
Hz, 1H, Fuc-H5), 4.11-4.01 (m, 5H, Fuc-H2, -H3, Glc-H2, -H3, Gal-H6a), 3.98 (dd, J = 5.9, 
11.0 Hz, 1H, Gal-H6b), 3.86-3.81 (m, 3H, Gal-H5, Glc-H4, -H5), 3.72 (dd, J = 4.7, 10.6 Hz, 
1H, Glc-H6a), 3.67-3.62 (m, 2H, Fuc-H4, Glc-H6b), 1.98, 1.93, 1.88, 1.87 (4 s, 12H, 4 
COCH3), 1.18 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C NMR (125 MHz, CDCl3): ! 170.2, 170.0, 
170.0, 169.5 (4 COCH3), 161.8 (COCCl3), 156.9, 138.6, 138.5, 138.2, 138.1, 129.6, 128.5, 
128.4, 128.4, 128.3, 128.3, 127.9, 127.7, 127.6, 127.5, 127.1, 123.0, 117.0 (30C, 5 C6H5), 
100.0 (Gal-C1), 97.8 (Glc-C1), 96.5 (Fuc-C1), 92.3 (CCl3), 80.2 (Glc-C4), 76.8 (Fuc-C4), 
76.5 (Glc-C3), 75.7 (Fuc-C3), 74.8 (Gal-C5), 74.6, 74.5, 73.2, 72.4 (4 CH2Ph), 71.2 (Fuc-
C2), 70.9 (Glc-C5), 70.8 (Gal-C3), 68.6 (Glc-C6), 68.3 (Gal-C2), 66.9 (2C, Fuc-C5, Gal-C4), 
60.5 (Gal-C6), 55.9 (Glc-C2), 20.8, 20.7, 20.6, 20.5 (4 COCH3), 16.9 (Fuc-C6); ESI-MS: m/z 
calcd for C62H68Cl3NO19 [M+Na]+: 1258.33; found: 1258.29; Anal. calcd: C, 60.17; H, 5.54; 
N, 1.13; found: C, 59.95; H, 5.58; N, 0.90. 
  
Phenyl !-D-galactopyranosyl-(1'3)-["-L-fucopyranosyl-(1'4)]-2-acetamido-2-deoxy-
!-D-glucopyranoside (4). To a solution of 9 (225 mg, 0.18 mmol) in MeOH (10 mL) was 
added a catalytic amount of NaOMe at rt. After stirring for 30 min the mixture was 
neutralized with AcOH and evaporated to dryness. Column chromatography on silica (petrol 
ether/EtOAc/MeOH, 6:3.6:0.4) afforded the benzylated intermediate (185 mg, 94%). A 
mixture of the intermediate (185 mg, 0.17 mmol), Pd(OH)2/C (50 mg) and NEt3 (100 &L) in 
dioxane/water (4:1, 10 mL) was hydrogenated (4 bar H2) in a Parr shaker for 5 h. ESI-MS 
analysis indicated complete reduction of the trichloroacetamide group to the acetamide. The 
mixture was filtered over celite and the filtrate was concentrated. The residue was dissolved 
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in dioxane/water (4:1, 10 mL), Pd(OH)2/C (50 mg) was added and the mixture was 
hydrogenated (4 bar H2) for 24 h. The catalyst was filtered off and the solution was 
concentrated under reduced pressure. The residue was purified by preparative LCMS to 
afford 4 (100 mg, 92%). 
["]D20 -56.1 (c 1.00, MeOH); 1H NMR (500 MHz, D2O): ! 7.35-7.30 (m, 2H, Ar-H), 7.08 (t, 
J = 7.4 Hz, 1H, Ar-H), 7.02 (d, J = 7.8 Hz, 2H, Ar-H), 5.10  (d, J = 8.1 Hz, 1H, Glc-H1), 4.99 
(d, J = 3.9 Hz, 1H, Fuc-H1), 4.83 (q, J = 6.6 Hz, 1H, Fuc-H5), 4.46 (d, J = 7.7 Hz, 1H, Gal-
H1), 4.15-4.08 (m, 2H, Glc-H2, -H3), 3.94 (dd, J = 2.0, 12.5 Hz, 1H, Glc-H6a), 3.86-3.80 (m, 
3H, Fuc-H3, Glc-H6b, Gal-H4), 3.80-3.73 (m, 3H, Glc-H4, Fuc-H2, -H4), 3.70-3.63 (m, 3H, 
Gal-H6, Glc-H5), 3.56 (dd, J = 3.4, 9.8 Hz, 1H, Gal-H3), 3.51 (dd, J = 4.9, 7.0 Hz, 1H, Gal-
H5), 3.45 (dd, J = 7.7, 9.8 Hz, 1H, Gal-H2), 1.95 (s, 3H, COCH3), 1.14 (d, J = 6.6 Hz, 3H, 
Fuc-H6); 13C NMR (125 MHz, D2O): ! 174.7 (CO), 156.8, 130.0, 123.5, 116.7 (6C, C6H5), 
102.9 (Gal-C1), 99.5 (Glc-C1), 98.1 (Fuc-C1), 75.9 (Glc-C3), 75.6 (Glc-C5), 74.8 (Gal-C5), 
72.3 (Gal-C3), 72.2 (Fuc-C4), 72.0 (Fuc-C2), 70.5 (Gal-C2), 69.2 (Fuc-C3), 68.4 (Gal-C4), 
67.8 (Glc-C4), 66.9 (Fuc-C5), 61.7 (Gal-C6), 59.6 (Glc-C6), 55.7 (Glc-C2), 22.2 (CH3), 15.4 
(Fuc-C6); HRMS: m/z calcd for C26H39NO15 [M+Na]+: 628.2212, found: 628.2211. 
Compound purity: 99.0 % (Rt 7.73 min, * 168-216 nm; HPLC system: Beckmann Gold; 
Column: Waters Atlantis dC18, 3&m, 4.6 ) 75mm; Mobile phase: A: H2O + 0.1% HCO2H; 
B: MeCN + 0.1% HCO2H; Gradient: 5% B ' 50% B over 20 min; Flow rate: 0.5 ml/min). 
  
2. Isothermal Titration Calorimetry (ITC) 
0 2 4 6 8 10 12 14
-1.00
-0.80
-0.60
-0.40
-0.20
0.00
-0.60
-0.40
-0.20
0.00
-50 0 50 100 150 200 250 300 350 400 450 500
Time (min)
!c
al
/s
ec
Molar Ratio
K
C
al
/M
ol
e 
of
 In
je
ct
an
t
 
Figure S1. ITC profile of phenyl Lea (4) titrated into DC-SIGN CRD-Fc.  
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Table S1. Thermodynamics of phenyl Lea binding to DC-SIGN CRD-Fc. Confidence intervals (95%) of the fit 
were within the standard deviations. a Stoichiometry fixed at 1; concentration expressed in terms of binding site.  
Compound N KD [&M] 'G° [kJ/mol] 'H° [kJ/mol] T'S° [kJ/mol] 
Phenyl Lea (4) 1a 582 ± 40 -18.5 ± 0.1 -28.0 ± 2.0 - 9.5 ± 2.1 
 
3. Saturation Transfer Difference (STD) NMR 
 
 
 
Figure S2. STD and reference NMR spectra of methyl Lea (2) (top) and phenyl Lea (4) (bottom) in presence of 
DC-SIGN CRD-Fc. 
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Figure S3. STD and reference NMR spectra of methyl Lex (1) (top) and phenyl Lex (3) (bottom) in presence of 
DC-SIGN CRD-Fc. 
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Table S2. Approximate percentage values determined from STD NMR spectra in presence of 
DC-SIGN CRD-Fc; “-“ protons show potentially STD signals, however, no quantification could be 
unambiguously achieved due to signal overlap or interference with water suppression. 
 Aglycones D-GlcNAc 
 Methyl Phenyl H1 H2 H3 H4 H5 H6 NAc 
Methyl Lea (2) 40%  - <40% <40% 65% 74% <45% 40% 
Methyl Lex (1) 30%  - <40% <40% 70-75% 70% - 123% 
Phenyl Lea (4)  140-205% - 164% 164% <127% - <148% 122% 
Phenyl Lex (3)  130-160% - - 100% - - - 190% 
 
 L-Fuc 
 H1 H2 H3 H4 H5 H6 
Methyl Lea (2) - 187% 106% 121% - 100% 
Methyl Lex (1) - 175% 95% 175% - 100% 
Phenyl Lea (4) - 218% 136% 218% - 100% 
Phenyl Lex (3) - - - 160% - 100% 
 
 D-Gal 
 H1 H2 H3 H4 H5 H6 
Methyl Lea (2) - 75% 60% <40% 75% - 
Methyl Lex (1) - 43% 67% 100% 71% - 
Phenyl Lea (4) - 82% 91% 133% 100% - 
Phenyl Lex (3) - 80% 80% - 80% - 
 
 
Experiments at different saturation times with phenyl Lea (4) 
The total recycle delay time was kept constant and the saturation time set to 0.7, 1, 2, and 3s. 
We determined relative STD intensities for specific protons of phenyl Lea (4) and compared 
the values to exclude T1 bias of different proton types (Table S4). In conclusion, different 
saturation times do not affect the intensity of aromatic protons and the overall binding 
epitope significantly. 
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Table S3. Ratio (STD/reference signal) determined from STD NMR spectra in presence of DC-SIGN CRD. The 
signals were normalized to the para aryl proton. For short saturation times STD effect is weak and signal of 
carbohydrate protons could not be determined doubtlessly. 
saturation time [s] 0.7 1 2 3 
Aryl H (meta)  0.8 0.9 0.8 0.9 
Aryl H (para)  1.0 1.0 1.0 1.0 
Aryl H (ortho)  0.7 0.7 0.7 0.8 
Gal-H2  - - 0.6 0.6 
NAc (CH3)  0.6 0.8 0.6 0.6 
Fuc-H6  0.7 0.6 0.5 0.5 
 
 
4. Molecular Dynamics 
 
 
 
Figure S4. Time evolution of inter-proton distance between each of the phenyl protons of phenyl Lewisa (4) and 
the closest proton of neighboring protein side chains in a 6 ns molecular dynamics simulation. 
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2.3    Synthesis of Glycomimetic Antagonists for DC-SIGN 
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2.3.1 Manuscript 2: Lex Mimics: The Role of N-Acetylglucosamine and 
D-Galactose in Binding to DC-SIGN 
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Lex Mimics: The Role of N-Acetylglucosamine and D-Galactose in Binding 
to DC-SIGN 
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Abbreviations: AIBN, Azodiisobutyrodinitrile; CAN, ceric ammonium nitrate; Cy, 
Cyclohexyl; DC, dendritic cells; DCE, 1,2-dichloroethane; DC-SIGN, DC-specific ICAM-3-
grabbing nonintegrin; DMF, N,N-dimethylformamide; DMTST, dimethyl(methylthio)-
sulfonium triflate; Fuc, fucose; LNFP III, lacto-N-fucopentaose III; Gal, galactose; GlcNAc , 
N-acetylglucosamine; HPLC, high-performance liquid chromatography; IC50, halfmaximal 
inhibitory concentration; ICAM, intercellular adhesion molecule; ITC, isothermal titration 
calorimetry; Lex, Lewisx ; MHC, major histocompatibility complex; MS, molecular sieves; 
NMR, nuclear magnetic resonance; TES, triethylsilane; TBAB, tetrabutylammonium 
bromide; TCDI, N,N-thiocarbonyl diimidazole; TLC, thin layer chromatography; TMSE, 2-
(trimethylsilyl)ethyl; TMSOTf, trimethylsilyl triflate; Ts, tosyl. 
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ABSTRACT 
As part of the innate immune system, dendritic cells (DCs) have the function of presenting 
antigens to other processing cells of the immune system, in paticular T-cells. 
DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN), one of the transmembrane receptors 
in DCs, is a C-type lectin and recognizes oligomannosides and fucose-containing Lewis 
blood group antigens, such as Lewisx (Lex), in a Ca2+ dependent manner. These structures are 
present in a series of pathogens, including viruses, bacteria, and yeasts. Many 
microorganisms evade the normal degradation mechanisms by binding to DC-SIGN and 
furthermore, exploit this interaction to efficiently infect the host. A blockage of this first 
interaction with appropriate DC-SIGN antagonists is therefore a promising therapeutic 
approach towards prevention of infectious diseases. 
Co-crystallization of DC-SIGN with Lex as part of lacto-N-fucopentaose III indicates that the 
terminal sugar residues D-Gal and L-Fuc are involved in binding, whereas the linking sugar 
D-GlcNAc is directed towards the solvent. L-Fuc is crucial for coordination of the Ca2+ ion in 
the binding site. In this study, we investigated the role Gal and D-GlcNAc in Lex-type 
structures for binding to DC-SIGN.  
We synthesized a series of trisaccharide mimics of Lex in which D-GlcNAc is replaced by a 
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol moiety. Variations of the D-Gal moiety include 
deoxy D-Gal derivatives as well as the D-Glc (epimer to D-Gal in the 4-position). 
Additionally, a disaccharide mimic without the respective D-Gal moiety was synthesized. 
Binding affinities obtained in a static cell-free competition assay and ITC data indicate a 
minor influence of 4- and 6-OH of Gal in Lex mimics binding to DC-SIGN. Furthermore, the 
affinity was improved by replacing the D-GlcNAc mimic with a methylcyclohexyl based 
mimic. ITC data of Lex and mimics indicated affinity in the low milimolar range and 
elucidated the thermodynamic properties of this interaction. Based on this information DC-
SIGN ligands with improved binding affinity and reduced structural complexity can be 
designed. 
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INTRODUCTION 
Immature dendritic cells (DCs), located in mucosal tissue, play an essential role in immune 
response as they are antigen-presenting cells.1 In general, pathogen-uptake initiates 
maturation and migration of the DC to the lymphatic system where the antigen is presented 
on the major histocompatibility complex (MHC) to resting T-cells.  
DC-specific ICAM-3-grabbing nonintegrin (DC-SIGN), located on the surface of DCs, was 
discovered to be one of the main receptors for recognition and internalization of pathogens.2 
DC-SIGN is a type II transmembrane protein with a C-terminal carbohydrate recognition 
domain (CRD). As member of the C-type lectin family, binding to DC-SIGN occurs in a 
Ca2+-dependent manner. Besides its function as a cell-adhesion receptor for the control of DC 
migration via intercellular adhesion molecule-2 (ICAM-2), DC-SIGN regulates the  
DC–T-cell interactions via ICAM-3 which is located on the surface of T-cells.2,3 The latter 
fact indicates the significant role of DC-SIGN in development of an immune response. A 
broad variety of pathogens including viruses (e.g. HIV, Ebola virus)4,5, bacteria (e.g. 
Mycobacterium tuberculosis, Helicobacter pylori)6,7, and yeasts (e.g. Candida albicans)8 
evolved mechanisms to evade the immune response. One major measure is making beneficial 
use of the interaction with DC-SIGN for an efficient establishment of infection.9,10 The 
mechanisms cover a multitude of simultaneous and ligand-specific processes including 
alteration of Toll-like receptor-mediated signaling cascades.11-13 The design of DC-SIGN 
ligands that can block the initial interaction with pathogens is a promising therapeutic 
approach towards prevention of infectious diseases.14 
The majority of pathogens bind with N-linked high-mannose oligosaccharides to DC-SIGN.15 
An established example for this is HIV that contains this mannan structure on its gp120 
envelope protein.16,17 HIV and Ebola were shown to escape the DC-mediated degradation 
mechanism.9,18-25 In fact, binding of these viruses to DC-SIGN rather triggers the effective 
trans-infection of T-cells via viral synapses.5,15,26  
Besides mannosylated structures, the L-Fuc embodying Lewis blood group antigens such as 
Lewisx (Lex, Gal!(1-4)[Fuc"(1-3)]GlcNAc) 1, prevalent on Schistosoma mansoni or 
Helicobacter pylori, are recognized by DC-SIGN.27 Naarding and Geijtenbeek showed that 
human milk containing Lex (1) in a multimeric manner inhibits HIV-1 gp120 binding to the 
CRD of DC-SIGN and the subsequent trans-infection of CD4+ T-cells.28 The minimal 
binding epitope for DC-SIGN is the Lex trisaccharide (1).28-31 Crystallographic data obtained 
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from DC-SIGN co-crystallized with lacto-N-fucopentaose III (LNFP III, Lex-D-Gal-D-Glc) 
that contains the Lex motif, revealed the " 1-3-linked L-Fuc coordinating the Ca2+ ion via its 
equatorial 3- and axial 4-OH group.29 The 2-OH of L-Fuc is positioned close to Val351 
allowing a van der Waals contact. Likewise, the NAc group in D-GlcNAc moiety of Lex 
forms a hydrophobic contact with Val351, which represents the only interaction with the 
protein mediated by this moiety. D-Gal is involved in a water-bridged H-bond of the 4-OH to 
Glu358 and direct H-bond of 6-OH with Asp367.29 Asp367 on its part is involved in a 
H-bond network with Glu358 and Lys373 (Figure 1).  
 
 
Figure 1. Binding mode of the resolved part of LNFP III derived from co-crystallization with DC-SIGN 
(PDB 1SL529). The Asp367-Lys373-Glu358 H-bonding network involved in D-Gal binding is highlighted. 
L-Fuc complexes the Ca2+ ion via its 3- and 4-OH, 2-OH of L-Fuc establishes a water bridged H-bond to Asp367 
and makes van der Waals contact with Val351 (not shown). 
 
Carbohydrates are highly polar, known to have unfavorable properties for drug development 
with respect to their pharmacokinetic and pharmacodynamic properties. Therefore, 
glycomimetics with reduced polarity but retained biological function are developed.32 In this 
study, we mimic one of the sugar moieties in Lex to improve the drug-like properties and 
affinity. We have previously shown that in case of E-selectin, replacement of the D-GlcNAc 
part of sialyl Lex with different cyclohexanediol derivatives improves the affinity in a static 
competitive binding assay up to a factor of 20.33,34 The D-GlcNAc motif mainly has the role 
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of a spacer that keeps the two residues at its 3- and 4-position (namely L-Fuc and D-Gal) in 
the correct spatial orientation, i.e. a conformation close to the bioactive conformation.35,36 
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol showed better preorganization of the core 
structure than a cyclohexanediol unit and hence higher affinity.33,37 
In a first approach, we attempted to apply these findings to the Lex–DC-SIGN interaction by 
replacing the D-GlcNAc part of the Lex trisaccharide by a (1R,2R,3S)-3-methyl-cyclohexane-
1,2-diol (Figure 2).  
 
 
Figure 2. Lex trisaccharide and general trisaccharide mimic. 
 
Moreover, to investigate the role of D-Gal in binding to DC-SIGN, we synthesized Lex 
mimics containing 2-, 3-, 4-, and 6-deoxygenated D-Gal moieties, the 4-OH epimeric 
compound (' D-Glc), as well as the respective disaccharide mimic lacking the D-Gal moiety 
entirely. These mimics were evaluated by means of a static competitive binding assay for 
affinity to DC-SIGN CRD. Selected compounds were additionally tested with isothermal 
titration calorimetry (ITC) to determine KD values and the thermodynamic profile of this 
interaction. With molecular modeling studies the experimental results were structurally 
interpreted. 
Information on the interactions between ligand and protein is essential for further 
development of high-affinity low molecular weight compounds, which can serve as starting 
point for a lead optimization program. 
 
RESULTS & DISCUSSION 
Synthesis of Lex mimics 
Retrosynthetically, the trisaccharide mimic 8 can be disconnected into the D-Gal derivative 
636,38 and the pseudo-disaccharide 533. Following an established route, the D-GlcNAc mimic 3 
is obtained in a 6-step synthesis starting from 2-cyclohexen-1-one (2).33 Fucosylation by in 
situ bromination of the thiofucoside 4 yielded the "-fucoside 5 which was glycosylated with 
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galactosyl donor 6 using dimethyl-(methylthio)sulfonium triflate (DMTST) as promoter. 
Subsequent deprotection yielded the trisaccharide mimic 8 (Scheme 1). 
 
Scheme 1. a) Prepared according to reference33; b) i) TBAB, 2,6-di-tert-butyl-4-methylpyridine, MS 4Å, CuBr2, 
DMF, CH2Cl2, r.t., 20 h, 43%; ii) ZnBr2, TES, CH2Cl2, r.t., 10 h, 63%, c) DMTST, MS 4Å, CH2Cl2, r.t., 16 h, 
49%; d)  Pd(OH)2/C, dioxane/water, ii) NaOMe, MeOH, 70%. 
 
A similar approach can be applied for the synthesis of the deoxy trisaccharide mimics. The 
synthesis of the respective 2-, 3-, 4-, and 6-deoxy D-Gal thioglycosides is described in the 
following. The 2-deoxy D-Gal derivative was prepared by reacting the peracetylated 
D-galactal (9) with thioethanol in the presence of ceric ammonium nitrate, following a 
published procedure39 (Scheme 2). In order to increase the yield in the later glycosylation 
step compound 10 was transformed into the armed perbenzylated derivative 11.  
 
 
Scheme 2. a) CAN, EtSH, CH2Cl2, 0°C to r.t., 1h, 58%; b) i) NaOMe, MeOH, r.t., 98%; ii) BnBr, DMF, 0°C to 
r.t., 72%. 
 
For all other D-Gal derivatives, participating neighboring groups in 2-position were 
introduced in order to favor !-glycosylation. For the synthesis of the 4-deoxy derivative 17, 
ethyl thiogalactoside 12 served as starting material. Following a published procedure the 
4,6-benzylidene acteal was formed and the 2- and 3-OH groups were benzoylated. After 
subsequent acetal cleavage and benzoylation in the 6-position, the 4-O-unprotected D-Gal 
derivative 15 was obtained.40 Application of standard Barton McCombie deoxygenation 
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condition, namely derivatization to the imidazolyl thiocarbamate (16) by use of 
N,N-thiocarbonyl diimidazole (TCDI) and subsequent deoxygenation with tributyltin hydride, 
afforded the 4-deoxy compound 17 in good yield (Scheme 3). 
 
Scheme 3. a) ","-Dimethoxytoluene, TsOH, CH3CN, 80%; b) BzCl, pyridine, 80%; c) i) ethylene glycol, 
CH2Cl2/TFA (5:1), ii) BzCl, pyridine, 79%; d) TCDI, dichloroethane, 4h, %, 90%;  e) Bu3SnH, AIBN, PhCH3, 
4h, %, 93%; 
 
The 3- and 6-deoxy D-Gal derivatives were synthesized from the 2-(trimethylsilyl)ethyl 
(TMSE) galactoside 1841. For the deoxygenation leading to the 3-deoxy derivative 24, Barton 
McCombieconditions were applied. Therefore, compound 20 was synthesized using a 
sequence of 3-selective benzylation via tin acetal formation ('19), followed by benzoylation 
of the residual OH-groups. Removal of benzyl in 3-position gave access to compound 21 that 
was deoxygenated as described above to give 3-deoxy derivative 23. Transformation of the 
TMSE aglycone into the thioglycoside was performed using boron trifluoride etherate for the 
transformation into the acetate and subsequently the thiophenyl derivative 24 (Scheme 4). 
 
 
Scheme 4. a) Bu2SnO, BnBr, Bu4NBr, PhCH3, (, 62%; b) BzCl, pyridine, CH2Cl2, 3h, 92%; c) NaBrO3, 
Na2S2O4, EtOAc/H2O, r.t., 2h, 89%, or Pd(OH)2/C,  dioxane/H2O, 1d, 95%; d) TCDI, DCE, (, 4-6h, 92%; e) 
Bu3SnH, AIBN, PhCH3, (, 4h, 86%; f) i) Ac2O, BF3·Et2O, PhCH3, 80% ("/!, 4:3), ii) PhSH, BF3·Et2O, CH2Cl2, 
68% ("/!, 1:1). 
 
The synthetic approach towards the 6-deoxy derivative 28 is shown in Scheme 5. 
6-O-selective tosylation ('25) with subsequent reduction of the tosyl group by means of 
lithium aluminium hydride afforded the fucoside 26. Benzoylation ('27) and transformation 
of the TMSE aglycon into thiophenyl afforded the 6-deoxy derivative 28. 
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Scheme 5. a) TsCl, pyridine, 0°C, 87%; b) LiAlH4, THF, (, 72%; c) BzCl, pyridine, 96%; d) i) Ac2O, 
BF3·Et2O, pyridine, 99%, ii) PhSH, BF3·Et2O, CH2Cl2, 47%. 
 
The pseudo-disaccharide 5 was glycosylated with the deoxy D-Gal donors 17, 24, 28 and the 
D-Glc derivative 2942 using DMTST as promoter yielding predominantly the !-glycosides 
(Scheme 6). For the 2-deoxy D-Gal derivative 11 missing a participating neighboring group 
in the 2-position, low temperature and low concentration with acetonitrile as assisting 
solvent43 were applied to obtain the protected !-glycosylated trisaccharide mimic 31 although 
in moderate yield. The final deprotection of the trisaccharide mimics 30-34 was performed 
using standard Zemplén conditions and hydrogenolysis with Pd(OH)2/C as catalyst to afford 
compounds 35-39 (Scheme 6).  
 
 
Scheme 6. Typical procedure for glycosylation and deprotection: glycosyl acceptor 5, donors 6, 17, 24, 28, and 
29, DMTST, MS 4Å, CH2Cl2, r.t., 16-24 h, 48-75% i) Pd(OH)2/C, dioxane/water, ii) NaOMe, MeOH 68-81%; 
conditions for donor 11: NIS, TMSOTf, MS 3Å, - 65°C, 1h, 14% (over two steps). 
The pseudo disaccharide 5 was accordingly treated with hydrogenolytic conditions to give 
the respective pseudo-disaccharide 40 (Scheme 7). 
O
RO
RO
OR
OTMSE
18
c)
26: R = H
27: R = Bz
O
HO
HO
OH
OTMSE
OH
O
HO
HO
OH
OTMSE
OTs
a) b) O
BzO
BzO
OBz
SPh
25 28
d)
6 29
R1 R2
OBz
OAc OAc
H
7
30
31
R3 R4
OBz
OAc H
H
R5
OBz
OAc
OBn
OBz H
H
OBz OBz
OBz OBz
32
33
34
OBz
H H
H OBz
OBz
H
OBz H
OBn OBn
OBz
R1 R2
OH
OH OH
H
8
35
36
R3 R4
OH
OH H
H
R5
OH
OH
OH H
H
OH OH
OH
37
38
39
OH
H H
H
OH
H
OH H
OH OH
OH
OH OH
OH
O
BzO
BzO
OBz
SPh
28
O
BzO
OBz
SPh
OBz
24
O
BzO
OBz
SEt
OBz
17
O
BnO
BnO SEt
OBn
11
O
BzO
BzO
OBz
SEt
OBn
OAcO
AcO
OAc
SEt
OAc
O
BnO
OBn
OBn
O
HO
5
a)
O
R4
R5
R1
O
BnO
OBn
OBn
O
OR2
b)
R3 O
R4
R5
R1
O
HO
OH
OH
O
OR2
R3
DC-SIGN 2.3.1 – Manuscript 2 
71 
 
 
Scheme 7. Deprotection of pseudodisaccharide 5. a) Pd(OH)2/C, dioxane/water, 1h, 91%. 
 
Docking of compounds and FEP calculations 
Automated docking (Glide44) of the Lex trisaccharide (1) and compound 8 (Figure 3) resulted 
in a binding mode similar to that of the Lex subunit in LNFP III in complex with DC-SIGN 
(see Figure 1). Mimicking the D-GlcNAc moiety, as expected, does not affect the binding 
mode since this part points to the solvent. The calcium ion is coordinated via the 3- and 4-OH 
group of L-Fuc, D-Gal participates in (water assisted) H-bonds. The NAc group in D-GlcNAc 
establishes a van der Waals contact with Val351. The same interaction is seen for the methyl 
group in 8 causing a minor reorientation of this amino acid side chain. 
 
Figure 3. Lex (1)  and Lex mimic (8) docked in 1SL5 maintain the orientation and interaction as the Lex subunit 
in LNFP III (compare Figure 1).29 
 
Likewise, the top-ranked binding pose of the pseudo-disaccharide 40 resembles the discussed 
binding mode for 1 and 8, i.e. L-Fuc coordinates the Ca2+ via its 3- and 4-OH (Figure 4). Due 
to the upright orientation no further contacts with the protein are established. 
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Figure 4. The pseudo-disaccharide 40 docked to the crystal structure of DC-SIGN (PDB 1SL5). Top-ranked 
pose resembles the orientation of the Lex subunit in LNFP III (see Figure 1).29 
 
We further performed free energy perturbation (FEP) calculations that show the influence of 
small structural changes on free binding energy. Therefore, mimic 8 was compared with its 
respective 3-, 4-, and 6-deoxy analogues (37, 38, 39). Two-nanosecond FEP simulations were 
performed starting from the docking pose found for 8. Results for ''G are shown in Table 1. 
Whereas 3-deoxygenation is predicted to marginally increase affinity, lacking of the 
OH-group in the 4- or 6-position is considered to decrease affinity by a factor of 3.5 and 2, 
respectively.  The predicted influence of the 4- and 6-OH group in binding to DC-SIGN 
correlates with crystallographic data. 
 
Table 1. 2.0 ns FEP simulation were performed to 
quantify the theoretical effect of deoxygenation, 
calculated ((G values are presented. 
Compound Estimated !!G vs. mimic 29 [kcal/mol] 
29 
direct Lewisx mimic –––– 
32 
 3-deoxy 
-0.13 ± 0.27 
(<1.3x increase in affinity) 
33 
 4-deoxy 
0.77 ± 0.22 
(~3.5x drop in affinity) 
34 
 6-deoxy 
0.49 ± 0.26 
(~2.2x drop in affinity) 
 
Binding Affinity 
Compounds 1, 8 and 35-40 were tested in a static competitive polymer binding assay with 
biotinylated polyacrylamide glycopolymer (Gal!(1-3)[Fuc$(1-4)]GlcNAc!-polyacrylamide, 
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Lea-PAA) as competitor for binding to DC-SIGN CRD-Fc. The affinities (IC50) listed in 
Table 2 were measured three times as duplicates. To ensure comparability of the experiments, 
the reference compound L-Fuc was tested in parallel on each individual microtiter plate. 
Despite the rather high deviation, the relative values from one experiment to another were 
consistent (data not shown).  
 
Table 2. IC50 values for binding to DC-SIGN CRD-Fc were determined in a target-based polymer 
binding assay for Lex (1) and the mimics 8 and 35-40 vs. biotinylated Lea-polyacrylamide polymer 
(Lea-PAA). ITC experiments were performed as single determination for 8, 39, 40 and duplicate for 1 
indicating a good reproducibility of the calorimetric experiment (entry 1); “n.d.” = not determined. 
Entry Structure 
IC50 
[mM] 
KD 
["M] 
"G° 
[kJ/mol] 
"H° 
[kJ/mol] 
-T"S° 
[kJ/mol] 
1 
 
3.8 (n=1) 
1068 ± 13 
(n=2) 
-17.0 ± 0.0 -23.8 ± 0.3 +6.9 ± 0.3 
2 
 
1.9 ± 0.4 645 -18.2 ± 0.5 -31.4 +13.2 
3 
 
1.8 ± 0.5 n.d. n.d. n.d. n.d. 
4 
 
2.5 ± 0.3 n.d. n.d. n.d. n.d. 
5 
 
2.1 ± 0.5 n.d. n.d. n.d. n.d. 
6 
 
2.9 ± 0.7 n.d. n.d. n.d. n.d. 
7 
 
4.7 ± 0.9 1277 -16.5 -29.7 +13.2 
8 
 
3.2 ± 0.8 1073 -16.9  -34.4 +17.5 
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All compounds bind in the low millimolar range with the highest affinities in this series for 8 
and 35 (Table 2, entry 2 and 3) and the lowest for 39 (Table 2, entry 7). Compared to Lex (1), 
the substitution of D-GlcNAc for a cyclohexanediol moiety (1'8) results in an affinity 
improvement by a factor of 2. Moreover, our data indicate that deoxygenation in 2- or 
3-position of D-Gal ('36, '37) does not affect binding affinity significantly. Also changing 
D-Gal to D-Glc ('35) does not impair binding affinity. A slight drop in affinity is observed 
for the 4-deoxygenated compound ('38), and a more apparent drop when deoxygenated in 
the 6-position ('39). These results are in accordance with crystallographic data that imply 
these two hydroxyl groups being involved in a hydrogen bond network.29 Our FEP 
calculations agree with these results within experimental accuracy. Hence, this provides 
further evidence that this group of deoxy Lex mimics binds DC-SIGN in the same orientation 
as observed in the LNFP III complex (1SL5). Nevertheless, the interaction of 4- and 6-OH of 
D-Gal with the protein is presumably rather weak, since a drop by a factor of only 2.5 is 
observed. To confirm this hypothesis we tested as well the disaccharide mimic 40 lacking the 
D-Gal moiety. In fact, binding is not abolished but comparable to Lex (1). A comparison with 
the 6-deoxy compound shows that affinity is regained. Bernardi et al. arrived at a similar 
conclusion with a series of  "-fucosylamides. The compounds lacking a D-Gal-like residue 
but still containing the L-Fuc moiety still show selective inhibition of DC-SIGN.45,46 
To get a deeper insight into the binding thermodynamics of Lex (1), 8, 39, and 40 to DC-
SIGN, ITC experiments were performed. In Table 2, KD values and the thermodynamic 
fingerprints are summarized (entry 1, 2, 7, and 8). Overall, the above discussed trend in 
affinity is supported by the KD values. Lex (1) showed binding affinity around 3.8 mM in our 
polymer binding assay and a KD of 1.1 mM in the ITC experiment. In both assay formats a 
gain in affinity by a factor of 2 was observed when the D-GlcNAc moiety is mimicked by 
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol ('8, KD=0.6 mM). This gain in affinity is lost 
again when the 6-position is deoxygenated ('39, KD=1.3 mM). Finally, the pseudo-
disaccharide 40 binds with near identical affinity as Lex (1) to DC-SIGN (KD=1.1 mM).  
All compounds reveal an enthalpy-driven binding, which is typical for carbohydrate–lectin 
interactions.47-49 The range of deviation concerning enthalpy and entropy contributions 
throughout the mimic series (8, 39, 40) is close to experimental precision limit. The 6-deoxy 
derivative 39 shows a smaller enthalpic contribution to binding than 8 (-29.7 vs. -31.4 
kJ/mol). Even though the results have to be regarded with caution, the observed trend in 
enthalpy is in accordance with the assumption that the 6-OH group of D-Gal is involved in 
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binding. However, when losing a substantial H-bond a drop in affinity in the range of one 
order of magnitude would be expected.50 Although, the desolvation of the deogygenated 
compound is favorable in terms of enthalpy, which can partly compensate the lost interaction 
with the protein. 
The pseudo-disaccharide 40 (entry 8) shows an improved enthalpy term compared to 8 
(entry 2). We reason that the absence of the entire D-Gal moiety results in a smaller polar 
surface area and therefore in a reduced desolvation penalty. This entails, despite the fact that 
no interaction with the protein can be established, a more favorable enthalpy term. The gain 
in enthalpy is accompanied and nearly compensated by unfavorable entropy. However, this is 
no classical enthalpy-entropy compensation. The unfavorable entropy term can rather be 
explained by different sizes of the binding interface (comparing 40 with 8) resulting in the 
release of fewer water molecules to bulk.  
Significant differences in the thermodynamic profile resulted for the modification of 
D-GlcNAc to methylcyclohexanediol (1'8). 8 revealed an improved enthalpy term, partly 
outweighed by an unfavorable entropic contribution. Basically, the exchange of D-GlcNAc is 
associated with two effects: 1) preorganization which should minimize entropic costs upon 
binding and 2) reduction of desolvation costs which is supposed to improve the enthalpy 
term. Interestingly, the ITC experiments revealed an ambiguous effect. Regarding the 
observed favorable enthalpic term, this is in accordance with a reduced desolvation energy 
that has to be paid upon introduction of a lipophilic moiety. Desolvation of polar surfaces is 
energetically more cost intensive than desolvation of lipophilic surfaces.51 The more 
unfavorable entropy term for 8 compared to 1 indicates that the effect of preorganization is 
not efficient in the present case. We are convinced that 1 and 8 bind in the same orientation to 
DC-SIGN, hence, the significant entropic costs can not result from different binding modes 
nor from conformational changes of the protein. Differences of the ligands polar and non-
polar surface areas affecting solvation and desolvation properties can more likely explain the 
different entropy terms. 
To the best of our knowledge, the only ITC data available on DC-SIGN up to now, have been 
reported by Holla and Skerra. They present KD values for mannose and a dimannoside with 
KD of 3.5 and 0.9 mM, respectively. The thermodynamic profile of these compounds is in 
accordance with our findings of an enthalpy-driven binding with an unfavourable entropy 
term.52 
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Molecular Dynamics Simulations 
The exchange of D-GlcNAc in Lex (1) by a methylcyclohexanediol moiety ('8) was 
expected to have an advantageous effect on affinity due to reduced desolvation costs and 
better preorganization.33,37,53 Although, an overall improved affinity was achieved, the 
entropic disadvantage of the mimic (throughout the series) compared to Lex (1) was 
unexpected. To prove our assumptions of preorganization, an exhaustive conformational 
search was done for both Lex (1) and 8. Comparing the energy of the global minimum with 
the energy of its bound conformation reflects the internal strain penalty paid by each ligand to 
reach its bound conformation. The results support our assumption of a pre-organized 
conformation of mimic 8 (reflected by the number of conformations obtained for both) 
leading to reduction of the strain penalty by 3.3 kcal/mol compared to Lex (1). Thus, binding 
of 8 to DC-SIGN would incur a lower enthalpic and entropic penalty compared to Lex (1). 
Concerning desolvation costs, less energy has to be paid to break the H-bond network of 
water molecules on non-polar surfaces, i.e. replacement of polar groups by lipophilic groups 
entails a favorable enthalpic contribution. Despite the fact, that a dominant part of the 
D-GlcNAc portion is solvent-exposed, the enthalpic gain in case of 8 can be explained by a 
partial desolvation of the cyclohexyl moiety as well as a reduced internal strain penalty.  
The higher entropic cost (-T((S > 6 kJ/mol) for 8 binding to DC-SIGN compared to 1 is 
controversial. The conformational search indicates that mimic 8 is more rigid than 1, which 
would result in less entropic costs upon binding.  
To investigate whether differences in solvation can account for the significant entropic costs 
the solvent-accessible surface area (SASA) was calculated and 10 ns molecular dynamics 
(MD) simulations were initiated. These data indicate a significant difference in the average 
solvent-exposed surface areas in the free state. 1 shows a larger SASA (675 ±9 Å2) than 8 
(620 ±8 Å2) resulting in the assembly of more water molecules on the surface of 1. In this 
respect, even only a partial desolvation of the D-GlcNAc moiety is assumed to result in the 
release of more water molecules with respect to 8 and can rationalize the differences in the 
entropy term (Figure 4).  
In case of Lex the preorganization of the core structure, which was substantial for 
high-affinity ligands in case of the selectins37, is therewith not as critical for binding as 
previously assumed. The impact of desolvation effects accompanying the solvent-exposed 
binding site in DC-SIGN predominates. 
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CONCLUSION 
We synthesized and evaluated a series of Lex mimics for their binding affinity to DC-SIGN 
and therewith their potential as DC-SIGN ligands. An exchange of the central D-GlcNAc 
moiety in Lex is associated with a gain in affinity. The contribution of D-Gal was investigated 
by a series of deoxy Lex derivatives. Mono-deoxygenation of D-Gal in positions 2, 3, 4, and 6 
proved that mainly the 4- and 6-OH contribute to binding. However, our results indicate that 
this interaction with the protein is not critical for binding. A mimic lacking the entire D-Gal 
moiety still showed affinity comparable to that of Lex.  
It is still a challenging task to design glycomimetic compounds with an improved interaction 
profile for this solvent-exposed binding site. Our study gives an insight into the 
thermodynamic properties of Lex and mimics thereof binding to DC-SIGN. It also shows that 
small changes in affinity can result from significant changes in the thermodynamic profile. 
Solvation effects have a remarkable impact on this binding interaction. Ultimately, we 
provided evidence that ligands with a reduced and more drug-like structure bind to DC-
SIGN. This is valuable information for the design of more potent, structurally simplified 
glycomimetic DC-SIGN ligands. 
 
EXPERIMENTAL SECTION 
Synthesis 
General Methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC, TOCSY). Chemical shifts are expressed in ppm in relation to the 
residual solvent signals (CHCl3, CHD2OD, and HDO) on the +-scale. Coupling constants J 
are given in Hertz (Hz). Multiplicities were specified as follows: s (singlet), d (doublet), dd 
(doublet of a doublet), t (triplet), q (quartet), m (multiplet). For assignment of resonance 
signals to the appropriate nuclei the following abbreviations were used: Fuc (fucose), Gal 
(galactose), MeCy (3-methylcyclohexane-1,2-diol), Imi (imidazole). Commercially available 
reagents were purchased from Fluka, Aldrich, Merck, and Abcr. Solvents were dried prior to 
use as indicated. Dichloromethane (CH2Cl2), 1,2-dichloroethane (DCE), and acetonitrile 
(CH3CN) were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Dimethylformamide 
(DMF), pyridine, and toluene were dried by distillation from calcium hydride. 
Tetrahydrofuran (THF) was dried by distillation from sodium/benzophenone. Methanol 
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(MeOH) was dried by refluxing with sodium methoxide and distilled immediately before use. 
Molecular sieves (3Å, 4Å) were activated under vacuum at 500ºC for 1 h immediately before 
use. Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck) and visualized by using UV light and/or by charring with a molybdate solution  
(a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10% H2SO4). Column chromatography was performed on a 
CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep normal phase disposable flash 
columns (silica gel, 40-63 µm). Reversed phase chromatography was performed on 
LiChroprepRP-18 (Merck, 40-63 µm). LC-MS separations were carried out using Sunfire C18 
columns (19 x 150 mm, 5.0 &m) on a Waters 2525 LC, equipped with Waters 2996 
photodiode array and Waters micromass ZQ MS for detection. Electron spray ionization mass 
spectra (ESI-MS) were obtained on a Waters micromass ZQ. HR-MS analysis were carried 
out using a Agilent 1100 LC equipped with a photodiode array detector and a Micromass 
QTOF I equipped with a 4 GHz digital-time converter. Optical rotations were measured using 
Perkin-Elmer polarimeter 341. Microanalysis was performed at the Institute of Organic 
Chemistry at the University of Basel, Switzerland. Compound purity was determined on an 
Agilent 1200 HPLC; ELS detector, Waters 2420; column: Waters Atlantis dC18, 3 µm,  
4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water + 0.1% TFA. 
Linear gradient was applied: 0 - 1 min 5% B; 1 - 15 min 5 to 70% B; 16 - 20 min 70 to 5% B 
flow: 0.5 mL/min. 
 
Ethyl 3,4,6-tri-O-acetyl-2-deoxy-1-thio-"-D-xylo-galactopyranoside (10) 
3,4,6-Tri-O-acetyl-1,5-anhydro-2-deoxy-D-lyxo-hex-1-enitol (300 mg, 1.1 mmol) and ceric 
ammonium nitrate (60 mg, 0.11 mmol, 0.1 eq) were stirred in dry CH3CN (2 ml) at 0°C 
under argon atmosphere. EtSH (0.41 ml, 5 eq, 5.5 mmol) in dry CH3CN (1 ml) was added 
dropwise and the reaction mixture was stirred for 2 d. The mixture was concentrated and 
purified by flash column chromatography (PE/EtOAc, 1:0'7:3). The product was obtained 
as "/! mixture in 66 % yield (":! (7:1). 
NMR data of the "-anomer are in accordance with literature data.39 
1H NMR (500 MHz, CDCl3): ) 5.53 (d, J = 5.6 Hz, 1H, H-1), 5.33 (s, 1H, H-4), 5.21 (d,  
J = 12.0 Hz, 1H, H-3), 4.54 (t, J = 6.2 Hz, 1H, H-5), 4.11 (d, J = 6.2 Hz, 2H, H-6a/b), 2.64 
(dq, J = 14.4, 7.3 Hz, 1H, CH2a), 2.54 (dq, J = 14.2, 7.3 Hz, 1H, CH2b), 2.42 (td, J = 12.8, 5.8 
Hz, 1H, H-2b), 2.19 – 1.95 (m, 9H, CH3), 1.87 (d, J = 9.2, 1H, H-2a), 1.28 (t, J = 7.4 Hz, 3H, 
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CH2-CH3); 13C NMR (125 MHz, CDCl3): ) 170.64, 170.41, 170.06 (3C, CO) 80.12 (C-1), 
66.98, 66.90 (3C, C-3, C-4, C-5), 62.56 (C-6), 30.46 (C-2), 24.96 (S-CH2), 20.98, 20.86 (3C, 
CH3), 14.90 (CH2-CH3); ESI-MS: m/z calcd for C14H22O7S [M+Na]+: 357.10, found: 357.03. 
 
Ethyl 3,4,6-tri-O-benzyl-2-deoxy-1-thio-"-D-xylo-galactopyranoside (11)39 
Compound 10 (200 mg, 0.6 mmol) was dissolved in dry MeOH (2 ml) under argon 
atmosphere. A catalytic amount of freshly prepared methanolic NaOMe solution (1 M) was 
added. After completion of the reaction (TLC and ESI-MS control), AcOH was added to 
neutralize the mixture. After removal of the solvent under reduced pressure, the crude 
product was purified by flash column chromatography on silica gel (CH2Cl2/MeOH, 
1:0'10:4) and yield ethyl 2-deoxy-1-thio-"-D-xylo-galactopyranoside39,54,55 (122 mg, 98%). 
The product was used for the next step without further characterization. 
Sodium hydride (53 mg, 4 eq, 1.32 mmol, 60 % suspension in oil) was suspended in dry 
DMF (0.8 ml) under argon atmosphere. The stirred suspension was cooled to 0 ºC and a 
solution of ethyl 2-deoxy-1-thio-"-D-xylo-galactopyranoside (68 mg, 0.33 mmol) in dry DMF 
(1.2 ml) was added followed by addition of BnBr (157 µl, 4 eq, 1.32 mmol). The mixture was 
stirred at room temperature for 1 h. After cooling to 0 ºC, the reaction was quenched by slow 
addition of MeOH and stirred for 20 min. The solvent was removed under reduced pressure 
and the crude product purified by flash column chromatography on silica gel (PE/EtOAc, 
1:0'1:1)to give 11 (113 mg, 72%). 
Spectroscopic data were in accordance with literature.39 
["]D20 = +174 (c = 0.102, CHCl3); 1H NMR (500 MHz, CD3OD): ) 7.40 – 7.21 (m, 15H, Ar-
H), 5.47 (d, J = 5.7 Hz, 1H, H-1), 4.84 (m, 1H, CH2), 4.63 – 4.41 (m, 5H, CH2), 4.26 (t,  
J = 6.3 Hz, 1H, H-5), 3.91 (s, 1H, H-4), 3.85 (m, 1H, H-3), 3.63 –3.51 (m, 2H, H-6), 2.62 (m, 
1H, S-CH2a), 2.55 – 2.38 (m, 2H, S-CH2b, H-2a), 1.92 (dd, J = 13.0, 4.5 Hz, 1H, H-2b), 1.23 
(t, J = 7.4 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): ) 140.15, 139.83, 139.57 (3 quart. 
Ar-C), 129.43, 129.40, 129.30, 129.26, 128.93, 128.78, 128.74, 128.70, 128.65 (15C, 15 Ar-
C), 81.55 (C-1), 76.41 (C-3), 75.62 (CH2), 75.10 (C-4), 74.35 (CH2), 71.47 (CH2), 71.24 (C-
5), 70.73 (C-6), 32.56 (S-CH2), 25.58 (C-2), 15.24 (CH3); ESI-MS: m/z calcd for C29H34O4S 
[M+Na]+: 501.21, found: 501.23. 
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Ethyl 2,3,6-tri-O-benzoyl-1-thio-!-D-galactopyranoside (15) 
Compound 15 was synthesized in three steps from ethyl 1-thio-!-D-galactopyranoside  12 
following a published procedure.40 
 
Ethyl 2,3,6-tri-O-benzoyl-4-O-(imidazol-l-ylthiocarbonyl)-1-thio-!-D-galacto-pyranoside 
(16) 
Compound 15 (161 mg, 0.3 mmol) was dissolved in dry DCE (1.5 ml) in a dry, argon-flushed 
flask. 1,1’-Thiocarbonyldiimidazole (96 mg, 1.5 eq, 0.5 mmol) was added and the sealed 
flask was refluxed until TLC showed complete consumption of starting material (approx. 
5 h). The solvent was evaporated and the crude product purified by flash column 
chromatography (PE/EtOAc, 1:0*2:1). Compound 16 was obtained as colorless foam (176 
mg, 90%). 
1H NMR (500 MHz, CDCl3): ) 8.40 (s, 1H, Imi-H), 7.98 (dd, J = 24.6, 7.4 Hz, 4H, Ar-H), 
7.77 (d, J = 7.5, 2H, Ar-H), 7.68 (s, 1H, Imi-H), 7.62 – 7.22 (m, 11H, Ar-H), 7.14 (s, 1H, 
Imi-H), 6.62 (s, 1H, H-3), 5.80 – 5.64 (m, 2H, H-2, H-3), 4.90 (d, J = 9.4 Hz, 1H, H-1), 4.64 
(d, J = 6.2 Hz, 1H, H-6b), 4.37 (m, 2H, H-4, H-6a), 2.83 (dd, J = 13.0, 6.6 Hz, 2H, SCH2), 
1.31 (t, J = 7.3 Hz, 3H, CH3); 13C NMR (126 MHz, CDCl3): ) 183.78 (C=S), 166.30, 165.95, 
165.58 (4C, 4CO), 139.16, 137.86, 134.10, 133.91, 131.92, 130.24, 130.13, 128.86, 118.12 
(18C, 3Imi-C, 15Ar-C), 84.73 (C-1), 76.81 (C-3), 75.14 (C-2),72.75 (C-4), 68.32 (C-2); 
61.95 (C-5), 24.74 (CH2), 15.28 (CH3). 
 
Ethyl 2,3,6-tri-O-benzoyl-4-deoxy-1-thio-!-D-xylo-hexopyranose (17)56 
A solution of the imidazolylthiocarbonyl derivative (160 mg, 0.25 mmol) in dry toluene 
(2 ml) and added dropwise to a refluxing solution of Bu3SnH (100 µl, 1.5 eq, 0.4 mmol) and 
a catalytic amount of AIBN in dry toluene (5 ml). After 5h, supplemental Bu3SnH (66 µl, 1 
eq, 0.25 mmol) was added to complete the conversion of the starting material. The reaction 
mixture was cooled to r.t. and the solvent was evaporated under reduced pressure. 
Purification by flash column chromatography (PE/EtOAc) afforded 17 (120 mg, 93%). 
Spectroscopic data were in accordance with literature data56 
1H NMR (500 MHz, CDCl3): ) 8.07 (dd, J = 8.3, 1.2 Hz, 2H, Ar-H), 8.01 – 7.97 (m, 2H, Ar-
H), 7.95 (dd, J = 8.3, 1.2 Hz, 2H, Ar-H), 7.58 (m, 1H, Ar-H), 7.53 – 7.41 (m, 4H, Ar-H), 7.37 
(dd, J = 15.9, 8.1 Hz, 4H, Ar-H), 5.51 – 5.42 (m, 2H, H-2, H-3), 4.74 (m, 1H, H-1), 4.47 (qd, 
J = 11.7, 5.1 Hz, 2H, H-6), 4.10 (m, 1H, H-5), 2.89 – 2.68 (m, 2H, SCH2), 2.51 (m, 1H, H-
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4a), 1.92 (m, 1H, H-4b), 1.35 – 1.18 (m, 3H, CH3); 13C NMR (125 MHz, CDCl3): ) 166.28, 
165.92, 165.62 (3CO), 133.38, 133.34, 133.31, 129.89, 129.80, 129.74, 129.50, 129.38, 
128.53, 128.50, 128.45 (18C, 18Ar-C), 83.92 (C-1), 73.73 (C-5), 72.66, 71.16 (C-2, C-3), 
66.03 (C-6), 33.27 (C-4), 24.41 (SCH2), 15.09 (CH3); ESI-MS: m/z calcd for C29H28O7S 
[M+Na]+:  543.14, found: 543.16. 
 
2-(Trimethylsilyl)ethyl 3-O-benzyl-!-D-galactopyranoside (19) 
A mixture of 2-(trimethylsilyl)ethyl !-D-galactopyranoside 1841 (202 mg, 0.72 mmol) and 
Bu2SnO (179 mg, 1 eq, 0.72 mmol) was suspended in dry toluene (15 ml) under argon and 
refluxed for 16 h. Bu4NI (266 mg, 1 eq, 0.72 mmol) and benzyl bromide (0.18 ml, 2.1 eq, 
1.51 mmol) were added and the mixture was refluxed for 6 h. Evaporation to dryness gave a 
residue which was purified by column chromatography on silica gel (EtOAc/MeOH, 
1:0*10:1) to give 2-(trimethylsilyl)ethyl 3-O-benzyl-!-D-galactopyranoside 19 (166 mg, 
62%). 
Spectroscopic data were in accordance with literature values.57 
1H NMR (500 MHz, CD3OD): ) 7.53 – 7.17 (m, 5H, Ar-H), 4.81 – 4.60 (m, 2H, CH2), 4.24 
(d, J = 7.8 Hz, 1H, H-1), 4.09 – 3.95 (m, 2H, OCH2a, H-4), 3.80 – 3.70 (m, 2H, H-6), 3.69 – 
3.57 (m, 2H, OCH2b, H-2), 3.44 (t, J = 6.1 Hz, 1H, H-5), 3.36 (dd, J = 9.6, 3.3 Hz, 1H, H-3), 
1.09 – 0.89 (m, 2H, CH2Si), 0.03 (s, 9H, Si(CH3)3); 13C NMR (126 MHz, CD3OD): ) 139.87, 
129.28, 129.08, 128.62 (Ar-C), 104.42 (C-1), 82.53 (C-3), 76.47 (C-5), 72.52 (PhCH2), 71.80 
(C-2), 68.03 (OCH2), 67.10 (C-4), 62.48 (C-6), 19.13 (CH2Si), -1.41 (Si(CH3)3); ESI-MS: 
m/z calcd for C18H30O6S [M+Na]+: 393.17, found: 392.96. 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-benzoyl-3-O-benzyl-!-D-galactopyranoside (20)58,59 
Compound 19 (500 mg, 1.35 mmol) was dissolved in anhydrous pyridine (5 ml) and cooled 
to 0°C under argon. BzCl (4.7 mmol, 3.5 eq, 0.54 ml) was added and the mixture was stirred 
and allowed to reach r.t. until TLC showed complete conversion of the starting material. 
Pyridine was removed by co-evaporation with toluene. The resulting residue was dissolved in 
CH2Cl2 (100 ml) and washed with satd. aq. NaHCO3 solution (100 ml) and brine (50 ml). The 
aq. phase was extracted with CH2Cl2 (2x 100 ml). The organic phase was dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography on silica gel (PE/EtOAc, 1:0*1:1) to yield 20 as resin in (850 mg, 
92%). 
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Spectroscopic data were in accordance with literature values.58,59 
1H NMR (500 MHz, CDCl3): ) 8.22 – 8.15 (m, 2H, Ar-H), 8.08 – 8.03 (m, 2H, Ar-H), 8.01 – 
7.96 (m, 2H, Ar-H), 7.59 (dt, J = 9.9, 7.4 Hz, 3H, Ar-H), 7.54 – 7.40 (m, 6H, Ar-H), 7.19 – 
7.03 (m, 5H, Ar-H), 5.91 (d, J = 2.7 Hz, 1H, H-4), 5.53 (dd, J = 9.9, 8.1 Hz, 1H, H-2), 4.70 
(d, J = 12.9 Hz, 1H, PhCH2a), 4.65 – 4.58 (m, 2H, H-1, H-6a), 4.50 (d, J = 12.8 Hz, 1H, 
PhCH2b), 4.44 (dd, J = 11.4, 6.1 Hz, 1H, H-6b), 4.08 (t, J = 6.9 Hz, 1H, H-5), 4.00 (m, 1H, 
O-CH2a), 3.79 (dd, J = 10.0, 3.4 Hz, 1H, H-3), 3.56 (td, J = 10.4, 6.5 Hz, 1H, O-CH2b), -0.09 
(s, 9H, Si(CH3)3); 13C NMR (126 MHz, CDCl3): ) 166.33, 166.07, 165.29 (3CO), 137.39, 
133.55, 133.40, 133.12, 130.31, 130.21, 130.03, 129.89, 129.77, 129.51, 128.65, 128.62, 
128.38, 128.08, 127.79 (Ar-C), 101.09 (C-1), 76.46 (C-3), 71.44, 71.41, 71.03 (C-2, C-5, 
PhCH2) 67.57 (OCH2), 66.79 (C-4), 62.79 (C-6), 18.07 (CH2Si), -1.40 (Si(CH3)3). 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-benzoyl-!-D-galactopyranoside (21) 
a) Compound 20 (205 mg, 0.30 mmol) was dissolved in dioxane/water  (4:1, v/v, 4 ml) and 
Pd(OH)2/C (10%) was added under argon atmosphere. The resulting suspension was 
hydrogenated on a Parr shaker (5 bar) for 20 h, the catalyst was filtered off and fresh 
Pd(OH)2/C was added the hydrogenation procedure repeated for 10 h. After complete 
transformation of the starting material, the catalyst was filtered off and the crude product was 
purified on silica gel (PE/EtOAc) to give 21 (170 mg, 95%). 
b) Compound 20 (204 mg, 0.30 mmol) was dissolved in EtOAc (4 ml) and then a solution of 
NaBrO3 (3 eq, 0.9 mmol, 136 mg) in water (3 ml) was added to the well stirred two-phase 
system. An aq. solution of Na2S2O4 (157 mg, 3 eq, 85% pure in 6 ml H2O) was added 
dropwise over 10 min at r.t. The reaction progress was controlled by TLC. After complete 
conversion of the starting material, the mixture was diluted with EtOAc (25 ml) and washed 
with an aq. solution of Na2S2O3 (2x 25 ml). The aq. phase was extracted with EtOAc (3x 
50ml), the combined organic phases were dried over Na2SO4, filtered, and concentrated. 
Flash column chromatography on silica gel (PE/EtOAc) gave 21 (171 mg, 87%) as a resin.  
["]D20 -5.6 (c 0.33, CHCl3); 1H NMR (500 MHz, CD3OD): ) 8.19 – 7.97 (m, 6H, Ar-H), 7.70 
– 7.37 (m, 9H, Ar-H), 5.74 (d, J = 3.2 Hz, 1H, H-4), 5.43 (dd, J = 10.0, 8.0 Hz, 1H, H-2), 
4.82 (d, J = 8.0 Hz, 1H, H-1), 4.49 (dd, J = 11.3, 7.1 Hz, 1H, H-6a), 4.41 (dd, J = 11.3, 5.4 
Hz, 1H, H-6b), 4.32 (t, J = 6.3 Hz, 1H, H-5), 4.24 (dd, J = 10.1, 3.5 Hz, 1H, H3), 4.01 (td,  
J = 9.9, 5.6 Hz, 1H, CH2a), 3.65 (td, J = 9.7, 6.7 Hz, 1H, CH2b), 0.98 – 0.75 (m, 2H, CH2), 
0.13 (s, 9H, (CH3)3); 13C NMR (126 MHz, CD3OD): ) 167.61, 167.51, 167.35 (3CO), 134.50, 
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134.39, 134.31, 131.53, 131.10, 131.02, 131.00, 130.76, 130.66, 129.63, 129.55, 129.49 
(15C, Ar-C), 102.26 (C-1), 74.34 (C-2), 72.76, 72.74 (C-4, C-5), 71.58 (C-3), 68.29 (CH2), 
63.99 (C-6), 18.89 (CH2), -1.40 ((CH3)3); HR-MS m/z calcd for C32H36O9Si [M+Na]+: 
615.2026, found: 615.2029. 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-benzoyl-3-O-(imidazol-l-ylthiocarbonyl)-!-D-
galactopyranoside (22) 
Compound 21 (113 mg, 0.19 mmol) was dissolved in dry DCE (1.5 ml) in an dry argon-
flushed flask. 1,1’-Thiocarbonyldiimidazole (61 mg, 0.342 mmol, 1.5 eq) was added and the 
sealed flask was refluxed until TLC control showed complete conversion (5 h). The solvent 
was evaporated and the crude product was purified by flash column chromatography 
(PE/EtOAc, 1:0 * 2:1). Compound 22 was obtained as colorless foam (120 mg, 92%). 
1H NMR (500 MHz, CDCl3): ) 8.11 – 8.08 (m, 2H, Ar-H), 8.02 (dd, J = 8.3, 1.2 Hz, 2H,  
Ar-H), 7.97 (dd, J = 8.3, 1.2 Hz, 2H, Ar-H), 7.66- 7.38 (m, 10H, Ar-H, Imi-H), 7.34 (dd,  
J = 4.8, 3.4 Hz, 1H, Imi-H), 6.84 (dd, J = 1.6, 0.7 Hz, 1H, Imi-H), 6.10 (d, J = 2.6 Hz, 1H, H-
4), 6.05 (dd, J = 10.3, 3.4 Hz, 1H, H-3), 5.84 (dd, J = 10.3, 7.9 Hz, 1H, H-2), 4.88 (t, J = 8.9 
Hz, 1H, H-1), 4.69 (dd, J = 11.4, 6.9 Hz, 1H, H-6b), 4.45 (dd, J = 11.4, 6.4 Hz, 1H, H-6a), 
4.33 (t, J = 6.6 Hz, 1H, H-5), 4.15 – 4.02 (m, 1H, CH2b), 3.74 – 3.62 (m, 1H, CH2a), 1.04 – 
0.77 (m, 2H, CH2(CH3)3), -0.01 – -0.11 (m, 9H, (CH3)3); ESI-MS: m/z calcd for 
C36H38N2O9SSi [M+H]+: 703.21, found:703.22. 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-benzoyl-3-deoxy-!-D-xylo-hexopyranoside (23) 
Bu3SnH (61 µl, 1.5 eq, 0.225 mmol) and a catalytic amount of azobisisobutyronitrile (AIBN) 
were refluxed in anhydrous toluene (2.5 ml) under argon. The 3-O-imidazolylthiocarbonyl 
derivative 22 (105 mg, 0.15 mmol) was dissolved in anhydrous toluene (1 ml) and added 
dropwise through a septum to the Bu3SnH solution. The resulting mixture was refluxed for 
further 6 h. The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (PE/EtOAc) to yield 23 (75 mg, 86%) as a 
foam. 
["]D20 -23.0 (c 0.17 , CHCl3); 1H NMR (500 MHz, CD3OD): ) 8.15 – 8.09 (m, 2H, Ar-H), 
8.03 – 7.96 (m, 4H, Ar-H), 7.67 – 7.55 (m, 3H, Ar-H), 7.54 – 7.39 (m, 6H, Ar-H), 5.50 (d,  
J = 0.9 Hz, 1H, H-4), 5.24 (ddd, J = 11.7, 7.8, 5.2 Hz, 1H, H-2), 4.89 (d, J = 7.9 Hz, 1H, 
H-1), 4.55 (dd, J = 11.3, 7.3 Hz, 1H, H-6a), 4.45 (dd, J = 11.3, 5.3 Hz, 1H, H-6b), 4.40 – 4.34 
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(m, 1H, H-5), 4.06 (td, J = 9.9, 5.5 Hz, 1H, OCH2a), 3.69 (td, J = 9.6, 6.8 Hz, 1H, OCH2b), 
2.57 (ddd, J = 14.1, 5.1, 3.4 Hz, 1H, H-3a), 2.17 (ddd, J = 14.4, 11.6, 3.1 Hz, 1H, H-3b), 1.01 
– 0.81 (m, 2H, CH2), -0.07 (s, 9H, Si(CH3)3); 13C NMR (125 MHz, CD3OD): ) 167.52, 
167.07, 166.97 (3CO), 134.64, 134.46, 134.39, 131.22, 131.05, 131.01, 130.78, 130.66, 
130.61, 129.75, 129.58, 129.56 (Ar-C), 103.08 (C-1), 75.48 (C-5), 69.91 (2C, C-2, C-4), 
67.93 (CH2), 64.31 (C-6), 33.77 (C-3), 18.88 (CH2Si), -1.34 (Si(CH3)3); HR-MS: m/z calcd 
for C32H36O8Si [M+Na]+: 599.2077, found: 599.2078. 
 
Phenyl 2,4,6-tri-O-benzoyl-3-deoxy-1-thio-!-D-xylo-hexopyranoside (24) 
A solution of 2-(trimethylsilyl)ethyl glycoside 23 (115 mg, 0.2 mmol) in dry toluene (1 ml) 
was treated with acetic acid anhydride (283 µl, 15 eq, 2 mmol) and BF3&Et2O (23 µl, 0.9 eq, 
0.18 mmol) and stirred at r.t. The reaction was monitored by TLC and diluted with 
dichloromethane (30 ml) after completion (8 h). The mixture was washed with NaHCO3 
solution (30 ml) and water (30 ml). The aq. phase was extracted with CH2Cl2 (3x 50 ml). The 
combined organic phases were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified on silica gel to give acetyl 2,4,6-tri-O-benzoyl- 3-deoxy-!-
D-xylo-hexopyranoside (46 mg, 80%, ":! (4:3). 
1H NMR (500 MHz, CDCl3): ) 8.17 – 8.08 (m, 3H), 8.05 – 7.90 (m, 7H), 7.66 – 7.37 (m, 
16H) (15 Ar-H of " and !, ratio 4:3), 6.57 (d, J = 3.2 Hz, 1H, H-1"), 6.05 (d, J = 8.1 Hz, 1H, 
H-1!), 5.64 (s, 1H, H-4"), 5.57 (m, 2H, H-2", H-4!), 5.42 (ddd, J = 11.3, 8.0, 5.1 Hz, 1H, 
H-2!), 4.63 – 4.35 (m, 6H, H-5", H-6", H-!5, H-6!), 2.84 – 2.73 (m, 1H, H-3a!), 2.55 – 
2.35 (m, 2H, H-3"), 2.18 (s, 3H, CH3"), 2.14 – 2.04 (m, 4H, H-3b!, CH3!). ESI-MS: m/z 
calcd for C29H26O9 [M+Na]+: 541.15; found: 541.08; Combustion analysis: calcd: C 67.18, H 
5.05, found: C 66.66, H 5.21. 
 
The acetyl glycoside (31 mg, 0.06 mmol) was dissolved in dry CH2Cl2 (0.5 ml) and PhSH 
(9 µl, 1.5 eq, 0.09 mmol) was added followed by BF3&Et2O (14 µl, 1.6 eq, 0.1 mmol). The 
mixture was stirred overnight, diluted with CH2Cl2 (25ml), washed with satd. aq. NaHCO3 
solution (25 ml) and the aq. phase was extracted with CH2Cl2 (3x 25 ml). The combined 
organic phases were dried over Na2SO4, filtered, concentrated, and the crude product was 
purified by flash column chromatography to yield 24 (30 mg, 68%, ":! (1:1). 
NMR of !-product 1H NMR (500 MHz, CDCl3): ) 8.10 – 7.99 (m, 6H, Ar-H), 7.68 – 7.42 
(m, 11H, Ar-H), 7.33 – 7.15 (m, 3H, Ar-H), 5.55 (s, 1H, H-4), 5.31 (m, 1H, H-2), 5.01 (d,  
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J = 9.9 Hz, 1H, H-1), 4.63 – 4.44 (m, 2H, H-6), 4.25 (d, J = 6.0 Hz, 1H, H-5), 2.75 (d,  
J = 14.1 Hz, 1H, H-3a), 2.06 (t, J = 12.6 Hz, 1H, H-3b); 13C NMR (125 MHz, CDCl3): ) 
166.21, 165.54, 165.22 (3CO), 133.54, 133.36, 133.30, 132.94, 132.39, 129.98, 129.81, 
129.80, 129.73, 129.61, 129.33, 128.84, 128.56, 128.51, 128.48, 127.96 (24C, Ar-C), 87.63 
(C-1), 77.26 (C-5), 67.87 (C-4), 66.35 (C-2), 63.35 (C-6), 34.75 (C-3); HR-MS: m/z calcd for 
C33H28O7S [M+Na]+: 591.1448, found: 591.1448. 
 
2-(Trimethylsilyl)ethyl 6-O-tosyl-!-D-galactopyranoside (25)60 
TMSE glycoside 1841 (280 mg, 1 mmol) was dissolved in anhydrous pyridine (4 ml) and p-
toluenesulfonyl chloride (230 mg, 1.2 eq, 1.2 mmol) was added at 0°C. The reaction mixture 
was stirred at 0°C and warmed to r.t. The reaction was monitored by TLC and was diluted by 
addition of EtOAc (100 ml) at completion (6 h), then washed with 1N HCl (100 ml), 
followed by satd. aq. NaHCO3 solution (100 ml) and brine (100 ml). The aq. phase was 
extracted repeatedly with EtOAc (3x 100 ml) and the combined organic layers were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification via flash column 
chromatography on silica gel (CH2Cl2/MeOH, 1:0*1:1) gave 25 (380 mg, 87%). 
["]D20 -32.6 (c  0.51, CHCl3); 1H NMR (500 MHz, CDCl3): ) 7.76 (d, J = 8.2 Hz, 2H, Ar-H), 
7.29 (d, J = 8.1 Hz, 2H, Ar-H), 4.32 – 4.07 (m, 3H, H-6, H-3, H-1), 4.02 – 3.82 (m, 2H, H-4, 
CH2a), 3.69 (t, J = 6.1 Hz, 1H, H-5), 3.64 – 3.48 (m, 2H, H-2, CH2b), 2.40 (s, 3H, PhCH3), 
1.07 – 0.77 (m, 2H, CH2), -0.01 (s, 9H, Si(CH3)3); 13C NMR (126 MHz, CDCl3): ) 145.46, 
145.17, 144.88, 132.76, 130.04, 128.02 (Ar-C), 102.46 (C-1), 73.24, 72.29, 70.95 (C-3, C-4, 
C-5), 68.81 (CH2), 68.48 (C-2), 67.74 (CH2), 21.73 (PhCH3), 18.32 (CH2Si), -1.36 
(Si(CH3)3); HR-MS m/z calcd for C18H30O8SSi [M+Na]+: 457.1323, found: 457.1320. 
 
2-(Trimethylsilyl)ethyl 6-deoxy-!-D-galactopyranoside (26)61 
Compound 25 (148 mg, 0.34 mmol) was dissolved in anhydrous THF (1.5 ml) and LiAlH4 
(26 mg, 2 eq, 0.68 mmol) was added. The mixture was refluxed for 1h. After cooling, EtOAc 
(50 ml) was added to quench the excess of reagent and subsequently water was added. The 
organic layer was washed with water (50 ml), the aqueous phase was extracted with EtOAc 
(3x 50ml). The organic phase was dried over Na2SO4, filtered, and concentrated. Flash 
column chromatography on silica gel (CH2Cl2/MeOH, 1:0 * 7:3) of the residue gave 26 (65 
mg, 72%) as an amorphous mass. 
Spectroscopic data are in accordance with literature.61 
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1H NMR (500 MHz, CDCl3): ) 4.21 (d, J = 7.3 Hz, 1H, H-1), 3.99 (ddd, J = 11.8, 9.6, 5.6 
Hz, 1H, CH2a), 3.72 (s, 1H, OH), 3.68 – 3.52 (m, 5H, H-2, H-3, H-4, H-5, CH2b), 3.34 (s, 1H, 
OH), 2.97 (s, 1H, OH), 1.33 (d, J = 6.5 Hz, 3H, H-6), 1.12 – 0.93 (m, 2H, CH2), 0.07 (s, 9H, 
Si(CH3)3)); 13C NMR (126 MHz, CDCl3): ) 102.68 (C-1), 74.07, 71.79, 71.74, 70.68 (C-2, C-
3, C-4, C-5), 67.49 (CH2), 18.41 (CH2), 16.45 (C-6), -1.29 ((CH3)3); ESI-MS m/z calcd for 
C11H24O5Si [M+Na]+: 287.13, found: 286.97.  
 
2-(Trimethylsilyl)ethyl 2,3,4-tri-O-benzoyl-6-deoxy-!-D-galactopyranoside (27) 
Compound 26 (74 mg, 0.28 mmol) was dissolved in dry pyridine (1.5 ml). BzCl (113 µl, 3.5 
eq, 0.98 mmol) was added at 0°C and the resulting mixture was stirred at r.t. until TLC 
showed complete conversion of the starting material (8 h). The solvent was removed by co-
evaporation with toluene. The resulting residue was dissolved in CH2Cl2 (25 ml) and washed 
with satd. aq. NaHCO3 solution (25 ml). The aq. phase was extracted with CH2Cl2 (3x 25 ml) 
The combined organic phases was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography 
(PE/EtOAc, 1:0*2:1) to gibe  27 (155 mg, 96%) as a white solid.  
[$]D20 +179 (c  0.28 , CHCl3); 1H NMR (500 MHz, CDCl3): ) 8.20 – 7.16 (m, 15H, Ar-H), 
5.74 (m, 2H, H-2, H-4), 5.54 (d, J = 10.4 Hz, 1H, H-3), 4.77 (d, J = 7.8 Hz, 1H, H-1), 4.17 – 
3.99 (m, 2H, H-5, O-CH2a), 3.63 (dd, J = 17.3, 9.1 Hz, 1H, O-CH2b), 1.36 (d, J = 6.1 Hz, 3H, 
H-6), 1.03 – 0.71 (m, 2H, CH2-Si), -0.06 (s, 9H, Si(CH3)3); 13C NMR (126 MHz, CDCl3): ) 
166.20, 165.88, 165.45, (3CO) 133.54, 133.31, 133.20, 130.16, 129.88, 129.81, 129.41, 
129.09, 128.66, 128.42, 128.39 (18C, 18Ar-C) 100.99 (C-1), 72.45 (C-3), 71.26, 70.00, 69.81 
(C-2, C-4, C-5), 67.77 (O-CH2-), 18.18 (-CH2-Si), 16.51 (C-6), -1.35 (Si(CH3)3);  
ESI-MS: m/z calcd for C32H36O8Si [M+Na]+: 599.21, found: 599.21; Combustion analysis: 
calcd: C 66.65, H 6.29, found: C 66.70, H 6.24. 
 
Phenyl 2,3,4-tri-O-benzoyl-6-deoxy-1-thio-!-D-galactopyranoside (28)62 
Glycoside 27 (40 mg, 0.07 mmol) was dissolved in dry toluene (0.5 ml) and Ac2O (100 µl, 
15 eq, 1.1 mmol) was added followed by addition of BF3&Et2O (8 µl 0.9 eq, 0.06 mmol) and 
the mixture was stirred at r.t. The reaction was monitored by TLC and diluted with CH2Cl2 
(25 ml) after completion. The mixture was washed with satd. aq. NaHCO3 solution (25 ml) 
and water (25 ml) and the aq. phases were extracted with CH2Cl2 (3x 25 ml). The combined 
organic phases were dried with Na2SO4, filtered, and concentrated under reduced pressure. 
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The residue was purified by flash column chromatography on silica gel before usage for the 
next step. Yield: 36 mg, 99%. 
The acetate (36 mg, 0.07mmol) was dissolved in dry CH2Cl2 (0.5 ml) and PhSH (11 µl, 1.5 
eq, 0.1 mmol) was added followed by BF3&Et2O (14 µl, 1.6 eq, 0.11 mmol). The mixture was 
stirred overnight at r.t. After complete transformation of the starting material the solution was 
diluted with CH2Cl2 and washed with satd. aq. NaHCO3 solution and the aq. phase was 
extracted with CH2Cl2. The organic phase was dried over Na2SO4, filtered, and concentrated. 
The crude product was purified by flash column chromatography on silica gel (PE/EtOAc, 
1:0*7:3). The !-anomer 20 (47%, 19 mg) was obtained as white solid. 
[$]D20 +136 (c 0.1, CHCl3); 1H NMR (500 MHz, CD3OD): ) 7.99 – 7.92 (m, 2H, Ar-H), 7.89 
– 7.82 (m, 2H, Ar-H), 7.73 – 7.37 (m, 14H, Ar-H), 7.24 (t, J = 7.9 Hz, 2H, Ar-H), 5.73 – 5.58 
(m, 3H, H-2, H-3, H-4), 5.17 (d, J = 9.4 Hz, 1H, H-1), 4.31 (q, J = 6.2 Hz, 1H, H-5), 1.31 (d, 
J = 6.4 Hz, 3H, H-6); 13C NMR (126 MHz, CD3OD): ) 167.35, 167.30, 166.81, 166.67, (4 
quart. Ar-C) 135.62, 134.75, 134.61, 134.47, 132.16, 130.82, 130.69, 130.57, 130.51, 130.33, 
129.91, 129.81, 129.63, 129.40 (20C, 20Ar-C), 85.55 (C-1), 74.93, 74.50, 72.93, 69.47, (C-2, 
C-3, C-4, C-5), 16.90 (C-6); HR-MS: m/z calcd for C33H28O7S [M+Na]+: 591.1448, found: 
591.1449.  
 
General procedure A (glycosylation): 
Thioglycoside (0.13 mmol, 1.3 eq) and glycosyl acceptor 533 (0.1 mmol, 1 eq) in dry CH2Cl2 
(3 ml) were added via syringe to activated molecular sieves (4Å, 0.8 g). A suspension of 
DMTST (3 eq, 0.3 mmol) and activated molecular sieves (4Å, 0.4 g) in dry CH2Cl2 (1 ml) 
was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST 
suspension was added via syringe to the other suspension. The reaction was stopped after 16-
24 h, filtered through celite and the celite was washed with CH2Cl2. The filtrate was 
successively washed with satd. aq. NaHCO3 and water. The aqueous layers were extracted 
with CH2Cl2. The combined organic layers were dried with Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified by column chromatography 
(PE/toluene/EtOAc, 10:10:1'5:5:1) to afford the trisaccharide mimic as a colorless foam. 
 
General procedure B (deprotection): 
A mixture of the according trisaccharide mimic (0.07 mmol) and Pd(OH)2/C (10%) in 
dioxane/water (4:1, v/v, 2.5 ml) was shaken in a Parr shaker under a hydrogen atmosphere 
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(atm. pressure to 5 bar). After complete cleavage of the benzyl groups the reaction mixture 
was filtered through celite. The celite was washed with MeOH, the filtrate was evaporated to 
dryness and dried in vacuo for 4 h before usage for the next step. The intermediate was 
dissolved in MeOH (1 ml) and a catalytical amount of freshly prepared methanolic NaOMe 
solution (1 M) was added at r.t. After complete deprotection the mixture was neutralized with 
AcOH and evaporated. The residue was purified by column chromatography on silica gel 
(CH2Cl2/MeOH 10:4) to yield the trisaccharide mimics. For biological testing the compounds 
were further purified by preparative HPLC. 
 
{(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-"-L-galactopyranosyl)oxy]-3-methyl-
cyclohex-1-yl} 2,3,4-tri-O-benzoyl-6-O-benzyl-!-D-galactopyranoside (7)  
Synthesized from 5 (55 mg, 0.1 mmol) and 636 (81 mg, 0.13 mmol) according to general 
procedure A to give trisaccharide mimic 7 (55 mg, 0.049mmol, 49%).  
[$]D20 -4.23 (c 0.25, CHCl3); 1H NMR (500 MHz, CDCl3): ) 8.01 – 7.90 (m, 4H, Ar-H), 7.80 
(d, J = 7.2 Hz, 2H, Ar-H), 7.56 – 7.47 (m, 2H, Ar-H), 7.45 – 7.07 (m, 29H, Ar-H), 5.96 (d,  
J = 3.3 Hz, 1H, Gal-H4), 5.70 (dd, J = 10.3, 8.2 Hz, 1H, Gal-H2), 5.51 (dd, J = 10.4, 3.5 Hz, 
1H, Gal-H3), 5.11 (d, J = 3.3 Hz, 1H, Fuc-H1), 4.91 (m, 2H, PhCH2a, Fuc-H5), 4.81 (m, 2H, 
PhCH2b, Gal-H1), 4.71 (m, 2H, PhCH2), 4.55 (m, 2H, PhCH2) 4.47 – 4.35 (d, J = 11.9 Hz, 
2H, PhCH2), 4.11 – 4.02 (m, 3H, Fuc-H2, Fuc-H4, Gal-H5), 3.74 – 3.63 (m, 3H, Fuc-H3, 
MeCy-H1, Gal-H6a), 3.60 (m, 1H, Gal-H6b), 3.28 (t, J = 9.2 Hz, 1H, MeCy-H2), 2.00 (s, 
1H, MeCy), 1.69 – 1.48 (m, 3H, MeCy), 1.42 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.35 – 1.10 (m, 
2H, MeCy), 1.06 (d, J = 6.6 Hz, 3H, Cy-CH3), 0.9 (m, 1H, MeCy); 13C NMR (126 MHz, 
CDCl3): ) 165.64, 165.55, 164.96 (3CO), 139.20, 138.91, 138.50, 137.41, 133.44, 133.17, 
129.78, 129.71, 129.67, 129.58, 129.48, 128.96, 128.53, 128.42, 128.40, 128.37, 128.28, 
128.26, 128.20, 127.80, 127.72, 127.68, 127.52, 127.37, 127.17 (42C, 42Ar-C), 99.91 (Gal-
C1), 97.74 (Fuc-C1), 81.20 (MeCy-C2), 80.82 (MeCy-C1), 80.24 (Fuc-C2), 79.50 (Fuc-C3), 
76.27 (Gal-C5), 75.01 (CH2), 74.22 (CH2), 73.69 (CH2), 72.69 (CH2), 72.64 (Fuc-C4), 72.29 
(Gal-C3), 69.67 (Gal-C2), 68.68 (Gal-C4), 67.64 (Gal-C6), 66.47 (Fuc-C5), 38.91 (MeCy), 
33.17 (MeCy), 30.74 (MeCy), 22.70 (Cy-CH2), 18.81 (Cy-CH3), 16.97 (Fuc-C6); ESI-MS 
m/z calcd for C68H70O14 [M+Na]+: 1133.47 found: 1133.55. 
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{(1R,2R,3S)-2-[(6-Deoxy-$-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} !-D-
galactopyranoside (8) 
Compound 7 (54 mg, 0.049 mmol) was deprotected according to standard procedure B to 
yield title compound 8 (15 mg, 0.034 mmol, 70%). 
[$]D20 -89.1 (c 0.20, MeOH); 1H NMR (500 MHz, D2O):: ) 4.99 (d, J = 4.1 Hz, 1H, Fuc-H1), 
4.80 (1H, Fuc-H5), 4.35 (d, J = 7.8 Hz, 1H, Gal-H1), 3.79 – 3.73 (m, 2H, Gal-H4, Fuc-H3), 
3.72 – 3.55 (m, 5H, Fuc-H2, Fuc-H3, Gal-H6, MeCy-H1), 3.50 (m, 2H, Gal-H3, Gal-H5), 
3.40 (dd, J = 9.8, 7.9 Hz, 1H, Gal-H2), 3.10 (t, J = 9.6 Hz, 1H, MeCy-H2), 2.01 (s, 1H, 
MeCy), 1.52 – 1.58 (m, 3H, MeCy), 1.15 (d, J = 8.7 Hz, 2H, MeCy), 1.06 (d, J = 6.6 Hz, 3H, 
Fuc-H6), 0.97 (d, J = 6.4 Hz, 4H, Cy-CH3, MeCy); 13C NMR (126 MHz, CD3OD): ) 102.40 
(Gal-C1), 100.31 (Fuc-C1), 84.60 (MeCy-C2), 79.89 (MeCy-C1), 74.94, 76.34 (Gal-C3, Gal-
C5), 73.84 (Fuc-C4), 72.24 (Gal-C2), 70.31, 71.38 (Fuc-C2, Fuc-C3), 70.16 (Gal-C4), 67.54 
(Fuc-C5), 62.93 (Gal-C6), 24.22, 31.90, 34.94, 40.35, (4C, MeCy), 19.59 (Fuc-C6), 16.74 
(MeCy); HR-MS: m/z calcd for C19H34O11[M+Na]+: 461.1993, found: 461.2003; HPLC-
purity > 99.5%, Rt = 5.335 min. 
 
{(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-"-L-galactopyranosyl)oxy]-3-methyl-
cyclohex-1-yl} 2,3,4,6-tetra-O-acetyl-!-D-glucopyranoside (30) 
Synthesized from 5 (55 mg, 0.1mmol) and 2942 (51 mg, 0.13 mmol) according to general 
procedure A, to give trisaccharide mimic 30 (60 mg, 0.068 mmol, 68%).  
1H NMR (500 MHz, CDCl3): ) 7.37 – 7.05 (m, 18H, Ar-H), 5.10 (m, 1H, Glc-H3), 5.00 (d,  
J = 3.8 Hz, 1H, Fuc-H1), 4.95 – 4.86 (m, 2H, Glc-H4, PhCH2), 4.84 – 4.56 (m, 7H, Glc-H2, 
Fuc-H5, PhCH2), 4.46 (d, J = 8.2 Hz, 1H, Glc-H1), 4.31 (dd, J = 12.3, 4.1 Hz, 1H, Glc-H6a), 
4.04 (m, 1H, Fuc-H2), 3.93 – 3.88 (m, 2H, Fuc-H3, Glc-H6b), 3.65 (d, J = 1.6 Hz, 1H, Fuc-
H4), 3.60 – 3.47 (m, 2H, Glc-H5, MeCy-H1), 3.18 (t, J = 9.1 Hz, 1H, MeCy-H2), 2.00 – 1.89 
(m, 10H, 3CH3, MeCy), 1.85 (s, 3H, CH3), 1.76 – 1.46 (m, 3H, MeCy), 1.27 – 1.09 (m, 5H, 
Fuc-H6, MeCy), 1.08 – 0.91 (m, 4H, Cy-CH3, MeCy); 13C NMR (126 MHz, CDCl3):  
) 170.54, 170.41, 169.65, 169.05 (4CO), 156.39, 139.05, 138.48, 129.15, 128.59, 128.41, 
128.33, 128.31, 128.22, 127.69, 127.59, 127.44, 127.19 (Ar-C), 99.41 (Glc-C1), 98.20 (Fuc-
C1), 81.98 (MeCy-C2), 81.11 (MeCy-C1), 80.31 (Fuc-C3), 78.25 (Fuc-C4), 76.47 (Fuc-C2), 
74.69, 74.57, 73.10, 72.61, 72.00, 71.32, 68.15 (Glc-C2, Glc-C3, Glc-C4, Glc-C5, 3PhCH2) 
66.35 (Fuc-C5), 62.04 (Glc-C6), 38.94, 33.28, 30.99, 22.76 (4MeCy), 20.79, 20.77, 20.74, 
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20.72 (4COCH3), 18.85 (Cy-CH3), 16.91 (Fuc-C6); ESI-MS: m/z calcd for C48H60O15 
[M+Na]+: 899.38, found: 899.41. 
 
{(1R,2R,3S)-2-[(6-Deoxy-$-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} !-D-
glucopyranoside (35) 
Compound 30 (50 mg, 0.057 mmol) was deprotected according to general procedure B and 
gave 35 (18mg, 0.041 mmol, 72%). 
[$]D20 -78.4 (c 0.14, MeOH); 1H NMR (500 MHz, D2O): ) 4.96 (d, J = 4.0 Hz, 1H, Fuc-H1), 
4.66 (m, 1H, Fuc-H5), 4.40 (d, J = 8.0 Hz, 1H, Glc-H1), 3.79 – 3.74 (m, 2H, Fuc-H3,  
Glc-H6a), 3.72 – 3.62 (m, 2H, Fuc-H2, Fuc-H4), 3.56 (tt, J = 12.1, 6.0 Hz, 1H, MeCy-H1), 
3.47 (m, 1H, Glc-H6b), 3.34 (t, J = 9.2 Hz, 1H, Glc-H3), 3.27 (ddd, J = 9.4, 7.2, 2.0 Hz, 1H, 
Glc-H5), 3.16 – 3.04 (m, 3H, Glc-H2, D-Glc-H4, MeCy-H2), 1.98 (m, 1H, MeCy), 1.59 – 
1.41 (m, 3H, MeCy), 1.20 – 1.08 (m, 2H, MeCy), 1.06 (m, 3H, Fuc-H6), 0.95 (m, 4H, MeCy, 
Cy-CH3); 13C NMR (126 MHz, D2O): ) 99.37 (Glc-C1), 99.02 (Fuc-C1), 84.48 (MeCy-C2), 
78.98 (MeCy-C1), 75.72 (2C, Glc-C3, D-Glc-C5), 73.11, 71.94, 70.22 (Glc-C2, Glc-C4, Fuc-
C4), 69.22 (Fuc-C3), 68.11 (Fuc-C2), 66.26 (Fuc-C5), 61.60 (Glc-C6), 38.65 (Cy-CH), 
33.09, 30.34, 22.47 (3MeCy), 18.03 (Cy-CH3), 15.56 (Fuc-C6); HR-MS m/z calcd for 
C19H34O11 [M+Na]+: 461.1993, found: 461.1999; HPLC-purity > 99.5%, Rt = 5.496 min. 
 
{(1R,2R,3S)-2-[(6-Deoxy-$-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 2- deoxy-!-
D-xylo-hexopyranoside (36) 
A mixture of thioglycoside 11 (57 mg, 0.12 mmol, 1.2 eq), acceptor 5 (55 mg, 0.1 mmol), 
and flame-dried molecular sieves (3Å, 1g) was suspended in CH2Cl2/CH3CN (10 ml, 1:3, 
v/v). The resulting mixture was stirred at room temperature for 10 min and at -65°C for an 
additional 20 min under argon, followed by the addition of N-iodosuccinimide (27 mg, 1.2 
eq, 0.12 mmol) and trimethylsilyl trifluoro-methanesulfonate (4.4 µl, 0.24 eq, 0.024 mmol). 
The reaction was monitored by TLC. After 2h the reaction mixture was quenched; a small 
volume of satd. aq. NaHCO3 solution and lumps of Na2S2O3 (s) were added and the mixture 
was warmed to r.t. The mixture was stirred and then filtered through a pad of celite. The 
filtrate was diluted with CH2Cl2 (30 ml) and washed with satd. aq. NaHCO3 solution (30 ml) 
and water (30 ml). The aq. Phase was extracted with CH2Cl2 (3x 30 ml). The combined 
organic phases were dried over Na2SO4, filtered, and concentrated. The residue was purified 
by flash column chromatography on silica gel (Pe/toluene/EtOAc gradient). Unreacted 
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starting material 5 and !-glycosylated product 31 were not separable. Hence, the mixture 
(54 mg) was submitted to the deprotection step. Debenzylation was performed as described in 
general procedure B. Yield: 14% over 2 steps (6 mg, 0.014 mmol). 
[$]D20 -96.5 (c  0.18, MeOH); 1H NMR (500 MHz, D2O): ) 5.07 (d, J = 3.9 Hz, 1H, Fuc-H1), 
4.75 (d, J = 9.4 Hz, 2H, Fuc-H5, Gal-H1), 3.92 – 3.83 (m, 2H, Fuc-H3, Gal-H3), 3.82 – 3.66 
(m, 6H, Fuc-H2, Fuc-H4, MeCy-H2, Gal-H6a, Gal-H6b, Gal-H4), 3.46 (m, 1H, Gal-H5), 
3.13 (s, 1H, MeCy-H1), 2.13 (s, 1H, MeCy), 1.88 (m, 1H, Gal-H2a), 1.74 – 1.51 (m, 4H, 
MeCy, Gal-H2b), 1.31 – 1.19 (m, 2H, MeCy), 1.16 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.04 (m, 4H, 
Cy-CH3, MeCy); 13C NMR (125 MHz, D2O): ) 99.84 (Fuc-C1), 97.90 (Gal-C1), 85.13 
(MeCy-C2), 79.37 (MeCy-C1), 76.10 (Gal-C5), 73.06 (Fuc-C4), 70.26, 69.24, 69.05 (Fuc-
C3, Gal-C3, Gal-C4), 67.79 (Fuc-C2), 67.50 (Fuc-C5), 62.94 (Gal-C6), 39.80 (MeCy), 34.78 
(Gal-C2), 34.17, 31.25, 23.64 (3MeCy), 19.21 (Cy-CH3), 16.65 (Fuc-C6); HR-MS: m/z calcd 
for C19H34O10 [M+Na]+: 445.2044, found: 445.2051; HPLC-purity > 99.5%, Rt = 7.696 min. 
 
{(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-"-L-galactopyranosyl)oxy]-3-methyl-
cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3- deoxy-!-D-xylo-hexopyranoside (32)  
Compound 32 was synthesized from 5 (27 mg, 0.05 mmol) and 24 (37 mg, 0.065 mmol) 
according to general procedure A. Yield: 27 mg, 0.027 mmol, 54 %.  
1H NMR  (500 MHz, CDCl3): ) 8.10 – 7.95 (m, 6H, Ar-H), 7.63 – 7.27 (m, 20H, Ar-H), 7.24 
– 7.16 (m, 4H, Ar-H), 5.47 (s, 1H, Gal-H4), 5.24 (s, 1H, Gal-H2), 5.09 (s, 1H, Fuc-H1), 4.98 
(d, J = 11.4 Hz, 1H, PhCH2), 4.90 (d, J = 6.5 Hz, 1H, Fuc-H5), 4.86-4.66 (m, 5H, Gal-H1, 
2PhCH2), 4.56 (d, J = 11.2 Hz, 1H, PhCH2), 4.45 – 4.31 (m, 2H, Gal-H6), 4.18 – 4.06 (m, 
3H, Fuc-H2, Fuc-H3, Gal-H5), 3.75 (s, 1H, Fuc-H4), 3.67 (s, 1H, MeCy-H1), 3.26 (t, J = 8.9 
Hz, 1H, MeCy-H2), 2.70 (d, J = 13.0 Hz, 1H, Gal-H3a), 2.08 (s, 1H, MeCy), 1.96 (t, J = 12.9 
Hz, 1H, Gal-H3b), 1.58 (s, 3H, MeCy), 1.46 – 1.13 (m, 5H, Fuc-H6, MeCy), 1.08 (d, J = 5.8 
Hz, 3H, Cy-CH3), 1.02 – 0.76 (m, 4H, MeCy); 13C NMR (DEPT-135, 126 MHz, CDCl3): ) 
133.48, 133.14, 133.07, 129.77, 129.53, 128.48, 128.44, 128.36, 128.14, 128.12, 127.75, 
127.44, 127.29, 127.13, 127.03 (Ar-C), 100.63 (Gal-C1), 98.00 (Fuc-C1), 81.84 (MeCy-C2), 
79.90, 79.81, 79.72, 76.37 (MeCy-C1, Fuc-C2, Fuc-C3, Fuc-C4), 75.06, 74.30, 74.18, 72.46 
(3PhCH2, Gal-C5), 67.93, 67.90 (Gal-C2, Gal-C4), 66.25 (Fuc-C5), 62.31 (Gal-C6), 38.87 
(MeCy), 33.46 (Gal-C3), 33.15, 30.58, 22.72 (3MeCy), 18.69 (Cy-CH3), 16.86 (Fuc-C6); 
ESI-MS: m/z calcd for C61H64O13 [M+Na]+: 1027.42, found: 1027.44. 
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{(1R,2R,3S)-2-[(6-Deoxy-"-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl}-3-deoxy-!-
D-xylo-hexopyranoside (37) 
Compound 32 was deprotected according to general procedure B to yield 37 (8 mg, 0.019 
mmol, 70%). 
[$]D20 -65.1 (c 0.14, MeOH); 1H NMR (500 MHz, D2O): ) 5.06 (d, J = 4.0 Hz, 1H, Fuc-H1), 
4.83 (m, 1H, Fuc-H5), 4.42 (d, J = 7.9 Hz, 1H, Gal-H1), 3.93 (s, 1H, Gal-H4), 3.85 (dd,  
J = 10.5, 3.3 Hz, 1H, Fuc-H3), 3.80 – 3.54 (m, 7H, Fuc-H2, Fuc-H4, MeCy-H1, Gal-H6a, 
Gal-H6b, Gal-H2, Gal-H5), 3.18 (t, J = 9.6 Hz, 1H, MeCy-H2), 2.20 – 2.03 (m, 2H, MeCy, 
Gal-H3a), 1.73 – 1.48 (m, 4H, MeCy, Gal-H3b), 1.23 (dd, J = 18.9, 10.5 Hz, 2H, MeCy), 
1.13 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.04 (d, J = 6.4 Hz, 4H, Cy-CH3, MeCy); 13C NMR (125 
MHz, D2O): ) 102.68 (Gal-C1), 99.90 (Fuc-C1), 85.38 (MeCy-C2), 79.29 (MeCy-C1), 78.90 
(Gal-C5), 73.08 (Fuc-C4), 70.28 (Fuc-C3), 69.22 (Fuc-C2), 67.51 (Fuc-C5), 66.72 (Gal-C4), 
66.26 (Gal-C2), 62.83 (Gal-C6), 39.74 (MeCy), 37.90 (Gal-C3), 34.20 (MeCy), 31.41 
(MeCy), 23.61 (MeCy), 19.15 (Cy-CH3), 16.49 (Fuc-C-6); HR-MS: m/z calcd for C19H34O10 
[M+Na]+: 445.2044, found: 445.2052; HPLC-purity > 99.5%, Rt = 6.268 min. 
 
{(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-"-L-galactopyranosyl)oxy]-3-methyl-
cyclohex-1-yl} 2,3,6-tri-O-benzoyl-4-deoxy-#-D-xylo-hexopyranoside (33)  
Compound 33 was synthesized from 5 (43.7 mg, 0.08 mmol) and 17 (54mg, 0.1 mmol) 
according to general procedure A. Yield: 60 mg, 0.06 mmol, 75%.  
1H NMR (500 MHz, CDCl3): ) 8.09 – 8.03 (m, 2H, Ar-H), 8.01 – 7.93 (m, 4H, Ar-H), 7.51 
(dt, J = 7.2, 3.1 Hz, 3H, Ar-H), 7.43 – 7.36 (m, 6H, Ar-H), 7.35 – 7.19 (m, 16H, Ar-H), 5.40 
– 5.30 (m, 2H, Gal-H2, Gal-H3), 5.05 (d, J = 3.1 Hz, 1H, Fuc-H1), 4.85 (q, J = 6.4 Hz, 1H, 
Fuc-H5), 4.83 – 4.66 (m, 5H, PhCH2, Gal-H1), 4.60 (d, J = 11.6 Hz, 1H, PhCH2), 4.46 (dd,  
J = 11.5, 4.3 Hz, 1H, Gal-H6a), 4.37 (dd, J = 11.5, 3.0 Hz, 2H, Gal-H6b, PhCH2), 4.08 – 3.95 
(m, 3H, Fuc-H2, Fuc-H3, Gal-H5), 3.69 – 3.60 (m, 2H, Fuc-H4, MeCy-H1), 3.22 (t, J = 9.1 
Hz, 1H, MeCy-H2), 2.49 (dd, J = 12.7, 2.2 Hz, 1H, Gal-H4a), 2.00 (d, J = 10.2 Hz, 1H, 
MeCy), 1.88 (m, 1H, Gal-H4b), 1.81 – 1.56 (m, 2H, MeCy), 1.52 (d, J = 10.4 Hz, 2H, 
MeCy), 1.35 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.07 (m, 5H, Cy-CH3 MeCy), 1.00 – 0.80 (m, 1H, 
MeCy); 13C NMR (126 MHz, CDCl3): ) 166.23, 166.13, 165.21 (3CO), 139.34, 139.21, 
138.69, 133.52, 133.42, 133.20, 129.93, 129.91, 129.81, 129.78, 129.52, 128.76, 128.55, 
128.48, 128.30, 128.27, 128.23, 128.05, 127.58, 127.41, 127.27 (Ar-C), 99.84 (Gal-H1), 
98.33 (Fuc-H1), 82.19 (MeCy-C2), 80.88 (MeCy-C1), 80.24, 78.97, 76.45 (Fuc-C2, Fuc-C3, 
Fuc-C4), 74.95, 74.49 (2PhCH2), 72.58, 72.34, 72.16 (Gal-C2, Gal-C3, PhCH2), 69.51 (Gal-
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C5), 66.30 (Fuc-C5), 66.16 (Gal-C6), 38.94 (MeCy), 33.30, 33.17 (Gal-C4, MeCy), 30.99, 
22.71 (MeCy), 18.79 (Cy-CH3), 17.03 (Fuc-C6); ESI-MS: m/z calcd for C61H64O13 [M+Na]+: 
1027.42, found: 1027.51. 
 
{(1R,2R,3S)-2-[(6-Deoxy-$-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 4-deoxy-!-
D-xylo-hexopyranoside (38) 
Compound 33 (50mg, 0.05 mmol) was deprotected according to general procedure B to yield 
38 (17 mg, 0.04 mmol, 81%). 
["]D20 -99.4 (c 0.19, MeOH); 1H NMR (500 MHz, D2O): ) 5.04 (s, 1H, Fuc-H1), 4.79 (Fuc-
H5 overlay with H2O), 4.40 (d, J = 7.8 Hz, 1H, Gal-H1), 3.84 (d, J = 10.6 Hz, 1H, Fuc-H3), 
3.79 – 3.71 (m, 2H, Fuc-H2, Fuc-H4), 3.71 – 3.46 (m, 5H, Gal-H3, Gal-H5, Gal-H6, MeCy-
H1), 3.16 (t, J = 9.5 Hz, 1H, MeCy-H2), 3.08 (t, J = 8.4 Hz, 1H, Gal-H2), 2.07 (s, 1H, Cy-
CH2a’), 1.91 (d, J = 8.3 Hz, 1H, Gal-H4b), 1.70 – 1.46 (m, 3H, MeCy), 1.24 (m, 3H, Gal-H4a, 
MeCy), 1.13 (d, J = 6.3 Hz, 3H, Fuc-H6), 1.04 (d, J = 5.6 Hz, 4H, Cy-CH3, MeCy);  
13C NMR (125 MHz, D2O, reference CD3OD): ) 102.16 (Gal-C1), 101.45 (Fuc-C1), 87.00 
(MeCy-C2), 81.22 (MeCy-C1), 77.31 (Gal-C2), 74.41, 74.40, 72.76 (Fuc-C4, Gal-C3, Gal-
C5), 71.63 (Fuc-C3), 70.56 (Fuc-C2), 68.69 (Fuc-C5), 66.57 (Gal-C6), 41.07 (MeCy), 36.89 
(Gal-C4), 35.53 (MeCy), 32.82 (MeCy), 24.90 (MeCy), 20.46 (Cy-CH3), 18.02 (Fuc-C6); 
HR-MS: m/z calcd for C19H34O10 [M+Na]+: 445.2044, found: 445.2053; HPLC-purity  
> 99.5%, Rt = 5.933 min. 
 
{(1R,2R,3S)-2-[(2,3,4-Tri-O-benzyl-6-deoxy-"-L-galactopyranosyl)oxy]-3-methyl-
cyclohex-1-yl} 2,3,4-tri-O-benzoyl-6-deoxy-!-D-galactopyranoside (34)  
Compound 34 was synthesized from 5 (40 mg,  0.073 mmol) and 28 (48 mg, 1.15 eq, 
0.84 mmol) according to general procedure. Yield: 35 mg, 0.035 mmol, 48%.  
1H NMR (500 MHz, CDCl3): ) 8.06 (d, J = 7.5 Hz, 2H, Ar-H), 7.96 (d, J = 7.5 Hz, 2H, Ar-
H), 7.81 (d, J = 7.6 Hz, 2H, Ar-H), 7.59 – 7.47 (m, 2H, Ar-H), 7.45 – 7.13 (m, 26H, Ar-H), 
5.77 – 5.65 (m, 2H, Gal-H2, Gal-H4), 5.51 (dd, J = 10.4, 3.5 Hz, 1H, Gal-H3), 5.10 (d,  
J = 2.3 Hz, 1H, Fuc-H1), 5.01 (d, J = 6.5 Hz, 1H, Fuc-H5), 4.88 (d, J = 11.5 Hz, 1H, PhCH2), 
4.85 – 4.72 (m, 4H, PhCH2, Gal-H1), 4.58 (d, J = 11.6 Hz, 1H, PhCH2a), 4.48 (d, J = 11.5 
Hz, 1H, PhCH2), 4.13 – 4.05 (m, 2H, Fuc-H2, Fuc-H3), 4.02 (d, J = 6.5 Hz, 1H, Gal-H5), 
3.73 – 3.64 (m, 2H, Fuc-H4, MeCy-H1), 3.29 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.02 (d, J = 10.6 
Hz, 1H, MeCy), 1.67 (s, 1H, MeCy), 1.54 (m, 1H, MeCy), 1.47 (d, J = 6.4 Hz, 3H, Fuc-H6), 
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1.28 (d, J = 6.4 Hz, 3H, Gal-H6), 1.16 (m, 1H, MeCy), 1.08 (d, J = 6.6 Hz, 3H, Cy-CH3), 
1.02 – 0.81 (m, 1H, MeCy); 13C NMR (125 MHz, CDCl3): ) 166.29, 165.75, 165.19 (3CO), 
139.38, 139.07, 138.60, 138.00, 133.65, 133.36, 133.24, 129.87, 129.78, 129.75, 129.67, 
129.17, 129.03, 128.72, 128.67, 128.49, 128.42, 128.36, 128.33, 128.28, 127.86, 127.69, 
127.43, 127.41, 127.27, 125.43 (Ar-C), 99.96 (Gal-C1), 97.92 (Fuc-C1), 81.21, 81.11, 80.19, 
79.67, 76.28 (MeCy-C1, MeCy-C2, Fuc-C2, Fuc-C3, Fuc-C4), 75.11, 74.46, 72.61 
(3PhCH2), 72.53 (Gal-C3), 71.69, 69.83, 69.69 (Gal-C2, Gal-C4, Gal-C5), 66.51 (Fuc-C5), 
39.22, 33.44, 31.14, 23.04 (4MeCy), 18.99 (Cy-CH3), 17.08 (Fuc-C6), 16.71 (Gal-C6); ESI-
MS: m/z calcd for C61H64O13 [M+Na]+: 1027.42, found: 1027.44. 
 
{(1R,2R,3S)-2-[(6-Deoxy-$-L-galactopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 6-deoxy-!-
D-galactopyranoside (39) 
Compound 34 (35 mg, 0.035 mmol) was deprotected according to general procedure B to 
give 39 (11 mg, 0.26 mmol, 74%). 
["]D20 -88.7 (c 0.2, MeOH); 1H NMR (500 MHz, D2O, CD3OD as reference): ) 5.09 (d, J = 
3.8 Hz, 1H, Fuc-H1), 4.84 (s, 1H, Fuc-H5), 4.47 (d, J = 7.9 Hz, 1H, Gal-H1), 3.90 (dd, J = 
10.5, 3.2 Hz, 1H, Fuc-H3), 3.84 – 3.75 (m, 2H, Fuc-2, Fuc-H4), 3.75 – 3.60 (m, 4H, Gal-H3, 
Gal-H4, Gal-5H, MeCy-H1), 3.48 (t, J = 8.9 Hz, 1H, Gal-H2), 3.20 (t, J = 9.5 Hz, 1H, MeCy-
H2), 2.14 (s, 1H, MeCy), 1.74 – 1.49 (m, 3H, MeCy), 1.27 – 1.20 (m, 5H, Gal-H6, MeCy), 
1.18 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.09 (d, J = 6.2 Hz, 4H, Cy-CH3, MeCy); 13C NMR (125 
MHz, D2O, CD3OD as reference): ) 100.51 (Gal-C1), 99.77 (Fuc-C1), 85.42 (MeCy-C2), 
79.50 (MeCy-C1), 73.94 (Gal-H2), 72.99 (Fuc-C4), 72.30, 71.31, 71.3 (Gal-C3, Gal-C4, Gal-
C5), 70.26 (Fuc-C3), 69.31 (Fuc-C2), 67.52 (Fuc-C5), 39.55 (MeCy), 34.15 (MeCy), 31.16 
(MeCy), 23.51 (MeCy), 19.09 (Cy-CH3), 16.63 (Gal-C6), 16.46 (Fuc-C6); HR-MS: m/z calcd 
for C19H34O10 [M+Na]+: 445.2044, found: 445.2048; HPLC-purity > 99.5%, Rt = 7.007 min. 
 
[(1R,2R,3S)-1-Hydroxy-3-methyl-cyclohex-2-yl] 6-deoxy-"-L-galactopyranoside (40) 
Compound 5 (32.8 mg, 0.06 mmol) was deprotected with Pd(OH)2/C (10%) in water/dioxane 
(1:4, 2.5 ml) under H2 (5 psi) to yield compound 40 (15 mg, 0.054 mmol, 91%).  
["]D20 = -119.3 (c = 0.60, MeOH); 1H NMR (500 MHz, D2O): ) 5.00 (s, 1H, Fuc), 4.30 (m, 
1H, Fuc-H5), 3.83 – 3.70 (m, 3H, Fuc-H2, Fuc-H3, Fuc-H4), 3.45 (s, 1H, MeCy-H1), 2.98 (t, 
J = 8.9 Hz, 1H, MeCy-H2), 1.91 (s, 1H, MeCy), 1.58 (m, 3H, MeCy), 1.23 (s, 2H, MeCy), 
1.12 (t, J = 5.8 Hz, 3H, Fuc-H6), 1.00 (t, J = 5.5 Hz, 4H, Cy-CH3, MeCy); 13C NMR (125 
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MHz, D2O, CD3OD as reference): ) 99.74 (Fuc-C1), 90.76 (MeCy-C2), 73.47 (MeCy-C1), 
72.84, 70.42, 69.31 (Fuc-C2, Fuc-C3, Fuc-C4), 67.88 (Fuc-C5), 38.05 (MeCy), 34.17, 34.11, 
23.75 (3MeCy), 18.88 (Cy-CH3), 16.29 (Fuc-C6); HR-MS m/z calcd for C13H24O6 [M+Na]+: 
299.1465, found: 299.1471; HPLC-purity > 99.5%, Rt = 7.749 min. 
 
Computational Methods 
Structure Preparation and Docking. For ligand docking the 1.8 Å resolution crystal 
structure of the carbohydrate recognition domain of DC-SIGN (PDB code 1SL5) was used. 
The downloaded structure was pre-processed using Maestro’s protein preparation wizard 
(Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011). Hydrogen atoms were 
added, bond orders were corrected, and protonation states were assigned to yield a fully 
atomistic model of the complex. Finally, this model was subjected to energy minimization 
using OPLS 2005 forcefield within heavy-atom RMSD of 0.3 Å to relive strain and steric 
clashes. For docking experiments, the co-crystallized ligand LNFP III was used to define the 
binding site before it was deleted. Additionally, two water molecules were common to 
several available crystal structures of DC-SIGN (W437 and W439 according to 1SL5 
numbering) and were, thus, used as part of the binding site. Ligand docking was then 
obtained through flexible docking using the default settings in Glide (Glide, version 5.5, 
Schrödinger, LLC, New York, NY, 2009). Resultant poses were visually inspected and the 
ones lacking key interactions with DC-SIGN (e.g. calcium coordination) were dismissed. 
 
Free energy perturbation (FEP). FEP coupled to MD simulations with explicit solvent is 
considered one of the reference computational approaches for estimating free energies.63 In 
FEP simulations, the system is gradually mutated from one state to another through multiple 
windows, and the effect of this perturbation onto the free energy is monitored.64 Since the 
structural changes in the deoxy derivatives (37, 38, 39) are relatively small compared to 8 
(replacing a hydroxyl group with a hydrogen), they are best suited for free energy predictions 
using FEP. For this purpose, the FEP implementation in Desmond was employed and the 
default settings were used. System setup similar to that used in our MD simulations was 
employed across 12 lambda-windows to simulate the transition from the un-perturbed 
(hydroxyl) to the fully perturbed (hydro) states. Due to the higher computational cost, the 
FEP simulations were 1.2 ns long.!
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Molecular Dynamics. Molecular dynamics (MD) simulations were carried out for docked 
ligands with Desmond65 using the OPLS 2005 force field as implemented in the Schrödinger 
2011 suite. Each system was solvated using an orthorhombic, TIP3P water 66 box with a 
minimum distance of 10 Å from the complex. Na+ and Cl- ions were added to neutralize the 
charges and account for physiological salt concentration (0.15 M). All systems were 
equilibrated using the default relaxation protocol (Desmond 2.2; Schrödinger, Inc., New 
York, NY) and simulated over the span 30 ns with a time step of 2.0 fs. The SHAKE 
algorithm67 was applied to all heavy-atom bound hydrogens. Production runs were carried out 
in the Martyna-Tobias-Klein isothermal-isobaric ensemble (NPT)68 using the Nose-Hoover 
barostat to maintain a constant temperature of 300 K.69 Energies and geometries were 
recorded in 1.2 ps intervals. Output trajectory were analyzed using component-interactions 
script in Maestro to compute interaction energies between the ligand and individual amino 
acids defining the binding site as well as the conserved calcium along the MD simulations. 
Non-bonded interactions were computed as the sum of OPLS 2005 Van der Waals and 
electrostatic terms. For Lex (1) and 8 the solvent accessible surface areas (SASA) were 
calculated using a water probe simulated as a sphere of radius 1.4 Å to map the complex 
surface at a resolution of 0.2 Å. 
 
Biological Evaluation  
Protein expression, competitive polymer assay, and ITC experiments were performed as 
previously described (Chapter 2.2.1). 
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2.3.1.1 Synthesis of (1R,2R,3S)-3-methyl-cyclohexane-1,2-diol as D-GlcNAc mimic 
 
The D-GlcNAc mimic 3, used for the synthesis of Lex trissacchride mimics (chapter 2.3.1), 
was synthesized according to a procedure developed by Daniel Schwizer, a former coworker, 
in the course of his PhD thesis.1 Starting from cyclohex-2-en-one (2) the D-GlcNAc mimic 3 
is accessible in a 6-step synthesis (Scheme 1). By bromination of the starting material 2 a 
sterically demanding group was introduced in "-position ('2.1). Subsequent Corey-Bakshi-
Shibata reduction led to alcohol 2.2 stereoselectively. After halogen-metal exchange with 
tert-BuLi and subsequent hydrolysis, the obtained secondary alcohol (R)-2.3 was tritylated to 
give 2.4. Epoxidation of compound 2.4 with m-chloroperoxybenzoic acid yielded epoxide 2.5 
with an anti-preference (syn:anti(7:3). The nucleophilic opening of epoxide 2.5 by higher-
order cyanocuprate Me2Cu(CN)Li2 in presence of BF3·Et2O afforded 3 in high yields. 
Fucosylation of the D-GlcNAc mimic 3 with fucosyl donor 42,3 was performed under in situ 
anomerization conditions to yield predominantly the "-fucoside. Detritylation of the 
cyclohexane derivative 3.1 in presence of ZnBr2 as mild Lewis acid and triethylsilane (TES) 
as trityl cation scavenger yielded the $-fucoside 5.  
 
 
Scheme 1. a) i) Br2, CH2Cl2, 0°C, 2.5 h, ii) Et3N, CH2Cl2, r.t., 2 h, 64%; b) (S)-$,$-diphenyl-prolinol, B(OMe)3, 
BH3·N,N-diethylaniline, THF, -10°C-0°C, 3.75 h, 93% (96% ee); c) i) t-BuLi, Et2O, -78°C to -20°C, 4.75 h, ii) 
aq. NaHCO3, -20°C-r.t., 1 h, 87%; d) Ph3CCl, CH2Cl2, DBU, r.t., 12 h, 79%; e) m-CPBA, NaHCO3, CH2Cl2; 
0°C-r.t., 5 h, 70% f) MeLi, CuCN, BF3·Et2O, THF, -78°C to -30°C, 5-8 h, 96% g) TBAB, 2,6-di-tert-butyl-4-
methylpyridine, MS 4Å, CuBr2, DMF, CH2Cl2, r.t., 20 h, 43%; h) ZnBr2, TES, CH2Cl2, r.t., 10 h, 63%. 
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2.3.2 (1R,2R)-cyclohexadiol as D-GlcNAc mimic 
 
In a previous study (chapter 2.3.1) we identified (1R,2R,3S)-methylcyclohexadiol as a 
feasible replacement for D-GlcNAc in Lex leading to a moderate improvement in affinity. 
However, the thermodynamic profile indicated non-optimal properties. Despite a gain in 
enthalpy (((H ( -7.6 kJ/mol), this replacement was accompanied by an unfavorable entropic 
term (-T((S ( 6.3 kJ/mol). For DC-SIGN, the concept of preorganization1,2 as realized for 
the Lex mimic 2* was outranged by desolvation effects.  
Since a cyclohexadiol-based mimic was shown to be more flexible, i.e. less preorganized 
compared to a methylcyclohexadiol-based,3 mimic 3 with (1R,2R)-cyclohexadiol replacing D-
GlcNAc was synthesized (Figure 1). 
 
 
Figure 1. Lex (1) and two Lex mimics with (1R,2R,3S)-methylcyclohexadiol ('2*) and (1R,2R)-cyclohexadiol 
('3) as replacment for GlcNAc. 
 
Trisaccharide mimic 3 was synthesized from pseudo-disaccharide 44  that was glycosylated 
!-selectively with galactosyl donor 55 using DMTST as promoter. Removal of benzoyl 
groups under Zemplén conditions and hydrogenolytic cleavage of benzyl groups yielded 
mimic 3 (Scheme 1). 
 
Scheme 1. a) Glycosyl acceptor 44 and donor 55, DMTST, MS4Å, CH2Cl2, r.t., 16 h; b) i) NaOMe, MeOH, 5 h; 
ii) Pd(OH)2/C, dioxane/water, 6 h; 22% over three steps. 
 
Mimic 3 was tested for affinity towards DC-SIGN in a target-based, competitive binding 
assay and by ITC experiments. The results are listed in Table 1 with data of Lex (1) and the 
respective methcyclohexadiol bearing mimic 2* for comparison. 
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Table 1. Results of the competitive polymer binding assay with DC-SIGN CRD and Lea-PAA as 
competitor. ITC experiments were performed at 278 K with DC-SIGN CRD. 
Entry Structure 
IC50 
[mM] 
KD 
["M] 
"G 
[kJ/mol] 
"H 
[kJ/mol] 
-T"S 
[kJ/mol] 
1 
 
3.8  
(n=1) 
1068 ± 13 
(n=2) -17.0 ± 0.0 -23.8 ± 0.3 6.9 ± 0.3 
2 
 
1.9 ± 0.4 645 -18.2 ± 0.5 -31.4 +13.2 
3 
 
0.7± 0.2 445 -19.1 -32.9 +13.8 
 
 
As discussed in chapter 2.3.1, the exchange of D-GlcNAc in Lex (1) by (1R,2R,3S)-
methylcyclohexadiol ('2*) entailed an improvement in affinity by a factor of two. With 
mimic 3 a further improvement in affinity compared to 2* (0.7 mM vs. 1.9 mM, respectively) 
was observed (Table 1). ITC experiments reveal a less pronounced effect with a KD of 
445 &M for 3 compared to 645 &M for 2*. 
The thermodynamic profile of 3 resembles the results found for 2*. Neither the enthalpic, nor 
the entropic contributions are significantly different. The cyclohexadiol derivative 3 is 
assumed to be more flexible.2,3,6 The degree of preorganization seems to be not relevant and 
with respect to 3 rather counterproductive for binding to DC-SIGN.  
In summary, this example illustrates the complexity in designing the proper mimic for a 
solvent-exposed binding site, such as in DC-SIGN. The replacement of D-GlcNAc by a 
simple cyclohexyl moiety is obviously effective in terms of conformational freedom and gain 
in affinity. Further optimization of this moiety should be directed towards improvement of 
solvation properties.  
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EXPERIMENTAL SECTION 
General Methods: see chapter 2.3.1 
Synthesis of (1R,2R)-2-hydroxycyclohexyl-2,3,4-tris-O-benzyl-6-deoxy-$-L-galactopyrano-
side  4 was done by a co-worker  (R.O. Duthaler) according to a published procedure.4 
 
(1R,2R)-1-O-(2,3,4-Tri-O-benzoyl-6-O-benzyl-!-D-galactosyl)-2-O-(2,3,4-tri-O-benzyl-6-
deoxy-$-L-galactosyl)-cyclohexane-1,2-diol (6) 
Compound 4 (107 mg, 0.2 mmol) and 5 (163 mg, 1.3 eq. 0.26 mmol) were dissolved in 
anhydrous CH2Cl2 (4.0 ml). Powdered activated molecular sieves 4Å (0.4 g) were added and 
the mixture was stirred at r.t. under argon. After 3.5 h, a solution of DMTST (155 mg, 3 eq, 
0.6 mmol) in anhydrous CH2Cl2 (1.5 mL) that had been stirred with molecular sieves 4Å 
(0.15 g) for 3.5 h, was added. After stirring for 30h, the solution was diluted with CH2Cl2 (30 
ml), filtered, and successively washed with satd. aq. NaHCO3 (50 ml) and brine (50 ml). The 
aqueous layers were extracted with CH2Cl2 (2x 50 ml) and the combined organic layers were 
dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by column chromatography (PE/MTBE, gradient) to afford an unseperable mixture of 
unreacted starting material and the trisaccharide mimic 6. This mixture was directly used for 
the next step. 
 
(1R,2R)-1-O-(!-D-galactosyl)-2-O-($-L-fucosyl)-cyclohexane-1,2-diol (6) 
Intermediate 6 (100 mg) was dissolved in MeOH (1 ml) and a catalytic amount of NaOMe 
(1M methanolic solution) was added at r.t. After stirring for 2h the mixture was neutralized 
with AcOH and evaporated. The residue was purified by column chromatography on silica 
gel (PE/EtOAc) and used for the next step.  
A mixture of debenzoylated intermediate and Pd(OH)2/C (10%) in dioxane/water (4:1, 1.5 
ml) was treated with H2 (atm. pressure) overnight. The reaction mixture was filtered over 
celite. The celite was washed with MeOH (15 ml). The filtrate was evaporated to dryness. 
The residue was purified by column chromatography on silica gel (DCM/MeOH, 1:0 '10:4) 
and to yield 3 (19 mg, 22% over 3 steps). For biological assays the product was further 
purified by preparative RP-HPLC. 
[a]D20 -119.4 (c 0.14, MeOH); 1H-NMR (500 MHz, MeOD): ) 4.89 (Fuc-H1), 4.61 (dd, J = 
13.1, 6.5 Hz, 1H, Fuc-H5), 4.31 (m, 1H, Gal-H1), 3.89 (dd, J = 10.1, 3.3 Hz, 1H, Gal-H3), 
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3.84 (s, 1H, Gal-H4), 3.82 – 3.65 (m, 5H, Cy-H, Fuc-H2, Fuc-H4, Gal-H6), 3.58 (td, J = 9.3, 
4.4 Hz, 1H, Cy-H), 3.53 – 3.43 (m, 3H, Fuc-H3, Gal-H2, Gal-H5), 2.07 (d, J = 2.5 Hz, 2H, 
Cy), 1.80 – 1.66 (m, 2H, Cy), 1.48 – 1.23 (m, 4H, Cy), 1.21 (d, J = 6.6 Hz, 3H, Fuc-H6); 13C-
NMR (126 MHz, MeOD) ): 102.64 (Gal-C1), 97.26 (Fuc-C1), 79.23, 77.40 (Cy-C1, Cy-C2), 
76.48, 74.97, 73.80, 72.67, 71.56, 70.22, 70.01 (Fuc-C2, Fuc-C3, Fuc-C4, Gal-C2, Gal-C3, 
Gal-C4, Gal-C5), 67.43 (Fuc-C5), 62.84 (Gal-C6), 30.84, 29.97, 24.38, 24.35 (Cy), 16.56 
(Fuc-C6); HR-MS: m/z calcd for C18H32O11 [M+Na]+: 447.1837, found: 447.1843. 
 
Biological evaluation 
Polymer binding assays and ITC experiments with DC-SIGN CRD-Fc were performed as 
described in chapter 2.3.1 by Meike Scharenberg, and Roland Preston, respectively (at the 
Institute of Molecular Pharmacy, University of Basel). 
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2.3.3 Synthesis of tetrahydropyran-based DC-SIGN antagonists 
 
BACKGROUND 
Binding of monovalent oligosaccharides to DC-SIGN is of weak nature. DC-SIGN 
recognizes mannosidic as well as fucosidic ligands. As a consequence of the shallow, 
solvent-exposed binding pocket offered by DC-SIGN, ligands are bound in multiple binding 
poses.1,2 Therefore, the design of high-affinity ligands is still a challenging task. 
Our analysis of binding modes of Lewis antigens with different aglycones (chapter 2.2.1) 
demonstrated that Lea and Lex bearing a phenyl moiety are able to establish an additional 
hydrophobic contact with Phe313 (Figure 1). During our studies, other research groups 
discovered as well the potential of this interaction to improve affinity of mannose- and 
fucose-based antagonists. Consequently, studies on introducing different residues allowing 
for an interaction with the hydrophobic cleft lined by Phe313 and Lys371 were initiated.3-5 
Addressing this site is also related to selectivity of DC-SIGN antagonists and presents 
therewith an additional benefit.4 
           
Figure 1. Structure of phenyl Lea (1)* and binding mode derived from docking to the crystal structure of DC-
SIGN (PDB 1SL56, Sameh Eid, Institute of Molecular Pharmacy, University of Basel). The phenyl aglycone 
addresses the hydrophobic cleft formed by Phe313 and Leu371, the GlcNAc moiety is arranged in proximity to 
protein surface. 
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To investigate the nature of the #-#-interaction, we determined the binding affinity of a Lea 
derivative bearing an electron-rich p-methoxyphenyl aglycone (Arjan Odedra, Institute of 
Molecular Pharmacy, University of Basel). This compound exhibited a twofold lower affinity 
to DC-SIGN CRD than phenyl Lea (1) (competitive polymer assay performed by Meike 
Scharenberg, Institute of Molecular Pharmacy, University of Basel). This can be ascribed to 
weaker interaction of the aromatic moiety of the ligand with Phe313 and Lys373. 
Consequently, electron-withdrawing groups were considered favorable. Free energy 
perturbation (FEP) simulations were initiated to support this hypothesis (Table 1). These 
calculations indicate for derivatives of phenyl Lea that both o- and m-fluoro-substitutions (2 
and 3) at the phenyl aglycone are associated with improvement of interaction energy. 
  
Table 1. FEP calculation of fluorophenyl Lea derivatives. Changes in free energy of binding are given relative 
to phenyl Lea (1). More negative values indicate a gain in affinity. 
 
   
''GFEP 
[kcal/mol] -2.3 ± 0.3 -2.7 ± 0.3 +1.6 ± 0.3 
 
 
Based on these data, we designed a new series of DC-SIGN antagonists (Figure 2). As we 
previously exchanged the D-GlcNAc moiety with an improvement in affinity (chapter 3.2.1 
and 3.2.2) we applied the same approach with this series. Consequently, an appropriate 
D-GlcNAc mimic as well as an aromatic moiety capable of addressing Phe313 were 
introduced. 
We decided to start from a glucal-derived D-GlcNAc mimic which allows introduction of 
different aromatic moieties via amide coupling in a late step of the synthesis (Schemes 
1 and 2). Our starting point for choosing an aromatic moiety were the FEP simulations of 
phenyl Lea derivatives (Table 1), indicating m-fluoro-substituted phenyl residue to be most 
beneficial. Crystallographic data derived for various ligands binding to DC-SIGN imply 
Phe313 to be a rather flexible residue, able to adjust its orientation.7 Hence, the binding site is 
supposed to be flexible enough to orient the phenyl ring in fluoroanilides 5, 6, and 7 
(Figure 2) close to Phe313.  
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In order to investigate effects of D-Gal in this series and the novel “lying” binding mode 
(described in chapter 2.2.1), D-Gal (6), hydroxyl (5) and hydrogen (7) at 3-position of the 
hexon amide based D-GlcNAc mimic were studied.  
 
 
Figure 2. General structure of amides. 
 
 
RESULTS AND DISCUSSION 
Synthesis of glucal building block8 
Starting from the peracetylated glucal 8, intermediate 11 was synthesized following a 
published procedure.8 Building block 11 was reacted with ethyl thiofucoside 129 under 
Ogawa conditions to yield 13 in up to 90% yield.10 Opening of the anisylidene acetal with 
NaCNBH3/TMSCl and BH3&THF/TMSOTf as suggested by Spohr et al.8 yielded a mixture of 
4-OH, 6-OH and 4,6-di-OH derivatives in an approximate 1:1:1 ratio. Regioselectivity could 
be improved with n-Bu2BOTf/BH3&THF, leading predominantly to the formation of the 6-OH 
compound 14a.11 However, during work-up the dihydroxy derivative 14b was formed in 
equal amount. Different work-up methods failed to improve this ratio.  
 
 
Scheme 1. a) Pd/C, H2, EtOH/EtOAc 1:1, 4 h, quant.; b) NaOMe, MeOH, r.t. 12-24 h, 98%; c) 4-methoxy-
benzaldehyde dimethyl acetal, DMF, camphor sulfonic acid, 40°C, 12 h, 69%; d) TBAB, 2,6-di-tert-butyl-4-
methylpyridine, MS 3Å, CuBr2, DMF, CH2Cl2, r.t., 20 h, 76%; e) Bu2BOTf, BH3&THF, 0°C, 1h, 72% of 14a, 
22% of 14b. 
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Synthesis of anilides 5 and 6 
 
 
Scheme 2. a) TEMPO, NaOCl, NaBr, TBAB, NaHCO3, r.t., 1h, 87%; b) DIC, HOBt, 73%; c) CAN, 
CH3CN/H2O (9:1), r.t., 44%; d) i) Pd(OH)2/C, dioxane/H2O, 52%; e) DMTST, MS 4Å, CH2Cl2, r.t., 12 h, 68%; 
f) i) Pd(OH)2/C, dioxane/H2O, ii) NaOMe, MeOH, 53%. 
 
Following a procedure from Huang et al.17 the free 6-OH group was oxidized using 2,2,6,6-
tetra-methylpiperidine-1-oxyl (TEMPO) and NaOCl. Spectroscopic characterization of the 
4-O-PMB-6-COOH derivative 15a was not possible most likely due to TEMPO remainders 
that could not be removed by excessive chromatographic purification. Direct transformation 
into the amide using standard coupling reagents yielded the 3-fluoro-anilide 16 in moderate 
yield. The PMB protection group was removed by treatment with ceric ammonium nitrate 
(CAN) to give 17. Further hydrogenolytic cleavage of the benzyl groups afforded test 
compound 5. Coupling of 17 with galactosyl donor 189 using dimethyl(methylthio)sulfonium 
triflate (DMTST) as promoter gave after deprotection test compound 6.  
 
 
Synthesis of deoxy derivative 7 
The attempt to access the deoxy derivative 7 via deoxygenation of compound 17 using 
Barton McCombie deoxygenation conditions failed, probably because transformation into the 
thiocarbonyl derivative is sterically and electronically disfavored. Therefore, the 
deoxygenated derivative was synthesized according to Scheme 3. The dihydroxy derivative 
14b was protected selectively in 6-O-position with TBDMS. 20 was transformed into the 
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imidazolylthiocarbonyl derivative ('21) and deoxygenated with tributyltinhydride according 
to standard Barton McCombiedeoxygenation conditions ('22). 
Deprotection of 22 yielded the 6-OH derivative (23) in 80% yield. Oxidation with 
TEMPO/NaOCl gave carboxylic acid 24 which was reacted with m-fluoroaniline to give 
amide 25. Final deprotection led to the anilide 7. 
 
 
 
Scheme 3. a) TBDMSCl, Et3N, pyridine, r.t., 1-3h, 73%; b) TCDI, DMAP, C4H4Cl2, 6h,: ), 55%; c) Bu3SnH, 
AIBN, PhCH3, 4h,: ), 80%; d) TBAF, AcOH, THF, 10h, r.t., 40-80%; e) TEMPO, NaOCl, NaBr, TBAB, 
NaHCO3, r.t., 1h, 75%; f) DIC, HOBt, DIPEA, CH2Cl2/DMF (1:1), 0°C, 12h, 65%; g) Pd(OH)2/C, H2 (atm.) 
dioxane/H2O (4:1), 67%; 
 
 
Synthesis of alcohol 27 and ester 30  
In addition to the three anilides, two compounds without aromatic moiety were synthesized. 
Compound 27 was obtained as outlined in Scheme 4. The silylether derivative 20 was 
glycosylated with 189 using DMTST to give primarily the !-galactoside 26. Cleavage of the 
silyl ether with TBAF, hydrogenolytic cleavage of benzyl groups, and removal of benzoyl 
groups under Zemplén conditions yielded 27.  
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Scheme 4. a) DMTST, 12h, r.t., 63%; b) i) TBAF; ii) NaOMe, methanol, r.t., 1h; iii) Pd(OH)2/C, H2 (atm. 
pressure), dioxane/water (4:1), 12h, 24%; 
 
The methyl ester was obtained via esterification of the carboxylic acid of 14b with 
trimethylsilyldiazomethane and subsequent deprotection of benzyl groups (Scheme 5). 
 
 
 
Scheme 5. a) TEMPO, NaOCl, NaBr, TBAB, NaHCO3, r.t., 1h, 62 %; b) TMSCHN2, toluene/methanol (3:2), 
r.t., 10h, 59%; b) Pd(OH)2/C, H2 (atm. pressure), dioxane/water (4:1), 12h, 53%; 
 
 
Biological evaluation  
Table 1 summarizes the results from a competitive polymer binding assay with 
DC-SIGN CRD-Fc vs. Lea-polyacrylamide (performed by Meike Scharenberg, Institute of 
Molecular Pharmacy, University of Basel). These affinity data indicate no significant 
improvement of binding affinity originating from the fluorophenyl moiety. However, the 
results further support the assumption that the D-Gal moiety is indeed not crucial for binding. 
Anilides 5, 6, and 7 have affinities around 1.1 mM, the respective methyl ester analogue 30 
exhibits the same affinity. A slight improvement was detected for the trisaccharide mimic 27. 
As a matter of fact, data for compound 27 are in accordance with the previous cyclohexadiol 
mimic (chapter 2.3.3). Most likely, this compound binds in the upright binding mode known 
from co-crystallization of LNFP III (Lex) with DC-SIGN.6 
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Table 1. IC50 values and relative IC50 values with phenyl Lea (1) as reference for binding to 
DC-SIGN CRD-Fc. (determined by Meike Scharenberg, University of Basel). 
Compound No. Structure IC50 [mM] rIC50 
Phenyl Lea (1) 
 
0.9 1 
5 
 
1.2 ± 0.8 
(n=3) 
1.3  
6 
 
1.1 ± 0.2 
(n=2) 
1.2  
7 
 
1 ± 0.5 
(n=3) 
1.1  
30 
 
1.1 ± 0.1 
(n=2) 
1.2 
27 
 
0.5 ± 0.2 
(n=2) 
0.7  
 
Our initial assumption for synthesis of this series was a comparable binding mode of 
compounds 5, 6, 7, and phenyl Lea (1). However, docking studies revealed a complex picture 
with diverse binding modes for these structures (Sameh Eid, Institute of Molecular 
Pharmacy, University of Basel).  
Figure 3 displays the top-ranked binding poses of 1 and 5. Both adopt an overall similar 
orientation with coordination of Ca2+ via 2- and 3-OH of L-Fuc. However, the phenyl moiety 
of mimic 5 is suboptimally arranged resulting in poor interaction with Phe313. Consequently, 
the affinity towards DC-SIGN is not improved. 
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Figure 3. Overlay of top-ranked docking poses for phenyl Lea (1, green carbons) and anilide 5 (orange carbons) 
derived by automated docking with DC-SIGN (PDB 1SL56, Sameh Eid, University of Basel). The Ca2+ is 
illustrated as magenta sphere. 
 
Compound 30 adopts an equal position as 5 (Figure 4). Despite no phenyl moiety being 
present in this mimic, the “lying” binding mode is favored. The D-GlcNAc mimic adopts an 
inverted orientation compared to 5, which allows a van der Waals contact of its lipophilic 
part with Phe313. Additionally, H-bonds can be established via the hydroxyl and the ester 
group with the protein (not shown). 
 
 
Figure 4. Comparison of top-ranked docking modes found for 5 (left) and 30 (right) obtained by automated 
docking with DC-SIGN CRD (PDB 1SL56, Sameh Eid, University of Basel). Mimics are oriented similarly, i.e. 
L-Fuc coordinates the Ca2+ (magenta sphere) via 2- and 3-OH. In 30 van der Waals contacts with Phe313 are 
established via the D-GlcNAc mimic. 
 
Mimic 6 that shows the closest resemblance to 1, surprisingly, adopts favorably the upright 
binding position as seen for Lex (Figure 5).6 In contrast to D-GlcNAc, the tetrahydropyran-
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based mimic can not establish H-bond interactions with the protein, additionally the 
orientation of the phenyl moiety is non-optimal in the lying binding mode, resulting in the 
preference of an upright binding position. In this orientation compound 6 can form a H-bond 
network similar as seen for Lex (Chapters 2.1 and 2.2.1), via its terminal D-Gal moiety. The 
deoxy mimic 7 revealed a top-ranked binding mode not related to any of the other binding 
modes (not shown). 
 
Figure 5. Mimic 6 docked into DC-SIGN CRD (PDB 1SL56, Sameh Eid, University of Basel) preferably adopts 
an upright binding position allowing interaction with DC-SIGN via Fuc and Gal 
 
Ultimately, coordination of calcium by L-Fuc is the only consistency in this series. Due to the 
poor interaction with Phe313 in the mimic series, the binding mode is adjusted individually 
by each ligand. The assumed advantageous contribution of a fluoro substituent, hence, could 
not be shown.  
In summary, this series of anilides (5, 6, 7) presents no significant advantage over phenyl Lea 
or other phenyl-lacking DC-SIGN antagonists (e.g. 27 and 30). Yet, despite the non-optimal 
arrangement of these compounds affinities were comparable to 1. The exchange of D-GlcNAc 
for a tetrahydropyran-based mimic is therewith feasible. Furthermore, affinity data for this 
series of compounds substantiates the insignificance of D-Gal for binding.  
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CONCLUSION 
The shallow binding site of DC-SIGN accommodates different types of oligosaccharides in 
different binding modes.1,12 As found previously, the introduction of a phenyl aglycone leads 
to improved affinity for Lea. When these findings were applied in this new series of 
DC-SIGN ligands, no further improvement of affinity was achieved. In spite of the flexibility 
of the DC-SIGN binding site and the ligands, the aromatic moiety present in this series could 
not be optimally positioned resulting in a poor interaction with Phe313. This led to different 
binding modes for each of the hexon amide derivatives. 
Other researchers follow the same approach and address this hydrophobic cleft by according 
modifications of L-Fuc and D-Man-based monovalent ligands.4,5,13 Though, to the best of our 
knowledge, up to now no high-affine monovalent, carbohydrate-based ligands for DC-SIGN 
have been developed. Our series of compounds demostrates the challenge of developing 
monovalent high-affinity antagonists for DC-SIGN. Crucial for the design of such ligands, is 
a comprehensive amount of experimental data, such as affinity data and crystallographic data. 
 
 
EXPERIMENTAL SECTION 
General Methods: Commercially available reagents were purchased from Fluka, Aldrich, 
Merck, and Abcr. Solvents were dried prior to use as indicated. Dichloromethane (CH2Cl2), 
1,2-dichloroethane (DCE), and acetonitrile (MeCN) were dried by filtration over Al2O3 
(Fluka, type 5016 A basic). DMF, pyridine, and toluene were dried by distillation from 
calcium hydride. Tetrahydrofuran (THF) was dried by distillation from 
sodium/benzophenone. Methanol (MeOH) was dried by refluxing with sodium methoxide 
and distilled immediately before use. Molecular sieves (3Å, 4Å) were activated under 
vacuum at 500ºC for 1 h immediately before use. Reactions were monitored by TLC using 
glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate 
and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography 
was performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep normal 
phase disposable flash columns (silica gel, 40-63 µm). Reversed phase chromatography was 
performed on LiChroprepRP-18 (Merck, 40-63 µm). LC-MS: separations were carried out 
using Sunfire C18 columns (19 x 150 mm, 5.0 &m) on a Waters 2525 LC, equipped with 
Waters 2996 photodiode array and Waters micromass ZQ MS: for detection. Electron spray 
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ionization mass spectra (ESI-MS:) were obtained on a Waters micromass ZQ. HR-MS: 
analysis were carried out using a Agilent 1100 LC equipped with a photodiode array detector 
and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Optical rotations 
were measured using Perkin-Elmer polarimeter 341. Microanalysis was performed at the 
Institute of Organic Chemistry at the University of Basel, Switzerland. Compound purity was 
determined on an Agilent 1200 HPLC; ELS detector, Waters 2420; column: Waters Atlantis 
dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water + 
0.1% TFA. Gradient A for compounds 5, 6, and 7; linear gradient: 0 - 2 min 2% B; 2-15 min 
2 to 50% B; 16 - 20 min 50 to 2% B flow: 0.5 mL/min. Gradient B for compound 30; linear 
gradient: 0 - 1 min 5% B; 1 - 15 min 5 to 70% B; 16 - 20 min 70 to 5% B flow: 0.5 mL/min. 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMBC, TOCSY). Chemical shifts are expressed in ppm in relation to the residual solvent 
signals (CHCl3, CHD2OD, and HDO) on the: )-scale. Coupling constants  
J are given in Hertz (Hz). Multiplicities were specified as follows: s (singlet), d (doublet), dd 
(doublet of a doublet), t (triplet), q (quartet), m (multiplet). For assignment of resonance 
signals to the appropriate nuclei the following abbreviations were used: Fuc (fucose), Gal 
(galactose), Hex (hexitol, hexonic acid, or hexon amide). 
 
1,5-Anhydro-2-deoxy-D-arabino hexitol (10) 
3,4,6-Tri-O-acetyl-1,5-anhydro-2-deoxy-D-arabino-hex-1-enitol (8) (4.50 g, 16.5 mmol) was 
dissolved in EtOAc/EtOH (1:1, v/v, 30 ml). Pd/C was added (0.4%, 20 mg) and the mixture 
was shaken overnight with a Parr shaker under H2 atmosphere (5 bar). The catalyst was 
filtered off and the product was used without further purification for the next step. The  
1,5-anhydro-2-deoxy-3,4,6-tri-O-acetyl-D-arabino hexitol (9) was dissolved in anhydrous 
MeOH (20 ml) and treated with a methanolic solution of NaOMe (1 M, 1 ml). Upon 
complete cleavage of the acetyl groups (12 h) the mixture was concentrated and purified by 
flash column chromatography (CH2Cl2/MeOH). Yield: 2.45 g, 96%. 
Spectroscopic data were in accordance with literature.14-16 
 
1,5-Anhydro-2-deoxy-4,6-O-(4-methoxybenzylidene)-D-arabino hexitol (11) 
Compound 11 was synthesized according to a procedure from Spohr et al.8 
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A solution of 10 (2.40 g, 16.2 mmol), p-methoxybenzaldehyde dimethyl acetale (2.80 ml, 
1 eq, 16.2 mmol)  and camphorsulfonic acid  (280 mg, 0.1 eq, 1.62 mmol) in DMF (20 ml) 
was stirred overnight at r.t. The solvent was co-evaporated with toluene, then EtOAc was 
added and the mixture was washed with water. The aqueous phase was extracted with EtOAc 
and the combined organic phases were dried over Na2SO4, filtered and concentrated. 
Successive crystallization of the product from EtOAc/n-hexane gave 11 (2.97 g, 69%). 
 
General procedure A for oxidation (adapted from Huang et al.17): 
Aqueous solutions of NaBr (1 M, 25  µL), tetrabutylammonium bromide (1 M, 50 µL), a 
satd. aq. solution of NaHCO3 (125 µL) and 2,2,6,6-tetramethyl-1-piperidinyl-N-oxide 
(TEMPO) (2.2 mg, 0.014 mmol, 0.3 eq) were added to a solution of alcohol (0.045 mmol) in 
CH2Cl2 (1 mL) and H2O (170 µL) in an ice-water bath. The resulted mixture was treated with 
an aqueous solution of NaOCl (150 µL, chlorine content not less than 4 %) and was stirred 
and warmed to r.t.  After complete conversion (2 h) water and CH2Cl2 were added and the 
phases were separated. The aqueous phase was extracted with EtOAc. The organic phases 
were combined and dried over Na2SO4, filtered, and concentrated. Flash column 
chromatography (CH2Cl2/MeOH gradient +0.1% AcOH) yielded the product.  
 
General procedure B for amide coupling: 
Starting material (0.1 mmol) was dissolved in anhydrous CH2Cl2/DMF (1 ml, v/v, 1:1) or 
anhydrous CH2Cl2. Hydroxybenzotriazole (HOBt) (14.9 mg, 1.1 eq,  0.11 mmol) and amine 
(48 µl, 5 eq, 0.5 mmol) were added. The mixture was cooled to 0°C and 
N,N’-diisopropylcarbodiimide (DIC) (16.5 µl, 1.1 eq, 0.11 mmol) was added. The mixture 
was stirred overnight and warmed to r.t. The reaction mixture was diluted with CH2Cl2 and 
then washed with NaHCO3 and brine. The aqueous phase was extracted with CH2Cl2 and the 
combined organic layers were dried with Na2SO4 and filtered. The solvent was evaporated 
under vacuum and the residue was purified by flash column chromatography. 
 
General Procedure C for deprotection by hydrogenation: 
A mixture of starting material (0.03 mmol) and Pd(OH)2/C (10%) in dioxane/water (4:1, 1 
ml) was treated with hydrogen at atmospheric pressure. The reaction was controlled by TLC. 
Upon completion the mixture was filtered, the solvent was removed under reduced pressure 
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and the resulting residue dried in vacuo. The crude product was either used for the next 
deprotection step or, in case of target compounds, purified by column chromatography on 
silica gel (CH2Cl2/MeOH). 
 
General Procedure D for saponification with NaOMe: 
To a solution of 12 (0.03 mmol) in dry MeOH (1 ml) was added a catalytical amount of 
freshly prepared NaOMe solution (1M) at r.t. Reaction was monitored by TLC. Upon 
completion the mixture was neutralized with 1N HCl and the solvent evaporated under 
reduced pressure. The residue was purified by column chromatography on silica gel 
(CH2Cl2/MeOH). 
 
1,5-Anhydro-2-deoxy-4,6-O-(4-methoxybenzylidene)-3-O-(6-deoxy-2,3,4-tri-O-benzyl)-
"-L-galactopyranosyl)-D-arabino-hexitol (13) 
A mixture of 11 (506 mg, 1.90 mmol), ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (12)18 
(1.82 g, 2 eq, 3.8 mmol), Bu4NBr (1.84 g, 3 eq, 5.7 mmol), 2,6-di-tert-butyl-4-
methylpyridine (1.17 g, 3 eq, 5.7 mmol), and powdered MS 4Å (3 g) in CH2Cl2 (12 mL) and 
DMF (3 mL) was stirred at r.t. under argon for 4 h. Then, CuBr2 (1.27 g, 3 eq, 5.7 mmol) was 
added and the reaction mixture was stirred at r.t. for 15 h. The reaction mixture was filtered 
through celite, the filtrate was diluted with CH2Cl2 and successively washed with satd. aq. 
NaHCO3 and brine. The aqueous layers were extracted successively with CH2Cl2. The 
combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene to 
dryness. The residue was purified by column chromatography (PE/Et2O, 7:1 to 5:1) to yield 
compound 13 (631 mg, 76%) as yellowish oil.   
["]D20 -80.7 (c 0.47, CHCl3); 1H NMR (500 MHz, CDCl3): ) 7.32 – 7.09 (m, 15H, Ar-H), 
7.09 – 6.99 (m, 2H, Ar-H), 6.73 (d, J = 8.7 Hz, 2H, Ar-H), 5.39 (s, 1H, MeOPhCH), 4.89 – 
4.79 (m, 2H, PhCH2, Fuc-H1), 4.77 – 4.66 (m, 2H, PhCH2), 4.63 – 4.46 (m, 3H, PhCH2), 
4.18 – 4.03 (m, 2H, Hex-H6b, Fuc-H5), 3.95 (dd, J = 10.1, 3.7 Hz, 1H, Fuc-H2), 3.90 – 3.77 
(m, 3H, Hex-H1b, Hex-H3, Fuc-H3), 3.65 (s, 3H, O-CH3), 3.62 – 3.52 (m, 2H, Hex-H4, Hex-
H6a), 3.47 (d, J = 2.3 Hz, 1H, Fuc-H4), 3.38 (t, J = 11.3 Hz, 1H, Hex-H1a), 3.21 (td, J = 9.8, 
4.9 Hz, 1H, Hex-H5), 1.89 (dd, J = 12.0, 3.8 Hz, 1H, Hex-H2b), 1.71 (qd, J = 12.9, 5.2 Hz, 
1H, Hex-H2a), 0.89 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CDCl3): ) 159.90, 
138.97, 138.65, 138.57, 130.32 (5 quart. Ar-C), 129.01, 128.34, 128.33, 128.32, 128.20, 
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128.14, 128.02, 127.68, 127.52, 127.41, 127.37, 127.31, 125.28 (17C, 17 Ar-C), 113.40 (2C, 
Ar-C), 101.27 (PhCH), 94.13 (Fuc-C1), 80.92 (Hex-C4), 79.53 (Fuc-C3), 77.85 (Fuc-C4), 
76.26 (Fuc-C2), 74.83, 73.39, 73.21, (3C, PhCH2), 72.07, 72.00 (Hex-C3, Hex-C5), 68.87 
Hex-C6), 66.27 (Hex-C1), 66.04 (Fuc-C5), 55.20 (O-CH3), 30.79 (Hex-C2), 16.45 (Fuc-C6); 
ESI-MS: m/z calcd for C41H46O9 [M+Na]+: 705.30, found: 705.37. 
 
1,5-Anhydro-2-deoxy-3-O-(6-deoxy-2,3,4-tri-O-benzyl-4-O-(4-methoxy-benzylidene)-"-
L-galactopyranosyl)-D-arabino-hexitol (14a) and 1,5-anhydro-2-deoxy-3-O-(6-deoxy-
2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-D-arabino-hexitol (14b) 
The procedure for acetal opening was adapted from reference11. 
A solution of 13 (695 mg, 1.00 mmol) and BH3&THF (1 M solution in THF, 8 ml, 8 eq, 
8.00 mmol) was cooled to -20 ºC and treated with Bu2BOTf (1 M solution in CH2Cl2, 1 ml, 
1 eq, 1 mmol). The reaction mixture was stirred and warmed from -20 to -5 ºC over 1.5 h 
under argon, then quenched with Et3N followed by the dropwise addition of MeOH. The 
reaction mixture was warmed to r.t. and evaporated to dryness. The residual syrup was 
coevaporated with toluene. Purification by flash chromatography on silica gel (PE/EtOAc 
gradient) afforded the C-6 alcohol 14a (505 mg, 72%) and the dihydroxylated side product 
14b (125 mg, 22%). 
Analytical data of 14a: 
["]D20 -42.5 (c 0.22 , CHCl3); 1H NMR (500 MHz, CDCl3): ) 7.38 – 7.10 (m, 15H, Ar-H), 
7.01 (d, J = 8.6 Hz, 2H, Ar-H), 6.71 (d, J = 8.6 Hz, 2H, Ar-H), 4.94 – 4.47 (m, 9H, 4 CH2, 
Fuc-H1), 3.97 (dd, J = 10.1, 3.6 Hz, 1H, Fuc-H2), 3.92 – 3.80 (m, 3H, Hex-H1a, Fuc-H3, 
Fuc-H5), 3.77 – 3.66 (m, 5H, Hex-H3, Hex-H6a, OCH3), 3.58 (d, J = 9.4 Hz, 1H, Hex-H6a), 
3.45 – 3.35 (m, 2H, Hex-H4, Fuc-H4), 3.30 (t, J = 11.4 Hz, 1H, Hex-H1b), 3.13 (m, 1H, 
Hex-H5), 1.89 (m, 1H, Hex-H2a), 1.52 (m, 1H, Hex-H2b), 0.85 (t, J = 6.9 Hz, 3H, Fuc-H6); 
13C NMR (126 MHz, CDCl3): ) 159.08 (quart Ar-C, PMB), 138.77, 138.62, 138.54 (quart. 
Ar-C), 130.31, 129.16, 128.41, 128.35, 128.30, 128.23, 128.12, 128.06, 128.01, 127.94, 
127.63, 127.57, 127.52 (14C, 14 Ar-C), 113.66 (Ar-C), 92.92 (Fuc-C1), 79.82 (Hex-C5), 
78.74 (Fuc-C3), 77.86 (Fuc-C4), 77.23 (Hex-C4), 76.17 (Fuc-C2), 75.20 (Hex-C3), 74.81, 
74.61, 73.22, 73.10 (4C, CH2), 66.26 (Fuc-C5), 65.34 (Hex-C1), 62.44 (Hex-C6), 55.21 
(OCH3), 29.72 (Hex-C2), 16.35 (Fuc-C6); ESI-MS: m/z calcd for C41H48O9 [M+Na]+: 707.32, 
found: 707.30. 
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Analytical data of 14b: 
["]D20 -33.5 (c 0.44, CHCl3); 1H NMR (500 MHz, CDCl3): ) 7.43 – 7.16 (m, 15H, Ar-H), 
4.97 (t, J = 9.8 Hz, 1H, PhCH2a), 4.92 (d, J = 3.9 Hz, 1H, Fuc-H1), 4.85 (2d, J = 11.8 Hz, 2H, 
PhCH2),  4.74 (m, 1H, CH2b), 4.64 (2d, J = 11.7 Hz, 2H, PhCH2), 4.13 – 4.02 (m, 3H, Fuc-
H2, H5), 4.02 – 3.83 (m, 3H, Hex-H1a, Hex-H6a, Fuc-H3), 3.76 (m, 1H, Hex-H6b), 3.68 (m, 
1H, Fuc-H4), 3.48 – 3.31 (m, 4H, Hex-H1b, Hex-H3, Hex-H4),  3.17 (m, 1H, Hex-H5), 2.36 
(s, 1H, OH), 2.13 (t, J = 6.3 Hz, 1H, OH), 1.97 (dd, J = 13.2, 4.7 Hz, 1H, Hex-H2a), 1.72 (m, 
1H, Hex-H2b),  1.14 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CDCl3): ) 138.65, 
138.45 (3C, 3 quart. Ar-C), 129.18, 128.63, 128.57, 128.50, 128.43, 128.37, 128.06, 127.97, 
127.90, 127.73, 127.59 (15C, 15 Ar-C), 97.59 (Fuc-C1), 82.74 (Hex-C3), 79.63 (Hex-C5), 
79.13 (Fuc-C3), 77.48 (Fuc-C4), 76.31 (Fuc-C2), 75.12, 73.69, 73.32 (3C, CH2), 71.77 (Hex-
C4), 67.60 (Fuc-C5), 65.84 (Hex-C1), 63.47 (Hex-C6), 31.27 (Hex-C2), 16.81 (Fuc-C6); HR-
MS: m/z calcd for C33H40O8 [M+Na]+: 587.2615, found: 587.2625. 
 
2,6-Anhydro-5-deoxy-3-O-(4-methoxybenzylidene)-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-
galactopyranosyl)-D-lyxo-hexonic acid (15) 
Compound 15 was synthesized according to general procedure A from 14a (330 mg, 
0.48 mmol). Yield: 87% (292 mg). Characterization by NMR failed presumably due to 
residual TEMPO. The product was therefore directly used for the amide coupling step. 
HR-MS: m/z calcd for C41H46O10 [M+Na]+: 721.2983, found: 721.2986. 
 
2,6-Anhydro-5-deoxy-3-O-(4-methoxybenzylidene)-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-
galactopyranosyl)-N-(3-fluorophenyl)-D-lyxo-hexonamide (16) 
Carboxylic acid 15 (133 mg, 0.19 mmol), CH2Cl2 (1 ml), HOBt (28 mg, 1.1 eq, 0.21 mmol), 
3-fluoro-aniline (91 &l, 5 eq, 0.95 mmol), and DIC (32 &l, 1.1 eq 0.21 mmol) were reacted 
according to general procedure B and yielded 16 (110 mg, 73%). 
["]D20 -40.4 (c 0.34 , CHCl3); 1H NMR (500 MHz, CD3OD): ) 7.58 – 7.51 (m, 1H, Ar-H), 
7.42 – 7.36 (m, 4H, Ar-H), 7.35 – 7.18 (m, 13H, Ar-H), 6.99 (d, J = 8.6 Hz, 2H, Ar-H), 6.82 
(m, 1H, Ar-H), 6.66 (d, J = 8.6 Hz, 2H, Ar-H), 5.02 (d, J = 3.6 Hz, 1H, Fuc-H1), 4.88 (d, J = 
11.3 Hz, 1H, PhCH2a), 4.76 – 4.63 (m, 4H, PhCH2), 4.57 (d, J = 11.3 Hz, 1H, PhCH2b), 4.47 
(d, J = 10.7 Hz, 2H, PhCH2), 4.03 (dd, J = 7.4, 2.5 Hz, 1H, Hex-H6a), 4.00 – 3.92 (m, 2H, 
Fuc-H2, Fuc-H5), 3.86 (dd, J = 10.2, 2.8 Hz, 1H, Fuc-H3), 3.79 (m, 2H, Hex-H2, Hex-H4), 
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3.71 – 3.63 (m, 4H, Hex-H3, O-CH3), 3.53 (d, J = 1.8 Hz, 1H, Fuc-H4), 3.45 (dd, J = 11.8, 
9.9 Hz, 1H, Hex-H6b), 2.08 (d, J = 9.0 Hz, 1H, Hex-H5a), 1.62 (m, 1H, Hex-H5b), 0.95 – 
0.84 (m, 3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 170.15 (Hex-C1), 164.25 (d, 
1JCF  = 242.8 Hz, Ar-CF), 160.72, 141.20 (d, 3JCF = 10.8 Hz, C-NHCO), 140.15, 140.00, 
139.94, 131.43 (5C, 5 quart. Ar-C), 131.29, 131.22, 130.83, 129.53, 129.50, 129.46, 129.29, 
129.28, 129.04, 128.87, 128.77, 128.75, 116.77, 116.75, 114.61, 111.96, 111.79, 108.46, 
108.25 (23C, 23 Ar-C), 94.37 (Fuc-C1), 81.55 (Hex-C2), 79.77, 79.55, 79.37 (Fuc-C3, Hex-
C3, Fuc-C4), 77.41 (Fuc-C2), 76.28, 75.78 (2PhCH2), 75.64 (Hex-C4), 74.11, 73.85 
(2PhCH2), 67.74 (Fuc-C5), 66.30 (Hex-C6), 55.70 (O-CH3), 30.29 (Hex-C5), 16.79 (Fuc-
C6); ESI-MS: m/z calcd for C47H50FNO9 [M+Na]+: 814.29, found: 814.34. 
 
2,6-Anhydro-5-deoxy-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-D-lyxo-
hexonamide (17) 
Compound 16 (32 mg, 0.04 mmol) was dissolved in CH3CN/H2O (9:1, 1 ml) and CAN 
(33 mg, 2 eq, 0.08 mmol) was added. The mixture was stirred at r.t. until TLC showed 
complete conversion (5-8 h), then diluted with CH2Cl2 and  washed  with  satd. aq. NaHCO3 
solution. The aqueous phase was extracted with CH2Cl2, the combined organic phases were 
dried over Na2SO4, filtered and concentrated. The crude product was purified by flash 
column chromatography (PE/EtOAc gradient) to give 17 (27 mg, 44%). 
1H NMR (500 MHz, CD3OD): ) 7.59 (dt, J = 11.3, 2.1 Hz, 1H, Ar-H), 7.42 – 7.22 (m, 17H, 
Ar-H), 6.86 – 6.79 (m, 1H, Ar-H), 5.03 (d, J = 2.4 Hz, 1H, Fuc-H1), 4.90 (d, J = 11.2 Hz, 1H, 
PhCH2), 4.77 – 4.57 (m, 5H, CH2), 4.28 (q, J = 6.5 Hz, 1H, Fuc-H5), 4.09 (m, 1H, Hex-H6a), 
4.03 – 3.96 (m, 2H, Fuc-H2, -H3), 3.81 (s, 1H, Fuc-H4), 3.78 – 3.65 (m, 3H, Hex-H4, -H3, -
H2), 3.53 (m, 1H, Hex-H6b), 2.14 – 2.04 (m, 1H, Hex-H5a), 1.72 – 1.58 (m, 1H, Hex-H5b), 
1.15 (t, J = 8.4 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 170.66 (Hex-C1), 164.25 
(d, 1JCF = 242.6 Hz), 141.08 (d, 3JCF = 10.9 Hz), 140.30, 140.11, 139.87, 131.21, 131.14, 
129.42, 129.38, 129.31, 129.24, 128.85, 128.74, 128.67, 128.58, 116.90 (d, 4JCF = 2.9 Hz), 
111.80 (d, 2JCF = 21.5 Hz), 108.50 (d, 2JCF = 26.5 Hz) (24C, Ar-C), 95.41 (Fuc-C1), 81.65 
(Hex-C2), 80.31, 79.57, 77.58, 77.45 (Fuc-C2, Fuc-C3, Fuc-C4, Hex-C4), 76.37, 74.18, 
73.88 (3PhCH2), 72.09 (Hex-C3), 67.90 (Fuc-C5), 66.44 (Hex-C6), 30.59 (Hex-C5), 16.92 
(Fuc-C6); HR-MS: m/z calcd for C39H42FNO8 [M+Na]+: 694.2787, found: 694.2786. 
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2,6-Anhydro-5-deoxy-4-O-(6-deoxy-"-L-galactopyranosyl)-N-(3-fluorophenyl)-D-lyxo-
hexonamide (5) 
Compound 17 (19.5 mg, 0.029 mmol) was deprotected according to general procedure C. The 
product was further purified by preparative HPLC to give 5. Yield: 6 mg, 52%. 
["]D20 -31.3 (c 0.37, MeOH/CHCl3, 2:1); 1H NMR (500 MHz, CD3OD): ) 7.60 (m, 1H, Ar-
H), 7.38 – 7.26 (m, 2H, Ar-H), 6.86 (m, 1H, Ar-H), 4.95 (d, J = 3.8 Hz, 1H, Fuc-H1), 4.31 (q, 
J = 6.6 Hz, 1H, Fuc-H5), 4.08 (dd, J = 11.8, 3.4 Hz, 1H, Hex-H6a),  3.85 – 3.64 (m, 6H, Fuc-
H2, Fuc-H3, Fuc-H4, Hex-H3, Hex-H4, Hex-H2), 3.55 (t, J = 11.2 Hz, 1H, Hex-H6b), 2.12 
(dd, J = 13.3, 4.5 Hz, 1H, Hex-H5a), 1.69 (m, 1H, Glc-H5b), 1.20 (d, J = 6.6 Hz, 3H, Fuc-
H6); 13C NMR (126 MHz, CD3OD): ) 170.69 (CO), 164.26 (d, 1JCF = 242.5 Hz, Ar-CF) 
131.17 (d, 3JCF = 9.3 Hz, Ar-C), 116.86 (Ar-C), 111.82 (d, 2JCF  = 21.5 Hz, Ar-C), 108.48 (d, 
2JCF = 26.6 Hz, Ar-C), 101.42 (quart. Ar-C), 97.17 (Fuc-C1), 81.82 (Hex-C2), 78.15 (Hex-
C4),  73.76, 72.45, 71.57, 69.83 (Hex-C3, Fuc-C2, Fuc-C3, Fuc-C4), 67.70 (Fuc-C5), 66.89 
(Hex-C6), 30.83 (Hex-C5), 16.60 (Fuc-C6); HR-MS: m/z calcd for C18H24FNO8 
[M+Na]+: 424.1378, found: 424.1385; HPLC: Purity > 99.5 %, Rt 11.062 min.  
 
2,6-Anhydro-5-deoxy-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-(1$4)-[2,3,4-
tri-O-benzoyl-6-O-benzyl-#-D-galactopyranosyl-(1$3)]-N-(3-fluorophenyl)-D-lyxo-
hexonamide (19) 
A solution of thiogalactoside 1819 (53 mg, 1.3 eq, 0.085 mmol) and glycosyl acceptor 17 (44 
mg, 0.07 mmol, 1 eq) in dry CH2Cl2 (2.5 mL) was added to activated MS 4Å (0.6 g) under 
argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST) (34 mg, 2 eq, 0.13 
mmol) and activated MS 4Å (0.3 g) in CH2Cl2 (1.3 mL) was prepared in a second flask. Both 
suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to 
the first suspension. The reaction was stopped after 12 h, filtered through celite and the celite 
was washed with CH2Cl2. The filtrate was successively washed with satd. aq. NaHCO3 and 
water. The aqueous layers were extracted with CH2Cl2. The combined organic layers were 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
flash column chromatography (PE/toluene/EtOAc, 10:10:1 to 5:5:1) to afford 19 (55 mg, 
68%) as colorless foam. 
1H NMR (500 MHz, CD3OD): ) 8.04 (d, J = 7.2 Hz, 2H, Ar-H), 7.75 (d, J = 7.3 Hz, 2H, Ar-
H), 7.71 – 7.63 (m, 3H, Ar-H), 7.57 – 7.47 (m, 3H, Ar-H), 7.46 – 7.37 (m, 2H, Ar-H), 7.34 – 
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7.05 (m, 26H, Ar-H), 6.85 (dd, J = 11.0, 5.7 Hz, 1H, Ar-H), 5.91 (d, J = 2.8 Hz, 1H, Gal-H4), 
5.71 – 5.63 (m, 2H, Gal-H2, Gal-H3), 5.32 (d, J = 7.6 Hz, 1H, Gal-H1), 4.97 (d, J = 3.4 Hz, 
1H, Fuc-H1), 4.74 – 4.45 (m, 6H, Fuc-H5, PhCH2), 4.42 – 4.26 (m, 5H, PhCH2, Gal-H5, 
Hex-H3), 4.07 – 3.87 (m, 4H, Hex-H6a, Fuc-H2, Fuc-H3, Hex-H4), 3.82 (d, J = 7.4 Hz, 1H, 
Hex-H2), 3.74 (dd, J = 9.7, 6.0 Hz, 1H, Gal-H6a), 3.70 – 3.62 (m, 2H, Fuc-H4, Gal-H6b), 
3.47 (m, 1H, Hex-H6b), 2.09 (dd, J = 13.5, 3.0 Hz, 1H, Hex-H5a), 1.68 – 1.56 (m, 1H, Hex-
H5b), 1.31 (t, J = 7.1 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 169.19, 167.47, 
167.03, 166.53 (3CO, Hex-C1), 164.28 (d, 1JCF = 242.9 Hz, Ar-CF) 141.32, 140.19, 140.16, 
139.99, 139.28, 134.97, 134.50, 134.31, 131.19, 130.80, 130.57, 130.46, 130.20, 130.03, 
129.40, 129.37, 129.36, 129.31, 129.25, 129.20, 129.07, 128.75, 128.71, 128.62, 128.60, 
128.47, 128.32, 116.83, 111.95, 108.46, 108.25, 101.54 (39C, 39Ar-C), 95.27 (Fuc-C1), 
80.74, 80.69, 80.30, 77.48 (Fuc-C2, Fuc-C3, Fuc-C4, Hex-C2), 76.49, 76.44, 74.58, 73.98, 
73.92, 73.87, 73.66, 73.56, 71.66 (4PhCH2, Hex-C3, Hex-C4, Gal-C2, Gal-C3, Gal-C5), 
70.68 (Gal-C4), 69.04 (Gal-C6), 67.83 (Fuc-C5), 65.62 (Hex-C6), 29.58 (Hex-C5), 17.29 
(Fuc-C6); ESI-MS: m/z calcd for C73H70FNO16 [M+Na]+: 1258.46, found: 1258.45. 
 
2,6-Anhydro-5-deoxy-(6-deoxy-"-L-galactopyranosyl)-(1$4)-[#-D-galactopyranosyl-
(1$3)]-N-(3-fluorophenyl)-D-lyxo-hexonamide (6) 
Compound 19 (24.7 mg, 0.02 mmol) was deprotected according to general procedures C and 
D. The product was further purified by preparative HPLC. Yield: 6 mg, 53%. 
[a]D20 -85.7 (c 0.08, MeOH); 1H NMR (500 MHz, CD3OD): ) 7.96 (d, J = 7.2 Hz, NH), 7.57 
(d, J = 11.2 Hz, 1H, Ar-H), 7.39 – 7.27 (m, 2H, Ar-H), 6.85 (t, J = 8.2 Hz, 1H, Ar-H), 4.91 
(d, J = 3.9 Hz, 1H, Fuc-H1), 4.62 (q, J = 6.5 Hz, 1H, Fuc-H5), 4.32 (d, J = 7.6 Hz, 1H, Gal-
H1), 4.12 – 4.06 (m, 1H, Hex-H6a), 4.03 (t, J = 8.8 Hz, 1H, Hex-H3), 3.96 – 3.82 (m, 3H, 
Hex-H2, Fuc-H3, Hex-H4), 3.81 – 3.63 (m, 5H, Gal-H4, Gal-H6, Fuc-H2, Fuc-H4), 3.57 (m, 
1H, Hex-H6b),  3.48 (dd, J = 9.6, 7.7 Hz, 1H, Gal-H2), 3.39 (m, 1H, Gal-H5), 3.30 (m, 1H, 
Gal-H3), 2.17 (d, J = 13.2 Hz, 1H, Hex-H5a), 1.73 (m, 1H, Hex-H5b), 1.19 (d, J = 6.6 Hz, 
3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 170.08 (Hex-C1), 164.22 (d, 1JC-F = 242.7 Hz, 
Ar-CF), 140.86 (quart. Ar-C), 131.12 (Ar-C), 128.58 (Ar-C), 117.32 (Ar-C), 112.04 (d, 2JC-F 
= 21.5 Hz, Ar-C), 108.85 (d, 2JC-F = 26.2 Hz, Ar-C), 103.63 (Gal-C1), 96.83 (Fuc-C1), 81.43 
(Hex-C2), 76.96 (Hex-C3), 74.92, 74.70,  73.71, 73.04, 71.40, 70.00, 69.93 (Gal-C2, Gal-C3, 
Gal-C5, Fuc-C2, Fuc-C3, Fuc-C4, Hex-C4), 67.57 (Fuc-C5), 66.50 (Hex-C6), 62.79 (Gal-
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C6), 30.68 (Hex-C5), 16.57 (Fuc-C6); HR-MS: m/z calcd for C24H34FNO13 
[M+Na]+: 586.1906, found: 586.1914; HPLC: Purity > 99.5 %, Rt 9.336 min. 
 
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-(6-deoxy-2,3,4-tri-O-
benzyl-"-L-galactopyranosyl)-D-arabino-hexitol (20) 
The dihydroxyl compound 14b (243 mg, 0.43 mmol) was dissolved in dry CH2Cl2 (5 ml). 
1H-Imidazole (73 mg, 2.5 eq, 1.1 mmol), a catalytic amount of DAMP, and TBDMSCl (78 
mg, 1.2 eq, 0.5 mmol) were added. The mixture was stirred at r.t. until TLC showed no 
further transformation (6 h). The reaction was quenched by addition of H2O and the mixture 
was extracted with EtOAc. The organic phase was dried over Na2SO4, filtered and the solvent 
removed under reduced pressure. The crude product was purified by flash column 
chromatography (PE/EtOAc gradient) to yield 20 (278 mg, 95%). 
[a]D20 -41.2 (c 0.12, CHCl3); 1H NMR (500 MHz, CDCl3): ) 7.63 – 7.15 (m, 15H, Ar-H), 4.99 
(d, J = 11.5 Hz, 1H, PhCH2a), 4.94 (d, J = 3.8 Hz, 1H, Fuc-H1), 4.85-4.66 (m, 5H, PhCH2), 
4.14 (m, 1H, Fuc-H5), 4.07 (m, 1H, Fuc-H2), 4.03 – 3.92 (m, 2H, Fuc-H3, Hex-H1a), 3.86 
(m, 2H, Hex-H6), 3.82 (s, 1H, OH), 3.71 (d, J = 1.8 Hz, 1H, Fuc-H4),  3.51 – 3.40 (m, 2H, 
Hex-H3, Hex-H4), 3.38 (m, 1H, Hex-H1b), 3.13 (m, 1H, Hex-H5), 1.94 (m, 1H, Hex-H2a), 
1.71 (m, 1H, Hex-H2b), 1.13 (d, J = 6.5 Hz, 3H, Fuc-H6), 0.90 (s, 9H, C(CH3)3), 0.08 (s, 6H, 
Si(CH3)2); 13C NMR (126 MHz, CDCl3): ) 139.00, 138.74, 138.57 (3 quart. Ar-C), 128.64, 
128.57, 128.52, 128.38, 128.05, 127.87, 127.82, 127.65, 127.55 (15C, 15 Ar-C), 96.74 (Fuc-
C1), 81.51 (Hex-C3), 80.22 (Hex-C5), 79.31 (Fuc-C3), 77.61 (Fuc-C4), 76.42 (Fuc-C2), 
75.05, 73.55, 73.37 (3PhCH2), 71.21 (Hex-C4), 67.20 (Fuc-C5), 65.73 (Hex-C1), 64.08 
(Hex-C6), 30.94 (Hex-C2), 26.16 ((CH3)3),, 18.66 (SiC(CH3)3), 16.75 (Fuc-C6), -5.14, -5.15 
(Si(CH3)2); ESI-MS: m/z calcd for C39H54O8Si [M+Na]+: 701.35, found: 701.30. 
 
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-4-(1H-imidazole-1-
carbothioate)-3-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-D-arabino-hexitol 
(21) 
Compound 20 (146 mg, 0.22 mmol) was dissolved in dry DCE (1 ml) under argon 
atmosphere. N,N’-Thiocarbonyldiimidazole (77 mg, 2 eq, 0.4 mmol) was added to the 
mixture. The flask was sealed and refluxed for 6 h. The solvent was evaporated  and the 
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crude product was purified by flash column chromatography to yield the thioimidazolyl 
intermediate 21 (151 mg, 89%) which was directly used for the next step. 
ESI-MS: m/z calcd for C43H56N2O8SSi [M+H]+: 789.36, found: 789.38. 
 
1,5-Anhydro-2,4-dideoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-3-O-(6-deoxy-2,3,4-tri-
O-benzyl-"-L-galactopyranosyl)-"-D-threo-hexitol (22) 
The imidazolylthiocarbonyl intermediate 21 (139 mg, 0.17 mmol) was dissolved in 
anhydrous toluene (1.5 ml) under argon atmosphere. This solution was added dropwise to a 
refluxing solution of Bu3SnH (67 µl, 1.5 eq, 0.2 mmol) with a catalytic amount of AIBN in 
anhydrous toluene (4 ml). The resulting mixture was refluxed for 6 h. The solvent was 
evaporated under reduced pressure and the crude mixture purified by flash column 
chromatography (bigger batches were dissolved in acetonitrile and the tin organyl remainders 
removed by extraction with hexane prior to chromatography). Compound 22 was obtained as 
colorless foam (93 mg, 85%). 
[a]D20 -53.0 (c 0.23, CHCl3); 1H NMR (500 MHz, CD3OD): ) 7.44 – 7.22 (m, 15H, Ar-H), 
5.02 (d, J = 3.1 Hz, 1H, Fuc-H1), 4.94 – 4.56 (m, 6H (overlaid by H2O) PhCH2), 4.03 – 3.90 
(m, 4H, Fuc-H2, Fuc-H3, Fuc-H5, Hex-H1a), 3.82 (s, 1H, Fuc-H4), 3.73 (m, 1H, Fuc-H3), 
3.66 (dd, J = 10.6, 5.4 Hz, 1H, Hex-H6a),  3.57 (dd, J = 10.6, 4.7 Hz, 1H, Hex-H6b), 3.45 – 
3.34 (m, 2H, Hex-H1b, Hex-H5), 2.03 – 1.89 (m, 2H, Hex-H4a, Hex-H2a), 1.49 (m, 1H, 
Hex-H2b), 1.36 (dd, J = 19.2, 7.2 Hz, 1H, Hex-H4b),  1.13 (d, J = 6.5 Hz, 3H, Fuc-H6), 0.91 
(s, 9H, C(CH3)3), 0.07 (d, J = 2.2 Hz, 2H, Si(CH3)2); 13C NMR (126 MHz, CD3OD): ) 
140.27, 140.08, 139.92 (3 quart Ar-C), 129.39, 129.37, 129.28, 129.23, 128.81, 128.79, 
128.66, 128.59 (15C, 15 Ar-C), 97.23 (Fuc-C1), 80.20 (Fuc-C3), 79.46 (Fuc-C4),  78.31 
(Hex-C5), 77.44 (Fuc-C2), 76.35 (PhCH2), 75.25 (Hex-C3), 74.02, 73.87 (2PhCH2), 67.92 
(Fuc-C5), 67.52 (Hex-C1), 66.91 (Hex-C6), 37.11 (Hex-C2), 33.45 (Hex-C4),  26.42 
(C(CH3)3), 19.24 (C(CH3)3), 16.96 (Fuc-C6), -5.18 (Si(CH3)2); ESI-MS: m/z calcd for 
C39H54O7Si [M+Na]+: 685.35, found: 685.41. 
 
1,5-Anhydro-2,4-dideoxy-3-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-"-D-
threo-hexitol (23) 
Compound 22 (57 mg, 0.086 mmol) was dissolved in THF (abs., 1 ml) under an argon 
atmosphere. TBAF (86 &l, 1 eq, 0.086 mmol) was added and the mixture stirred. AcOH 
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(100 &l) was added. After 5 h another 0.5 eq of TBAF (43 &l) was added and the mixture 
stirred for 10 h. The reaction mixture was diluted with H2O and the aqueous phase extracted 
with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated. 
The crude product was purified by flash column chromatography (PE/EtOAc, 1:0 to 6:4) to 
yield 23 (38 mg, 81%). 
1H NMR (500 MHz, CDCl3): ) 7.43 – 7.22 (m, 15H, Ar-H), 4.97 (m, 2H, PhCH2a, Fuc-H1), 
4.90 – 4.65 (m, 5H, PhCH2), 4.10 – 3.99 (m, 2H, Hex-H1a, Fuc-H2), 3.96 – 3.88 (m, 2H, 
Fuc-H3, Fuc-H5), 3.73 (m, 1H, Hex-H3), 3.66 (d, J = 2.0 Hz, 1H, Fuc-H4),  3.57 (m, 2H, 
Hex-H6), 3.47 – 3.37 (m, 2H, Hex-H1b, Hex-H5), 1.90 (m, 1H, Hex-H2a), 1.78 (m, 1H, Hex-
H4a), 1.58 (m, 1H, Hex-H2b), 1.47 (m, 1H, Hex-H4b), 1.10 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C 
NMR  (126 MHz, CDCl3): ) 139.09, 138.82, 138.69 (3 quart. Ar-C), 128.59, 128.50, 128.47, 
128.34, 128.10, 127.89, 127.75, 127.61, 127.57 (15C, 15 Ar-C), 95.76 (Fuc-C1), 79.49 (Fuc-
C3), 77.82 (Fuc-C4), 76.85 (Hex-C5), 76.45 (Fuc-C2), 74.99, 73.42 (3C, 3 PhCH2), 72.79 
(Hex-C3), 66.57 (Fuc-C5), 66.20, 66.07 (Hex-C1, Hex-C6), 35.11 (Hex-C4),  32.05 (Hex-
C2), 16.80 (Fuc-C6); HR-MS: m/z calcd for C33H40O7 [M+Na]+: 571.2666, found: 571.2663. 
 
2,6-Anhydro-3,5-dideoxy-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-D-
threo-hexonic acid (24) 
Alcohol 23 (45 mg, 0.082 mmol) was oxidized according to general procedure A. The crude 
product was purified on silica gel prior to usage in the next step. Yield: 34 mg (80% purity), 
74%. 
HR-MS: m/z calcd for C33H38O8 [M+Na]+: 585.2459, found: 585.2457. 
 
2,6-Anhydro-3,5-dideoxy-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-N-(3-
fluorophenyl)-D-threo-hexonamide (25) 
Carboxylic acid 24 (26 mg, 0.047 mmol) was coupled with 3-fluoroaniline (45 &l, 10 eq, 0.47 
mmol) using HOBt (7 mg, 1.1 eq, 0.052 mmol) and DIC (8 &l, 1.1eq, 0.052 mmol) according 
to general procedure B with following modification: after 5 h DIPEA (4 &l, 0.5 eq, 0.02 
mmol) was added. Yield: 20 mg, 65% 
1H NMR (500 MHz, CD3OD): ) 7.60 – 7.53 (m, 1H, Ar-H), 7.45 – 7.18 (m, 17H, Ar-H), 6.84 
(dd, J = 10.9, 5.3 Hz, 1H, Ar-H), 5.05 (d, J = 3.6 Hz, 1H, Fuc-H1), 4.91 (m, 1H, CH2a),  4.77 
– 4.71 (m, 3H, CH2), 4.70 – 4.59 (m, 2H, CH2), 4.20 (dd, J = 11.6, 2.7 Hz, 1H, Hex-H6a), 
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4.04 – 3.79 (m, 6H, Fuc-H2, Fuc-H3, Fuc-H4, Fuc-H5, Hex-H2, Hex-H4), 3.56 (m, 1H, Hex-
H6b),  2.38 (m, 1H, Hex-H3a), 1.99 (m, 1H, Hex-H5a), 1.66 – 1.51 (m, 2H, Hex-H5b, Hex-
H3b), 1.18 – 1.14 (m, 3H, Fuc-H6); 13C NMR (126 MHz, CDCl3): ) 169.12 (Hex-C1), 
163.13 (d, 1JCF = 244.9 Hz, Ar-CF), 139.02, 138.91, 138.84, 138.69, 130.25, 130.17, 128.56, 
128.49, 128.46, 128.34, 128.08, 127.79, 127.74, 127.61, 127.58, 115.16, 115.13 (20C, 20 Ar-
C), 111.28 (d, 2JCF = 21.2 Hz, Ar-C), 107.38 (d, 2JCF = 26.3, Ar-C), 95.72 (C-1), 79.46 (Fuc-
C2), 77.87 (Fuc-C4), 76.37, 76.13 (Fuc-C3, Hex-C2), 75.05, 73.51, 73.37 (3PhCH2), 71.98 
(Hex-C4), 66.80 (Fuc-C5), 66.15 (Hex-C6), 36.19 (Hex-C3), 31.55 (Hex-C5), 14.33 (Fuc-
C6); ESI-MS: m/z calcd for C39H42FNO7 [M+Na]+: 678.28, found: 678.37. 
 
2,6-Anhydro-3,5-dideoxy-4-O-(6-deoxy-"-L-galactopyranosyl)-N-(3-fluorophenyl)-D-
threo-hexonamide (7) 
Compound 25 (19 mg, 0.03 mmol) was deprotected according to standard procedure C to 
yield after HPLC purification title compound 7 (7 mg, 67%). 
[a]D20 -138.0 (c 0.06 , MeOH); 1H NMR (500 MHz, CD3OD): ) 7.57 (m, 1H, Ar-H), 7.39 – 
7.26 (m, 2H, Ar-H), 6.85 (m, 1H, Ar-H), 4.97 (d, J = 11.0 Hz, 1H, Fuc-H1), 4.20 (dd, J = 
11.8, 3.5 Hz, 1H, Hex-H6a),  4.01 (m, 2H, Fuc-H5, Hex-H2 ), 3.89 (m, 1H, Hex-H4), 3.78 – 
3.70 (m, 2H, Fuc-H2, Fuc-H3), 3.68 (m, 1H, Fuc-H4), 3.58 (dt, J = 12.4, 2.1 Hz, 1H, Hex-
H6b), 2.45 (m, 1H, Hex-H3a), 2.04 (dd, J = 12.9, 2.2 Hz, 1H, Hex-H5a), 1.66 – 1.48 (m, 2H, 
Hex-H5b, Hex-H3b), 1.23 (t, J = 9.3 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 
171.96 (Hex-C1), 165.23 (1JCF = 242.9 Hz, Ar-CF), 140.75 (d, 3JCF = 10.8 Hz, Ar-C), 131.20 
(d, 2JCF = 9.4 Hz, Ar-C), 117.12 (Ar-C), 111.95 (d, 2JCF = 21.5 Hz, Ar-C), 108.65 (d, 2JCF = 
26.5 Hz, Ar-C), 98.99 (Fuc-C1), 77.32 (Hex-C2), 74.59 (Hex-C4),  73.68 (Fuc-C4), 71.64, 
69.83 (Fuc-C2, Fuc-C3), 67.91 (Fuc-C5), 67.11 (Hex-C6), 37.72 (Hex-C3), 32.76 (Hex-C5), 
16.47 (Fuc-C6); HR-MS: m/z calcd for C18H24FNO7 [M+Na]+: 408.1429, found: 408.1437; 
HPLC: Purity > 99.5%, Rt 13.029 min. 
 
1,5-Anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-(6-deoxy-2,3,4-tri-O-
benzyl-"-L-galactopyranosyl)-(1$3)-[2,3,4-tri-O-benzoyl-6-O-benzyl-#-D-
galactopyranosyl-(1$4)]-D-arabino-hexitol (26) 
A solution of thiogalactoside 1219 (81 mg, 1.3 eq, 0.13 mmol) and glycosyl acceptor 20 (68 
mg, 0.1 mmol) in dry CH2Cl2 (3 ml) was added to activated MS 3Å (0.8 g) under argon. A 
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suspension of DMTST (83 mg, 0.32 mmol, 3.2 eq) and activated MS 3Å (0.4 g) in CH2Cl2 
(1.6 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the 
DMTST suspension was added via syringe to the other suspension. The reaction was stopped 
after 12 h, filtered through celite and the celite washed with CH2Cl2. The filtrate was 
successively washed with satd. aq. NaHCO3 and water. The aqueous layers were extracted 
with CH2Cl2. The combined organic layers were dried with Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified by flash column chromatography 
(petroleum ether/toluene/ethyl acetate, 10:10:1 to 5:5:1) to afford compound 26 as colourless 
foam. Yield: 78 mg, 63%. 
1H NMR (500 MHz, CD3OD): ) 8.09 – 8.04 (m, 2H, Ar-H), 7.97 – 7.92 (m, 2H, Ar-H), 7.76 
– 7.71 (m, 2H, Ar-H), 7.67 (t, J = 7.5 Hz, 1H, Ar-H), 7.60 – 7.51 (m, 3H, Ar-H), 7.47 – 7.40 
(m, 3H, Ar-H),  7.34 – 7.21 (m, 15H, Ar-H), 7.20 – 7.14 (m, 4H, Ar-H), 7.13 – 7.05 (m, 3H, 
Ar-H), 5.90 (d, J = 3.2 Hz, 1H, Gal-H4), 5.76 (dd, J = 10.4, 8.2 Hz, 1H, Gal-H2), 5.59 (dd, J 
= 10.4, 3.6 Hz, 1H, Gal-H3),  5.26 (d, J = 8.2 Hz, 1H, Gal-H1), 4.94 (d, J = 3.7 Hz, 1H, Fuc-
H1), 4.77 (q, J = 6.5 Hz, 1H, Fuc-H5), 4.73 – 4.50 (m, 5H, PhCH2), 4.44 – 4.30 (m, 3H, 
PhCH2), 4.16 (t, J = 6.5 Hz, 1H, Gal-H5), 4.06 (dd, J = 10.1, 2.8 Hz, 1H, Fuc-H3),  3.98 – 
3.90 (m, 3H, Fuc-H2, Hex-H5, Hex-H6a), 3.85 (dd, J = 11.7, 3.9 Hz, 1H, Hex-H1a), 3.79 – 
3.63 (m, 5H, Fuc-H4, Gal-H6, Hex-H6b, Hex-H3), 3.30 (m, 1H, Hex-H1b), 2.93 (d, J = 
8.1 Hz, 1H, Hex-H4), 2.01 (d, J = 8.2 Hz, 1H, Hex-H2a), 1.55 (m, 1H, Hex-H2b), 1.41 (d, J 
= 6.5 Hz, 3H, Fuc-H6), 0.98 (s, 9H, C(CH3)3), 0.16 (s, 3H, SiCH3), 0.10 (s, 3H, SiCH3); 13C 
NMR (126 MHz, CD3OD): ) 167.43, 166.57 (3C, 3 CO), 140.21, 140.15, 139.85, 139.28, 
135.09, 134.77, 134.62, 131.20, 130.75, 130.55, 130.49, 130.09, 129.76, 129.47, 129.37, 
129.35, 129.31, 129.26, 128.91, 128.76, 128.64, 128.59, 128.53, 128.50, 128.24 (42C, 42 Ar-
C), 101.76 (Gal-C1), 94.72 (Fuc-C1), 81.91 (Hex-C4), 80.72, 80.63 (Fuc-C3, -C4), 77.45 
(Fuc-C2), 76.61 (Hex-C5), 76.47 (PhCH2), 75.01 (Hex-C3), 74.58 (PhCH2), 74.51 (Gal-C5), 
73.87, 73.80 (2PhCH2), 73.55 (Gal-C3), 71.82 (Gal-C2), 70.73 (Gal-C4), 69.07 (Gal-C6), 
67.55 (Fuc-C5), 66.34 (Hex-C1), 62.93 (Hex-C6), 31.67 (Hex-C2), 26.61 (C(CH3)3), 19.28 
(C(CH3)3), 17.34 (Fuc-C6), -4.70, -5.01 (Si(CH3)2); ESI-MS: m/z calcd for C73H82O16Si 
[M+Na]+: 1265.53, found: 1265.50. 
 
 
 
 
 
DC-SIGN 2.3.3 – Synthesis of Antagonists 
129 
1,5-anhydro-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-(6-deoxy-"-L-
galactopyranosyl)-(1$3)-[#-D-galactopyranosyl-(1$4)]-D-arabino-hexitol (27) 
Trisaccharide mimic 26 (78 mg, 0.063 mmol) was deprotected with TBAF (1 eq, 63 &l) to 
yield the 6-OH compound. After aqueous work up and purification on silica gel the 
compound was deprotected according to general procedures C and D to yield 27 (7 mg, 
24%).  
1H NMR (500 MHz, D2O): ) 5.04 (d, J = 3.8 Hz, 1H, Fuc-H1), 4.72 (q, J = 6.7 Hz, 1H, 
Fuc-H5), 4.46 (d, J = 7.7 Hz, 1H, Gal-H1), 4.03 (dd, J = 11.7, 4.4 Hz, 1H, Hex-H6a), 3.94 
(dd, J = 17.7, 8.5 Hz, 3H, Fuc-H3, Gal-H4, Hex-H6a), 3.88 – 3.70 (m, 7H, Fuc-H2, Fuc-H4, 
Gal-H6, Hex-H3, Hex-H5, Hex-H6b), 3.70 – 3.59 (m, 2H, Gal-H3, Gal-H5), 3.57 – 3.47 (m, 
2H, Gal-H2, Hex-H1b), 3.44 (m, 1H, Hex-H4), 2.20 (d, J = 11.6 Hz, 1H, Hex-H2a), 1.63 (d, 
J = 6.6 Hz, 1H, Hex-H2b), 1.21 (d, J = 6.6 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, D2O): ) 
102.02 (Gal-C1), 94.78 (Fuc-C1), 80.09 (Hex-C4), 74.93 Gal-C5), 74.46, 74.13 (Hex-C3, 
Hex-C5) 72.49 (Fuc-C4), 71.98 (Gal-C3), 71.49 (Gal-C2), 69.53, 68.37, 67.76 (Fuc-C2, Fuc-
C3, Gal-C4), 66.52 (Fuc-C5), 65.23 (Hex-C1), 61.42 (Gal-C6), 60.21 (Hex-C1), 29.72( Hex-
C2), 15.14 (Fuc-C6); HR-MS: m/z calcd for C73H82O16Si [M+Na]+: 479.1735, found: 
479.1744. 
 
2,6-Anhydro-5-deoxy-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galactopyranosyl)-D-lyxo-
hexonic acid (28) 
14b (230 mg, 0.41 mmol) was oxidized according to general procedure A. The crude product 
was purified on silica gel and used directly for the next step. Yield: 147 mg, 62%. HR-MS: 
m/z calcd for C34H40O9 [M+Na]+: 615.2565, found: 615.2572. 
 
Methyl 2,6-anhydro-5-deoxy-4-O-(6-deoxy-2,3,4-tri-O-benzyl-"-L-galacto-pyranosyl)-D-
lyxo-hexonate (29) 
Carboxylic acid 28 (42 mg, 0.1 mmol) was dissolved in toluene/MeOH (3:2, v/v, 1 ml), and a 
solution of TMSCHN2 (75 µl, 2M in hexane, 1.1 eq, 0.11 mmol) was added. The mixture was 
stirred at r.t. until TLC showed no further transformation (5 h). The solvent was removed 
under reduced pressure and the crude product purified by flash column chromatography 
(CH2Cl2/EtOAc 1:0 to 7:3) to give 29. Yield: 24 mg, 58%. 
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1H NMR (500 MHz, CD3OD): ) 7.43 – 7.23 (m, 15H, Ar-H), 5.00 (d, J = 8.9 Hz, 1H, Fuc-
H1), 4.91 (d, J = 11.2 Hz, 1H, CH2a), 4.79 – 4.59 (m, 5H, CH2),  4.19 (q, J = 6.5 Hz, 1H. 
Fuc-H5), 4.03 (m, 1H, Hex-H6a), 3.99 – 3.95 (m, Fuc-H2, Fuc-H3), 3.81 (s, 1H, Fuc-H4), 
3.78 (dd, J = 8.0, 4.0 Hz, 1H, Hex-H3), 3.75 – 3.70 (m, 3H, CH3), 3.69 – 3.60 (m, 2H, Hex-
H2, Hex-H4),  3.46 (m, 1H, Hex-H6b), 2.06 (m, 1H, Hex-H5a), 1.58 (ddd, J = 14.7, 12.4, 4.6 
Hz, 1H, Hex-H5b), 1.14 (d, J = 6.5 Hz, 3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 
171.91 (Hex-C1), 140.29, 140.10, 139.86 (3 quart. Ar-C), 129.41, 129.39, 129.30, 129.23, 
128.83, 128.74, 128.66, 128.59 (15C, 15Ar-C), 95.41 (Fuc-C1), 80.72,  80.22, 79.54, 77.38, 
76.81 (5C, Hex-C3, Hex-C2, Fuc-C2, Fuc-C3, Fuc-C4), 76.35, 74.16, 73.85 (3PhCH2), 71.85 
(Hex-C4), 67.94 (Fuc-C5), 66.01 (Hex-C6), 52.63 (COOCH3), 30.11 (Hex-C5), 16.89 (Fuc-
C6); HR-MS: m/z calcd for C34H40O9 [M+Na]+: 615.2565, found: 615.2572. 
 
2,6-Anhydro-5-deoxy-4-O-(6-deoxy-"-L-galactopyranosyl)-D-lyxo-hexonic acid methyl 
ester (30) 
Compound 29 (24 mg, 0.04 mmol) was deprotected according to general procedure C to yield 
title compound 30 after purification via flash column chromatography on silica gel and 
preparative HPLC. Yield: 7 mg, 53%. 
[a]D20 -117.9 (c 0.13, MeOH); 1H NMR (500 MHz, CD3OD): ) 4.92 (d, J = 3.5 Hz, 1H, Fuc-
H1), 4.23 (q, J = 6.4 Hz, 1H, Fuc-H5), 4.03 (ddd, J = 11.8, 4.6, 2.9 Hz, 1H, Hex-H6a), 3.83 – 
3.71 (m, 6H, CH3, Fuc-H2, Fuc-H3, Hex-H3), 3.71 – 3.58 (m, 3H, Fuc-4, Hex-2, Hex-4),  
3.49 (m, 1H, Hex-H6b), 2.10 (m, 1H, Hex-H5a), 1.62 (m, 1H, Hex-H5b), 1.20 (d, J = 6.6 Hz, 
3H, Fuc-H6); 13C NMR (126 MHz, CD3OD): ) 172.02 (Hex-C1), 97.27 (Fuc-C1), 80.95 
(Hex-C2), 77.36, 73.74, 72.12, 71.56, 69.78, (5C, Fuc-C2, Fuc-C3, Fuc-C4, Hex-C3, Hex-
C4), 67.77 (Fuc-C5), 66.40 (Hex-C6), 52.66 (CH3), 30.33 (Hex-C5), 16.58 (Fuc-C6); HR-
MS: m/z calcd for C13H22O9 [M+Na]+: 345.1156, found: 345.1165; HPLC: Purity > 99%, Rt = 
4.877 min. 
 
Abbreviations: AIBN, Azobisisobutyronitrile; CAN, ceric ammonium nitrate; CRD, 
carbohydrate recognition domain; DCs, Dendritic cells; DC-SIGN, Dendritic cell-specific 
intercellular adhesion molecule-3 grabbing nonintegrin; DIC, N,N’-Diisopropyl-
carbodiimide; DIPEA, N,N-Diisopropylethylamine; DMAP, 4-Dimethylaminopyridine; 
DMF, N,N-Dimethyl-formamide; DMTST, Dimethyl(methylthio)-sulfonium triflates; Fuc, 
fucose; Gal, galactose; HOBt, N-Hydroxybenzotriazol; HPLC, High performance/pressure 
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liquid chromatography; IC50, Inhibitory concentration 50%; Lea, Lewisa; Lex, Lewisx; LNFP 
III, lacto-N-fucopentaose III; Man, mannose; MHC, major histocompatibility complex; MD, 
molecular dynamics; NMR, nuclear magnetic resonance; PAA, polyacrylamide; PDB, protein 
data bank; rIC50, Relative IC50; TBAB, Tetrabutyl-ammonium bromide; TBAF, 
Tetrabutylammonium fluoride; TBDMSCl, tert-Butyldimethylsilyl chloride; TEMPO, 
2,2,6,6-Tetramethylpiperidine-1-oxyl; TMSE, Trimethylsilylethyl. 
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Microbial Lectins  
Plant-derived hemagglutinins were the first lectins to be discovered in the late 19th century.1 
In the following century, the agglutinating effect on erythrocytes was also noted for bacteria 
demonstrating the existence of microbial lectins. Until today, the family of Enterobacteriacae 
lectins is the best investigated one. These lectins are involved in various biological functions 
such as recognition, signaling, and as especially important for bacterial pathogens in 
adhesion. Recognition of glycoconjugates on mammalian cell surfaces for adherence and 
invasion of bacteria is the first and crucial step in infections.2 By firm adhesion, the natural 
cleansing process is circumvented. Moreover, adhesion facilitates nutrition, release of toxins 
and entry of the bacteria into the cell.  
Commonly, bacterial lectins assemble in a multimeric manner and form filamentous 
organelles, termed fimbriae or pili. These oligomers elevate from the bacterial surface and 
represent an important virulence factor.3-5  
Fimbriae of the enterobacterial family include mannose-specific type 1 fimbriae,6 galabiose-
specific P-fimbriae,7 N-acetylglucosamine-specific F17 fimbriae.8 Type 1 fimbriae are 
present on e.g. Escherichia coli (E. coli), Salmonella typhimurium, and Nisseria gonorrhoea. 
The carbohydrate recognition domain (CRD) is located at the tip of the fimbrium as part of 
the terminal subunit, designated FimH in type 1 fimbriae,9 PapG for P fimbriae,10 and F17G 
for F17 fimbriae.11 The carbohydrate-specificity of these lectins determines ultimately the 
tissue tropism. As aforementioned, P fimbriae favor galabiose (Gal!1-4Gal") structures 
which are expressed in the upper part of the kidneys,12 whereas type 1 fimbriae recognize 
mannose-containig glycoproteins such as uroplakin Ia (UPIa) that is highly abundant on 
urothelial bladder cells.13,14 This explains the involvement of these lectins in urinary tract 
infections (UTIs) and kidney infections caused by E. coli.15  
 
Urinary Tract Infection 
Uropathogenic E. coli  (UPEC) is the major causative agent in UTIs, one of the most 
prevalent and cost-intensive infectious disease.15-17 Women are particularly affected,16,18 
however, also patients suffering from diabetes, spinal cord injuries, or suppressed immune 
system have a high risk of experiencing an UTI.19-21 The host defense mechanisms includes 
cleansing by flow of urine, myriad antimicrobial molecules, and effector immune cells. 
Expression of fimbriae allowing for adherence of bacteria is an important virulence factor to 
circumvent these defense mechanisms. Type 1 pili with the lectin FimH at their very tip are 
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responsible for initial colonization of the bladder cells with UPEC by recognition of the 
mannose-bearing UPIa.4,14 An untreated UTI can ascend and lead to infection of the bladder 
(cystitis) and in a late stage to infection of the kidneys (pyelonephritis).15  
 
 
Figure 1. Infection cycle of uropathogenic Escherichia coli (UPEC), taken from Cegelski et al.22. Binding of 
UPEC to the urothelial bladder cells is mediated by type 1 pili, in particular FimH – uroplakin Ia interaction. 
This results in invasion into the host cells, replication, and formation of biofilm-like intracellular bacterial 
communities (IBCs). Within the IBCs bacteria are protected from host immune response and antibiotic 
treatment and can persist for months in a quiescent state. UPECs can re-emerge from IBCs and infect 
neighboring cells, which is associated with recurrence of infection. Furthermore, UPECs can penetrate deeper 
into the bladder tissue.  
 
The adherence of bacteria is the initial and crucial step of an infection cycle (Figure 1); it 
protects the bacteria from being washed out by the flow of urine and allows for entry into the 
tissue resulting in an UTI.23,24 However, this also activates the innate immune defense, such 
as the influx of neutrophils to the site of infection, exfoliation of infected bladder cells, and 
further inflammatory responses.25 Nonetheless, UPEC developed means to evade these 
responses and instead invade deeper into the tissue. The bacteria form biofilm-like structures, 
termed intracellular bacterial communities (IBCs), which allows them to stay in a quiescent 
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state and survive for an extended period of time.26,27 Protected from external influences, such 
as host immune response or antibiotics, bacteria can re-emerge from IBCs and infect 
neighboring cells (Figure 1). Formation of IBCs is considered to be the reason for recurrence 
of infection as well as resistance to treatment with antibiotics. As a matter of fact, up to 50% 
of the infected patients will experience a relapse of the infection within the first six 
month.17,28 
 
Type 1 Fimbriae 
Type 1 fimbriae are filamentous organelles.6,29 A single type 1 fimbriae is a 7 nm wide 
and 1-3 µm long surface polymer and built up of thousands of copies of the major subunit 
protein FimA. These subunits are organized as a rigid, helical rod followed by a short linear 
and flexible tip composed of the subunits FimF, FimG, and FimH. The lectin FimH is located 
at the distal end of this linear fimbrillar tip and comprises the mannose-specific CRD.9,30-32 
The assembly of type 1 pili takes place in the periplasm via the chaperone/usher pathway 
(Figure 2).33 This pathway is a conserved bacterial secretion system and is also used for the 
assembling of other fimbriae, such as P fimbriae.34 The periplasmic scaffolding protein 
FimC, the chaperone, and outer membrane assembly platform FimD, the usher, are needed 
for the biogenesis of the pilus. The FimC forms binary complexes with the monomeric pili 
subunits in the periplasmic space and guaranties their proper folding and delivery to FimD. 
The latter catalyzes the assembly of the subunits and enables the translocation of the growing 
fiber across the outer membrane to the cell surface.34-37 
Each subunit presents an incomplete immunoglobulin (Ig)-like fold, missing a C-terminal 
!-strand. The chaperone FimC provides the missing !-strand until the diffusion to FimD and 
the integration of the subunit in the growing pili. Then, FimC is replaced and the Ig-like fold 
is completed by an N-terminal extension from the following subunit. This donor strand 
complementation process accounts for strong intermolecular interactions between the 
subunits and a considerable stability of the type 1 pili.38-40 
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Figure 2. Schematic representation of pilus assembly taken from Puorger et al.39 The chaperone FimC forms 
complexes with the newly translocated subunits (FimA, FimG, FimF and FimH) in the periplasm thereby 
mediating correct folding and delivery to the assembly platform FimD (usher). The usher catalyzes pilus subunit 
assembly and enables translocation of folded subunits across the outer membrane.  
 
The expression of type 1 pili is a phase variable process alternating between fimbriated and 
non-fimbriated states of the bacterium. Nine fim genes contain the genetic information for the 
assembly of fimbriae. The mentioned phase variation is controlled by an invertible promoter 
region which is located upstream of fimA gene and controls the transcription of downstream 
fim genes (FimA, FimC, FimD, FimF, FimG, and FimH).41 The orientation of this promoter 
determines the fate of pili and can either be ‘on-phase’ resulting in pili expression or ‘off-
phase’ resulting in silencing of the fim gene cluster.42,43 FimB and FimE can both regulate the 
inversion of the promoter, FimE from on-to-off and FimB in both directions.44  
Several factors influence the phase switch including activity of these recombinases dependent 
on growth conditions.43,45 Moreover, cross-talk between different gene clusters, e.g. the 
activated P fimbriae gene switches the fim gene to off-phase results in no simultaneous 
expression of type 1 and P pili. This allows for ascending of bacteria into the kidneys. Hence, 
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the fimbriae expression is adjusted to the infection status and environmental conditions and 
seems to be crucial for the survival and pathogenicity of the bacteria.46  
 
FimH 
FimH is a 29 kDa protein composed of 279 amino acid residues. In contrast to the other Fim 
subunits, FimH consists of two Ig-like domains, the N-terminal pilin domain and the C-
terminal lectin domain. The pilin domain connects FimH with the following FimG protein 
(compare Figure 2) and is characterized by the structural relation to the other pilus subunits, 
i.e. the incomplete Ig-like fold. The lectin domain comprises two !-sheets, one large and 
continuous, the other one smaller and split. At the distal end of the !-sandwich, opposite to 
the region where the lectin domain is connected with the pilin domain, a single CRD is 
located that is capable of accommodating "-D-mannosides. 
Due to the missing donor strand for a complete fold, the monomeric FimH unit is not stable 
and proteolytically degraded, hence, crystallization was not achieved so far.47 The first crystal 
structure of FimH in complex with the chaperone FimC (and cyclohexylbutanoyl-N-
hydroxyethyl-D-glucamide that was added for crystallization) was solved in 1999.31 To date, 
five more crystal structures of FimH(–FimC) have been solved.30,48-51 Based on these data, it 
was found that FimH adopts two conformations, the low- and the high-affinity conformation; 
a comparison is depicted in Figure 3.31,51 In the low-affinity state the pilin and the lectin 
domain of FimH interact with each other via the interdomain region. This interaction induces 
a twist in the !-sandwich fold of the lectin domain and results in a compressed overall 
structure accompanied by an opening of the mannose-binding site.51 The high-affinity state is 
characterized by a separation of the the lectin and pilin domain due to a disrupted 
interdomain region. This leads to an untwist of the pilin domain and an elongated overall 
structure, though, the mannose binding pocket is tightened and referred to as active.51  
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Figure 3. Comparison of low-affinity (left side, PDB 3JWN) and high-affinity (right side, PDB 1KLF) 
conformation of FimH (Modeled by Adam Zalewski, University of Basel).51 In the high-affinity state the lectin 
domain is elongated with a tight mannose-binding site. In the low-affinity state the lectin domain interacts with 
the pilin domain at the interdomain region. These interdomain interactions lead to a twist in the !-sandwich fold 
of the lectin domain, which results in a compressed overall structure and an open mannose-binding site.  
 
A switch from the low- to the high-affinity state can be achieved upon tensile force. The 
mechanical force is capable of disrupting the interdomain region resulting in the allosteric 
switch.52,53 Since the low-affinity conformation is stabilized by intra-molecular interactions, 
this mechanism is also called allosteric autoinhibition.51 Such a force-induced switch along 
with enhanced affinity to a ligand are characteristic for catch bonds.54 The physiological 
function of catch bonds is considered to facilitate adhesion under flow conditions. A critical 
step in UTIs is the adherence of bacteria to the urothelium, which is challenged by the flow 
of urine that is nothing else than application of force. It was found that, according to the catch 
bond behavior, the FimH–UPIa interaction becomes stronger under sheer stress, which results 
in stabilized attachment and bacterial accumulation.55-57  
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The Carbohydrate Recognition Domain 
The CRD of FimH represents a deep negatively charged pocket with hydrophobic amino acid 
residues lining the rim. (Figure 4).  
 
 
Figure 4. Crystal structure of FimC–FimH complex bound to !-D-methyl-mannoside (left, PDB 1KLF30, 
modeled by Adam Zalewski, Institute of Molecular Pharmacy, University of Basel) and the interacting protein 
residues with the same ligand (right), adapted from Hung et al.30. Coloring of the receptor resembles the 
electrostatic potential surface with positively charged residues shown in blue, negatively charged residues in 
red, and neutral and hydrophobic residues in white. Residues of the hydrophobic ridge are labeled; Tyr48, Ile52 
and Tyr137 form the ‘tyrosine gate’ at the entrance of the binding site. D-mannose establishes an extensive 
H-bond network with the residues Phe1, Asn46, Asp47, Asp54, Gln133, Asn135, Asp140, and Phe142 (shown 
in ball-and-stick, H-bonds are highlighted in purple, W1: water molecule in the binding site).30 
 
FimH selectively binds !-configurated D-mannose ligands. Hydrophilic side chains of the 
amino acids in the binding pocket establish a vast network of hydrogen bonds with each of 
the hydroxyl groups (except for the anomeric oxygen) of an !-D-mannopyranoside. 
Additionally, hydrophobic interactions are formed. The interacting residues are Phe1, Asn46, 
Asp47, Asp54, Gln133, Asn135, Asp140, and Phe142. Three hydrophobic amino acids at the 
entrance of the binding pocket (Tyr48, Ile52 and Tyr137) form the so called “tyrosine gate”.30 
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FimH Antagonists 
UTIs are generally treated with antibiotics. However, the excessive use of the latter 
encounters resistance development of bacteria, which entails recurrence of infections and 
high medical costs.58 This explains the urgent need for alternative treatment and prevention 
strategies. An anti-adhesion therapy provides a promising approach.59-62 FimH antagonists 
that are capable of blocking the lectin FimH would avoid adhesion of the bacterium to the 
urothelium and hence ultimately lead to clearance of the microbes by the bulk flow of urine. 
This different mode of action is advantageous to antibiotics in terms of susceptibility to 
resistance development.  
!-D-mannosides can prevent the type 1 pili-mediated agglutination of yeast cells.63-65 
Mannose, methyl !-D-mannoside (1), and mannan were among the first ligands to be 
identified to inhibit yeast aggregation in the presence of UPEC. Thereupon, many natural 
oligomannosides and multimeric mannose dendrimers have been studied followed by 
mannosides bearing aromatic aglycones (3, 4, Figure 5). The latter have been proven 
significantly more potent than their methyl analogue 1.66 Without any information on the 
CDR, Sharon and Ofek proposed a model on the increments the binding site should present. 
Thus, a hydrophobic region was assumed to be in proximity to the carbohydrate binding site  
that overall has strong specificity for !-configuration.66 By now, crystallographic data 
elucidated the 3D structure of the FimH CRD and various bound ligands and furnish 
evidence for the initial model.48,67 Based on these data aromatic aglycones were supposed to 
insert between both sides of the hydrophobic rim, in that manner a "-" stacking with Tyr48 
and Tyr137 is established. Hence, this binding mode is termed ‘in-binding mode’. A similar 
binding mode is assumed for alkyl aglycones.48 Affinity of these alkyl mannosides towards 
FimH was found to be increasing with growing chain length. The best inhibitory potency was 
achieved with a seven-membered alkyl chain (2).48  
Antagonists developed since then can be categorized accordingly as, long-chain alkyl 
mannosides and mannosides with variously substituted aromatic aglycones.68 The most recent 
group of antagonists includes mannosides with extended aglycones.68 An overview of 
antagonists is given in Figure 5. 
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Figure 5. FimH antagonists. Alkyl !-D-mannopyranoside: Methyl !-D-mannopyranoside (1)69,  
n-heptyl !-D-mannopyranoside (2);48 p-nitrophenyl !-D-mannopyranosides, p-NPMan (3) and  
p-NoClPMan (4);66 squaric acid derivative 5;70 p-substituted  biphenyl !-D- mannopyranosides  6, 7, 8;50,71 drug 
and ester prodrug: 3,5, disubstituted biphenyl !-D- mannopyranosides 9, 1050,72.  
 
To date, the squaric acid derivatives (e.g. 5, Figure 5) and biphenyl mannosides (e.g. 6-10, 
Figure 5) are amongst the most promising antagonists for FimH with affinity in the low 
nanomolar range.50,70,72 
Crystallography studies of compound 9 with FimH revealed a novel binding mode for 
biphenyl mannosides.50 Instead of the aglycone located within the tyrosine gate this ligand 
binds in the so called ‘out binding mode’ addressing only Tyr48 by !-! interaction 
(Figure 6). Additionaly, an electrostatic interaction with Arg98 is discussed.50 
 
 
Figure 6. ‘In’ and ‘out’ binding mode of FimH-ligand complexes. FimH CRD in complex with n-butyl !-D-
mannopyranoside (left, PDB entry 1TR748) reveals in-binding, and with the biphenyl derivative 9 (right, PDB 
entry 3MCY50) out-binding.  
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The first assays for biological evaluation of these mannosidic compounds were based on 
measuring the effect, i.e. the inhibitory potency, on agglutination of yeast cells in presence of 
UPEC.66,73 Equivalent approaches involve hemagglutination of erythrocytes.69 Up to now, 
many more assay formats have been developed, including ELISA-based74,75, surface plasmon 
resonance48,76, and cell-based adhesion assays (e.g. fluorescence-activated cell sorting)77.  
Depending on the assay format the inhibitory potencies reported as IC50 values differ. 
Amongst others, the reason for that are differences in the UPEC strains used, such as FimH 
mutations, or on the conformational state of the FimH subunit depending e.g. on shear stress 
and resulting in distinct affinities for ligands. For comparability, generally relative IC50 
values are presented with either methyl !-D-mannoside (1) or n-heptyl !-D-mannoside (2) as 
reference compounds that exhibit low micromolar and nanomolar affinity, respectively. 
The potential of !-D-mannosides as alternative treatment strategy was demonstrated with in 
vivo mouse infections studies where the bacterial infections could be reduced considerably by 
application of !-D-mannoside (1) or n-heptyl !-D-mannoside (2).49,78,79 Concerning the 
development of an orally available drug good pharmacokinetics and -dynamics are a 
prerequisite. Intestinal absorption and renal clearance are key issues for orally dosed FimH 
antagonists to reach the therapeutic target in the bladder and the optimization of these 
properties is still a challenging task. One approach to address that matter was the design of 
ester-prodrugs.71 The ester form of a biphenylcarboxylate (7) is expected to facilitate 
intestinal absorption due to higher lipophilicity and the subsequent hydrolysis by carboxyl 
esterases in the small intestine and liver releases the active principle (8) that is prone to renal 
elimination. This study revealed a small molecule FimH antagonist with a proven reducing 
effect on colony forming units in the bladder. Ultimately, this substantiates the potential of 
orally available FimH antagonists as anti-adhesives for the treatment of UTIs. 
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ABSTRACT 
FimH is a bacterial lectin enabling the adhesion of E. coli to urothelial sells, the initial 
interaction leading to urinary tract infections. X-ray data of mannose derivatives co-
crystallized with FimH reveal a conserved water molecule deep within the binding pocket. 
This study is focused on the displaceability of this water by a n-heptyl !-D-mannoside 
modified in the 2-position. In case the water molecule is no structural water its replacement 
can lead to a substantially improved binding affinity. Since binding studies with the modified 
mannoside 2 revealed a complete loss of affinity, a detailed molecular modeling investigation 
was performed. The results indicated a distortion of the ligand binding pose with a 
nonoptimal interaction profile explaining the loss in affinity. 
 
INTRODUCTION 
Adhesion to host cells is the initial step, when bacteria establish infections. In urinary tract 
infections (UTIs), uropathogenic Escherichia coli (UPEC) are the causative pathogens.1-4 
With the lectin FimH located at the tip of filamentous organelles, attachment of bacteria to 
the urothelial cells is provided.5-7 This first step of recognition and therewith adherence is 
crucial for the establishment of an infection. Adherence prevents bacteria from being washed 
out by the bulk flow of urine. FimH is a mannose-specific lectin recognizing glycoconjugates 
such as uroplakin Ia prevalent on the urothelial cells. Treatment of UTIs with antibiotics is 
causing increasingly resistance problems. Therefore, alternative therapeutics are urgently 
required. The development of anti-adhesive agents that are able to prevent the crucial 
interaction with the urothelial cells presents a promising approach.8, 9 
In the course of developing small-molecule FimH antagonists, various alkyl and aryl !-D-
mannosides have been reported with low nanomolar affinities for FimH.10,11-14 All of these 
FimH antagonists bear an unmodified mannose moiety. Approaches towards the replacement 
of this entity by other carbohydrates or deoxy mannosides lead to a substantial loss in affinity 
indicating the high specificity of FimH for !-D-mannosides. The latter was rationalized by 
crystallographic data revealing that each of the hydroxyl groups in mannose establishes one 
or more H-bonds (Figure 1).15  
FimH 3.2.1 – Manuscript 3 
155 
 
Figure 1. Binding mode of n-heptyl mannoside 1 as ribbon representation with highlighted H-bonding network 
derived from docking to the CRD of FimH (PDB 1UWF16). The water molecule maintains on average a 
maximum of two hydrogen bonds at a time. 
 
The analysis of X-ray data on apo and holo FimH crystal structures revealed a conserved 
water molecule within the mannose binding pocket (Figure 1).12, 16-20 The successful 
displacement of such a water molecule by a proper modification of the ligand is associated 
with an affinity improvement driven by the entropic gain upon release of the water 
molecule.21 This concept has successfully been applied in drug-discovery before.22  
The goal of this study was to investigate the displacement of the conserved water molecule in 
the CRD of FimH. Therefore, a modified ligand was designed and synthesized expected to 
result in a gain in binding energy, while also offering a structurally new antagonist species 
which can be beneficial regarding selectivity.23  
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RESULTS AND DISCUSSION 
Design and synthesis of the new ligand 
In several crystal structures12, 16-20 a water molecule mediated the interaction of 2-OH of 
mannose with FimH (Figure 1). Since molecular dynamics (MD) simulations indicated that 
this water molecule does not form stable interactions with the protein, its displacement 
through an antagonist modified in the 2-position offers the opportunity to increase affinity, 
predominantly by an improved entropy term.24 
 
Figure 2. Modified 2-O-extended analogue 2 docked in FimH (PDB 1UWF16) representing the optimal scenario 
with displacement of water.  
 
Molecular modeling studies suggested that an extension at the C2 position of mannose could 
offer the mentioned benefits. Accordingly, a n-heptyl !-D-mannoside (1) with the 2-OH 
group replaced by an 2-hydroxyethoxy moiety ("2) was selected for chemical synthesis and 
subsequent biological evaluation (Figure 2).  
 
Figure 3. Heptyl mannoside (1)16 and modified ligand with extension at position C2 of mannose (2). 
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The 2-O-modified mannoside 2 was synthesized from n-heptyl !-D-mannoside (1)16 in four 
steps (Scheme 2). Firstly, the 4,6-O-benzylidene acetal ("3) was formed, followed by 
3-selective benzylation ("4). The ethoxy moiety was introduced as TBS protected 2-bromo-
ethanol ("5) an final deprotection under Zemplén conditions yielded the target compound 2. 
 
 
Scheme 2. a) benzaldehyde dimethyl acetal, DMF, CSA, 12h, r.t., 63%; b) i) Bu2SnO, toluene, #, 5h, ii), BnBr, 
TBAB, toluene, #, 8h, 80%; c) (2-bromoethoxy)-tert-butyldimethylsilane, NaH, DMF, 12h, r.t., 36%; d) 
Pd(OH)2/C, H2 (atm. pressure), toluene/H2O (4:1), 12h, 91%. 
 
We performed isothermal titration calorimetry (ITC) to determine the dissosiaction constant 
and the thermodynamic fingerprint of 2. However, these experiments showed no binding of 
the mannoside 2 to FimH. To elucidate this unexpected loss in affinity, with respect to 1  
(KD = 7.3 ± 1.8 nM)25, more in-depth computational methods were initiated. 
 
Molecular dynamics 
A suitable ligand structure does not guarantee improved binding energetics. Among other 
reasons, this is due to the fact that for obtaining a desired binding mode, enthalpic costs for 
partly desolvation of protein and ligand have to be paid. The additional rotatable bonds 
introduced in 2 that are restrained upon binding might have led to increased ligand internal 
strain and entropic costs. These penalties needed to be overcompensated by a gain in solvent 
entropy upon release of the water molecule (up to 2 kcal/mol for displacing a single water 
molecule21) and improved protein-ligand interactions. To inspect the interplay of these 
energy contributions, ensembles of frames obtained from MD simulations for both 2 and 1 
were post-processed with the Molecular Mechanics Generalized Born Surface Area (MM-
GBSA) method. The calculations were further augmented with Rigid Rotor-Harmonic 
Oscillator (RRHO) entropy approximations. Though the current field of molecular modeling 
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provides potentially more advanced methods26, the chosen setup allowed for uniquely 
detailed insight into the contributions of specific binding energy components (Table 1). 
 Table 1. Results of MM-GBSA/RRHO calculations, including selected energy components. All values 
[kcal/mol] obtained as averages over 250 frames extracted from 30 ns simulations for the parent (1) and child 
(2) compound. Due to the method specifics and lack of some entropy components, these values are expected to 
be overestimated. 
 
 
The obtained data strongly indicated that if the modified ligand were to displace the 
conserved water molecule and assume the favorable docking conformation (Figure 2) while 
maintaining the same interactions as 1, it would benefit from a substantial increase in binding 
energy. This increase would be in fact large enough (relative calculated !!G of 
12.8 kcal/mol) to insure correct compound ranking in spite of potential inaccuracies of the 
implemented methods27. Based on these findings we conclude that the modified compound 
failed to assume the favorable docking pose.   
In order to obtain the most favorable pose (Figure 2B), the employed docking software 
required removal of the conserved water molecule from the FimH binding site. Although this 
approach was justified by the exchange of the molecule with the bulk solvent (observed in a 
corresponding simulation of the apo FimH structure), an attempt to dock the modified 
compound in presence of the molecule was also made. As a result, a pose with an inferior 
score compared to 1 and a noticeable distortion of the hydrogen-bond network was obtained 
(Figure 3). A subsequent MD simulation did not yield an improvement of this pose. 
Interactive inspection of the simulation revealed that the buried water molecule was 
immobilized by a steric clash with the ligand impairing the exchange with the bulk solvent 
and hampering an optimal binding. Further simulations revealed progression of the distortion 
to a point where several crucial interactions with the protein were lost. 
  1 2 
MM-GBSA !GCoulomb -31.9 -37.5 
MM-GBSA !GLipophilic -30.6 -37.8 
MM-GBSA !GSolvation 18.8 19.0 
MM-GBSA !GvdW -23.7 -28.9 
MM-GBSA !GTotal -67.1 -81.8 
Ligand strain 4.5 6.5 
Protein strain 11.1 12.4 
RRHO entropy 17.8 19.7 
MM-GBSA + RRHO -49.3 -62.1 
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Figure 3. Binding mode (probable scenario) of ligand 2 to the crystal structure of FimH (PDB 1UWF16). 
Ligand accommodates a distorted binding mode, impairing optimal interaction. The water molecule is not 
displaced. (left: ribbon representation, right: shell presentation). 
 
Finally, we compared the bound and solution conformations of the extended ligand 2. An 
analysis of the free ligand MD simulations implied that conformations close to the one 
required for favorable binding were scarcely populated (Figure 4). Taken together, this 
implied that the modified ligand could neither approach the receptor in a favorable 
conformation nor adapt its shape within the binding site. This scenario likely reflects the 
obtained ITC data. 
 
Figure 4. Superposition (mannose heavy atoms) of docked (ball and stick) and MD poses (black wires; 50 
representative frames) for the modified mannosidic compound 2.  
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CONCLUSION 
This study was focused on the displacement of a water molecule within the mannose binding 
pocket of FimH. Although, we had no indication for a structural role of this water molecule, 
an antagonist designed to replace it, showed no affinity for FimH in the ITC experiment. MD 
studies revealed that the proper spatial arrangement of the hydroxyethoxy chain, i.e. the 
bioactive conformation, was not populated in solution. Ligand rearrangement inside the 
binding site is not possible due to steric clashes with the protein and the trapped water 
molecule. This forces a distorted binding mode of 2 impairing optimal binding interaction as 
reflected by the experimental data. Furthermore, molecular modeling allowed for some 
additional insights. Specifically, desolvation energy, strain and entropy penalties prevent the 
ligand from assuming the pose necessary for binding. Given the previously unsuccessful 
attempts of replacing the mannose with other carbohydrate moieties16, our results further 
indicate that the CRD of FimH does not tolerate modifications on the physiological ligand D-
mannose. In addition, this is an example that the displacement of a water molecule is not a 
unambiguous concept to improve affinity. Even if the water molecule in question is not of 
structural type, failing to displace a single solvent molecule with a ligand modification may 
have devastating effects on the potency of the latter.   
 
EXPERIMENTAL SECTION 
Synthesis 
General Methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC, TOCSY). Chemical shifts are expressed in ppm in relation to the 
residual solvent signals (CHCl3, CHD2OD, and HDO) on the !-scale. Coupling constants J 
are given in Hertz (Hz). Multiplicities were specified as follows: s (singlet), d (doublet), dd 
(doublet of a doublet), t (triplet), q (quartet), m (multiplet). For assignment of resonance 
signals to the appropriate nuclei the following abbreviation was used: hep (heptyl). 
Commercially available reagents were purchased from Fluka, Aldrich, Merck, Abcr. Solvents 
were dried prior to use as indicated. Dichloromethane (CH2Cl2) was dried by filtration over 
Al2O3 (Fluka, type 5016 A basic). N,N-dimtehylformamide (DMF), pyridine, and toluene 
were dried by distillation from calcium hydride. Methanol (MeOH) was dried by refluxing 
with sodium methoxide and distilled immediately before use. Molecular sieves were 
activated under vacuum at 500ºC for 1 h immediately before use. Reactions were monitored 
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by TLC using glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV 
light and/or by charring with a molybdate solution (a 0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column 
chromatography was performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using 
RediSep normal phase disposable flash columns (silica gel, 40-63 µm). Reversed phase 
chromatography was performed on LiChroprepRP-18 (Merck, 40-63 µm). LC-MS 
separations were carried out using Sunfire C18 columns (19 x 150 mm, 5.0 !m) on a Waters 
2525 LC, equipped with Waters 2996 photodiode array and Waters micromass ZQ MS for 
detection. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ. HR-MS analysis were carried out using a Agilent 1100 LC equipped with a 
photodiode array detector and a Micromass QTOF I equipped with a 4 GHz digital-time 
converter. Optical rotations were measured using Perkin-Elmer polarimeter 341. 
Microanalysis was performed at the Institute of Organic Chemistry at the University of Basel, 
Switzerland. Compound purity was determined on an Agilent 1100 HPLC; detector ELS, 
Waters 2420; column: Waters Atlantis dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% 
TFA; B: 90% acetonitrile + 10% water + 0.1% TFA.  
 
n-Heptyl 4,6-O-benzylidene-!-D-mannopyranoside (3) 
To a solution of n-heptyl "-D-mannopyranoside 116 (120 mg, 0.43 mmol) in dry DMF (6.0 
ml) benzylaldehyde dimethylacetate (98 µl, 1.5 eq) and camphor sulfonic acid (catalytic 
amount) were added at r.t. The reaction mixture was stirred at 50°C for 5 h, then diluted with 
DCM (50 ml), washed with 5% aq. NaHCO3 solution (50 ml), brine (50 ml), and dried over 
Na2SO4. The solvent was removed under reduced pressure and the residue was purified by 
flash chromatography on silica gel (PE/EtOAc 3:1 to 3:2) to give 3 (100 mg, 63%) as a 
glassy solid.  
1H NMR (500 MHz, CD3OD): ! 7.51-7.49 (m, 2H, Ar-H), 7.37-7.33 (m, 3H, Ar-H), 5.60 (s, 
1H, PhCH), 4.77 (d, J = 1.0 Hz, 1H, H-1), 4.18 (dd, J = 10.0, 4.5 Hz, 1H, H-6a), 3.95-3.90 
(m, 2H, H-3, H-4), 3.88 (m, 1H, H-2), 3.81 (t, J = 10.0 Hz, 1H, H-6b), 3.76-3.41 (m, 2H, H-
5, OCH2C6H13), 3.46 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 1.62 (m, 2H, OCH2CH2C5H11), 
1.36 (m, 8H, OC2H4C4H8CH3), 0.91 (t, J = 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR (126 
MHz, CD3OD): ! 139.31, 129.87, 129.02, 127.52 (Ar-C), 103.36 (PhCH), 102.59 (C-1), 
80.20 (C-3), 72.74 (C-2), 69.87 (C-6), 69.61 (C-4), 68.77 (OCH2C6H13), 65.25 (C-5), 33.01, 
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30.57, 30.17, 27.29, 23.70, 14.46 (OCH2C6H13); ESI-MS: calcd for C20H30O6 [M+Na]+, 
389.19, found 389.06. 
  
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-!-D-mannopyranoside (4) 
To a solution of 3 (80 mg, 0.218 mmol) in dry toluene (4 ml) was added dibutyltin oxide (112 
mg, 0.456 mmol) at rt. The reaction suspension was refluxed for 6 h, concentrated to dryness 
under reduced pressure. To a solution of the product generated above in dry toluene (8 ml) 
was added tetrabutylammonium bromide (TBAB) (147 mg, 0.456 mmol) and benzyl bromide 
(59 µL, 0.5 mmol). The mixture was stirred at 95°C overnight, concentrated to dryness, and 
purified by flash chromatography on silica gel (PE/EtOAc 9:1 to 4:1) to give 4 (172 mg, 
91%) as colorless oil.  
[!]D20 +34.2 (c 1.43, MeOH); 1H NMR (500 MHz, CDCl3): " 7.51-7.49 (m, 2H, Ar-H), 7.40-
7.33 (m, 8H, Ar-H), 5.62 (s, 1H, PhCH), 4.86 (m, 1H, H-1), 4.87 (d, J = 11.5 Hz, 1H, 
PhCH2), 4.73 (d, J = 11.5 Hz, 1H, PhCH2), 4.27 (m, 1H, H-6a), 4.14-4.06 (m, 2H, H-4, H-2), 
3.94 (dd, J = 9.5, 3.0 Hz, 1H, H-3), 3.88-3.82 (m, 2H, H-5, H-6b), 3.67 (m, 1H, OCH2C6H13), 
3.41 (m, 1H, OCH2C6H13), 2.64 (s, 1H, OH), 1.57 (m, 2H, OCH2CH2C5H11), 1.29 (m, 8H, 
OC2H4C4H8CH3), 0.89 (t, J = 7.0 Hz, 3H, OC2H4C4H8CH3); 13C NMR (126 MHz, CDCl3): " 
138.05, 137.53, 128.90, 128.45, 128.22, 127.88, 127.77, 126.01 (Ar-C), 101.52 (PhCH), 
99.87 (C-1), 78.93 (C-4), 75.79 (C-3), 73.04 (PhCH2), 70.10 (C-2), 68.92 (C-6), 67.97 
(OCH2C6H13), 63.19 (C-5), 32.75, 29.37, 29.05, 26.04, 22.61, 14.09 (OCH2C6H13); HR-MS: 
calcd for C27H36O6 [M+Na]+, 479.2410, found 479.2414. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-2-O-(2-((tert-butyldimethylsilyl)oxy)-ethoxy))-!-
D-mannopyranoside (5)  
A solution of 4 (60 mg, 0.131 mmol) in anhydrous DMF (1 ml) was cooled to 0°C. NaH 
(60% dispersion in oil, 15.7 mg, 3 eq, 0.39 mmol) was added and the resulting suspension 
was stirred for 10 min. (2-Bromoethoxy)-tert-butyldimethylsilane (110 µl, 3 eq, 0.39 mmol) 
was added and the mixture was stirred for 8 h and warmed to r.t. The mixture was poured on 
ice and the resulting emulsion was extracted repeatedly with EtOAc. The combined organic 
phases were dried with Na2SO4, filtered, concentrated and the solvent removed under reduced 
pressure. The crude product was purified by flash column chromatography on silca gel 
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(Petroleum ether/EtOAc gradient with 0.1% NEt3). The product 5 was isolated (29 mg, 39%) 
along with unreacted starting material (17 mg, 28%) and TBS-deprotected product. 
[a]D20 +27.4 (c 0.78, CHCl3) 1H NMR (500 MHz, CDCl3): ! 7.51 (dd, J = 8.1, 6.4 Hz, 2H, 
Ar-H), 7.43 – 7.21 (m, 8H, Ar-H), 5.62 (s, 1H, PhHC), 4.90 – 4.82 (m, 2H, H-1, PhCH2a), 
4.73 (d, J = 12.2 Hz, 1H, PhCH2b), 4.25 (dd, J = 10.0, 4.5 Hz, 1H, H-6a), 4.15 (m, 1H, H-4), 
3.97 – 3.62 (m, 9H, H-2, H-3, H-5, H-6b, OCH2aC6H13, 2PhCH2), 3.37 (dt, J = 9.5, 6.6 Hz, 
1H, OCH2bC6H13), 1.56 (p, J = 6.7 Hz, 2H, OCH2CH2C5H11), 1.38 – 1.22 (m, 8H, 
OC2H4C4H8CH3), 0.97 – 0.83 (m, 12H, OC2H4C4H8CH3, SiC(CH3)3 ), 0.08 (d, J = 1.5 Hz, 
6H, Si(CH3)2); 13C NMR (126 MHz, CDCl3): ! 138.97, 137.90, 128.89, 128.39, 128.29, 
127.57, 127.54, 126.17 (12, Ar-C), 101.53 (CH-Ph), 100.01 (C-1), 79.39 (C-4), 78.86 (C-2), 
76.72 (H-3), 73.85 (CH2), 73.23 (CH2Ph), 69.09 (C-6), 67.96 (CH2C6H13), 64.21 (C-5), 63.43 
(CH2OTBS), 31.89, 29.61, 29.22, 26.24 (4C, CH2C6H13, SiC(CH3)3), 26.06 (SiC(CH3)3), 
22.76 (C5H10CH2CH3), 14.23 (C6H12CH3), -5.14, -5.20 (2C, Si(CH3)2); ESI-MS: calcd for 
C35H54O7Si [M+Na]+: 637.35, found 637.36. 
 
n-Heptyl 2-O-(2-hydroxyethyl)-!-D-mannopyranoside (2)  
Compound 5 (23 mg, 0.073 mmol) was dissolved in dioxane/water (4:1, v/v, 1.2 ml). 
Pd(OH)2/C (10%) was added and the benzyl groups were hydrogenolytically cleaved by 
treatment with H2 under atmospheric pressure. The dispersion was stirred overnight and upon 
completion of the reaction the catalyst was filtered off. ESI-MS indicated complete cleavage 
of TBS group. The crude product was purified by column chromatography, preparative 
HPLC, and P2 size exclusion chromatography. The product was obtained as colorless resin 
(11 mg, 91%). 
[a]D20 +44.4 (c 0.97 , MeOH); 1H NMR (500 MHz, CD3OD): ! 4.87 (d, J = 1.4 Hz, 1H, H-1), 
3.81 (dd, J = 11.7, 2.3 Hz, 1H, H-6a), 3.76 – 3.58 (m, 8H, H-3, hep-C(1)H2a, 2 PhCH2, H-6b, 
H-4), 3.56 (dd, J = 3.5, 1.6 Hz, 1H, H-2), 3.49 (ddd, J = 9.6, 5.8, 2.3 Hz, 1H, H-5), 3.42 (dt, J 
= 9.6, 6.4 Hz, 1H, hep-C(1)H2b), 1.67 – 1.52 (m, 2H, hep-CH2), 1.45 – 1.24 (m, 8H, hep-
CH2), 0.91 (t, J = 7.0 Hz, 3H, hep-CH3); 13C NMR (126 MHz, CD3OD): ! 98.74 (C-1, 
1JCH = 168 Hz), 81.08 (C-2), 74.63 (C-5), 73.88 (CH2), 72.72 (C-3), 69.04 (C-4), 68.66 (hep-
C-1), 62.86 (C-6), 62.47 (CH2), 32.99, 30.66, 30.25, 27.34, 23.68 (5C, CH2), 14.41 (CH3); 
HR-MS: calcd for C15H30O7 [M+Na]+: 345.1884, found 345.1883; HPLC: purity > 99.5 %, Rt 
9.740 min; gradient: 5% ! 70% MeCN over 20 min, 1.0 ml/min. 
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Molecular Modeling 
For all experiments a 1.69 Å resolution crystal structure (PDB code 1UWF) of the FimH-
CRD was used. Initial protein-ligand complexes were obtained through flexible docking 
using Glide (Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009). Molecular 
dynamics (MD) simulations were carried out with Desmond28 using the OPLS 2005 force 
field as implemented in the Schrödinger 2011 suite (Maestro, version 9.2, Schrödinger, LLC, 
New York, NY, 2011). Each system was solvated using an orthorhombic, TIP3P water29 box 
with a minimum distance of 10 Å from the complex. Na+ and Cl- ions were added to 
neutralize the charges and account for physiological salt concentration (0.15 M). Long-range 
electrostatic interactions were handled using the particle mesh Ewald summation.30 All 
systems were equilibrated using the default relaxation protocol (Desmond 2.2; Schrodinger, 
Inc., New York, NY) and simulated over the span 30 ns (2 ns for the initial compound 
screening) with a time step of 2.0 fs. The SHAKE algorithm31 was applied to all heavy-atom 
bound hydrogens. Production runs were carried out in the Martyna-Tobias-Klein isothermal-
isobaric ensemble (NPT)32 using the Nose-Hoover barostat to maintain a constant 
temperature of 300 K.33 Energetic and structural data were recorded in 3.0 ps intervals. To 
obtain representative poses, trajectory clustering was performed based on ligand heavy atom 
RMSDs (1000 snapshots per simulation with 0.5 Å cutoff between clusters) using a 
hierarchical average-linkage algorithm. Molecular mechanics-generalized Born surface area 
(MM-GBSA) and Rigid Rotor-Harmonic Oscillator (RRHO) calculations were performed on 
ensembles of 250 MD snapshots using the default settings implemented in Prime (Prime, 
version 3.0, Schrödinger, LLC, New York, NY, 2011.) and MacroModel (MacroModel, 
version 9.9, Schroodinger, LLC, New York, NY, 2011.). All images were generated using 
Maestro. 
 
Isothermal Titration Calorimetry 
ITC experiments were performed according to a previously reported procedure.34 FimH-CRD 
was dialyzed over night at 4 °C against assay buffer using Slide-A-Lyzer dialysis cassettes 
with 10 kDa cut-off (Thermo Fisher Scientific, Waltham, MA, USA). A final protein 
concentration of 18 !M was used. The ligand was diluted to 300 !M in assay buffer (20 mM 
HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 7.4). The measurements were performed with a 
MicroCalTM VP-ITC instrument (GE Healthcare, Northampton, MA, USA; sample cell 
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volume of 1.4523 mL) at 25 °C or 37 °C, 307 rpm stirring speed, and 10 !cal/s reference 
power. The samples were preheated to 3°C below the measurement temperature and degassed 
for 5 minutes prior to the measurements. Titration was started after steady baseline 
equilibration was reached with an initial 2 !L injection. Ligand was injected in 15 !L steps 
with a spacing of 10 minutes to ensure non-overlapping peaks. Baseline adjustments and 
peak integration were performed using the Origin 7 software (OriginLab, Northampton, MA, 
USA). No heat of interaction was observed at 25 °C. Since this may be a consequence of an 
silent reaction in terms of enthalpy, the measurement was repeated at 37 °C with the same 
outcome. 
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ABSTRACT 
Urinary tract infections (UTIs) are a serious health issue affecting millions of people and 
accounting for intensive medical costs. Increasing resistance to antibiotics demands a new 
strategy to deal with this infectious disease. FimH is a bacterial lectin on the tip of 
filamentous organelles expressed on E. coli, the causative agent of UTIs. This lectin 
establishes the attachment on bladder epithelial cells by recognizing mannosidic 
glycoproteins. Blocking this bacterial interaction with host cells would lead to clearance of 
the bacterium by the bulk flow of urine, which rationalizes the extensive search for potent 
FimH antagonists. 
In this study, we synthesized a series of o-chloro-biphenyl !-D-mannosides with different 
substituents at the outer aromatic moiety applying the Topliss approach. We evaluated their 
potency as FimH antagonists in a target-based assay and determined solubility, lipophilicity, 
and for the most promising candidates, permeability properties. Our comprehensive study of 
these compounds revealed tolerated properties and hinted to a promising cyano substituted 
FimH antagonist. 
 
INTRODUCTION 
Adhesion to host cells is a prerequisite for microbes to efficiently establish infections. This 
initial contact is mediated by lectins located at the tip of bacterial fimbriae recognizing 
carbohydrate structures on the cell surface. 
Escherichia coli (E. coli) is the causative pathogen in urinary tract infections (UTIs).[1] UTIs 
are among the most prevalent and widespread infectious deseases.[1b,1c] Therewith, UTIs 
account for significant morbidity as well as high medical costs.[1b,2] A treatment with 
antibiotics frequently encounters resistance.[3] New therapeutic strategies for the treatment 
and prevention of UTIs are therefore urgently required.  
FimH is a bacterial lectin located at the tip of type 1 fimbriae that are expressed on E. coli. It 
recognizes glycoproteins located on urothelial cells such as uroplakin Ia and mediates the 
attachment of the bacterium to the host cell. This is a crucial step for bacterial survival. It 
prevents clearance of E. coli by the bulk flow of urine and furthermore facilitates the invasion 
into host cells.[2b,4] Hence, inhibiting this first interaction is a promising therapeutic approach 
to prevent and treat UTIs.[5] 
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FimH is a mannose-specific lectin, which contains a monomeric carbohydrate recognition 
domain (CRD) that is responsible for binding to the carbohydrate epitope of the host tissue.  
Sharon and coworkers explored various mannosides and oligomannosides with micromolar to 
millimolar affinities as potential antagonists for FimH.[6] The first crystal structure of FimH 
was solved in 1999[7], and since then various crystallographic studies of FimH ligands have 
followed.[8] Based on these studies the reported affinities can be rationalized. The CRD of 
FimH accommodates the mannose in a deep cavity with the hydroxyl groups forming an 
extensive hydrogen bond network. At the entrance to this cavity a hydrophobic rim is formed 
by the amino acids Tyr48, Tyr137, and Ile52, referred to as “tyrosine gate”.[8a] The latter 
enables the accommodation of aliphatic and aromatic aglycones. Already the introduction of 
a simple alkyl aglycone, such as in n-heptyl !-D-mannopyranoside (1), led to nanomolar 
affinity.[8b] With aromatic aglycones a further improvement of the inhibitory potency was 
achieved.[9] To date, biphenyl mannosides, such as 2-4 (Figure 1), are among the most 
promising inhibitors with exellent pahrmacodynamic and pharmacokinetic properties.[10] 
In a recently published study, we reported a beneficial effect on binding affinity by 
introducing substituents at the biphenyl moiety vicinal to the mannose moiety.[10c] A chloro 
("4) or trifluoromethyl substituent in this position allows for a van der Waals contact 
leading to an improvement in affinity by a factor of two to three.  
 
 
Figure 1. FimH antagonists; n-heptyl !-D-mannopyranoside (1) used as reference compound, the meta-
substituted biphenyl derivative 2[11] and the para-substituted analogues 3[10b] and 4[10b] exhibit nanomolar 
affinities.  
 
The crystal structure of FimH co-crystallized with biphenyl mannoside 2 (Figure 2) 
demonstrated the mannose moiety being involved in a vast H-bond network similar to heptyl 
mannoside 1. The biphenyl aglycone binds in the out-docking mode establishing a 
#-# stacking interaction of the second phenyl moiety with Tyr48 of the tyrosine gate.[11] For 
the biphenyl derivative 4 a similar out-docking mode was suggested.[10b]  
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Figure 2. X-ray structure of biphenyl mannoside 2 taken from Han et al.[11] (PDB 3MCY). Electron density 
(mesh) and surface electrostatic potential of FimH with positive and negative potential displayed in blue and 
red, respectively. Amino acids Tyr48, Tyr137, and Arg98 are involved in interactions with the biphenyl 
aglycones. 
 
In this study, we focused on modifications of the outer phenyl ring of the biphenyl aglycone. 
In order to investigate the nature of the !-! stacking with Tyr48 the Topliss approach was 
applied.[12] Based on the Hansch analysis[13], this approach is a step-by-step SAR study of 
subsitutents on aromatic moieties. Each substituent has specific properties regarding 
hydrophobic, electronic, and steric effects. The Topliss operational scheme (vide infra) is 
used as a guideline to efficiently optimize the substitution pattern on aromatic rings.[12]  
Starting from the optimized 3’-chloro-biphenyl aglycone, substituents were introduced on the 
outer phenyl ring according to the Topliss protocol[12] and binding affinities were tested in a 
target-based competitive polymer assay. We furthermore determined basic pharmacokinetic 
properties, i.e. solubility and lipophilicity of the compounds. Finally, for the most promising 
candidates, permeability was tested.  
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RESULTS AND DISCUSSION 
Synthesis 
We synthesized a series of biphenyl mannosides in analogy to previously described 
routes.[10b,10c] Peracetylated !-D-mannose (5) was coupled with 2-chloro-4-iodophenole using 
BF3·Et2O. Introduction of substituted phenyl moieties via Suzuki coupling with aryl boronic 
acids or pinacol ester (in case of 3-CN) gave after deprotection under Zemplén conditions 
compound 8a-s (Scheme 1). 
 
Scheme 1. a) 2-chloro-4-iodophenole, BF3"Et2O, 40°C, 20h, 76%; b) Aryl boronic acid derivative, 
Pd(dppf)2"CH2Cl2, K3PO4, DMF, 80°C, 5-12h;  45-90%; c) NaOMe, MeOH, 5-12h, 34-95%. 
 
 
For choosing substituents on this second phenyl moiety, we applied the Topliss approach. 
This approach categorizes substituents according to their hydrophobicity # and their 
electronic effects $; steric effects are only partially considered. Depending on the affinity 
towards FimH (IC50 values) the substituents were successively chosen according to the 
Topliss scheme (Figure 3).  
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Figure 3. Operational scheme adapted from Topliss[12]. Flow diagram allows the identification of most 
promising substituents with respect to binding affinity (M = more active, E = equally active, L = less active, 
compare to previous compound). Faded substituents were not investigated. 
 
 
Biological Evaluation 
In this study, we envisaged investigating the effects of various substituents on binding 
affinity and physicochemical properties. The affinity to the FimH CRD was determined in a 
cell-free competitive binding assay.[14] Furthermore, solubility, lipophilicity, and permeability 
data predictive for intestinal absorption into circulation and subsequent excretion into the 
urine were determined. Aqueous solubility limits the maximal concentration of antagonist 
dissolved in the intestinal fluids and hence availability for absorption. Therefore, a minimal 
solubility of at least 50 !g/ml was envisaged.[15] Lipophilicity quantified by the octanol water 
distribution coefficient (logD)[16] is a key determinant for both, membrane permeability and 
renal excretion.[17] The former improves with increase in lipophilicity unless transporter 
mediated processes are involved. The latter is favored by hydrophilicity, limiting antagonist 
reabsorption from the glomerular filtrate and non-renal elimination pathways.[18] 
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Table 1. The cell-free competitive binding assay[14] is based on the interaction of biotinylated polymer-bound 
trimannoside as competitor with the CRD of FimH. The affinities are reported as IC50 and relative to parent 
compound 8a as rIC50. Heptyl !-D-mannoside (1) was tested on each plate as reference compound. Aqueous 
solubility and lipophilicity (logD7.4) were determined according to standard protocols. Promising compounds 
were further tested in a PAMPA assay for information on permeability. 
Compound IC50 
[nM] 
rIC50 logD7.4 
(mean ± SD) 
Solubility [!g/ml] 
(mean ± SD) / pH 
PAMPA log Pe 
[log cm/s] 
(mean ± SD) / pH 
1 
 
73 ± 7.9 2.4 1.7 ± 0.0 >3000 n.d. 
8a 
 
30.2 1 2.6 ± 0.1 5.5 ± 0.2 / 7.4 n.d. 
8b 
 
22.0 0.73 3.3 ± 0.1 3.5 ± 0.3 / 7.4 n.d. 
8e 
 
39.5 1.31 3.4 ± 0.1 22 ± 0 / 7.4 n.d. 
8g 
 
37.6 1.24 2.3 ± 0.0 117 ± 7 / 7.4 -5.0 ± 0.1 / 7.4 
8h 
 
18.5 0.61 3.3 ± 0.0 7.4 ± 0.2 / 7.4 n.d. 
8i 
 
23.2 0.77 2.7 ± 0.1 3.8 ± 0.4 / 7.4 n.d. 
8r 
 
10.1 0.33 2.1 ± 0.0 192 ± 5 / 7.4 -5.2 ± 0.0 / 7.4 
8s 
 
21.3 0.71 2.1 ± 0.1 16 ± 0 / 7.4 n.d. 
8j 
 
15.6 0.52 3.0 ± 0.0 7.1 ± 0.6 / 7.4 n.d. 
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Table 1. (Continued) 
Compound IC50 
[nM] 
rIC50 logD7.4 
(mean ± SD) 
Solubility [!g/ml] 
(mean ± SD) / pH 
PAMPA log Pe 
[log cm/s] 
(mean ± SD) / pH 
8k 
 
17.3 0.57 3.2 ± 0.0 5.7 ± 0.7 / 7.4 n.d. 
8q 
 
17.9 0.59 2.1 ± 0.0 227 ± 5 / 7.4 -5.1 ± 0.0 / 7.4 
8o 
 
25.4 0.84 3.3 ± 0.1 36 ± 1 / 7.4 n.d. 
8p 
 
13.1 0.43 2.4 ± 0.1 23 ± 2 / 7.4 -4.9 ± 0.1 / 7.4 
8l 
 
18.3 0.61 2.9 ± 0.0 135 ± 24 / 7.4 -4.6 ± 0.2 / 7.4 
8m 
 
20.9 0.69 3.1 ± 0.1 28 ± 1 / 7.4 -4.4 ± 0.1 / 7.4 
8n 
 
48.5 1.61 2.4 ± 0.0 > 280 / 7.4 -4.6 ± 0.1 / 7.4 
8c 
 
17.2 0.57 n.d. 2.3 ± 0.2 / 7.4 n.d. 
8d 
 
34.2 1.13 n.d. 1.0 ± 0.2 / 7.4 n.d. 
8f 
 
21.9 0.73 n.d. 8.0 ± 0.8 / 7.4 n.d. 
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Binding Affinity  
Affinity of the unsubstituted parent compound 8a was in the low nanomolar range and 
exhibited a twofold higher binding affinity compared to n-heptyl mannoside (1). Introduction 
of hydrophobic residues is often accompanied by affinity improvement.[12] Accordingly, the 
first substitution proposed is the introduction of a 4-chloro substituent. In the present case, 
the 4-chlorophenyl 8b showed a slight improvement in affinity compared to the unsubstituted 
parent compound 8a. Following the outer right branch of the Topliss tree (Figure 3), 
hydrophobicity was further increased by the introduction of a 3,4-dichloro substituted phenyl 
(!8c), leading to only marginally improved affinity. With a 3-trifluoromethyl-4-
chlorophenyl (!8d) the affinity was slightly reduced to the level of the unsubstituted 
biphenyl 8a. These observations indicate a too pronounced electron withdrawing and 
hydrophobic character of the latter substituents. Therefore, also the neighboring branches of 
the Topliss scheme were investigated. To elucidate whether the biological activity depends 
mainly on the electron withdrawing effect, the 4-trifluoromethyl (!8e), the 2,4-dichloro 
(!8f), and the 4-nitro (!8g) bearing compounds were tested. These strong electron-
withdrawing groups did not improve binding affinity compared to the chloro-substituted 
compounds 8b and 8c.  
These results clearly indicate a non-optimal "/#-balance. Since the effect of the 4-chloro 
substituent (!8b) on affinity was not significantly different compared to the parent 
compound 8a, a less electron withdrawing or a less hydrophobic group might be favorable. 
We therefore introduced substitutents according to the middle branch of the Topliss scheme. 
Starting with a substituent with –# , i.e. electron-donating, and +" properties, a methyl group 
was introduced in 4-position (!8h). This compound showed a retained binding affinity. Both 
substituents, chloro and methyl, have similar properties concerning hydrophobicity, however, 
the methyl group has a weak electron-donating effect. In order to investigate whether electron 
donating groups are acceptable, we synthesized the 4-methoxy compound (!8i). In fact, 
binding affinity was in the same range as for the 4-chloro derivative 8b. Proceeding 
according to the Topliss scheme, we introduced methyl and chloro in the 3-position (!8j, 
!8k). However, the affinity was unchanged. Introduction of these substituents in the 2-
position (2-CH3!8l, 2-Cl!8m) resulted in a marginally reduced binding affinity compared 
to the respective 3- or 4-substituted compounds. Introducing a 2-methoxy group (!8n), 
which has strong electron-releasing properties and a low hydrophobicity parameter, gave the 
lowest binding affinity in this series. Considering the volume of this group, the loss in affinity 
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could also result from steric hindrance and hence a non-optimal binding geometry. A 
trifluoromethyl group in the 3-position (!8o), being less electron withdrawing than in the 
4-position led to a slightly better affinity than in the 4-position, however, no improvement 
compared to chloro or methyl substituents.  
Up to that point, none of the substituents introduced improved the affinity notably comparing 
to 4-chloro substitution. Therefore, a less hydrophobic but still electron withdrawing group 
might yield better results. When introduced in the 3-position (!8p), a nitro group has lower 
hydrophobic and electron withdrawing effects compared to the 4-nitro and, indeed, binding 
affinity of 8p was increased almost threefold with respect to 8g. A cyano group was shown to 
be adavantageous in many aspects and a suitable replacement for a chloro substituent.[19] 
Introducing cyano in the 3-position (!8q) could not improve affinity, however, when 
introduced in the 4-position (!8r), the highest binding affinity in this series was obtained. 
An acetyl group in 4-position (!8s) was expected to have similar properties. However, the 
binding affinity was in same range as for the 4-chloro derivative 8b. Obviously, a range of 
different substituents can support this "-" interaction. However, our results indicate that 
strongly electron withdrawing groups (4-nitro) or sterically demanding groups (2-methoxy) 
are less favoured.  
With the Topliss approach, a cyano-group in the 4-position was identified as suitable 
substituent for improved affinity. Looking at the " and # values of a cyano group (4-CN:  
" = -0.57, # = 0.66)[13b] the similarity to a carboxylic acid group that is present in previous, 
highly affine biphenyl mannosides[10b] (4-COOH: " = -0.32, # = 0.45)[13b] becomes apparent. 
Both groups show rather low hydophobicity and considerable electron withdrawing effects. 
The nitro group shows the same tendency. However the electron withdrawing character in the 
para-position is relatively strong (NO2: " = -0.28, #p = 0.78, #m =0.71). The less electron 
withdrawing meta-NO2 shows a threefold improved affinity over its para-analogue (8p vs. 
8g), which can be seen as an indication for the importance of the optimal "/#-balance. 
Undertaking a similar approach, Han et al. found that the introduction of electron-
withdrawing substituents in 3- and 5-position is advantageous in case of an unsubstituted first 
phenyl ring.[11] The best inhibitor in their study was an 3,5-di-amide-bearing biphenyl 
mannoside. An additional contact of the introduced substituents with Arg89 was discussed in 
this context. However, based on our findings of a rather small range in affinity, this seems 
rather unlikely. Interestingly, in their series with an unsubstituted inner phenyl ring, the 
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cyano substituted compounds showed a vice-versa effect compared to our results, i.e. in a 
hemagglutination assay the 3-cyano showed better inhibitory potency than a 4-cyano. The 
chloro-substituent on the inner ring surely influences the electronic properties of the second 
outer ring and therewith the affinity towards FimH. In our case, the electron poor inner 
phenyl can account for the preference of the cyano in 4-position, with a more electron-
withdrawing effect, over 3-position. 
In summary, compared to the unsubstituted biphenyl compound 8a an electron-withdrawing 
or even a slightly electron-donating substituent are both advantageous leading to a two- to 
threefold improvement in binding affinitiy. Introduction of strongly electron-withdrawing 
substituents at the 4-position seems disadvantageous regarding the nitro (8g) and the 
trifluormethyl (8e) substituted derivatives. Likewise, the introduction of a bulky electron-
donating group at the 2-position (methoxy, 8n) is unfavourable in terms of affinity. A 
significant improvement in affinity was obtained with the 4-cyano substituted compound 8r. 
We further evaluated the affinity of this compound by isothermal titration calorimetry (ITC). 
The experiment revealed enthalpically driven binding of 8r to FimH CRD with a KD of 
0.75 nM (!G°: -52.1 kJ/mol, !H°: -61.5 kJ/mol, T!S°: +9.4 kJ/mol at 25°C). 
 
Physicochemical Properties 
Obviously, small substituents in position 2, 3, or 4 of the biphenyl aglycone affect aqueous 
solubility and lipophilicity of the FimH antagonist. As the hydrophobicity parameter ![20] is 
defined by its logP(octanol/water) value the same general trend is reflected by our data, e.g. 
"Cl = log Pchlorobenzene - log Pbenzene = 0.7[12,20]    
"Cl (experimental) = logD7.4 (8b) - logD7.4 (8a) = 3.3 - 2.6= 0.7 
"CN = log Pchlorobenzene - log Pbenzene = -0.57[12] 
"CN (experimental) = logD7.4 (8r) - logD7.4 (8a) = 2.1 - 2.6= -0.5 
Low solubility and moderate lipophilicity were determined for the unsubstituted parent 
compound (8a). Adding apolar substituents in position 3 or 4, such as methyl ("8h, 8j), 
chloro ("8b, 8k), or trifluoro methyl ("8c, 8o) markedly increased logD7.4, whereas 
4-methoxy ("8i) and 4-acetyl ("8s) lead to lower lipophilicity. However, none of these 
substituents enhanced solubility beyond 50 #g/ml. By contrast, the 4-nitro substituted 
derivative 8g showed markedly higher solubility, however, the same substituent in position 3 
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(!8p) was much less effective. The cyano substituent (!8q, 8r) enhanced solubility above 
the critical limit as well, regardless of its position. Both, nitro and cyano reduced lipophilicity 
of the antagonist and, as a result, permeability. However, the permeation through an artificial 
membrane (PAMPA) still predicted high in vivo absorption.[21]  
In contrast to the 3- or 4-substituents, which did either not improve solubility at all or only on 
the expense of lipophilicity, 2-methyl (!8l) and 2-methoxy (!8n) increased both, 
lipophilicity and the maximum amount of dissolved antagonist.  This is in agreement with the 
v. d. Waals volumes of these groups which result in a bigger distortion angle of the two 
phenyl moieties compared to a H-substituent at this position (data not shown). Nonetheless, 
we observed that moving methyl, methoxy, or chloro from the 4- or 3- position to the 
2-position lowered logD7.4, as a general trend. As for 3,4-disubstituted and 2,4-disubstituted 
biphenyl derivatives, the antagonists 8c, 8d, and 8f were scarcely soluble in aqueous medium. 
In summary, only few substituents (2-methyl, 2-methoxy, 3- and 4-cyano, and 4-nitro) rose 
aqueous solubility beyond 50 !g/ml leading to sufficient antagonist concentrations in the 
intestinal fluids. Nevertheless, all biphenyl derivatives bearing these substituents achieved 
substantial permeability, which, in combination with high aqueous solubility, suggested high 
systemic availability after oral dosing. Finally, we consider the nitro and cyano substituents 
most favorable for renal excretion. Adding nitro or cyano to the outer aromatic ring 
moderately reduced lipophilicity and therefore susceptibility to tubular reabsorption or 
hepatic metabolism, which results in high availability of the biphenyl mannoside in the 
urinary bladder.  
 
CONCLUSION 
The crystal stucture for biphenyl mannosides binding to FimH has been solved[11], yet, the 
electronic property of Tyr48 is not entirely understood. To address this matter, we 
synthesized a series of substituted biphenyl mannosides following the Topliss decision tree. 
The biological evaluation of these compounds indicated that a broad range of substituents is 
accepted and mostly improves affinity. Both, electron-withdrawing as well as weakly 
electron-releasing groups, lead to an improvement in affinity compared to the parent 
compound 8a, though, the former effect appears more relevant. The sensitive balance of 
hydrophobic and electronic properties in addition to steric effects has been proven 
fundamental. The Topliss-based approach gave an insight into hydrophobic and electronic 
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properties and their influence on affinity. Physicochemical data complete this SAR study by 
elucidating the correlation of substitution pattern with solubility and permeability properties. 
As a result, the 2’-chloro-4-cyano substituted biphenyl mannoside 8r was identified as FimH 
antagonist with improved affinity accompanied by appropriate physicochemical properties. 
 
EXPERIMENTAL SECTION 
Synthesis 
General Methods 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMBC, TOCSY). Chemical shifts are expressed in ppm in relation to the residual solvent 
signals (CHCl3, CHD2OD, and HDO) on the !-scale. Coupling constants J are given in Hertz 
(Hz). Multiplicities were specified as follows: s (singlet), d (doublet), dd (doublet of a 
doublet), t (triplet), q (quartet), m (multiplet). For assignment of resonance signals to the 
appropriate nuclei the following abbreviations were used: Ar, aryl. Commercially available 
reagents were purchased from Fluka, Aldrich, Acros, and Abcr. Solvents were dried prior to 
use as indicated. Dichloromethane (CH2Cl2) was dried by filtration over Al2O3 (Fluka, type 
5016 A basic). N,N-dimtehylformamide (DMF) was dried by distillation from calcium 
hydride. Methanol (MeOH) was dried by refluxing with sodium methoxide and distilled 
immediately before use. Molecular sieves were activated under vacuum at 500ºC for 1 h 
immediately before use. Reactions were monitored by TLC using glass plates coated with 
silica gel 60 F254 (Merck) and visualized by using UV light and/or by charring with a 
molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography was 
performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) using RediSep normal phase 
disposable flash columns (silica gel, 40-63 µm). Reversed phase chromatography was 
performed on LiChroprepRP-18 (Merck, 40-63 µm). LC-MS separations were carried out 
using Sunfire C18 columns (19 x 150 mm, 5.0 !m) on a Waters 2525 LC, equipped with 
Waters 2996 photodiode array and Waters micromass ZQ MS for detection. Electron spray 
ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. HR-MS 
analysis were carried out using a Agilent 1100 LC equipped with a photodiode array detector 
and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Optical rotations 
were measured using Perkin-Elmer polarimeter 341. Microanalysis was performed at the 
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Institute of Organic Chemistry at the University of Basel, Switzerland. Compound purity was 
determined on an Agilent 1200 HPLC; ELS detector, Waters 2420; column: Waters Atlantis 
dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water + 
0.1% TFA. Linear gradient: 0 - 1 min 5% B; 1 - 15 min 5 to 70% B; 16 - 20 min 70 to 5% B 
flow rate: 0.5 ml/min. All compounds used for biological assays are at least of 95% purity 
based on HPLC analytical results. 
Compound 2 was prepared according to a published procedure.[22] 
 
2-Chloro-4-iodo-phenyl 2,3,4,6-tetra-O-acetyl-!-D-mannopyranoside (2)  
In a dry flask activated MS4Å (300 mg), !-D-mannose pentaacetate (390 mg, 0.77 mmol), 2-
chloro-4-iodophenol (235 mg, 1.2 eq, 0.9 mmol) were dissolved in dry CH2Cl2 (3 ml) under 
argon atmosphere. BF3·Et2O (freshly distilled, 290 µl, 3eq, 2.3 mmol) was added dropwise 
and the mixture and stirred for 20h at 40°C. After cooling to room temperature the mixture 
was diluted with CH2Cl2 (75 ml), filtered through celite, washed with satd. aq. NaHCO3 (75 
ml) solution, water (75 ml), and brine (75 ml). The organic phase was dried over Na2SO4 and 
concentrated under reduced pressure. The crude product was purified via flash column 
chromatography (PE->PE/EE 1:1) to yield the product in 76% (345 mg). 
Spectroscopic data were in accordance with literature. [22]  
 
General procedure A for the synthesis of biphenyl compounds 
A two-neck flask was charged with 2 (100 mg, 1.0 eq), phenylboronic acid or boronate (1.1 
eq), Pd(Cl2)dppf·CH2Cl2 (0.03 eq), K3PO4 (2 eq), and a stirring bar under argon atmosphere. 
Then anhydrous DMF (2 ml) was added. The mixture was flushed with argon and degassed 
for 5min, then heated to 80°C and stirred 5-12h. The reaction mixture was cooled to r.t., 
diluted with EtOAc (50 ml), washed with H2O (50 ml), brine (50 ml), and then dried over 
Na2SO4, concentrated and purified by normal phase flash chromatography (PE/EtOAc, 
gradient) to afford biphenyl compounds 7a-s. 
  
General procedure B for deacetylation. To a solution of 7 (1.0 eq) in dry MeOH (2 mL) 
was added freshly prepared methanolic NaOMe solution (1 M, 0.1 eq) under argon. The 
mixture was stirred at r.t. until the reaction was complete (monitored by TLC, 2-8h), then 
neutralized with acetic acid, filtered and concentrated in vacuo. The residue was purified by 
normal phase flash chromatography (CH2Cl2/MeOH, 10:1->8:1) to afford 8a-s as white 
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solids. Further purification for biological testing was performed via reversed phase 
preparative HPLC. 
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-biphenyl (7a) 
In a dry flask activated MS4Å (150 mg), !-D-mannose pentaacetate (156 mg, 1 eq, 
0.4 mmol), 2-chloro-4-phenylphenol (98 mg, 1.2 eq, 0.48 mmol) were dissolved in dry 
CH2Cl2 (1.5 ml) under argon atmosphere. BF3·Et2O (freshly distilled, 148 µl, 3 eq, 1.2 mmol) 
was added and the mixture stirred for 24 h at 40°C. After cooling down to room temperature 
the mixture was diluted with CH2Cl2 (50 ml), filtered through celite, washed with satd. aq. 
NaHCO3 solution (50 ml), H2O (50 ml), and brine (50 ml). The organic phase was dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified via flash 
column chromatography (PE/EE, 1:0 to 1:1) to yield compound 7a (166 mg, 77%). 
[a]D20 +72.0 (c 0.47, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.56 (d, J = 1.6 Hz, 1H, Ar-H), 
7.45 (d, J = 7.4 Hz, 2H, Ar-H), 7.32 (dt, J = 39.4, 7.4 Hz, 4H, Ar-H), 7.17 (m, 1H, Ar-H), 
5.63 – 5.42 (m, 3H, H-1, H-2, H-3), 5.33 (t, J = 10.1 Hz, 1H, H-4), 4.22 (dd, J = 12.2, 5.3 Hz, 
1H, H-6a), 4.14 (m, 1H, H-5), 4.04 (d, J = 12.2 Hz, 1H, H-6b), 2.14 (s, 3H, CH3), 2.06 – 1.88 
(m, 9H, 3CH3); 13C NMR (126 MHz, CDCl3): ! 170.61, 170.08, 169.91, 169.90 (4CO), 
150.64, 139.28, 137.64, 129.25, 129.06, 127.78, 126.97, 126.40, 124.82, 117.43 (12C, Ar-C), 
96.86 (C-1), 69.90 (C-5), 69.50 (C-2), 68.93 (C-3), 66.01 (C-4), 62.26 (C-6), 21.01, 20.85, 
20.82, 20.80 (4CH3); ESI-MS: m/z calcd for C26H27ClO10 [M+Na]+: 557.12, found: 557.17. 
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-chloro-biphenyl (7b) 
Prepared according to general procedure A from 2 (30 mg, 0.052 mmol), 4-chloro-
phenylboronic acid (9 mg, 0.57 mmol), Pd(dppf)Cl2"CH2Cl2 (1.3 mg, 1.6 µmol) and K3PO4 
(22 mg, 0.1 mmol). Yield: 16 mg (54%) as a white solid. 
[a]D20 +97.8 (c 0.54, CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.66 – 7.23 (m, 7H, Ar-H), 
5.67 (s, 1H, H-1), 5.49 – 5.43 (m, 2H, H-2, H-3), 5.25 (t, J = 10.0 Hz, 1H, H-4), 4.13 (dd,  
J = 12.1, 5.4 Hz, 1H, H-6a), 4.05 (ddd, J = 10.1, 5.4, 2.1 Hz, 1H, H-5), 3.98 (dd, J = 12.2, 2.2 
Hz, 1H, H-6b), 2.14 – 1.80 (m, 12H, 4CH3); 13C NMR (126 MHz, CD3OD): ! 172.17, 
171.51, 171.48 (4C, CO), 151.81, 139.07, 137.34, 134.80, 130.12, 129.73, 129.31, 127.49, 
125.65, 118.86 (12C, Ar-C), 97.67 (C-1), 71.23 (C-5), 70.50, 70.24 (C-2, C-3), 66.97 (C-4), 
63.29 (C-6), 20.58, 20.55 (4C, CH3); ESI-MS: m/z calcd for C26H26Cl2O10 [M+Na]+: 591.08, 
found: 591.11. 
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3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3,4-dichloro-biphenyl 
(7c) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 3,4-dichloro-
phenylboronic acid (228mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 52 mg (64%) as a white solid. 
[!]D20 +66.5 (c 0.23, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.59 (dt, J = 8.9, 4.4 Hz, 2H, 
Ar-H), 7.50 (d, J = 8.3 Hz, 1H, Ar-H), 7.41 – 7.31 (m, 2H, Ar-H), 7.24 (d, J = 8.6 Hz, 1H, 
Ar-H), (5.66 – 5.58 (m, 2H, H-1, H-2), 5.55 (d, J = 1.9 Hz, 1H, H-3), 5.41 (t, J = 10.1 Hz, 
1H, H-4), 4.29 (dd, J = 12.3, 5.2 Hz, 1H, H-6a), 4.18 (ddd, J = 10.1, 5.1, 2.1 Hz, 1H, H-5), 
4.10 (m, 1H, H-6b), 2.21 (d, J = 6.2 Hz, 3H, CH3), 2.15 – 1.97 (m, 9H, 3CH3); 13C NMR 
(126 MHz, CDCl3): ! 170.60, 170.11, 169.92, 169.89 (4CO), 151.29, 139.26, 135.03, 133.24, 
132.06, 131.01, 129.15, 128.81, 126.32, 126.18, 125.12, 117.41 (12Ar-C), 96.80 (C-1), 69.99 
(C-5), 69.45 (C-3), 68.88 (C-2), 65.93 (C-4), 62.22 (C-6), 21.01, 20.85, 20.83 (4C, CH3); 
ESI-MS: m/z calcd for C26H26Cl3O10 [M+Na]+: 625.04, found: 625.02.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-trifluoromethyl-4-
chloro-biphenyl (7d) 
Prepared according to general procedure A from 2 (80 mg, 0.137 mmol), 3-trifluoro-4-
chlorophenylboronic acid (34 mg, 0.151 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 4 µmol) and 
K3PO4 (58 mg, 0.27 mmol). Yield: 70 mg (80%) as a white solid. 
[!]D20 +60.7 (c 0.27 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.95 (d, J = 1.9 Hz, 1H, Ar-
H), 7.84 (dd, J = 8.3, 2.0 Hz, 1H, Ar-H), 7.79 (d, J = 2.3 Hz, 1H, Ar-H), 7.72 – 7.58 (m, 2H, 
Ar-H), 7.44 (m, 1H, Ar-H), 5.80 (s, 1H, H-1), 5.60 – 5.51 (m, 2H, H-2, H-3), 5.36 (t, J = 10.0 
Hz, 1H, H-4), 4.24 (dd, J = 12.2, 5.3 Hz, 1H, H-6a), 4.18 – 4.05 (m, 2H, H-5, H-6b), 2.20 (d, 
J = 3.4 Hz, 3H, CH3), 2.08 (d, J = 3.0 Hz, 3H, CH3), 2.02 (d, J = 2.8 Hz, 3H, CH3), 1.96 (d,  
J = 3.9 Hz, 3H, CH3); 13C NMR (126 MHz, CD3OD): ! 172.17, 171.49, 171.47 (4C, CO), 
152.43, 139.86, 135.79, 133.40, 132.76, 130.00, 127.78, 126.84, 125.87, 118.88 (12C, Ar-C), 
97.65 (C-1), 71.28 (C-5), 70.49, 70.21 (C-2, C-3), 66.94 (C-4), 63.28 (C-5), 20.59, 20.56, 
(4C, CH3); ESI-MS: m/z calcd for C27H25Cl2F3O10 [M+Na]+: 659.07, found: 659.03.  
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3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-trifluoromethyl-
biphenyl (7e) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 4-trifluoromethyl-
phenylboronic acid (28 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 46 mg (57%) as a white solid. 
[!]D20 +63.8 (c 0.31 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.84 – 7.77 (m, 3H, Ar-H), 
7.74 (d, J = 8.3 Hz, 2H, Ar-H), 7.64 (dd, J = 8.6, 2.3 Hz, 1H, Ar-H), 7.43 (d, J = 8.6 Hz, 1H, 
Ar-H), 5.81 (s, 1H, H-1), 5.60 – 5.54 (m, 2H, H-2, H-3), 5.36 (t, J = 10.0 Hz, 1H, H-4), 4.24 
(dd, J = 12.2, 5.4 Hz, 1H, H-6a), 4.14 (ddd, J = 10.0, 5.4, 2.2 Hz, 1H, H-5), 4.09 (dd,  
J = 12.2, 2.2 Hz, 1H, H-6b), 2.20 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.01 (d, J = 5.3 Hz, 3H, 
CH3), 1.95 (s, 3H, CH3); 13C NMR (126 MHz, CD3OD): ! 172.18, 171.52, 171.50, 171.48 
(4CO), 152.30, 144.19, 136.90, 130.12, 128.39, 127.89, 126.94, 126.91, 125.75, 118.82 (12C, 
Ar-C), 97.62 (C-1), 71.26 (C-5), 70.49, 70.21 (C-2, C-3), 66.95 (C-4), 63.28 (C-6), 20.59, 
20.58, 20.55 (4C, CH3); ESI-MS: m/z calcd for C27H26ClF3O10 [M+Na]+: 625.11, found: 
625.02.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-2,4-dichloro-biphenyl 
(7f) 
Prepared according to general procedure A from 2 (79 mg, 0.14 mmol), 2,4-dichloro-
phenylboronic acid (28 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 48 mg (59%) as a white solid. 
[!]D20 +58.8 (c 0.56 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.60 – 7.30 (m, 6H, Ar-H), 
5.79 (s, 1H, H-1), 5.61 – 5.53 (m, 2H, H-2, H-3), 5.35 (m, 1H, H-4), 4.24 (dt, J = 11.9, 5.9 
Hz, 1H, H-6a), 4.18 – 4.06 (m, 2H, H-5, H-6b), 2.19 (d, J = 7.8 Hz, 3H, CH3), 2.10 – 2.05 
(m, 3H, CH3), 2.01 (d, J = 5.9 Hz, 3H, CH3), 1.98 – 1.94 (m, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): !: ! 172.18, 171.51, 171.48 (4C, CO), 152.01, 138.68, 135.51, 135.36, 134.29, 
133.49, 132.33, 130.72, 130.24, 128.66, 124.79, 118.03 (12Ar-C), 97.63 (C-1), 71.27 (C-5), 
70.49 (C-3), 70.23 (C-2), 66.96 (C-4), 63.30 (C-6), 20.60, 20.56, (4C, CH3); ESI-MS: m/z 
calcd for C26H25Cl3O10 [M+Na]+: 652.04, found: 653.04.  
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3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-nitro-biphenyl (7g) 
Prepared according to general procedure A from 2 (41 mg, 0.07 mmol), 4-nitro-
phenylboronic acid (13 mg, 0.08 mmol), Pd(dppf)Cl2"CH2Cl2 (1.7 mg, 2 µmol) and K3PO4 
(30 mg, 0.14 mmol). Yield: 31 mg (76%) as a light-yellow solid. 
[!]D20 +77.1 (c 0.58 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 8.34 – 8.26 (m, 2H, Ar-H), 
7.89 – 7.77 (m, 3H, Ar-H), 7.67 (dd, J = 8.6, 2.3 Hz, 1H, Ar-H), 7.43 (d, J = 8.7 Hz, 1H, Ar-
H), 5.81 (s, 1H, H-1), 5.60 – 5.52 (m, 2H, H-2, H-3), 5.36 (m, 1H, H-4), 4.23 (dd, J = 12.1, 
5.3 Hz, 1H, H-6a), 4.18 – 4.04 (m, 2H, H-5, H-6b), 2.20 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.02 
(s, 3H, CH3), 1.95 (s, 3H, CH3); 13C NMR (126 MHz, CD3OD): ! 172.14, 171.49, 171.48, 
171.45 (4CO), 152.73, 148.64, 146.63, 135.95, 130.32, 128.73, 128.11, 125.84, 125.18, 
118.76 (12C, Ar-C), 97.59 (C-1), 71.28 (C-5), 70.45, 70.17 (C-2, C-3), 66.91 (C-4), 63.26 
(C-6), 20.59, 20.58, 20.56 (4C, CH3); ESI-MS: m/z calcd for C26H26ClNO12 [M+Na]+: 
602.10, found: 602.06.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-methyl-biphenyl (7h) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 4-methyl-
phenylboronic acid (20 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 50 mg (67%) as a white solid. 
[!]D20 +71.9 (c0.43, CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.67 (d, J = 2.2 Hz, 1H, Ar-
H), 7.52 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 7.47 (t, J = 7.3 Hz, 2H, Ar-H), 7.35 (d, J = 8.6 Hz, 
1H, Ar-H), 7.25 (d, J = 7.9 Hz, 2H, Ar-H), 5.75 (s, 1H, H-1), 5.59 – 5.52 (m, 2H, H-2, H-3), 
5.34 (t, J = 10.0 Hz, 1H, H-4), 4.23 (dd, J = 12.1, 5.5 Hz, 1H, H-6a), 4.17 (m, 1H, H-5), 4.09 
(dd, J = 12.1, 2.1 Hz, 1H, H-6b), 2.37 (s, 3H, PhCH3), 2.20 (s, 3H, CH3), 2.12 – 1.92 (m, 9H, 
3CH3); 13C NMR (126 MHz, CDCl3): ! 170.64, 170.10, 169.94, 169.91 (4CO), 150.42, 
137.66, 137.63, 136.41, 129.78, 129.03, 126.81, 126.18, 124.80, 117.47 (12C, Ar-C), 96.90 
(C-1), 69.89, 69.53, 68.95 (C-5, C-3, C-2), 66.04 (C-4), 62.29 (C-6), 21.23, 21.02, 20.86, 
20.83, 20.82 (5CH3); ESI-MS: m/z calcd for C27H29ClO10 [M+Na]+: 571.13, found: 571.08.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-methoxy-biphenyl (7i) 
Prepared according to general procedure A from 2 (59.6 mg, 0.1 mmol), 
4-methoxyphenylboronic acid (17 mg, 0.112 mmol), Pd(dppf)Cl2"CH2Cl2 (2.5 mg, 3 µmol) 
and K3PO4 (43 mg, 0.2 mmol). Yield: 52 mg (90 %) as a white solid. 
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[!]D20 +73.7 (c 0.53 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.64 (d, J = 2.2 Hz, 1H, Ar-
H), 7.56 – 7.46 (m, 3H, Ar-H), 7.33 (d, J = 8.6 Hz, 1H, Ar-H), 7.05 – 6.95 (m, 2H, Ar-H), 
5.73 (s, 1H, H-1), 5.56 (dd, J = 8.1, 3.4 Hz, 2H, H-2, H-3), 5.35 (dd, J = 15.7, 5.7 Hz, 1H, H-
4), 4.23 (dd, J = 12.1, 5.5 Hz, 1H, H-6a), 4.17 (ddd, J = 10.0, 5.6, 2.1 Hz, 1H, H-5), 4.09 (dd, 
J = 12.1, 2.1 Hz, 1H, H-6b), 3.83 (s, 3H, OCH3), 2.19 (s, 3H, CH3), 2.09 – 1.92 (m, 9H, 
3CH3); 13C NMR (126 MHz, CD3OD): ! 172.19, 171.52, 171.48 (4C, CO), 161.04, 151.01, 
138.58, 132.80, 129.26, 128.85, 127.01, 125.50, 118.93, 115.43 (12C, Ar-C), 97.76 (C-1), 
71.18 (C-5), 70.52, 70.30 (C-2, C-3), 67.01 (C-4), 63.32 (C-6), 55.77 (OCH3), 20.59, 20.58, 
20.56 (4C, CH3); ESI-MS: m/z calcd for C27H29ClO11 [M+K]+: 603.12, found: 602.99.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-methyl-biphenyl (7j) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 3-methyl-
phenylboronic acid (20 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 51 mg (69%) as a white solid. 
[!]D20 +78.2 (c 0.36 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.68 (d, J = 2.1 Hz, 1H, Ar-
H), 7.53 (dd, J = 8.6, 2.1 Hz, 1H, Ar-H), 7.34 (dt, J = 15.1, 10.4 Hz, 4H, Ar-H), 7.17 (d,  
J = 7.4 Hz, 1H, Ar-H), 5.76 (s, 1H, H-1), 5.59 – 5.52 (m, 2H, H-2, H-3), 5.35 (t, J = 9.9 Hz, 
1H, H-4), 4.24 (dd, J = 12.1, 5.5 Hz, 1H, H-6a), 4.17 (m, 1H, H-5), 4.09 (dd, J = 12.1, 2.1 
Hz, 1H, H-6b), 2.40 (s, 3H, PhCH3), 2.19 (d, J = 6.1 Hz, 3H, CH3), 2.09 – 1.94 (m, 9H, 
3CH3); 13C NMR (126 MHz, CD3OD): ! 172.20, 171.53, 171.49 (4C, CO), 151.44, 140.37, 
139.83, 138.93, 129.93, 129.75, 129.40, 128.41, 127.52, 125.47, 124.90, 118.82 (12Ar-C), 
97.71 (C-1), 71.19 (C-5), 70.51, 70.28 (C-2, C-3), 66.99 (C-4), 63.31 (C-6), 21.52 (PhCH3), 
20.60, 20.59, 20.56 (4C, CH3); ESI-MS: m/z calcd for C27H29ClO10 [M+Na]+: 571.13, found: 
571.13.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-chloro-biphenyl (7k) 
Prepared according to general procedure A from 2 (81 mg, 0.138 mmol), 3-chloro-
phenylboronic acid (24 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 4 µmol) and K3PO4 
(59 mg, 0.28 mmol). Yield: 57 mg (75%) as a white solid. 
[!]D20 +67.3 (c 0.27 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.71 (t, J = 7.8 Hz, 1H, Ar-
H), 7.66 – 7.31 (m, 6H, Ar-H), 5.78 (s, 1H, H-1), 5.61 – 5.51 (m, 2H, H-2, H-3), 5.35 (t,  
J = 10.1 Hz, 1H, H-4), 4.23 (dd, J = 12.2, 5.4 Hz, 1H, H-6a), 4.19 – 4.02 (m, 2H, H-5, H-6b), 
2.19 (s, 3H, CH3), 2.11 – 1.92 (m, 9H, 3CH3); 13C NMR (126 MHz, CD3OD): ! 172.18, 
171.50, 171.48 (4C, CO), 152.04, 142.44, 137.09, 135.96, 131.56, 129.89, 128.65, 127.75, 
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127.67, 126.23, 125.67, 118.82 (12C, Ar-C) 97.66 (C-1), 71.23, 70.49, 70.23 (C-2, C-3, C-5), 
66.95 (C-4), 63.28 (C-6), 20.59, 20.58, 20.55 (4C, CH3); ESI-MS: m/z calcd for C26H26Cl2O10 
[M+Na]+: 591.08, found: 590.99.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-2-methyl-biphenyl (7l) 
Prepared according to general procedure A from 2 (79 mg, 0.14 mmol), 2-methyl-
phenylboronic acid (20 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 39 mg (53%) as a white solid. 
[!]D20 +62.9 (c 0.42 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.37 (dd, J = 12.9, 5.2 Hz, 
2H, Ar-H), 7.29 – 7.19 (m, 4H, Ar-H), 7.16 (d, J = 6.9 Hz, 1H, Ar-H), 5.76 (s, 1H, H-1), 5.59 
– 5.54 (m, 2H, H-2, H-3), 5.35 (m, 1H, H-4), 4.28 – 4.03 (m, 3H, H-5, H-6), 2.25 (s, 3H, 
CH3), 2.19 (d, J = 6.8 Hz, 3H, CH3), 2.08 (s, 3H, CH3), 2.02 (s, 3H, CH3), 1.98 (s, 3H, 
CH3);13C NMR (126 MHz, CD3OD): ! 172.19, 171.54, 171.50 (4C, CO), 151.24, 141.25, 
139.60, 136.36, 132.01, 131.48, 130.60, 129.93, 128.82, 127.04, 124.80, 118.24 (12Ar-C), 
97.81 (C-1), 71.21 (C-5), 70.52, 70.31 (2C, C-2, C-3), 67.02 (C-4), 63.35 (C-6), 20.60, 20.56, 
20.52 (5C, CH3); ESI-MS: m/z calcd for C27H29ClO10 [M+Na]+: 571.13, found: 571.08.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-2-chloro-biphenyl (7m) 
Prepared according to general procedure A from 2 (81 mg, 0.138 mmol), 2-chloro-
phenylboronic acid (24 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 4 µmol) and K3PO4 
(59 mg, 0.28 mmol). Yield: 52 mg (66%) as a white solid. 
[!]D20 +64.7 (c 0.42 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.48 (dd, J = 8.9, 1.7 Hz, 2H, 
Ar-H), 7.39 – 7.30 (m, 5H, Ar-H), 5.77 (s, 1H, H-1), 5.64 – 5.52 (m, 2H, H-2, H-3), 5.35 (m, 
1H, H-4), 4.24 (dd, J = 12.1, 5.6 Hz, 1H, H-6a), 4.17 (ddd, J = 10.0, 5.6, 2.0 Hz, 1H, H-5), 
4.08 (m, 1H, H-6b), 2.19 (s, 3H, CH3), 2.07 (s, 3H, CH3), 2.01 (s, 3H, CH3), 1.96 (s, 3H, 
CH3); 13C NMR (126 MHz, CD3OD): ! 172.16, 171.50, 171.45 (4C, CO), 151.72, 139.84, 
136.70, 133.35, 132.42, 132.34, 131.10, 130.31, 130.24, 128.37, 124.63, 117.98 (12Ar-C), 
97.64 (C-1), 71.22 (C-5), 70.47, 70.24 (C-2, C-3), 66.96 (C-49, 63.29 (C-6), 20.62, 20.61, 
20.60, 20.57 (4CH3); ESI-MS: m/z calcd for C26H26Cl2O10 [M+Na]+: 591.08, found: 591.00.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-2-methoxy-biphenyl (7n) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 2-methoxy-
phenylboronic acid (23 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 34 mg (45%) as a white solid. 
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[!]D20 +75.0 (c 0.52 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.58 (d, J = 2.1 Hz, 1H, Ar-
H), 7.42 (dd, J = 8.6, 2.1 Hz, 1H, Ar-H), 7.38 – 7.25 (m, 3H, Ar-H), 7.08 (d, J = 8.2 Hz, 1H, 
Ar-H), 7.02 (m, 1H, Ar-H), 5.76 (s, 1H, H-1), 5.58 (dd, J = 8.5, 3.2 Hz, 2H, H-2, H-3), 5.37 
(dd, J = 15.7, 5.8 Hz, 1H, H-4), 4.26 (dd, J = 12.1, 5.6 Hz, 1H, H-6a), 4.19 (ddd, J = 10.0, 
5.7, 2.0 Hz, 1H, H-5), 4.12 (dt, J = 8.5, 5.3 Hz, 1H, H-6b), 3.82 (s, 3H, OCH3), 2.21 (s, 3H, 
CH3), 2.10 (s, 3H, CH3), 2.04 (s, 3H, CH3), 1.98 (s, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): ! 172.23, 171.54, 171.49 (4C, CO), 157.81, 150.91, 136.27, 132.31, 131.42, 
130.27, 130.11, 129.80, 124.42, 122.00, 118.00, 112.60 (12Ar-C), 97.63 (C-1), 71.16, 70.53, 
70.30 (C-2, C-3, C-5), 67.02 (C-4), 63.31 (C-6), 55.99 (OCH3), 20.60, 20.59, 20.57 (4C, 
CH3); ESI-MS: m/z calcd for C27H29ClO11 [M+Na]+: 587.13, found: 587.17.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-trifluoromethyl- 
biphenyl (7o) 
Prepared according to general procedure A from 2 (80 mg, 0.137 mmol), 3-trifluoromethyl-
phenylboronic acid (29 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 4 µmol) and K3PO4 
(58 mg, 0.27 mmol). Yield: 69 mg (83%) as a white solid. 
[!]D20 +62 (c 0.49 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 7.86 (d, J = 11.7 Hz, 2H, Ar-
H), 7.77 (d, J = 2.2 Hz, 1H, Ar-H), 7.71 – 7.59 (m, 3H, Ar-H), 7.43 (d, J = 8.6 Hz, 1H, Ar-
H), 5.80 (s, 1H, H-1), 5.66 – 5.53 (m, 2H, H-2, H-3), 5.38 (dd, J = 13.1, 6.9 Hz, 1H, H-4), 
4.31 – 4.06 (m, 3H, H-5, H-6), 2.28 – 1.93 (m, 12H, 4CH3); 13C NMR (126 MHz, CD3OD):  
! 172.15, 171.49, 171.47, 171.46 (4C, CO), 152.19, 141.43, 136.92, 132.36 (q, 2JCF = 32 Hz), 
131.56, 130.93, 128.9 (q, 1JCF = 279 Hz), 126.69, 125.77, 125.29 (q, 3JCF = 3.76 Hz), 124.53, 
124.35 (q, 3JCF = 3.89 Hz), 118.88 (12C, Ar-C), 97.66 (C-1), 71.24 (C-5), 70.47 (C-3), 70.22 
(C-2), 66.94 (C-4), 63.27 (C-6), 20.59, 20.58, 20.56, 20.55 (4CH3). ESI-MS: m/z calcd for 
C27H26ClF3O10 [M+Na]+: 641.08, found: 641.07.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-nitro-biphenyl (7p) 
Prepared according to general procedure A from 2 (80 mg, 0.137 mmol), 3-nitro-
phenylboronic acid (25 mg, 0.151 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 4 µmol) and K3PO4 
(58 mg, 0.27 mmol). Yield: 55 mg (69%) as a white solid. 
[!]D20 +70.6 (c 0.23 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 8.44 (t, J = 1.9 Hz, 1H, Ar-
H), 8.23 (m, 1H, Ar-H), 8.02 (dd, J = 7.8, 0.6 Hz, 1H, Ar-H), 7.82 (d, J = 2.3 Hz, 1H, Ar-H), 
7.77 – 7.61 (m, 2H, Ar-H), 7.44 (d, J = 8.7 Hz, 1H, Ar-H), 5.81 (s, 1H, H-1), 5.63 – 5.54 (m, 
2H, H-2, H-3), 5.38 (dd, J = 12.4, 7.6 Hz, 1H, H-4), 4.26 (dd, J = 12.2, 5.3 Hz, 1H, H-6a), 
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4.16 (ddd, J = 10.1, 5.3, 2.2 Hz, 1H, H-5), 4.10 (m, 1H, H-6a), 2.22 (s, 3H, CH3), 2.10 – 1.92 
(m, 9H, 3CH3); 13C NMR (126 MHz, CD3OD): ! 172.16, 171.49, 171.47, 171.46 (4CO), 
152.47, 150.23, 142.04, 136.00, 133.90, 131.33, 130.07, 127.85, 125.86, 123.29, 122.34, 
118.88 (12Ar-C), 97.66 (C-1), 71.26 (C-5), 70.45, 70.21 (2C, C-2, C-3), 66.92 (C-4), 63.26 
(C-6), 20.60, 20.59, 20.56 (4C, CH3); ESI-MS: m/z calcd for C26H26ClNO12 [M+Na]+: 
602.10, found: 602.11.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-3-cyano-biphenyl (7q) 
Prepared according to general procedure A from 2 (80 mg, 0.137 mmol), 
3-cyanophenylboronic acid pinacol ester; (35 mg, 0.151 mmol), Pd(dppf)Cl2"CH2Cl2 (3.4 mg, 
4 µmol) and K3PO4 (58 mg, 0.27 mmol). Yield: 57 mg (74%) as a white solid. 
[!]D20 +66.2 (c 0.6 , CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.83 – 7.73 (m, 2H, Ar-H), 7.62 
(dd, J = 10.4, 5.0 Hz, 2H, Ar-H), 7.55 (t, J = 7.8 Hz, 1H, Ar-H), 7.41 (dd, J = 8.6, 2.2 Hz, 
1H, Ar-H), 7.33 – 7.23 (m, 2H, Ar-H), 5.61 (dt, J = 7.8, 3.7 Hz, 2H, H-1, H-3), 5.54 (dd,  
J = 3.3, 1.9 Hz, 1H, H-2), 5.39 (t, J = 10.1 Hz, 1H, H-4), 4.27 (dd, J = 12.3, 5.2 Hz, 1H, H-
6a), 4.22 – 4.05 (m, 2H, H-5, H-6b), 2.21 (s, 3H, CH3), 2.14 – 1.99 (m, 9H, 3CH3); 13C NMR 
(126 MHz, CDCl3): ! 170.83, 170.23, 170.12, 170.04 (4CO), 151.35, 140.43, 134.98, 131.29, 
131.11, 130.39, 129.89, 129.18, 126.39, 125.07 (10Ar-C), 118.60 (CN), 117.37, 113.04 (Ar-
C), 96.60 (C-1), 69.83 (C-5), 69.29 (C-3), 68.85 (C-2), 65.80 (C-4), 62.14 (C-6), 24.54, 
20.78, 20.64, 20.62 (4C, CH3); ESI-MS: m/z calcd for C27H26ClNO10 [M+Na]+: 582.11, 
found: 582.11.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-biphenyl-4-carbonitril 
(7r) 
Prepared according to general procedure A from 2 (79 mg, 0.135 mmol), 4-cyano-
phenylboronic acid (22 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 
(57 mg, 0.27 mmol). Yield: 57 mg (75%) as a white solid. 
[a]D20 +77.7 (c 0.5, CHCl3); 1H NMR (500 MHz, CDCl3): ! 7.72 (d, J = 8.3 Hz, 2H, Ar-H), 
7.63 (dd, J = 10.4, 5.2 Hz, 3H, Ar-H), 7.43 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 7.27 (d, J = 8.6 
Hz, 1H, Ar-H), 5.64 – 5.59 (m, 2H, H-1, H-2), 5.54 (dd, J = 3.2, 1.9 Hz, 1H, H-3), 5.41 (t, J 
= 10.1 Hz, 1H, H-4), 4.28 (dd, J = 12.3, 5.2 Hz, 1H, H-6a), 4.17 (ddd, J = 10.0, 5.1, 2.1 Hz, 
1H, H-5), 4.10 (dd, J = 12.3, 2.2 Hz, 1H, H-6b), 2.21 (s, 3H, CH3), 2.12 – 2.00 (m, 9H, 
3CH3); 13C NMR (126 MHz, CDCl3): ! 170.54, 170.08, 169.90, 169.84, (4C, CO) 151.67, 
143.61, 135.29, 132.87, 129.41, 127.53, 126.60, 125.20, 118.79, 117.36, 111.47 (13C, Ar-C, 
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CN), 96.72 (C-1), 70.00 (C-5), 69.39 (C-3), 68.82 (C-2), 65.86 (C-4), 62.16 (C-6), 20.98, 
20.81, 20.79, 20.78 (4C, CH3); ESI-MS: m/z calcd for C27H26ClNO10 [M+Na]+: 582.11, 
found: 582.05.  
 
3’-Chloro-4’-(2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyloxy)-4-acetyl-biphenyl (7s) 
Prepared according to general procedure A from 2 (64.3 mg, 0.11 mmol), 
4-acetylphenylboronic acid (27 mg, 0.12 mmol), Pd(dppf)Cl2"CH2Cl2 (2.7 mg, 3 µmol) and 
K3PO4 (47 mg, 0.22 mmol). Yield: 52 mg (82%) as a white solid. 
[!]D20 +76.9 (c 0.62 , CHCl3); 1H NMR (500 MHz, CD3OD): ! 8.04 (d, J = 8.4 Hz, 2H, Ar-
H), 7.77 (d, J = 2.2 Hz, 1H, Ar-H), 7.71 (d, J = 8.4 Hz, 2H, Ar-H), 7.61 (dd, J = 8.6, 2.2 Hz, 
1H, Ar-H), 7.38 (d, J = 8.7 Hz, 1H, Ar-H), 5.78 (s, 1H, H-1), 5.60 – 5.51 (m, 2H, H-2, H-3), 
5.35 (dd, J = 13.0, 7.0 Hz, 1H, H-4), 4.23 (dd, J = 12.2, 5.4 Hz, 1H, H-6a), 4.17 – 4.01 (m, 
2H, H-5, H-6b), 2.62 (s, 3H, PhCOCH3), 2.20 (s, 3H, CH3), 2.01 (dd, J = 33.9, 30.1 Hz, 9H, 
3CH3); 13C NMR (126 MHz, CD3OD): ! 199.93 (PhCOCH3), 172.14, 171.49, 171.46, 171.45 
(4CO), 152.26, 144.91, 137.30, 137.07, 130.24, 130.03, 127.92, 127.82, 125.70, 118.78 (12C, 
Ar-C), 97.62 (C-1), 71.23 (C-5), 70.46, 70.21 (C-2, C-3), 66.93 (C-4), 63.27 (C-6), 26.73 
(PhCOCH3), 20.61, 20.59, 20.57 (4C, CH3); ESI-MS: m/z calcd for C28H29ClO11 [M+Na]+: 
599.13, found 599.05.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-biphenyl (8a) 
Prepared according to general procedure B from 7a (101 mg, 0.19 mmol). Yield: 65 mg 
(93%) as a white solid. 
[!]D20 +87.5 (c 0.067 , MeOH/CHCl3 1:1); 1H NMR (500 MHz, CD3OD): ! 7.63 (d, J = 2.2 
Hz, 1H, Ar-H), 7.59 – 7.48 (m, 3H, Ar-H), 7.42 (dd, J = 12.3, 5.0 Hz, 3H, Ar-H), 7.32 (t,  
J = 7.4 Hz, 1H, Ar-H), 5.58 (d, J = 1.5 Hz, 1H, H-1), 4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.01 
(dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.83 – 3.64 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, 
CD3OD): ! 152.67, 140.68, 137.91, 129.99, 129.49, 128.52, 127.72, 127.50, 125.24, 118.73 
(12C, Ar-C), 100.86 (C-1), 75.97 (C-5), 72.43 (C-3), 71.90 (C-2), 68.26 (C-4), 62.69 (C-6); 
HR-MS: m/z calcd for C18H19ClO6 [M+Na]+: 389.0762, found 389.0764; HPLC-purity: 
98.9%, Rt = 10.371 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)- 4-chloro-biphenyl (8b) 
Prepared according to general procedure B from 7b (45.6 mg, 0.08 mmol). Yield: 20 mg 
(62%) as a white solid. 
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[!]D20 +69.9 (c 0.42, MeOH); 1H NMR (500 MHz, CD3OD): ! 7.66 (d, J = 2.2 Hz, 1H), 
7.59 – 7.54 (m, 2H), 7.51 (dd, J = 8.6, 2.3 Hz, 1H), 7.46 – 7.40 (m, 3H) 7xaryl CH, 5.58 (d, 
J = 1.6 Hz, 1H, H-1), 4.11 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.99 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 
3.81 – 3.69 (m, 3H, H-4, H-6), 3.65 (ddd, J = 9.8, 5.5, 2.4 Hz, 1H, H-5); 13C NMR 
(126 MHz, CD3OD): ! 152.92, 139.33, 136.43, 134.57, 130.05, 129.44, 129.23, 127.44, 
125.32, 118.70 (12 C, Ar-C), 100.79 (C-1), 75.99 (C-5), 72.40 (C-3), 71.86 (C-2), 68.23 
(C-4), 62.66 (C-6); HR-MS:: m/z calcd for C18H18Cl2O6 [M+Na]+: 423.0373, found 423.0378; 
HPLC-purity > 99.5%, Rt = 11.334 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-3,4-dichloro-biphenyl (8c) 
Prepared according to general procedure B from 7c (45.3 mg, 0.08 mmol). Yield: 26 mg, 
(80%) as a white solid. 
[!]D20 +92.8 (c 0.24 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.70 (d, J = 2.1 Hz, 1H, Ar-
H), 7.63 (d, J = 2.2 Hz, 1H, Ar-H), 7.56 – 7.41 (m, 4H, Ar-H), 5.60 (d, J = 1.6 Hz, 1H, H-1), 
4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.81 – 3.69 (m, 3H, 
H-4. H-6), 3.64 (ddd, J = 9.7, 5.4, 2.4 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD):  
! 153.28, 140.97, 134.91, 133.84, 132.38, 131.98, 129.50, 129.49, 127.51, 127.42, 125.38, 
118.60 (12Ar-C), 100.68 (C-1), 75.99 (C-5), 72.38 (C-3), 71.81 (C-2), 68.19 (C-4), 62.63 (C-
6); IR (KBr), " = 3370 (O-H stretch), 1468cm-1; HR-MS: m/z calcd for C18H17Cl3O6 
[M+Na]+: 456.9983, found 456.9984; HPLC-purity > 99.5%, Rt = 12.021 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-3-trifluoromethyl-4-chloro-biphenyl (8d) 
Prepared according to general procedure B from 7d (76 mg, 0.12 mmol). Yield:  18 mg, 
(36%) as a white solid. 
[!]D20 +83 (c 0.34 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.95 – 7.44 (m, 6H, Ar-H), 
5.61 (d, J = 1.4 Hz, 1H, H-1), 4.11 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 
1H, H-3), 3.83 – 3.68 (m, 3H, H-4, H-6), 3.63 (ddd, J = 9.6, 5.4, 2.3 Hz, 1H, H-5 ); 13C NMR 
(126 MHz, CD3OD): ! 153.48, 140.08, 134.83, 133.32, 132.64, 132.04, 129.79 (7Ar-C), 
128.7 (PhCF3, q, 1JCF = 246 Hz), 126.71, 126.67, 125.51, 123.27, 118.69 (5Ar-C), 100.70 
(C-1), 76.05 (C-5), 72.39 (C-3), 71.82 (C-2), 68.21 (C-4), 62.66 (C-6); HR-MS: m/z calcd for 
C19H17Cl2F3O6 [M+Na]+: 491.0246, found 491.0250; HPLC-purity > 99.5%, Rt = 12.207 min.  
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-4-trifluoromethyl-biphenyl (8e) 
Prepared according to general procedure B from 7e (36.2 mg, 0.06 mmol). Yield:  25 mg, 
(95%) as a white solid. 
[!]D20 +83 (c 0.24 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.84 – 7.40 (m, 7H, Ar-H), 
5.62 (d, J = 1.2 Hz, 1H, H-1), 4.13 (dt, J = 12.0, 6.0 Hz, 1H, H-2), 4.01 (dd, J = 9.5, 3.4 Hz, 
1H, H-3), 3.84 – 3.71 (m, 3H, H-4, H-6), 3.65 (m, 1H, H-5); 13C NMR (126 MHz, CD3OD): 
! 153.33, 144.34, 135.92, 130.42 (q, 2JCF = 32 Hz), 128.3 (q, 1JCF = 246 Hz), 128.28, 126.90 
(q, 3JCF = 3.7 Hz), 125.38, 124.69, 118.62, (12C, Ar-C), 100.65 (C-1), 75.96 (C-5), 72.38 (C-
3), 71.80 (C-2), 68.16 (C-4), 62.57 (C-6); HR-MS: m/z calcd for C19H18ClF3O6 [M+Na]+: 
457.0636, found 457.0641; HPLC-purity > 99.5%, Rt = 12.068 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-2,4-dichloro-biphenyl (8f) 
Prepared according to general procedure B from 7f (28.4 mg, 0.05 mmol). Yield:  15 mg, 
(73%) as a white solid. 
[!]D20 +82.2 (c 0.22 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.59 – 7.28 (m, 6H, Ar-H), 
5.60 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.4, 3.4 Hz, 
1H, H-3), 3.83 – 3.61 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, CD3OD): ! 153.12, 
138.93, 135.19, 134.62, 134.33, 133.51, 132.03, 130.68, 130.18, 128.60, 124.47, 117.95, 
(12Ar-C), 100.82 (C-1), 76.05 (C-5), 72.41 (C-3), 71.86 (C-2), 68.25 (C-4), 62.69 (C-6); HR-
MS: m/z calcd for C18H17Cl3O6 [M+Na]+: 456.9983, found 456.9989; HPLC-purity > 99.5%, 
Rt = 11.922 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-4-nitro-biphenyl (8g) 
Prepared according to general procedure B from 7g (27.3 mg, 0.05 mmol). Yield:  16 mg, 
(83%) as a white solid. 
[!]D20 +100.2 (c 0.20 , MeOH); 1H NMR (500 MHz, CD3OD): ! 8.32 (d, J = 8.8 Hz, 2H, Ar-
H), 8.00 (s, 1H, Ar-H), 7.86 (d, J = 8.8 Hz, 2H, Ar-H), 7.82 (d, J = 2.2 Hz, 1H, Ar-H), 7.67 
(dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 7.52 (d, J = 8.7 Hz, 1H, Ar-H), 5.66 (d, J = 1.3 Hz, 1H, H-1), 
4.14 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.02 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.85 – 3.71 (m, 3H, 
H-4, H-6), 3.65 (ddd, J = 9.6, 5.4, 2.3 Hz, 1H, H-5); 13C NMR (126 MHz, CD3OD):  
! 153.86, 148.53, 146.97, 135.06, 130.04, 128.64, 128.10, 125.53, 125.16, 118.60 (12C, Ar-
C), 100.68 (C-1), 76.09 (C-5), 72.41 (C-3), 71.82 (C-2), 68.22 (C-4), 62.67 (C-6); HR-MS: 
m/z calcd for C18H18ClNO8 [M+Na]+: 434.0613, found 434.0614; HPLC-purity > 99.5%,  
Rt = 10.199 min.  
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-4-methyl-biphenyl (8h) 
Prepared according to general procedure B from 7h (38 mg, 0.07 mmol). Yield: 14 mg, 
(53%) as a white solid. 
[!]D20 +95.1 (c 0.22 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.60 (d, J = 2.2 Hz, 1H, Ar-
H), 7.51 – 7.37 (m, 4H, Ar-H), 7.23 (d, J = 8.0 Hz, 2H, Ar-H), 5.56 (d, J = 1.4 Hz, 1H, H-1), 
4.11 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.82 – 3.64 (m, 4H, 
H-4, H-5, H-6), 2.36 (s, 3H, CH3); 13C NMR (126 MHz, CD3OD): ! 152.40, 138.43, 137.87, 
137.74, 130.59, 129.23, 127.53, 127.21, 125.18, 118.73, (12C, Ar-C), 100.86 (C-1), 75.91 
(C-5), 72.41 (C-3), 71.89 (C-2), 68.24 (C-4), 62.66 (C-6), 21.08 (CH3); HR-MS: m/z calcd 
for C19H21ClO6 [M+Na]+: 403.0919, found 403.0924; HPLC-purity: 97.3%, Rt = 11.078 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-4-methoxy-biphenyl (8i) 
Prepared according to general procedure B from 7i (25 mg, 0.05 mmol). Yield:  13 mg, 
(72.8%) as a white solid. 
[!]D20 +84.5 (c 0.16 , CHCl3/MeOH 1:1); 1H NMR (500 MHz, CD3OD): ! 7.58 (d, J = 2.2 
Hz, 1H, Ar-H), 7.53 – 7.43 (m, 3H, Ar-H), 7.39 (d, J = 8.6 Hz, 1H, Ar-H), 6.98 (d, J = 8.8 
Hz, 2H, Ar-H), 5.55 (d, J = 1.4 Hz, 1H, H-1), 4.11 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.99 (dt,  
J = 11.8, 5.9 Hz, 1H, H-3), 3.82 (s, 3H, CH3), 3.82 – 3.62 (m, 4H, H-4, H-5, H-6); 13C NMR 
(126 MHz, CD3OD): ! 160.88, 152.14, 137.70, 133.08, 129.00, 128.77, 126.97, 125.20, 
118.81, 115.38 (12C, Ar-C), 100.92 (C-1), 75.91 (C-5), 72.41 (C-3), 71.90 (C-2), 68.26 (C-
4), 62.68 (C-6), 55.76 (CH3); HR-MS: m/z calcd for C19H21ClO6 [M+Na]+: 419.0868, found 
419.0865; HPLC-purity > 99.5%, Rt = 10.135 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-3-methyl-biphenyl  (8j) 
Prepared according to general procedure B from 7j (40.6 mg, 0.07 mmol). Yield: 26 mg, 
(92%) as a white solid. 
[!]D20 +98.5 (c 0.304, MeOH); 1H NMR (500 MHz, CD3OD): ! 7.61 (d, J = 2.2 Hz, 1H, Ar-
H), 7.39 (ddt, J = 26.7, 15.1, 4.9 Hz, 5H, Ar-H), 7.15 (d, J = 7.3 Hz, 1H, Ar-H), 5.56 (d,  
J = 1.5 Hz, 1H, H-1), 4.11 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.99 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 
3.84 – 3.62 (m, 4H, H-4, H-5, H-6), 2.39 (s, 3H, CH3); 13C NMR (126 MHz, CD3OD):  
! 152.59, 140.64, 139.76, 138.07, 129.88, 129.48, 129.21, 128.37, 127.48, 125.18, 124.85, 
118.71, (12Ar-C) 100.87 (C-1), 75.95 (C-5), 72.43 (C-3), 71.91 (C-2), 68.27 (C-4), 62.68 
(C-6), 21.53 (CH3); HR-MS: m/z calcd for C19H21ClO6 [M+Na]+: 403.0919, found 403.0925; 
HPLC-purity > 99.5%, Rt = 11.092 min.  
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-3-chloro-biphenyl (8k) 
Prepared according to general procedure B from 7k (34 mg, 0.06 mmol). Yield: 15 mg, 
(62%) as a white solid. 
[!]D20 +96.1 (c 0.21 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.64 (d, J = 1.9 Hz, 1H, Ar-
H), 7.57 (s, 1H, Ar-H), 7.55 – 7.29 (m, 5H, Ar-H), 5.59 (s, 1H, H-1), 4.12 (s, 1H, H-2), 4.00 
(dd, J = 9.5, 3.3 Hz, 1H, H-3), 3.83 – 3.69 (m, 3H, H-4, H-6), 3.64 (m, 1H, H-5); 13C NMR 
(126 MHz, CD3OD): ! 153.12, 142.67, 136.15, 135.88, 131.47, 129.57, 128.42, 127.66, 
127.59, 126.13, 125.32, 118.64 (12Ar-C), 100.74 (C-1), 75.98 (C-5), 72.39 (C-3), 71.84 
(C-2), 68.21 (C-4), 62.65 (C-6); HR-MS: m/z calcd for C18H18Cl2O6 [M+Na]+: 423.0373, 
found 423.0378; HPLC-purity > 99.5%, Rt = 11.211 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-2-methyl-biphenyl (8l) 
Prepared according to general procedure B from 7l (26 mg, 0.05 mmol). Yield:  17 mg, 
(95%) as a white solid. 
[!]D20 +88 (c 0.22 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.40 – 6.93 (m, 7H, Ar-H), 
5.47 (d, J = 1.5 Hz, 1H, H-1), 4.02 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 3.90 (dd, J = 9.4, 3.4 Hz, 
1H, H-3), 3.74 – 3.55 (m, 4H, H-4, H-5, H-6), 2.14 (s, 3H, CH3); 13C NMR (126 MHz, 
CD3OD): ! 152.30, 141.49, 138.70, 136.37, 131.70, 131.42, 130.62, 129.84, 128.67, 126.97, 
124.50, 118.20, (12Ar-C), 100.97 (C-1), 75.97 (C-5), 72.42 (C-3), 71.91 (C-2), 68.28 (C-4), 
62.70 (C-6), 20.52 (CH3); HR-MS: m/z calcd for C19H21ClO6 [M+Na]+: 403.0919, found 
403.0922; HPLC-purity > 99.5%, Rt = 10.895 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-2-chloro-biphenyl (8m) 
Prepared according to general procedure B from 7m (38.7 mg, 0.07 mmol). Yield: 20 mg, 
(73%) as a white solid. 
[!]D20 +85.6  (c 0.3 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.53 – 7.24 (m, 7H, Ar-H), 
5.60 (d, J = 1.3 Hz, 1H, H-1), 4.13 (dd, J = 3.2, 1.8 Hz, 1H, H-2), 4.01 (dd, J = 9.5, 3.4 Hz, 
1H, H-3), 3.86 – 3.64 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, CD3OD): ! 152.84, 
140.11, 135.85, 133.40, 132.43, 132.05, 131.05, 130.18, 130.15, 128.30, 124.32, 117.89, 
(12Ar-C), 100.83 (C-1), 75.98 (C-5), 72.39, 71.86, (C-3, C-2), 68.23 (C-4), 62.66 (C-6); HR-
MS: m/z calcd for C18H18Cl2O6 [M+Na]+: 423.0373, found 423.0378; HPLC-purity > 99.5%, 
Rt = 9.782 min.  
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-2-methoxy-biphenyl (8n) 
Prepared according to general procedure B from 7n (26.6 mg, 0.05 mmol). Yield:  15 mg, 
(80%) as a white solid. 
[!]D20 +81.2 (c 0.12 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.51 (s, 1H, Ar-H), 7.41 – 
6.93 (m, 6H, Ar-H), 5.56 (d, J = 1.4 Hz, 1H, H-1), 4.11 (dd, J = 3.3, 1.8 Hz, 1H, H2), 4.00 
(dd, J = 9.4, 3.4 Hz, 1H, H-3), 3.82 – 3.79 (m, 3H, CH3), 3.79 – 3.66 (m, 4H, H-4, H-5, H-6); 
13C NMR (126 MHz, CD3OD): ! 157.83, 152.11, 135.39, 132.06, 131.40, 130.08, 130.05, 
124.14, 121.98, 117.93, 112.62, (12C, Ar-C) 100.87 (C-1), 75.89 (C-5), 72.41 (C-3), 71.91 
(C-2), 68.26 (C-4), 62.67 (C-6), 56.01 (CH3); HR-MS: m/z calcd for C19H21ClO7 [M+Na]+: 
419.0868, found 419.0871; HPLC-purity > 99.5%, Rt = 10.475 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-3-trifluoromethyl-biphenyl (8o) 
Prepared according to general procedure B from 7o (60 mg, 0.1 mmol). Yield:  39 mg, (91%) 
as a white solid. 
[!]D20 +84.3 (c 0.42 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.87 – 7.78 (m, 2H, Ar-H), 
7.70 – 7.44 (m, 5H, Ar-H), 5.61 (d, J = 1.1 Hz, 1H, H-1), 4.13 (dd, J = 3.0, 1.7 Hz, 1H, H-2), 
4.01 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.84 – 3.60 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, 
CD3OD): ! 153.25, 141.66, 135.98, 132.30 (PhCF3, q, 1JCF = 246 Hz), 131.45, 130.85, 
128.68 (q, 2JCF = 32 Hz), 126.71, 125.42, 125.05 (q, 3JCF = 3.8 Hz) 124.55, 124.23(q,  
3JCF = 3.8 Hz), 118.68 (12Ar-C), 100.71 (C-1), 75.99 (C-5), 72.39 (C-3), 71.82 (C-2), 68.20 
(C-4), 62.64 (C-6); HR-MS: m/z calcd for C19H18ClF3O6 [M+Na]+: 457.0636, found 
457.0640; HPLC-purity: 97%, Rt = 11.743 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-3-nitro-biphenyl (8p) 
Prepared according to general procedure B from 7p (48 mg, 0.08 mmol). Yield:  32 mg, 
(94%) as a white solid. 
[!]D20 +93.2 (c 0.52 , MeOH); 1H NMR (500 MHz, CD3OD): ! 8.47 – 7.97 (m, 3H, Ar-H), 
7.80 – 7.48 (m, 4H, Ar-H), 5.63 (s, 1H, H-1), 4.11 (m, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 
1H, H-3), 3.82 – 3.58 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, CD3OD): ! 153.56, 
150.26, 142.38, 135.13, 133.86, 131.29, 129.78, 127.82, 125.53, 123.09, 122.28, 118.70 
(12Ar-C), 100.71 (C-1), 76.06 (C-5), 72.40 (C-3), 71.82 (C-2), 68.21 (C-4), 62.66 (C-6); HR-
MS: m/z calcd for C18H18ClNO8 [M+Na]+: 434.0613, found 434.0612; HPLC-purity > 99.5%, 
Rt = 10.172 min.  
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-biphenyl-3-carbonitril (8q) 
Prepared according to general procedure B from 7q (84 mg, 0.15 mmol). Yield: 14 mg, 
(34%) as a white solid. 
[!]D20 +96.3 (c 0.23 , MeOH); 1H NMR (500 MHz, CD3OD): ! 8.03 – 7.88 (m, 2H, Ar-H), 
7.71 (dd, J = 16.5, 5.0 Hz, 2H, Ar-H), 7.65 – 7.54 (m, 2H, Ar-H), 7.48 (d, J = 8.6 Hz, 1H, Ar-
H), 5.61 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 
Hz, 1H, H-3), 3.85 – 3.56 (m, 4H, H-4, H-5, H-6); 13C NMR (126 MHz, CD3OD): ! 153.45, 
142.02, 135.30, 132.39, 132.00, 131.28, 131.15, 129.71, 127.74, 125.49 (10Ar-C), 119.62 
(CN), 118.68, 114.15 (2Ar-C), 100.72 (C-1), 76.04 (C-5), 72.40 (C-3), 71.83 (C-2), 68.21 
(C-4), 62.66 (C-6); HR-MS: m/z calcd for C19H18ClNO6 [M+Na]+: 414.0715, found 
414.0715; HPLC-purity > 99.5%, Rt = 9.759 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-biphenyl-4-carbonitril (8r) 
Prepared according to general procedure B from 7r (36 mg, 0.06 mmol). Yield: 12 mg (48%) 
as a white solid. 
[!]D20 +109.4 (c 0.23 , MeOH); 1H NMR (500 MHz, CD3OD): ! 7.80 – 7.72 (m, 5H, Ar-H), 
7.59 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-H), 5.62 (d, J = 1.4 Hz, 1H, 
H-1), 4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd, J = 9.5, 3.4 Hz, 1H, H-3), 3.83 – 3.68 (m, 
3H, H-4, H-6), 3.63 (ddd, J = 9.6, 5.4, 2.3 Hz, 1H, H-5); 13C NMR  (126 MHz, CD3OD):  
! 153.65, 145.15, 135.42, 133.86, 129.82, 128.53, 127.87, 125.47, 119.70, 118.59 (12C, Ar-
C), 111.97 (CN), 100.66 (C-1), 76.05 (C-5), 72.39 (C-3), 71.80 (C-2), 68.20 (C-4), 62.65 (C-
6); IR (KBr), " = 3400 (O-H stretch), 2227 (C#N stretch), 1606, 1487 (Ar C=C bending)  
cm-1; HR-MS: m/z calcd for C19H18ClNO6 [M+Na]+: 414.0715, found 414.0721; HPLC-
purity > 99.5%, Rt = 9.785 min.  
 
3’-Chloro-4’-(!-D-mannopyranosyloxy)-4-acetyl-biphenyl (8s) 
Prepared according to general procedure B 7s (32 mg, 0.06 mmol). Yield: 21 mg, (93%) as a 
white solid. 
[!]D20 +103.2 (c 0.27 , MeOH); 1H NMR (500 MHz, CD3OD): ! 8.06 (d, J = 8.4 Hz, 2H, Ar-
H), 7.74 (dd, J = 8.6, 5.3 Hz, 3H, Ar-H), 7.61 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 
Hz, 1H, Ar-H), 5.61 (d, J = 1.3 Hz, 1H, H-1), 4.12 (dd, J = 3.3, 1.8 Hz, 1H, H-2), 4.00 (dd,  
J = 9.5, 3.4 Hz, 1H, H-3), 3.83 – 3.59 (m, 4H, H-4, H-5, H-6), 2.63 (s, 3H, CH3); 13C NMR 
(126 MHz, CD3OD): ! 200.02 (CO), 153.40, 145.29, 137.16, 136.20, 130.22, 129.76, 127.86, 
127.80, 125.39, 118.61 (12C, Ar-C), 100.72 (C-1), 76.03 (C-5), 72.40 (C-3), 71.83 (C-2), 
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68.22 (C-4), 62.66 (C-6), 26.71 (CH3); HR-MS: m/z calcd for C20H21ClO7 [M+Na]+: 
431.0868, found 431.0869; HPLC-purity: 98.8%, Rt = 9.375 min.  
 
Biological Evaluation 
Competitive binding assay. A recombinant protein consisting of the CRD of FimH linked 
with a thrombin cleavage site (Th) to a His6-tag (FimH-CRD-Th-His6) was expressed in E. 
coli strain HM125 and purified by affinity chromatography.[14] To determine the affinity of 
the various FimH antagonists, a competitive binding assay described previously[14] was 
applied. Microtiter plates (F96 MaxiSorp, Nunc) were coated with 10  µg/ml!solution of 
FimH-CRD-Th-His6 in 20 mM HEPES, 50 mM NaCl, and 1 mM CaCl2, pH 7.4 (assay buffer), 
100 µl per well, overnight at 4°C. The coating solution was discarded, and the wells were 
blocked with 3 % BSA in assay buffer (150 µl per well) for 2 h at 4°C. After three washing 
steps with assay buffer (150 µl per well), a fourfold serial dilution of the test compound (50 
µl per well) in assay buffer containing 5% DMSO and streptavidinperoxidase coupled Man-
!(1–3)[Man-!(1–6)]-Man-"(1–4)-GlcNAc-"(1–4)-GlcNAc" polyacrylamide (TM-PAA) 
polymer (50 µl per well of a 0.5 µg/ml solution) were added. On each individual microtiter 
plate, n-heptyl !-D-mannopyranoside (1) was tested in parallel. The plates were incubated for 
3 h at 25°C and 350 rpm and then carefully washed four times with 150 µl per well assay 
buffer. After the addition of 100 µl per well of 2,2’-azino-di-(3-ethylbenzthiazoline-6-
sulfonic acid) (ABTS) substrate, the colorimetric reaction was al- lowed to develop for 4 min 
and then was stopped by the addition of 2% aqueous oxalic acid before the optical density 
(OD) was measured at 415 nm on a microplate reader (Spectramax 190, Molecular Devices, 
CA, USA). The IC50 values of the compounds tested in duplicate were calculated with Prism 
software (GraphPad Soft- ware Inc., La Jolla, CA, USA). The IC50 defines the molar 
concentration of the test compound that decreases the maximal specific binding of TM-PAA 
polymer to FimH-CRD by 50%. The relative IC50 (rIC50) is the ratio of the IC50 of the test 
compound to the IC50 of n-heptyl !-D-mannopyranoside (1). 
 
Isothermal Titration Calorimetry. The thermodynamic characterization of the interactions 
between FimH CRD and the ligand was measured by ITC as previously described.[10c] The 
protein was dialyzed over night at 4 °C against assay buffer using Slide-A-Lyzer dialysis 
cassettes with 10 kDa cut-off (Thermo Fisher Scientific, Waltham, MA, USA). The final 
protein concentration was 4.8 !M. The ligand was diluted to 60 !M in assay buffer (20 mM 
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HEPES, 150 mM NaCl, and 1 mM CaCl2, pH 7.4). Dilution enthalpy was determined by 
ligand in assay buffer titration. A final concentration of 0.5 % DMSO was present in the 
ligand and protein solution. The measurements were performed with a MicroCalTM VP-ITC 
instrument (GE Healthcare, Northampton, MA, USA; sample cell volume of 1.4523 mL) at 
25 °C, 307 rpm stirring speed, and 10 !cal/s reference power. The samples were preheated to 
22 °C and degassed for 5 minutes prior to the measurements. Titration was started after 
steady baseline equilibration was reached with an initial 2 !L injection, which was excluded 
from subsequent data analysis. Ligand was injected in 5 !L steps with a spacing of 10 
minutes to ensure non-overlapping peaks. Sigmoidal binding curves with complete saturation 
at the end of each experiment were obtained. Baseline adjustments and peak integration were 
performed using the Origin 7 software (OriginLab, Northampton, MA, USA). The parameters 
KD (dissociation constant), N (stoichiometry), and !H° (change in enthalpy) were determined 
using non-linear least-square fitting in Microsoft Excel and the Solver add-in (Frontline 
Systems Inc., Incline Village, NV) according to Ziegler et al.[23] The thermodynamic 
parameters !G° (change in free energy) and T!S° (change in enthalpy) were calculated using 
equation 1, 
!G° = !H° – T!S° = RTlnKA = –RTlnKD   (Eq. 1) 
where T is the absolute temperature and R is the universal gas constant (8.314 J mol–1 K–1). 
The quantity c = Mt(0) KD-1, where Mt(0) is the initial macromolecule concentration, was 
above 1000. The determination of KD and T!S° is therefore not reliable, !H is nonetheless 
accurate.[24]  
 
Physicochemical and in vitro Pharmacokinetic Studies 
Materials. DMSO, 1-Propanol, and 1-Octanol were purchased from Sigma-Aldrich. PAMPA 
System Solution, GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered from pIon 
(Woburn, MA, USA). Acetonitrile (MeCN) was bought from Acros Organics (Geel, 
Belgium).  
 
logD7.4 determination. The in silico prediction tool ALOGPS[25] was used to estimate the 
logP values of the compounds. Depending on these values, the compounds were classified 
into three categories: hydrophilic compounds (logP below zero), moderately lipophilic 
compounds (logP between zero and one) and lipophilic compounds (logP above one). For 
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each category, two different ratios (volume of 1-Octanol to volume of buffer) were defined as 
experimental parameters (Table 2). 
 
Table 2. Compound classification based on estimated logP values. 
Compound type logP ratio (1-Octanol / buffer) 
hydrophilic < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-Octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 !M. For each compound, six determinations, i.e. 
three determinations per 1-Octanol:buffer ratio, were performed in different wells of a 96-
well plate. The respective volumes of buffer containing analyte (1 !M) were pipetted to the 
wells and covered by saturated 1-Octanol according to the chosen volume ratio. The plate 
was sealed with aluminum foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 
plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and 
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by LC-MS.  
logD7.4 was calculated from the 1-Octanol:buffer ratio (o/b), the initial concentration of the 
analyte in buffer (1 !M), and the concentration of the analyte in buffer (cB) with equation (1): 
 (1) 
 
LC-MS measurements. Analyses were performed using an 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara, 
CA, USA) equipped with electrospray ionization. The system was controlled with the Agilent 
MassHunter Workstation Data Acquisition software (version B.01.04). The column used was 
an Atlantis® T3 C18 column (2.1 x 50 mm) with a 3-!m particle size (Waters Corp., 
Milford, MA, USA). The mobile phase consisted of two eluents: eluent A (H2O, containing 
0.1% formic acid, v/v) and eluent B (acetonitrile, containing 0.1% formic acid, v/v), both 
delivered at 0.6 mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 
min, and then hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% 
! 
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A/5% B, resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, 
collision energy, polarity were optimized individually for each analyte, and the molecular ion 
was followed for each compound in the multiple reaction monitoring mode. The 
concentrations of the analytes were quantified by the Agilent Mass Hunter Quantitative 
Analysis software (version B.01.04). 
 
Solubility. Solubility was determined in a 96-well format using the !SOL Explorer solubility 
analyzer (pIon, version 3.4.0.5). Measurements were performed at pH 7.4 in triplicates. Three 
wells of a deep well plate were filled with 300 !L of aqueous universal buffer solution. 
Aliquots (3 !L) of compound stock solution (100 mM in DMSO) were added and thoroughly 
mixed. The final sample concentration was 1 mM, the residual DMSO concentration was 
1.0% (v/v) in the buffer solutions. After 15 h, the solutions were filtrated (0.2 !m 96-well 
filter plates) using a vacuum to collect manifold (Whatman Ltd., Maidstone, UK) to remove 
any precipitates. Equal amounts of filtrate and 1-Propanol were mixed and transferred to a 
96-well plate for UV detection (190 to 500 nm, SpectraMax 190, Molecular Devices, 
Sunnyvale, CA, USA). The amount of material dissolved was calculated by comparison with 
UV spectra obtained from reference samples, which were prepared by dissolving compound 
stock solution in a 1:1 mixture of buffer and 1-Propanol (final concentrations 0.167 mM). 
 
Parallel Artificial Membrane Permeation Assay (PAMPA). Values of logPe were 
determined in a 96-well format with the PAMPA[21b] permeation assay. Measurements were 
performed at pH 7.4 in quadruplicates. Four wells of a deep well plate were filled with 650 
!L System Solution. Samples (150 !L) were withdrawn from each well to determine the 
blank spectra by UV-spectroscopy (SpectraMax 190). Then, analyte dissolved in DMSO was 
added to the remaining System Solution to yield 50 !M solutions. To exclude precipitation, 
the optical density was measured at 650 nm, with 0.01 being the threshold value. Solutions 
exceeding this threshold were filtrated. Afterwards, samples (150 !L) were withdrawn to 
determine the reference spectra. Further 200 !L were transferred to each well of the donor 
plate of the PAMPA sandwich (pIon, P/N 110 163). The filter membranes at the bottom of 
the acceptor plate were infused with 5 !L of GIT-0 Lipid Solution, and 200 !L of Acceptor 
Sink Buffer were filled into each acceptor well. The sandwich was assembled, placed in the 
GutBoxTM, and left undisturbed for 16 h. Then, it was disassembled and samples (150 !L) 
were transferred from each donor and acceptor well to UV-plates. Quantification was 
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performed by UV spectroscopy. The logPe-values were calculated with the aid of the 
PAMPA Explorer Software (pIon, version 3.5). 
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ABSTRACT 
 
Urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia coli 
(UPEC) belong to the most prevalent infectious diseases worldwide. For the successful 
establishment of an UTI, the adhesion of bacteria to urothelial cells is a crucial first step, 
protecting the bacteria from the natural defense mechanisms as urine flow or the host 
immune system. The attachment of UPEC to host cells is mediated by FimH, a mannose-
binding adhesin at the tip of type 1 pili, which are expressed on the bacterial surface. To date, 
UTIs are mainly treated with antibiotics, leading to the ubiquitous problem of increasing 
resistance against most of the currently available antimicrobials. Therefore, new treatment 
strategies are urgently needed, avoiding selection pressure and thereby affording a reduced 
risk of resistance. Here, we describe the development of an orally available FimH antagonist. 
Starting from the carboxylate substituted biphenyl !-D-mannoside 6 affinity as well as the 
relevant pharmacokinetic parameters (solubility, permeability, renal excretion) could be 
substantially improved by a bioisosteric approach. With 3’-chloro-4’-(!-D-
mannopyranosyloxy)-biphenyl-4-carbonitrile (11j) a FimH antagonist with an optimal in 
vitro PK/PD profile was identified. The para-cyano substituent conferred lipophilicity and 
high binding to plasma proteins, which slowed down the rate of renal excretion. Despite 
higher lipophilicity, antagonist 11j was insusceptible to CYP450 mediated metabolism, and 
as a consequence predominantly eliminated via the renal pathway. Finally, in vivo 
experiments confirmed the excellent PK-profile of 11j with steady renal excretion for more 
than eight hours after oral application, suggesting a long-lasting anti-adhesive effect. Finally, 
orally applied 11j was effective in a mouse model of UTI by reducing the bacterial load in 
the bladder by over 1000-fold. 
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INTRODUCTION 
 
Urinary tract infection (UTI) is one of the most frequent infectious diseases worldwide and 
affects millions of people every year.1 In more than 70% of the reported cases, uropathogenic 
Escherichia coli (UPEC) is the causal pathogen.2 Acute, uncomplicated lower urinary tract 
infection, commonly referred to as cystitis, requires an antibiotic treatment for symptom 
relief (i.e. reduction of dysuria, frequent and urgent urination, bacteriuria, pyuria) and for 
prevention of more devastating or even life threatening complications like pyelonephritis and 
urosepsis.3,4 However, the repeated use of antibacterial chemotherapeutics provokes 
antimicrobial resistance leading to treatment failure.5 Hence, a new approach for the 
prevention and treatment of UTI with orally applicable therapeutics is urgently needed.6 
 
UPEC undergo a well-defined infection cycle within the host.7 The key step in pathogenesis 
is bacterial adhesion to the epithelial cells in the lower urinary tract.8 This interaction 
prevents UPEC from clearance by the bulk flow of urine and enables the bacteria to colonize 
the epithelial cells. The adhesion is mediated by the virulence factor FimH located at the tip 
of bacterial type 1 pili.9,10 FimH consists of two immunoglobulin-like domains: the N-
terminal lectin domain and – connected by a short linker – the C-terminal pilin domain.11 The 
lectin domain encloses the carbohydrate recognition domain (CRD) that binds to the 
oligomannosides of the glycoprotein uroplakin Ia on the epithelial cell surface.12 The pilin 
domain anchors the adhesin to the pilus and regulates the switch between the two 
conformational states of the CRD with high and low affinity for mannosides, respectively. 
 
More than three decades ago, Sharon and co-workers described various oligomannosides and 
aryl !-D-mannosides as potential antagonists of the FimH-mediated bacterial adhesion.13,14 
However, only weak interactions in the milli- to micromolar range were observed. In recent 
years, several high-affinity monovalent !-D-mannopyranosides have been reported.15-24 Their 
improved affinities are based on optimal interactions with the main structural features of the 
CRD.25-28 First, the mannose binding pocket accommodating the mannose moiety by means 
of an extended hydrogen bond network and, second, the entrance to the binding site 
composed of three hydrophobic amino acids (Tyr48, Tyr137, and Ile52) and therefore 
referred to as ‘tyrosine gate’ hosting aliphatic and aromatic aglycones. As an example, n-
heptyl !-D-mannopyranoside (1) exhibits nanomolar affinity due to hydrophobic contacts of 
the alkyl aglycone with the hydrophobic residues of the tyrosine gate.15 Furthermore, 
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aromatic aglycones, such as present in the mannosides 2-10 (Figure 1), provide strong !-! 
stacking interactions with the tyrosine gate. These interactions are further favored by the 
addition of an electron withdrawing substituent on the terminal ring of the biaryl portion.18,19 
 
 
 
Figure 1. Monovalent FimH antagonists exhibiting nanomolar affinities. 
 
Recent in vivo PK studies in mice proved the high potential of the biphenyl "-D-mannosides 
4 and 7 for an oral treatment, although high doses (! 50 mg/kg) were necessary to achieve the 
minimal concentrations required for the anti-adhesive effect in the urinary bladder.19,21,22 
Moreover, the therapeutic effect could only be maintained for a few hours, i.e. four hours for 
a po (per os) single-dose application of 7 (50 mg/kg), because of rapid elimination by 
glomerular filtration and low reabsorption from the primary urine in the renal tubules.19 
 
To date, the physicochemical properties affecting the rate of renal excretion, i.e. lipophilicity 
and plasma protein binding (PPB), or metabolic liabilities promoting non-renal elimination 
pathways have been barely investigated for FimH antagonists. The goal of the present study 
was to optimize the biphenyl "-D-mannoside with respect to oral bioavailability and renal 
excretion. Starting from antagonist 6, we synthesized new biphenyl derivatives, characterized 
their affinity to the CRD, structurally investigated their binding mode, and determined 
physicochemical and pharmacokinetic parameters predictive for intestinal absorption and 
renal elimination. Furthermore, we determined in vivo PK (pharmacokinetic) of the most 
promising new antagonists in a mouse model. The compound with the best PK profile 
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proofed effective in reducing the bacterial loads upon bladder infection in a mouse model of 
UTI. 
 
RESULTS AND DISCUSSION 
 
As previously reported, the carboxylate substituent present in the biphenyl mannoside 6 – its 
electron withdrawing potential being essential for an enhanced drug target interaction – 
strongly decreases the lipophilicity of the antagonist (log D7.4 < -1.519) in comparison to the 
n-heptyl (! 1, log P = 1.719) or the unsubstituted biphenyl aglycone (! 10, log P = 2.124). 
Since low lipophilicity is a major reason for low intestinal absorption and rapid renal 
excretion of the systemically available antagonist,19,23 we aspired to improve oral 
bioavailability as well as renal excretion by replacing the carboxylate in 6 with various 
bioisosteric groups29 (Figure 2). 
 
 
Figure 2. Bioisosteric replacement of the carboxylic acid substituent of biphenyl "-D-mannopyranoside 6. 
 
Synthesis. Iodide 12 was prepared from peracetylated mannose and 4-iodophenol in the 
presence of BF3·Et2O.24 In a palladium-catalyzed Miyaura-Suzuki coupling30 with the 
boronic acid or boronate derivatives 13a-g, the biphenyl derivatives 14a-g were obtained in 
good to excellent yields. Final deprotection yielded the test compounds 11a-g. Utilizing 
microwave-assisted reaction condition,31 the conversion of arylnitrile 14g to tetrazole 15 
proceeded rapidly and with good yield. After deprotection of 15 using Zemplén conditions, 
the test compound 11h was obtained (Scheme 1). 
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Scheme 1. a) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C, 4 h (14a-g, 44-99%); b) NaOMe, MeOH, rt, 4 h (11a-
h, 29-86%); c) TMSN3, Bu2Sn(O), DME, 150 °C, µW, 10 min, 81%. 
 
The cyanobenzamide derivative 11i (Scheme 2) was obtained from 6 by peracetylation (! 
16) followed by conversion of the carboxylic acid into its acid chloride with 1-chloro-N,N,2-
trimethyl-1-propenylamine.32 Without isolation, the acid chloride was reacted with sodium 
hydrogen cyanamide in DMF followed by deacetylation under Zemplén conditions to yield 
the test compound 11i. 
 
 
 
Scheme 2. a) i) Ac2O, DMAP, pyridine, 0 °C to rt, overnight; ii) satd. NaHCO3 aq., DCM, rt, 2 h (16, 53%); b) 
1-chloro-N,N,2-trimethyl-1-propenylamine, toluene, 0 °C to rt, 2 h; c) NaH, NH2CN, DMF, 0 °C to rt, 
overnight; d) NaOMe, MeOH, rt, 4 h (11i, 21% for three steps). 
 
Finally, to further improve the pharmacokinetic properties of mannoside 11g (see Table 3), a 
chloride substituent was introduced to the ortho-position of the aromatic ring adjacent to the 
anomeric oxygen. For its synthesis, peraceylated "-D-mannose (17) was coupled with 2-
chloro-4-iodophenol (18) using BF3#Et2O as promotor (! 19, 76%). After the introduction of 
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the second aromatic ring by Miyaura-Suzuki coupling (! 20, 75%), deprotection yielded 
mannoside 11j (Scheme 3). 
 
 
 
Scheme 3. a) BF3"Et2O, CH2Cl2, 40 °C (76%); b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C (75%); c) NaOMe, 
MeOH, rt, 4 h (48%). 
 
Binding Affinity. The binding affinity of heptyl mannoside 1, the biphenyl mannosides 5, 6, 
10, and the bioisosteres 11a-j was determined in a competitive fluorescence polarization 
assay (FP-assay) and with isothermal titration calorimetry (ITC). A protein construct 
consisting of the CRD with a C-terminal His-tag with a thrombin cleavage site (FimH-CRD-
Th-His6) was used for all experiments.33 
 
Competitive Fluorescence Polarization Assay. For the rapid evaluation of binding affinity, 
we established a competitive binding assay based on fluorescence polarization (FP). Similar 
formats have been applied before for the detection of carbohydrate-lectin interactions.18,34 In 
this assay, the antagonist of interest displaces a fluorescently labeled competitor from the 
binding site, thereby causing a reduction in fluorescence polarization.35 To identify the 
optimal competitor, fluorescein isothiocyanate (FITC) was connected to the FimH ligand 8 
by three linkers of different lengths (! 21-23, Scheme 4). For optimal sensitivity and signal-
to-noise ratio, three main parameters need to be considered: (i) the affinity of the competitor 
should not be impaired by the fluorescent label, (ii) the conformational flexibility of the label 
upon binding of the competitor to the CRD should be low and (iii) the fluorescence properties 
of the label should not be affected by the connected ligand.36-38 A change in fluorescence 
properties was observed for reporter ligand 21 in which the label was linked to the biphenyl 
agylcone by an amide bond. The absorption spectrum revealed a lack of the characteristic 
fluorescein absorption peak at 494 nm (Scheme 4), likely due to an extension of the 
conjugated system to the biphenyl moiety of the ligand. The elongated saturated spacer 
groups in competitors 22 and 23 ensured that the expected spectral properties of the dye were 
retained (Scheme 4). 
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Scheme 4. a) 1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholinomethylene)] 
methanaminium hexafluorophosphate (COMU), NEt3, fluoresceinamine, DMF, rt, 7 h (21, 19%); b) i. DIC, 
NHS, N-Boc-ethylenediamine, DMF, rt, 12 h; ii. TFA, DCM, rt, 10 min (68% over two steps), iii. fluorescein 
isothiocyanate (FITC), NEt3, DMF, rt, 3 h (22, 48%); c) i. DIC, NHS, N-Boc-PEG2-NH2, DMF, rt, 14 h; ii. 
TFA, DCM, rt, 30 min (62% over two steps); iii. FITC, DMF, rt (23, 65%). 
 
For the determination of their binding affinity, fixed concentrations of the reporter ligands 22 
and 23 were incubated for 24 h with a linear dilution of the FimH-CRD (0-100 nM). FP was 
measured using a plate reader, with polarized excitation at 485 nm, and emission at 528 nm 
measured through appropriately oriented polarizers. Fitting the single-site binding function of 
Cooper39 to the observed FP data resulted for compound 22 in a dissociation constant (KD = 
1.7 nM, Figure 3A) similar to that of the unlabeled parent compound 8,19 whereas 23 showed 
a five-fold lower affinity (9.9 nM) (Scheme 4). Therefore, the reporter ligand 22 fulfills all 
characteristics as an optimal competitor and was used for the FP assay. 
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Figure 3. A) Direct binding curve of the labeled competitor 22 obtained by adding a linear dilution of FimH-
CRD (0-100 nM) and a constant concentration of competitor 22 (5 nM). The KD was determined by fitting the 
experimental data to a single-site binding fit that accounts for ligand depletion. In three FP based direct binding 
experiments the KD of competitor 22 was determined to be 1.7 nM. B) Inhibition curve of n-heptyl mannoside 
(1) from the competitive FP assay. The IC50 value was determined by nonlinear least-squares fitting to a 
standard 4-parameter equation. A modified Cheng-Prusoff equation was used to calculate the corresponding KD 
value (KD = 28.3 nM). 
 
For the test compounds 1, 5, 6, 10, and 11a-j, a 24 h incubation time was applied before FP 
was measured due to the long residence time of FimH antagonists (t1/2 > 3.5 h, Figure 3B40). 
The 24 h incubation period was empirically determined to be necessary to reach equilibrium 
between reporter ligand and compound of interest. IC50 values were obtained by nonlinear 
least-squares regression (standard four-parameter dose response curve) and converted to KD 
values using a modified Cheng-Prusoff equation.35 This equation accounts for the ligand 
depletion effect in competitive titrations involving high-affinity interaction partners present 
in similar concentrations. Under these conditions, the free concentration of an interacting 
species cannot be assumed to equal the total concentration. 
The KD values determined for the test compounds 1, 5, 6, 10, and 11a-j are summarized in 
Table 1. Against our expectations, the biphenyl mannosides 6 and 10 exhibit similar affinities 
(Table 1), despite the presence of an electron withdrawing carboxylate substituent in 
antagonist 6. According to the crystal structure of FimH co-crystallized with the sulfonamide 
derivative 11e (Figure 4A), the outer aromatic ring of the biphenyl aglycone forms !-! 
interactions with the electron rich Tyr48, which is part of the tyrosine gate of FimH.15 A 
reduction of electron density of the aglycone by the electron withdrawing carboxylate was 
expected to enforce these !-! stacking interactions and lead to improved affinity. However, 
this beneficial effect might be compensated by an entropic penalty originating from the 
improved !-! stacking to Tyr48 that might lead to the reduced flexibility of both protein and 
antagonist. Furthermore, a beneficial enthalpy effect might be partially compensated by an 
enthalpy penalty originating from the desolvation of the charged 10 carboxylate41 (see also 
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experimental part). Although this substituent is solvent exposed, at least a partial desolvation 
may be necessary upon antagonist binding. To prove this assumption, we replaced the 
carboxylate by the corresponding methyl ester (! 5)19 in order to reduce the desolvation 
penalty and, as predicted by the Hammett constant !p,42 to further improve the "-" stacking. 
Indeed, a six-fold improvement in affinity was achieved. However, since the methyl ester 
undergoes rapid enzyme-mediated hydrolysis in vivo,19 it will not be available at the place of 
action in the urinary bladder. The methyl ester was therefore replaced by metabolically stable 
bioisosteres29 exhibiting comparable electron withdrawing properties42 (Table 1, entries 5-
13). The most potent derivatives 11d, 11e and 11g showed affinities in the low nanomolar 
range. 
As previously reported,24 a chloro substituent in the ortho-position of the aromatic ring 
adjacent to the anomeric oxygen is favorable for affinity and improves the physicochemical 
properties relevant for oral bioavailability. Indeed, the corresponding antagonist 11j was the 
most potent compound tested in this study. 
 
Table 1. Affinities (KD) of FimH antagonists to FimH-CRD-Th-His6; dissociation constants (KD) were 
determined in a competitive fluorescence polarization assay. 
 
Entry Compd 
 
Affinity 
KD [nM] 
1 1  28.3 ± 5.0 
2 10 
 
15.1 ± 2.2 
3 6 
 
17.9 ± 1.5 
4 5 
 
3.6 ± 0.9  
5 11a 
 
2.8 ± 0.3 
6 11b 
 
2.9 ± 0.5 
OR
OHO
OH
HO
OH
O
O
O
OH
O
O
OMe
O
O
O
NH2
O
O
NHMe
FimH 3.2.3  – Manuscript 5 
214 
7 11c 
 
3.0 ± 0.1 
8 11d 
 
1.7 ± 0.2 
9 11e 
 
2.7 ± 0.4 
10 11f 
 
3.7 ± 0.2 
11 11g 
 
2.0 ± 0.6 
12 11h 
 
5.7 ± 0.1 
13 11i 
 
8.4 ± 0.3 
14 11j 
 
< 1a) 
 
a) The KD value of 11j was approximated to be in the subnanomolar range. The IC50 value obtained in the 
competitive FP assay was equal to the lowest value that can be resolved by the assay, indicating stoichiometric 
titration of 11j due to its high affinity. Consequently, its KD must be below the KD of competitor 22. 
 
Isothermal Titration Calorimetry (ITC). To further confirm our hypothesis regarding !-! 
stacking and desolvation, we performed ITC experiments with unsubstituted biphenyl 
mannoside 10, the carboxylic acid 6, and the bioisosteres 11b-e, g and j (Table 2). ITC 
allows the simultaneous determination of the stoichiometry (N), the change in enthalpy (!H) 
and the dissociation constant (KD) for ligand-protein binding.43,44 The reliable determination 
of these three parameters requires well-defined sigmoidal titration curves characterized by the 
dimensionless Wiseman parameter c (c = Mt(0) KD-1, where Mt(0) is the initial 
macromolecule concentration).45 To be sure that data can be fitted with confidence, the c-
value should be between 1 and 1,000 (ideally between 5 and 500),46 which could be achieved 
for the antagonists 6 and 10. For titrations involving low micromolar Mt(0) and interactions 
in the low nanomolar or picomolar range, as suggested for the bioisosteres 11b-j, c-values 
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above 1,000 were expected. Since these conditions lead to steep titration curves that do not 
allow the determination of the curve slope representing 1/KD, we applied an alternative, 
competitive format referred to as displacement assay.47,48 First, FimH-CRD-Th-His6 was pre-
incubated with the low affinity antagonist n-heptyl 2-deoxy-!-D-mannopyranoside (24, for 
synthesis see supporting information). The high-affinity bioisosteres of interest were titrated 
into the protein-ligand complex giving well-defined sigmoidal titration curves.  
 
Table 2. Thermodynamic parameters from ITC for selected FimH-antagonists binding to FimH-CRD-Th-His6; 
n, stoichiometric correction factor; CI, confidence interval from fitting.  
 
Entry Compd 
 
KD [nM] 
(95 % CI) 
"G 
[kJ/mol] 
"H [kJ/mol] 
(95 % CI) 
-T"S 
[kJ/mol] n 
Type of 
measurement 
1 10 
 
17.7 
(14.1 – 22.3) -44.2 
-45.0 
(-44.5 – -45.6) 0.8 1.07 direct 
2 6 
 
15.0 
(13.4 – 16.7) -44.7 
-48.7 
(-48.4 – -49.0) 4.0 1.05 direct 
3 11b 
 
4.3 
(3.2 – 5.6) -47.8 
-54.5 
(-54.1 – -54.9) 6.7 1.02 
competitive 
vs. 24 
4 11c 
 
5.0 
(3.8 – 6.6) -47.4 
-54.5 
(-54.1 – -54.8) 7.1 0.97 
competitive 
vs. 24 
5 11d 
 
3.0 
(2.1 – 4.2) -48.7 
-52.3 
(-51.5 – -53.1) 3.6 0.99 
competitive 
vs. 24 
6 11e 
 
3.5 
(2.9 – 4.3) -48.2 
-52.2 
(-51.6 – -52.8) 3.9 1.06 
competitive 
vs. 24 
7 11g 
 
2.8 
(2.3 – 3.3) -48.8 
-58.2 
(-57.8 – -58.6) 9.4 1.00 
competitive 
vs. 24 
8 11j 
 
1.3 
(1.1 – 1.6) -50.7 
-60.9 
(-60.4 – -61.4) 10.1 1.01 
competitive 
vs. 24 
9 24 
 
9’386 
(8’555 – 
10’287) 
-28.7 -19.5 (-19.1 – -20.0) -9.1 1.00 direct 
 
The resulting KD values (Table 2) correspond well with the data obtained from the FP assay 
(Table 1). A comparison of the thermodynamic fingerprints of antagonists 10 and 6 reveals 
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that the more favorable enthalpic contribution resulting from facilitated !-! stacking leads to 
a net enthalpy gain (""H: -3.7 kJ/mol). However, an even greater increase in enthalpy is 
likely countered by the enthalpy costs for desolvation of the electron withdrawing 
carboxylate.  
The gain in enthalpy is in turn compensated by an unfavorable entropy (-T""S: 3.2 kJ/mol) 
as a result of the reduced flexibility of both the antagonist and the Tyr48 side-chain caused by 
the improved interaction. This is not entirely outweighed by the beneficial entropy 
contribution related to the partial desolvation of the carboxylate and the related release of 
water into the bulk. Added together, the enthalpy and entropy contributions of antagonists 10 
and 6 result in similar affinities (KD: 17.7 and 15.0 nM, respectively).  
In contrast, the replacement of the carboxylate group by various neutral bioisosteres (entries 
3-6) reduces the enthalpy costs for desolvation (see calculated free energies of desolvation, 
experimental part) and therefore leads to a markedly improved enthalpy (""H: -3.5 to -5.8 
kJ/mol). As a result, an up to fivefold improvement of the KD values was achieved. Finally, 
with a cyano substituent (entries 7 & 8), the enthalpy term was further improved (""H: -3.7 
kJ/mol) due to a reduced desolvation penalty and improved !-! stacking interactions. 
However, this beneficial component is again partially compensated by a decrease in entropy. 
This can be attributed, first, to the loss of flexibility of the tightly bound ligand (Figure 4B) 
and, second, to the smaller surface area of the cyano substituent compared to amide, 
sulfonamide and sulfone, which results in a smaller number of water molecules being 
released to bulk upon binding. 
 
X-ray Crystallography. To determine the binding poses of the bioisosters, we co-
crystallized the compounds 11e or 11j with FimH-CRD (Figure 4). Atomic resolution crystal 
structures were obtained at 1.07 Å (11e) and 1.10 Å (11j). As observed in previous 
mannoside co-crystal structures,15,18,27 the mannose moiety forms an extensive hydrogen 
bond network to the well-defined binding site with all of its hydroxyl groups.  The biphenyl 
aglycone is located between the tyrosine gate residues (Tyr48/Tyr137). The !-! stacking of 
the second aromatic ring of the aglycone to the side chain of Tyr48 contributes most to the 
interaction energy of the aglycone moiety. Interactions to the Tyr137 side-chain on the other 
hand are only limited. Whereas a previously published crystal structure of a biphenyl 
mannoside in complex with FimH-CRD suffers from crystal contacts of binding site residues 
(Tyr48 side-chain to backbone oxygen of Val27) possibly causing the distortion of the 
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binding site,18 the binding site of our structures are mostly solvent exposed. This revealed the 
flexibility of the aglycone in the FimH-CRD/11e structure, since the electron density towards 
the solvent-exposed sulfonamide indicates that there is not one single orientation. Therefore, 
the aglycone was modeled in two distinct poses. In contrast, in the FimH-CRD/11j structure 
the amino acid side chain of Y48 can be modeled in two distinct rotamers, suggesting 
flexibility also of the receptor. 
 
 
Figure 4. Ligand binding poses determined by X-ray co-crystallization with compounds 11e resolved to 1.07 Å 
(A) and 11j resolved to 1.10 Å (B). The electron density surrounding the aglycone of 11e indicates flexibility of 
the aglycone and was modeled in two poses. Both compounds bind in a similar pose with a well-defined 
hydrogen network surrounding the mannose moiety and π-π stacking interactions between the second aromatic 
ring and Tyr48 side-chain (A). In contrast, in the FimH-CRD/11j structure the amino acid side chain of Y48 can 
be modeled in two distinct rotamers, suggesting flexibility also of the receptor (B). 
 
Physicochemical Properties and In Vitro Pharmacokinetics. Intestinal absorption and 
renal excretion are prerequisites for a successful oral treatment of UTI with FimH 
antagonists. Furthermore, reabsorption of antagonist from the renal ultrafiltrate is desirable 
for maintaining the minimal anti-adhesive concentration in the target organ, namely the 
bladder, over an extended period of time. To estimate the influence of the bioisostere 
approach on oral bioavailability and the rate of renal excretion, we determined lipophilicity 
by means of the octanol-water distribution coefficient (log D7.4),49 aqueous solubility, and 
membrane permeability in the artificial membrane permeability assay (PAMPA)50 and the 
colorectal adenocarcinoma (Caco-2) cell monolayer model.51 
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Table 3. Physicochemical and in vitro pharmacokinetic parameters. 
 
Caco-2 Papp, 
[10-6 cm/s]e) Compd pKaa) log D7.4b) Solubility [!g/mL] / pHc) 
PAMPA log Pe 
[cm/s] / pHd) a!b b!a 
PPB fb [%]f) 
Metabolic 
stability t1/2 
[min]g) 
1 --- 1.65 > 3000 -4.89 7.0 ± 0.6 9.4 ± 0.2 81 13 
10 --- 2.1 ± 0.1 21 ± 1 / 7.4 -4.7 ± 0.1 / 7.4 10.0 ± 0.9 19.0 ± 1.2 93 ± 1 n.d. 
5 --- 2.14 33.8 / 6.51 -4.7 4.23 n.d. 93 1.0 
6 3.88 < -1.5 > 3000 / 6.61 no permeation n.d. n.d. 73 > 60 
11a --- 0.5 ± 0.1 12 ± 1 / 7.4 -6.8 ± 0.3 / 7.4 0.12 ± 0.01 0.61 ± 0.03 n.d. n.d. 
11b --- 0.8 ± 0.0 122 ± 13 / 7.4 -9.2 ± 1.4 / 7.4 1.10 ± 0.82 0.87 ± 0.15 n.d. n.d. 
11c --- 0.2 ± 0.1 > 250 / 7.4 -7.8 ± 0.3 / 7.4 0.18 ± 0.07 1.30 ± 0.03 48 ± 2 > 60 
11d --- 0.4 ± 0.0 246 ± 17 / 7.4 -7.2 ± 0.0 / 7.4 0.36 ± 0.01 1.76 ± 0.12 99 ± 1 > 60 
11e --- 0.7 ± 0.1 > 250 / 7.4 -8.6 ± 0.2 / 7.4 0.28 ± 0.23 1.82 ± 0.14 > 99 > 60 
11f 6.5 1.1 ± 0.0 > 150 / 3.0 > 150 / 7.4 
-7.7 ± 0.8 / 5.0 
-8.8 ± 0.1 / 7.4 0.40 ± 0.02 1.90 ± 0.17 n.d. n.d. 
11g --- 1.4 ± 0.0 186 ± 4 / 7.6 -5.7 ± 0.0 / 7.4 2.0 ± 0.1 13.2 ± 2.1 99 ± 0 > 60 
11h 3.7 -1.4 ± 0.1 11 ± 0 / 3.0 273 ± 2 / 7.4 
-9.3 ± 1.4 / 5.0 
-8.8 ± 1.4 / 7.4 0.17 ± 0.00 0.22 ± 0.01 n.d. n.d. 
11i 2.5 -1.1 ± 0.1 > 150 / 3.0 > 150 / 7.4 
-6.8 ± 0.2 / 5.0 
-7.0 ± 0.1 / 7.4 0.22 ± 0.14 0.29 ± 0.03 n.d. n.d. 
11j --- 2.1 ± 0.0 192 ± 5 / 7.4 -5.2 ± 0.0 / 7.4 2.2 ± 0.4 22.1 ± 1.5 89 ± 1 > 60 
 
a) pKa values were determined by NMR spectroscopy; b) Octanol-water distribution coefficients (log D7.4) were 
determined by a miniaturized shake-flask procedure at pH 7.4, values represent the mean ± SD of sextuplicate 
measurements;49 c) Kinetic solubility was measured in a 96-well format using the !SOL Explorer solubility 
analyzer at the indicated pH in triplicate; d) Pe = effective permeability: passive permeation through an artificial 
membrane was determined by the parallel artificial membrane permeation assay (PAMPA), values represent the 
mean ± SD of quadruplicate measurements performed at the indicated pH;50 e) Papp = apparent permeability: 
permeation through a Caco-2 cell monolayer was assessed in the absorptive (a!b) and secretory (b!a) 
directions in triplicate;51 f) Plasma protein binding (PPB) was determined by equilibrium dialysis in triplicate;52 
g) Metabolic stability was determined by incubating the compounds (2 !M) with pooled rat liver microsomes 
(RLM, 0.5 mg/mL) in presence of NADPH (1 mM, compounds 1, 6, 11c-e, g, j) or without NADPH (compound 
5);53 n.d. = not determined. 
 
Oral Bioavailability. Oral bioavailability relies on compound dissolution in the 
gastrointestinal fluids, permeation through the membranes lining the intestine, and stability 
against first pass metabolism.54,55 In turn, permeability and potency define the minimum 
aqueous solubility required for an orally dosed compound.56 For our FimH antagonist, we 
therefore aimed to exceed the solubility limit of 50 !g/mL in order to achieve substantial 
absorption through the intestinal mucosa. Sufficient aqueous solubility was reported for n-
heptyl "-mannopyranoside (1).19 The unsubstituted biphenyl "-D-mannopyranoside 10 as 
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well as the antagonists bearing a methylcarboxylate, carboxamide, or tetrazole substituent in 
its unionized state (compounds 5, 11a and 11h) were found to be scarcely soluble due to the 
apolar and planar character of the aglycone.24,57 By contrast, the polar carboxylic acid moiety 
present in antagonist 6 or the substituents in the bioisosteres 11b-j enhanced the observed 
solubility beyond the limit of 50 !g/mL. Permeability data derived from PAMPA58 and the 
Caco-2 model59 suggest high permeation of the moderately lipophilic antagonists 1, 10, and 5 
(log D7.4 > 1.6) through the intestinal membranes. The bioisosteres 11a-f, h, i, although 
slightly more permeable than the strongly hydrophilic carboxylic acid derivative 6, show only 
moderate values of permeability compared to n-heptyl !-mannopyranoside (1) or the 
unsubstituted biphenyl mannoside 10. However, the para-cyanobiphenyl derivatives 11g and 
11j display elevated log D7.4 and effective permeability (log Pe) in the range for successful 
intestinal absorption. Featuring both high aqueous solubility and elevated membrane 
permeability, the para-cyano substituted bioisosteres 11g and 11j are thus the most promising 
candidates for oral absorption. Moreover, combining the bioisosteric replacement with the 
addition of a chloro substituent in the ortho-position of the aromatic ring adjacent to the 
anomeric oxygen (" 11j)24 resulted in the most advantageous physicochemical profile for 
oral bioavailability. 
 
Renal Excretion. The rate of renal excretion depends on the rate of glomerular filtration and 
the propensity to tubular secretion and reabsorption of an antagonist.60 Only the fraction that 
is not bound to plasma proteins is expected to enter the glomerular filtrate.61 Plasma protein 
binding (PPB) data indicating the fraction bound (fb) are listed in Table 2.52 The biphenyls 6 
and 11c were identified as moderate binders to plasma proteins (fb " 65%), which suggests a 
low impact of PPB on antagonist filtration. The fb values of the antagonists 1, 10, 5, and 11j 
were between 80 and 93%, whereas the bioisosteres 11d, e, and g showed particularly high 
protein binding (fb # 99%) implying slow compound entry into the primary urine. However, 
the kinetic aspects of PPB, that is, association and dissociation rate constants, remain to be 
determined to quantify precisely the influence of PPB on filtration.62 
Furthermore, log D7.4 was identified as key determinant of tubular reabsorption.63-65 
Accordingly, lipophilic compounds are predominantly reabsorbed from the renal filtrate. 
Given that renal clearance is the major route of elimination, this will result in a slow but 
steady excretion into the bladder. In contrast, hydrophilic compounds are poorly reabsorbed 
and thus quickly renally eliminated, which leads to high initial compound levels in the urine 
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but narrows the time range where the minimal anti-adhesive concentration is maintained. 
Consequently, low log D7.4 as shown for the antagonists 6, 11h, and 11i implies low tubular 
reabsorption and rapid elimination of the filtered molecules by the urine. Otherwise, log D7.4 
between 0.2 and 0.7, such as determined for the bioisosteres 11a-e, suggests increasing 
propensity to tubular reuptake, whereas log D7.4 > 1 as shown for heptyl mannoside 1 and the 
biphenyl mannosides 10, 5, 11g, 11f, and 11j is optimal for tubular reabsorption from the 
glomerular filtrate and thus for slow renal clearance. 
 
Metabolic Stability. Increasing lipophilicity is usually paralleled by increasing susceptibility 
to metabolism.66 Liabilities towards metabolic clearance pathways which prevent the intact 
antagonist from reaching the target in the bladder were therefore of interest. To assess their 
propensity to cytochrome P450 (CYP450)-mediated metabolism, heptyl mannoside 1, the 
carboxylic acid derivative 6, and the bioiosteres 11c-e, g, j were incubated with rat liver 
microsomes (RLM, 0.5 mg/mL) in presence of the cofactor !-nicotinamide adenine 
dinucleotide phosphate (NADPH).53 To confirm the high propensity of the methyl ester 
present in antagonist 5 to carboxylesterase (CES)-mediated hydrolysis, this antagonist was 
incubated with RLM only. The profiles of unchanged compound versus time revealed high 
susceptibility of heptyl mannoside 1 to CYP450-mediated metabolism (t1/2 = 13 min) and 
rapid hydrolysis of the ester 5 by the hepatic CES (t1/2 = 1.0 min). Otherwise, the bioisosteres 
11c-e,g & j were stable against enzyme-mediated bioconversion (t1/2 > 60 min) suggesting 
lower propensity to metabolic, non-renal elimination pathways. 
Considering PPB, lipophilicity, and metabolic stability data, we therefore expected (i) a 
steady release of compounds 11d, e, g, j into the bladder because of high PPB decelerating 
glomerular filtration (11d, e, g) and/or high log D7.4 supporting tubular reabsorption (11g, j), 
(ii) a fast excretion of antagonist 6 and 11c via the urine due to low PPB and low log D7.4, 
and (iii) a rapid clearance of heptyl mannoside 1 from the body by renal and metabolic 
pathways. Compounds featuring high propensity to renal excretion as major route of 
elimination (11c, 11e and 11j) were selected for in vivo PK studies in a mouse model.  
 
Pharmacokinetic Studies in C3H/HeN Mice. This first part of our study explored the 
predicted effects of lipophilicity, PPB, and metabolic stability on antagonist disposition and 
elimination upon a single dose iv application (50 mg/kg) of compounds 11c and 11e. The PK 
parameters of these applications and those of the previously published carboxylate 6 are 
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summarized in Table 4. The Table also contains the results of the iv administration of 
compound 11j (0.625 mg/kg). 
 
Table 4. Pharmacokinetic parameters determined after a single iv application of compounds 6a, 11c, 11e and 
11j in female C3H/HeN mice. Values were calculated using PKSolver.67 C0, initial concentration; Vz, volume of 
distribution in terminal phase; AUC, Area under the curve; CLtot, total clearance; Cmax, maximal concentration. 
Compd Plasma Urine 
 C0 (!g/mL) Dose (mg/kg) Vz (mL) t1/2 (h) AUC0-inf (!g x h/mL) CLtot (mL/h) Cmax (!g/mL) 
619 40 50 25.2 0.33 23.5 53.1 300 
11c 109.7 50 28.3 0.4 25.3 49.4 4611 
11e 151.6 50 19.5 1.9 175.1 7.1 387 
11j 0.36 0.625 52.8 0.17 0.07 218 10 
 
 
In contrast to the fast plasma clearance of antagonists 6 and 11c (Figure 5A), the methyl 
sulfonamide bioisostere 11e attained higher initial concentration in plasma (C0) and lower 
total clearance (CLtot). Therefore, it could be detected until six hours post application, 
resulting in markedly higher plasma AUC. The observed high C0 of compound 11e may be 
attributed to a small volume of distribution (Vz) resulting from the high PPB (fb " 99%).61 In 
urine (Figure 5B), the carboxylic acid 6 and the morpholinomethanone 11c displayed high 
levels immediately following administration and a rapid concentration decrease within the 
first two hours, reflecting the rapid elimination from plasma. Fast renal excretion as major 
route of elimination can be rationalized by the physicochemical properties of the antagonists 
6 and 11c, that is, moderate PPB and log D7.4, as well as high metabolic stability. Otherwise, 
the methyl sulfonamide bioisostere 11e showed sustained compound levels in urine over a 
period of two hours and subsequent slow decrease until six hours post administration. This 
sustained renal excretion is a result of the interplay of the antagonist’s elevated PPB and log 
D7.4. 
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Figure 5. Antagonist concentrations in (A) plasma and (B) urine after a single iv application of 6, 11c, and 11e 
(50 mg/kg).  
 
In a second study, the para-cyano bioisostere 11j, characterized by a high oral absorption 
potential, but low solubility, was administered as a single dose iv (0.625 mg/kg) and po (1.25 
mg/kg). The plasma concentration curve upon iv dosing displays a steep decline within the 
first hour post application, while the po curve shows a prolonged period where absorption 
and elimination are in equilibrium (Figure 6A). The urine concentration profiles (Figure 6B) 
parallel the plasma curves obtained by the two modes of application, i.e. high plasma 
clearance upon iv bolus injection led to high initial antagonist levels in urine and a rapid 
concentration decline. By contrast, sustained plasma concentrations upon po administration 
resulted in prolonged urine levels. As a result, urine concentrations exceed the minimum 
level required for the anti-adhesive effect (minimal anti-adhesion concentration, MAC90),23 
determined by flow cytometry68 (0.094 !g/ml), for more than eight hours upon oral single-
dose administration, proving the high potential of the para-cyano biphenyl mannoside for the 
oral treatment of UTI (Figure 6B). 
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Figure 6. Antagonist concentrations in (A) plasma and (B) urine after a single iv and po application of 
compound 11j (iv: 0.625 mg/kg; po: 1.25 mg/kg). MAC90, minimal anti-adhesive concentration to inhibit 90% 
adhesion (0.094 !g/ml). 
 
Infection study in C3H/HeN Mice. Based on the promising PK profile of 11j, six mice were 
inoculated with UTI89 following an oral application of 11j (1.25 mg/kg) 40 min prior to 
infection. Three hours after inoculation, animals were sacrificed and bladder and kidneys 
were removed. Organs were homogenized and analysed for bacterial counts. The results were 
compared to ciprofloxacin (CIP), used as standard antibiotic therapy against UTI89.69 The 
median reduction in bacterial counts of the mice treated with 11j and CIP compared to the 
control group are displayed in Figure 7.  
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Figure 7. Treatment efficacy in the UTI mouse model 3 h after infection. The bars depict the median reduction 
of bacterial counts after application of 1.25 or 10 mg/kg 11j p.o. or 8 mg/kg CIP s.c. (representing the murine 
dose equivalent to a human standard dose).70 The baseline represents the median counts of the untreated control 
group. 
The median value in the untreated control group showed bacterial counts of 6.6 Log10 colony 
forming units (CFU) in the bladder and 6 Log10 CFU in the kidneys. After oral application of 
1.25 mg/kg of 11j, bacterial loads in the bladder decreased by 1.7 Log10 CFU and 1.08 Log10 
CFU in the kidneys. The lower reduction in the kidneys is most likely due to the differing 
adhesion mechanisms between bladder and kidneys (type 1 pili vs P-pili), which is not 
targeted by 11j.71 With CIP (8 mg/kg s.c.) a substantial reduction in both, bladder and 
kidneys (median reductions of 2.44 Log10 and 2.47 Log10, respectively) was observed. 
Despite the low oral dose of 11j, the approximately 100-fold reduction of CFU in the bladder 
promised en even higher effect upon dose increase. To increase solubility of 11j, a basic 
formulation was used,. When 10 mg/kg were applied, bacterial loads in the bladder decreased 
by 3.4 Log10 CFU/ml, exceeding the effect of CIP, but only 0.5 Log10 CFU in the kidneys. 
Based on this large reduction after an oral application of 10 mg/kg, 11j has a large potential 
for further development.  
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SUMMARY AND CONCLUSION 
 
Recently, numerous monovalent alkyl and aryl !-D-mannopyranosides have been described 
as potent FimH antagonists. However, most of them suffer from insufficient pharmacokinetic 
properties, i.e. modest bioavailability and short duration of the therapeutic effect in the 
bladder, their site of action. As a consequence, high doses at short intervals are required to 
achieve anti-adhesive effects over an extended period of time. Therefore, the goal of the 
present study was an appropriate optimization of the pharmacokinetic profile of biphenyl !-
D-mannopyranosides while keeping their high affinity to the CRD of FimH. The starting 
point was the biphenyl-carboxylate 6 where the critical carboxylate was replaced by 
bioisosteres.29,72 
With a series of bioisosteres a three- to fivefold improvement of affinity was achieved 
compared to 6. Although binding necessitates only partial desolvation of the carboxylate and 
its bioisosteric replacements, a reduction of the enthalpy penalty for desolvation41 was 
identified as the source of the improved affinity exhibited by the bioisosteres. 
Thermodynamic evaluation of antagonists 11b-e revealed almost identical enthalpy 
contribution to binding. However, for antagonists with the para-cyano substituent (11g & 
11j) an enhancement of up to -8.7 kJ/mol was observed, indicating a reduced desolvation 
penalty and an improved stacking as derived from the crystal structure of 11j co-crystallized 
with the CRD of FimH (Figure 4B). On the other hand, higher affinity originating from a 
reduction of conformational flexibility of ligand and protein resulted in a concomitant 
entropy penalty of up to 6.5 kJ/mol. 
In addition to the improved pharmacodynamics, the relevant pharmacokinetic parameters 
(solubility, permeability, renal excretion) could also be substantially improved. With 3’-
chloro-4’-(!-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (11j), a FimH antagonist with 
an optimal in vitro PK/PD profile was identified. The para-cyano substituent conferred 
lipophilicity and high binding to plasma proteins, which slowed down the rate of renal 
excretion. Despite higher lipophilicity, antagonist 11j was insusceptible to CYP450 mediated 
metabolism, and therefore predominantly eliminated via the renal pathway. In vivo 
experiments confirmed the excellent PK-profile of 11j with steady renal excretion for more 
than eight hours after oral application, suggesting a long-lasting anti-adhesive effect. Finally, 
orally applied 11j (10 mg/kg) was effective in a mouse model of UTI by reducing the 
bacterial load in the bladder by over 1000-fold. Improvement of solubility, enabling the 
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application of higher dosages of 11j, will possibly lead to an even higher bacterial reductions, 
which will be the subject of future investigations. 
 
EXPERIMENTAL SECTION 
 
Synthesis 
The synthesis of compounds 11a-f, 11i, 14a-f, 16, 19, and 24, including compound 
characterization data, can be found in the Supporting Information. 
 
General methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD or HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ. The LC/HRMS analysis were carried out using a Agilent 1100 LC equipped 
with a photodiode array detector and a Micromass QTOF I equipped with a 4 GHz digital-
time converter. Microwave-assisted reactions were carried out with a CEM Discover and 
Explorer. Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck) and visualized by using UV light and/or by charring with a molybdate solution (a 
0.02 M solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10% H2SO4). MPLC separations were carried out on a CombiFlash 
Companion or Rf (Teledyne Isco) equipped with RediSep normal-phase or RP-18 reversed-
phase flash columns. LC-MS separations were done on a Waters system equipped with 
sample manager 2767, pump 2525, PDA 2525 and micromass ZQ. All compounds used for 
biological assays are at least of 95% purity based on HPLC analytical results. Commercially 
available reagents were purchased from Fluka, Aldrich, Alfa Aesar or abcr GmbH & Co. KG 
(Germany). Solvents were purchased from Sigma-Aldrich or Acros and were dried prior to 
use where indicated. Methanol (MeOH) was dried by refluxing with sodium methoxide and 
distilled immediately before use. Dimethoxyethane (DME) was dried by filtration over Al2O3 
(Fluka, type 5016 A basic).  
 
4’-(2,3,4,6-Tetra-O-acetyl-!-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (14g). A 
Schlenk tube was charged with aryl iodide 1224 (330 mg, 0.60 mmol), 4-cyanophenylboronic 
acid (13g, 96 mg, 0.65 mmol), Pd(dppf)Cl2"CH2Cl2 (15 mg, 0.018 mmol), K3PO4 (192 mg, 
3.2.3 FimH –Manuscript 5 
 
 
227 
0.90 mmol) and a stirring bar. The tube was closed with a rubber septum and was evacuated 
and flushed with argon. This procedure was repeated once, and then anhydrous DMF (2 mL) 
was added under a stream of argon. The mixture was degassed in an ultrasonic bath and 
flushed with argon for 5 min, and then stirred at 80 °C overnight. The reaction mixture was 
cooled to rt, diluted with EtOAc (50 mL), and washed with water (50 mL) and brine (50 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was 
purified by MPLC on silica gel (petroleum ether/EtOAc) to afford 14g (187 mg, 59%) as 
colorless oil. [!]D20 +72.9 (c 0.8, MeOH); 1H NMR (500 MHz, CD3OD): ! = 7.73-7.71 (m, 
2H, Ar-H), 7.65-7.64 (m, 2H, Ar-H), 7.57-7.53 (m, 2H, Ar-H), 7.21-7.19 (m, 2H, Ar-H), 
5.60-5.57 (m, 2H, H-1, H-3), 5.47 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-
4), 4.30 (dd, J = 5.1, 12.2 Hz, 1H, H-6a), 4.14-4.08 (m, 2H, H-6b, H-5), 2.22, 2.07, 2.06, 2.04 
(4 s, 12H, 4 COCH3); 13C NMR (126 MHz, CD3OD): ! = 170.62, 170.14, 170.11, 169.83 (4 
CO), 156.16, 144.87, 134.05, 132.77, 128.64, 127.46 (Ar-C), 119.05 (CN), 117.15, 110.77 
(Ar-C), 95.86 (C-1), 69.42 (2C, C-2, C-5), 68.90 (C-3), 65.94 (C-4), 62.16 (C-6), 21.01, 
20.84, 20.82 (4C, 4 COCH3); ESI-MS: m/z: Calcd for C27H27NNaO10 [M+Na]+: 548.2, found: 
548.2. 
 
4’-(!-D-Mannopyranosyloxy)-biphenyl-4-carbonitrile (11g). To a solution of 14g (40 mg, 
0.08 mmol) in dry MeOH (5 mL) was added freshly prepared 1 M NaOMe/MeOH (0.1 eq) 
under argon. The mixture was stirred at rt until the reaction was complete (monitored by 
TLC), then neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and concentrated 
in vacuo. The residue was purified by MPLC on silica gel (DCM/MeOH, 10:1-7:1) to afford 
11g (16 mg, 60%) as white solid. 1H NMR (500 MHz, CD3OD): ! = 7.82-7.75 (m, 4H, Ar-
H), 7.69-7.63 (m, 2H, Ar-H), 7.30-7.23 (m, 2H, Ar-H), 5.58 (d, J = 1.7 Hz, 1H, H-1), 4.05 
(dd, J = 1.8, 3.4 Hz, 1H, H-2), 3.94 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.83-3.71 (m, 3H, H-4, H-
6a, H-6b), 3.62 (ddd, J = 2.5, 5.3, 9.8 Hz, 1H, H-5). The spectroscopic data were in 
accordance with literature values.18 
 
5-(4’-(2,3,4,6-Tetra-O-acetyl-!-D-mannopyranosyloxy)-biphenyl-4-yl)-1H-tetrazole (15). 
A Schlenk tube was charged with 14g (30 mg, 0.06 mmol), trimethylsilyl azide (16 µL, 0.12 
mmol), dibutyltin oxide (2 mg, 0.006 mmol), DME (1 mL) and a stirring bar. The mixture 
was heated to 150 °C for 10 min by microwave irradiation. The reaction mixture was cooled 
to rt, and then concentrated in vacuo. The residue was purified by MPLC on silica gel 
(DCM/MeOH, 9:1-8:1) to afford 15 (26 mg, 81%) as colorless oil. [!]D20 +56.1 (c 0.3, 
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MeOH); 1H NMR (500 MHz, CDCl3): ! = 8.25-8.15 (m, 2H, Ar-H), 7.75-7.65 (m, 2H, Ar-
H), 7.60-7.55 (m, 2H, Ar-H), 7.20-7.17 (m, 2H, Ar-H), 5.64-5.55 (m, 2H, H-1, H-3), 5.49 
(dd, J = 1.7, 3.3 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.3, 12.4 Hz, 1H, 
H-6a), 4.17-4.06 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3); 13C NMR 
(126 MHz, CDCl3): ! = 170.67, 170.14, 170.11, 169.81 (4 CO), 155.61, 128.36, 127.84, 
127.49, 116.93 (Ar-C), 95.78 (C-1), 69.36 (C-5), 69.26 (C-2), 68.90 (C-3), 65.89 (C-4), 62.12 
(C-6), 20.92, 20.76, 20.73 (4 COCH3); ESI-MS: m/z: Calcd for C27H28N4NaO10 [M+Na]+: 
591.2, found: 591.1. 
 
5-(4’-(!-D-Mannopyranosyloxy)-biphenyl-4-yl)-1H-tetrazole (11h). Prepared according to 
the procedure described for 11g from 15 (26 mg, 0.03 mmol). Yield: 18 mg (quant.) as a 
white solid. [!]D20 +112.1 (c 0.1, MeOH/H2O, 2:1); 1H NMR (500 MHz, CD3OD): ! = 7.98-
7.96 (m, 2H, Ar-H), 7.72-7.71 (m, 2H, Ar-H), 7.58-7.54 (m, 2H, Ar-H), 7.16-7.13 (m, 2H, 
Ar-H), 5.46 (d, J = 1.7 Hz, 1H, H-1), 3.94 (dd, J = 1.9, 3.5 Hz, 1H, H-2), 3.83 (dd, J = 3.4, 
9.5 Hz, 1H, H-3), 3.68-3.61 (m, 3H, H-4, H-6a, H-6b), 3.52 (ddd, J = 2.5, 5.4, 9.7 Hz, 1H, H-
5); 13C NMR (126 MHz, CD3OD): ! = 158.19, 145.07, 134.97, 129.29, 128.74, 128.55, 
118.26 (Ar-C), 100.13 (C-1), 75.52 (C-5), 72.42 (C-3), 71.98 (C-2), 68.33 (C-4), 62.69 (C-6); 
HRMS: m/z: Calcd for C19H21N4O6 [M+H]+: 401.1456, found: 401.1450. 
 
4’-(2,3,4,6-Tetra-O-acetyl-!-D-mannopyranosyloxy)-3’-chloro-biphenyl-4-carbonitrile 
(20). Prepared according to the procedure described for 14g from aryl iodide 1923 (79 mg, 
0.135 mmol), 13g (22 mg, 0.15 mmol), Pd(dppf)Cl2"CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 (57 
mg, 0.27 mmol). Yield: 57 mg (75%) as a white solid. [!]D20 +77.7 (c 0.5, CHCl3); 1H NMR 
(500 MHz, CDCl3): ! = 7.72 (d, J = 8.3 Hz, 2H, Ar-H), 7.63 (m, 3H, Ar-H), 7.43 (dd, J = 2.2, 
8.6 Hz, 1H, Ar-H), 7.27 (d, J = 8.6 Hz, 1H, Ar-H), 5.64-5.59 (m, 2H, H-1, H-2), 5.54 (dd, J = 
1.9, 3.2 Hz, 1H, H-3), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.2, 12.3 Hz, 1H, H-6a), 
4.17 (ddd, J = 2.1, 5.1, 10.0 Hz, 1H, H-5), 4.10 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.21 (s, 3H, 
COCH3), 2.12- 2.00 (m, 9H, 3 COCH3); 13C NMR (126 MHz, CDCl3): ! = 170.54, 170.08, 
169.90, 169.84, (4C, CO) 151.67, 143.61, 135.29, 132.87, 129.41, 127.53, 126.60, 125.20, 
118.79, 117.36, 111.47 (Ar-C, CN), 96.72 (C-1), 70.00 (C-5), 69.39 (C-3), 68.82 (C-2), 65.86 
(C-4), 62.16 (C-6), 20.98, 20.81, 20.79, 20.78 (4 COCH3); ESI-MS: m/z: Calcd for 
C27H26ClNNaO10 [M+Na]+: 582.1, found: 582.1. 
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3’-Chloro-4’-(!-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (11j). Prepared 
according to the procedure described for 11g from 20 (36 mg, 0.06 mmol). Yield: 12 mg 
(48%) as a white solid. [!]D20 +109.4 (c 0.23, MeOH); 1H NMR (500 MHz, CD3OD): ! = 
7.80-7.72 (m, 5H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-
H), 5.62 (d, J = 1.4 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 
Hz, 1H, H-3), 3.83-3.68 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 2.3, 5.4, 9.6 Hz, 1H, H-5); 
13C NMR  (126 MHz, CD3OD): ! = 153.65, 145.15, 135.42, 133.86, 129.82, 128.53, 127.87, 
125.47, 119.70, 118.59 (Ar-C), 111.97 (CN), 100.66 (C-1), 76.05 (C-5), 72.39 (C-3), 71.80 
(C-2), 68.20 (C-4), 62.65 (C-6); IR (KBr), ! = 3400 (OH), 2227 (C"N), 1606, 1487 (Ar-
C=C) cm-1; HRMS: m/z: Calcd for C19H18ClNNaO6 [M+Na]+: 414.0715, found: 414.0721. 
 
3'-Chloro-N-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-4'-(!-D-
mannopyranosyloxy)-biphenyl-4-carboxamide (21). Compound 8 (10.0 mg, 0.024 mmol), 
fluoresceinamine isomer I (12.7 mg, 0.037 mmol) and COMU (20.9 mg, 0.049 mmol) were 
dissolved in dry DMF (1 mL), then NEt3 (10 µL, 0.073 mmol) was added and the mixture 
was stirred at rt for 7 h. 1 N HCl in DMF was added until acid reaction on pH paper and the 
mixture was concentrated. The residue was dissolved in DCM/MeOH (3:1) and loaded onto a 
silica gel column. The complex mixture of compounds was only partially resolved. The 
fractions containing the product were collected, concentrated and purified by preparative 
HPLC (gradient water/MeCN containing 0.2% HCO2H), to afford compound 21 (5 mg, 
19%). [!]D20 +21.1 (c 0.1, MeOH); 1H NMR (500 MHz, CD3OD): ! = 8.26 (d, J = 8.4 Hz, 
2H, Ar-H), 7.88-7.74 (m, 3H, Ar-H), 7.66 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.51 (d, J = 8.7 
Hz, 1H, Ar-H), 7.29 (dd, J = 1.9, 5.3 Hz, 2H, Ar-H), 7.19 (dd, J = 2.1, 8.3 Hz, 1H, Ar-H), 
7.08-6.99 (m, 2H, Ar-H), 6.95 (d, J = 8.7 Hz, 1H, Ar-H), 6.72 (dd, J = 5.5, 10.6, Hz, 2H, Ar-
H), 6.61 (dd, J = 2.3, 8.7 Hz, 1H, Ar-H), 5.65 (s, 1H, H-1), 4.15 (dd, J = 1.8, 3.2 Hz, H-2), 
4.03 (dd, J = 3.4, 9.5, Hz, H-3), 3.87-3.72 (m, 3H, H-4, H-6a, H-6b), 3.65 (m, 1H, H-5); 13C 
NMR (126 MHz, CD3OD): ! = 137.50, 136.01, 131.90, 130.24, 130.20, 129.87, 129.24, 
128.03, 127.91, 125.79, 125.46, 124.73, 118.99, 118.76, 118.65 (Ar-C), 100.73 (C-1), 76.06 
(C-5), 72.42 (C-3), 71.85 (C-2), 68.24 (C-4), 62.69 (C-2); ESI-MS: m/z: Calcd for 
C39H31ClNO12 [M+H]+: 740.2, found: 740.2. 
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3'-Chloro-N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-
thioureido)ethyl)-4'-(!-D-mannopyranosyloxy)-biphenyl-4-carboxamide (22). To a 
stirred solution of compound 8 (25 mg, 0.061 mmol) in dry DMF (1 mL), NHS (21 mg, 0.183 
mmol) was added, followed by DIC (9.2 mg, 0.073 mmol). The mixture was stirred at rt for 2 
h, then N-Boc-ethylendiamine (10.7 mg, 0.067 mmol) was added and the reaction was stirred 
for 10 h. It was then cooled down to 0 °C, diluted with water and concentrated. 
Chromatography on silica gel (DCM/MeOH) yielded 23 mg (0.042 mmol, 68%) of tert-butyl 
(3’-chloro-4’-(!-D-mannopyranosyloxy)-biphenyl-4-yl-carboxamido)ethyl)carbamate. This 
product was dissolved in CH2Cl2 (3 mL) and TFA (1 mL) was added. The solid dissolved 
during addition of TFA. After 10 min the reaction was complete. The mixture was evaporated 
and excess TFA was removed in high vacuum. The intermediate N-(2-aminoethyl)-3'-chloro-
4'-(!-D-mannopyranosyloxy)-biphenyl-4-carboxamide TFA salt (23 mg, 0.042 mmol, quant.) 
was used directly in the next step. It was dissolved in dry DMF (0.5 mL) and NEt3 (12.8 mg, 
0.127 mmol) was added. The mixture was cooled to 0 °C, then FITC (14.8 mg, 0.038 mmol) 
was added and the mixture was stirred for 3 h in the dark. The mixture was then co-
evaporated with water, taken up in MeOH/10% aq. acetic acid and evaporated. 
Chromatography on silica gel (DCM/MeOH) yielded compound 22, contaminated with 
triethylammonium acetate. The compound was then re-dissolved in MeOH, and 0.5 N HCl in 
MeOH was added. The mixture was evaporated and chromatographed on silica gel, to yield 
pure 22 (15 mg, 47%). [!]D20 +12.1 (c 0.3, MeOH); 1H NMR (500 MHz, CD3OD): ! = 8.12 
(s, 1H), 7.92 (d, J = 8.3 Hz, 2H, Ar-H), 7.70 (dd, J = 5.0, 13.1 Hz, 2H, Ar-H), 7.64 (d, J = 8.3 
Hz, 2H, Ar-H), 7.54 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.46 (d, J = 8.7 Hz, 1H, Ar-H), 7.09 (d, 
J = 8.2 Hz, 1H, Ar-H), 6.74 (s, 2H), 6.69 (d, J = 1.4 Hz, 2H, Ar-H), 6.55 (d, J = 8.4 Hz, 2H, 
Ar-H), 5.63 (d, J = 1.3 Hz, H-1), 4.15 (dd, J = 1.8, 3.1 Hz, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, H-
3), 3.94 (s, 2H, CH2), 3.86-3.64 (m, 6H, H-4, H-5, H-6, CH2); 13C NMR (126 MHz, CD3OD): 
! = 153.21, 143.84, 136.41, 129.66, 129.18, 127.76, 127.70, 125.37, 118.64, 103.62 (Ar-C), 
100.75 (C-1), 76.00 (C-5), 72.41 (C-3), 71.86 (C-2), 68.24 (C-4), 62.69 (C-6), 40.76 (CH2); 
ESI-MS: m/z: Calcd for C42H37ClN3O12S [M+H]+: 842.2, found: 842.2. 
 
3'-Chloro-N-(2-(2-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thioureido)ethoxy)ethoxy)ethyl)-4'-(!-D-mannopyranosyloxy)-biphenyl-4-
carboxamide (23). Compound 8 (280 mg, 0.68 mmol) was dissolved in dry DMF (5 mL) 
under argon, then NHS (235 mg, 2.04 mmol) was added, followed by DIC (0.12 mL, 0.78 
mmol) and the mixture was stirred at rt for 4 h, then Boc-PEG2-NH2 (186 mg, 0.75 mmol) 
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was added, and the mixture was stirred at rt under argon for 10 h. It was then slowly diluted 
with water and concentrated. The residue was purified by chromatography on silica gel 
(DCM/MeOH) to give tert-butyl (2-(2-(2-(3'-chloro-4'-(!-D-mannopyranosyloxy)-biphenyl-
4-ylcarboxamido)ethoxy)ethoxy)ethyl)carbamate (300 mg, 0.468 mmol, 69%). Then, the 
carbamate was suspended in DCM (3 mL) and TFA (1 mL) was added dropwise at rt. After 
30 min, the solvents were evaporated and the crude mixture was dissolved in CHCl3/MeOH 
(6:4 + 0.5% conc. NH4OH) and transferred to a silica gel column, eluting with the same 
solvent mixture, to yield N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3'-chloro-4'-(!-D-
mannopyranosyloxy)-biphenyl-4-carboxamide (228 mg, 90 %). A fraction of the amine (10 
mg, 0.018 mmol) was dissolved in dry DMF (0.5 mL) and cooled to 0 °C. FITC (6.5 mg, 
0.017 mmol) was added and the mixture was stirred for 1 h. The mixture was concentrated 
and the residue was purified by chromatography on silica (DCM/MeOH), to yield 23 (10 mg, 
65%). 1H NMR (500 MHz, CD3OD): ! = 8.21 (d, J = 1.4 Hz, 1H, Ar-H), 7.88 (d, J = 8.3 Hz, 
2H, Ar-H), 7.68 (d, J = 2.2 Hz, 2H, Ar-H), 7.63 (d, J = 8.3 Hz, 2H, Ar-H), 7.53 (dd, J = 2.2, 
8.6 Hz, 1H, Ar-H), 7.43 (d, J = 8.7 Hz, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H), 6.68 (d, J 
= 2.3 Hz, 2H, Ar-H), 6.65 (dd, J = 2.6, 8.6 Hz, 2H, Ar-H), 6.53 (dd, J = 1.6, 8.7 Hz, 2H, Ar-
H), 5.61 (d, J = 1.3 Hz, 1H, H-1), 4.14 (dd, J = 1.8, 3.2, Hz, 1H, H-2), 4.03 (dd, J = 3.4, 9.5 
Hz, 1H, H-3), 3.93-3.53 (m, 16H), 3.37 (s, 2H, NCH2), 1.30 (s, 2H, CH2); 13C NMR (126 
MHz, CD3OD): ! = 170.01 (CO), 153.17, 143.72, 136.37, 134.37, 130.39, 129.69, 129.04, 
127.78, 127.73, 125.35, 118.60, 103.60 (Ar-C), 100.72 (C-1), 75.97 (C-5), 72.41 (C-3), 
71.86, 71.40, 70.59 (5C, C-2, OCH2), 68.23 (C-4), 62.64 (C-6), 49.88, 45.49, 40.97 (CH2);  
ESI-MS: m/z: Calcd for C46H45ClN3O14S [M+H]+: 930.2, found: 930.4. 
 
Competitive Fluorescence Polarization Assay 
 
Expression and purification of CRD of FimH. A recombinant protein consisting of the 
CRD of FimH linked to a 6His-tag via a thrombin cleavage site (FimH-CRD-Th-His6) was 
expressed in E. coli strain HM125 and purified by affinity chromatography as previously 
described.33 
 
KD determination of FITC-labeled ligands. The functionalized ligands (22, 23) were 
prepared as a 10 mM stock solution in pure DMSO (Sigma Aldrich, Buchs, Switzerland). All 
further dilutions of compounds and FimH-CRD-Th-His6 protein were prepared in assay 
buffer (20 mM HEPES, 150 mM NaCl, 50 !g/mL BSA, pH 7.4). BSA was added to the assay 
buffer to prevent non-specific binding of protein to the plastic surface. Binding isotherms for 
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the fluorescent ligands were obtained in direct binding studies by adding a constant 
concentration of ligand (final concentration 5 nM) and a linear dilution of protein (final 
concentration 0-100 nM) to a final volume of 200 !L in 96-well, black, flat bottom NBSTM 
plates (Corning Inc., Corning, NY, USA). After incubating the plate for 24 h at rt with gentle 
shaking, the fluorescence polarization was measured with the SynergyTM H1 Hybrid Multi-
Mode Microplate Reader (BioTek Instruments Inc., Winooski, VT, USA) with polarized 
excitation at 485 nm and emission measured at 528 nm through polarizing filters parallel and 
perpendicularly oriented to the incident polarized light. KD values were determined by 
plotting the FP readout as a function of the protein concentration and applying the following 
single-site binding equation (Equation 1) that accounts for ligand depletion: 
 
! 
Sobs = SF + (SB " SF ) # (
CP +CL + KD " (CP +CL + KD )2 " 4CPCL
2CL
)  (1) 
where Sobs is the observed signal from the ligand, SF is the signal from free ligand, SB is the 
signal from bound ligand, CP is the total concentration of protein, and CL is the total 
concentration of ligand.39 
 
KD Determination of FimH Antagonists. The fluorescently labeled ligand 22 was used for 
the competitive fluorescence polarization assay. A linear dilution of non-labeled FimH 
antagonist with final concentrations ranging from 0-10 !M was titrated into 96-well, black, 
flat bottom NBSTM plates (Corning Inc.) to a final volume of 200 !L containing a constant 
concentration of protein (final concentration 25 nM) and FITC-labeled ligand which was 
fixed at a higher concentration in competitive binding assays than in direct binding 
experiments to obtain higher fluorescence intensities (final concentration 20 nM). Prior to 
measuring the fluorescence polarization, the plates were incubated on a shaker for 24 h at rt 
until the reaction reached equilibrium. The IC50 value was determined with Prism (GraphPad 
Software Inc., La Jolla, CA, USA) by applying a standard four-parameter IC50 function. The 
obtained IC50 values were converted into their corresponding KD values using the derivation 
of the Cheng-Prusoff equation.35 This variation of the Cheng-Prusoff equation is applied to 
competition assays with tight-binding inhibitors, and includes terms to correct for ligand 
depletion effects. However, the KD for antagonists having a higher affinity towards FimH 
than the labeled ligand could not be accurately determined.35 
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Isothermal Titration Calorimetry (ITC) 
 
All ITC experiments were performed with the FimH-CRD-Th-His6 protein using a VP-ITC 
instrument from MicroCal, Inc. (GE Healthcare, Northampton, MA, USA) with a sample cell 
volume of 1.4523 mL. The measurements were performed with 2.5 or 5% DMSO at 25 °C, a 
stirring speed of 307 rpm, and 10 !cal s-1 reference power. The protein samples were 
dialyzed in assay buffer prior to all experiments. Compounds 6, 10, and 24 were measured in 
a direct fashion by titration of ligand (120-2,000 !M) into protein (10-55 !M) with injections 
of 3-6 !L at intervals of 10 min to ensure non-overlapping peaks. The quantity c = Mt(0) KD–
1, where Mt(0) is the initial macromolecule concentration, is of importance in titration 
microcalorimetry. The c-values of the direct titrations were below 1’000 and thus within the 
reliable range. For the compounds 11b-e, 11g and 11j additional competitive ITC 
experiments were performed due to their high affinity resulting in c-values above 1’000 for 
direct titrations. These ligands (600 !M) were titrated into protein (30 !M), which was 
preincubated with compound 24 (300 !M) resulting in sigmoidal titration curves. Due to 
slow reaction kinetics, titration intervals of 20 min were used. 
Baseline correction and peak integration was performed using the Origin 7 software  
(OriginLab, Northampton, MA, USA). An initial 2 !L injection was excluded from data 
analysis. Baseline subtraction and curve-fitting with the three variables N (concentration 
correction factor), KD (dissociation constant), and "H° (change in enthalpy) was performed 
with the SEDPHAT software version 10.40 (National Institute of Health). A global fitting 
analysis was performed for the competition titration (compounds 11b-e, 11g or 11j 
competing for the protein binding site with compound 24) and the direct titration of the 
competitor (compound 24 binding to protein) to fit for KD. "H° and N were fitted from direct 
titrations of compounds 11b-e, 11g or 11j into protein. For the compounds 6, 10 and 24 
binding to protein all variables could be determined from a global analysis of the direct 
titration.   
The thermodynamic parameters were calculated with the following equation (Equation 2): 
 
! 
"G° = "H°#T"S° = RT lnKD = #RT lnKA  (2) 
where "G°, "H°, and "S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R is the universal gas constant (8.314 J mol-1 
K-1). The 95 %-confidence intervals of the measurements were calculated for the two 
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variables KD and !H° with the 1-dimensional error surface projection within the SEDPHAT 
software. 
Calculation of the Free Energy of Desolvation. The three dimensional representation for 
each of the aglycons (4-methoxy biphenyl scaffold, Figure 7) was built in the Maestro73 
modeling environment and the global minimum conformation was identified by performing 
500 iterations of the mixed torsional/low-mode conformational sampling in combination with 
the OPLS-2005 force-field and the implicit solvent model (water) as implemented in the 
Macromodel 9.9.74 The global minimum structures were used as input for the AMSOL 7.1 
program76 to obtain the free energy of desolvation !Gdes  (Table 5) with the SM5.4A 
solvation model76 and the AM177 level of theory (used keywords “AM1 SM5.4A 
SOLVNT=WATER TRUES”). 
 
Figure 7. The 4-methoxy biphenyl scaffold of aglycons. 
Table 5. Aqueous free energy of desolvation.    
R !Gdes [kJ/mol] 
neutral  
H 15.6 
CONHCH3 39.9 
COOCH3 23.0 
SO2NHCH3 65.5 
SO2CH3 56.4 
4-morpholine amide 45.3 
CN 22.0 
  
deprotonated  
COO- 298.2 
SO2-N--Me 342.0 
 
 
Determination of the MAC90 by flow cytometry 
 
The MAC90 was determined in principle as in the previously published flow cytometry 
assay,68 but with some modifications. The human epithelial bladder carcinoma cell line 5637 
(DSMZ, Braunschweig, Germany) was grown in RPMI 1640 medium, supplemented with 
10% fetal calf serum (FCS), 100 U/mL penicillin and 100 "g/mL streptomycin at 37 °C, 5% 
CO2. All solutions were purchased from Invitrogen (Basel, Switzerland). The cells were 
RO
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subcultured 1:6 twice per week [using Trypsin/EDTA (Sigma-Aldrich) for the detachment]. 
Two days before infection, 1.8 ! 105 cells were seeded in each well of a 24-well plate in 
RPMI 1640 containing 10% FCS without antibiotics. The cell density was approximately 3-5 
! 105 cells/well at the assay day. 
For infection, the GFP-expressing clinical E. coli isolate UTI8978 (UTI89 wt) and the GFP-
expressing FimA-H knock-out strain UTI89 !fimA-H were used (strains were provided by 
Prof. Urs Jenal, Biocenter, University of Basel, Switzerland).68 Bacteria were cultivated at 37 
°C in 10 mL Luria-Bertani (LB) broth (Becton, Dickinson and Company) overnight, 
harvested by centrifugation (3800 rpm, 10 min) and washed three times in phosphate 
buffered saline (PBS, Sigma-Aldrich) and a bacterial solution of OD600 of 0.75 in RPMI + 
10% FCS was prepared. For the determination of the MAC90 value, the IC90, linear dilutions 
of the FimH-antagonist were prepared in 5% DMSO and PBS. Bacteria and antagonists were 
pre-incubated for 10 min at 37 °C, before cells were infected with either only 200 "L 
bacterial solution of UTI89 or UTI89 !fimA-H (positive and negative controls), or 225 "L of 
the pre-incubated bacteria-antagonist mixture. Infection lasted for 1.5 h, during this time 
infected cells were incubated at 37 °C. Then, cells were washed with PBS and detached from 
wells by the addition of 150 "L trypsin and incubation at 37 °C for 10 min, before flushing 
from wells PBS containing 2% FCS and transferred to tubes. To dilute the trypsin, cells were 
centrifuged at 13000 rpm, 1 min, 600 "L of the supernatant was discarded and the pellet was 
re-suspended in the remaining 300 "L PBS containing 2% FCS. Samples were stored on ice 
until measurement. Before analysis with the flow cytometer (Becton Dickinson, 
FACSCanto II), the samples were gently mixed and filtered using a 35 "m nylon mesh 
(Corning Life Sciences) to prevent cellular aggregation. Cells were gated with linear scaling 
for side scatter (SSC) and forward scatter (FSC) and GFP intensity of live cells was 
evaluated. IC90 values were determined by plotting the concentration of the antagonist in a 
logarithmic mode versus the mean fluorescence intensity (MFI) of living cells and by fitting a 
dose response curve (variable slope, four parameters) with the prism software (GraphPad 
Prism). 
 
X-ray analysis of the antagonists 11e and 11j co-crystallized with FimH-CRD 
 
FimH-CRD-11e co-crystallization. Initial FimH-CRD (18 mg/mL in 20 mM HEPES pH 
7.4) crystals were obtained in complex with 4-(5-nitroindolin-1-yl)phenyl "-D-
mannopyranoside (5 mM).23 Crystals were grown in sitting-drop vapor diffusion at 20 °C 
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with 200 nL of protein-antagonist mixture together with 200 nL precipitant solution in well 
D3 (0.2 M sodium phosphate monobasic monohydrate, 20% w/v PEG 3,350) of the PEG/Ion 
HTTM screen (Hampton Research, CA, USA). Cubic crystals appeared within one week, 
which served as cross-seeding crystals. A solution of FimH-CRD (20 mg/mL) and 11e (5 
mM) was mixed with 0.2 M sodium phosphate monobasic monohydrate, 20% w/v PEG 400 
with 0.5 !L of each solution. Streak-seeding was performed after one day of incubation. 
Cubic FimH-CRD-11e crystals formed within 24 h. Crystals were flash cooled to 100 K with 
perfluoropolyether cryo oil (Hampton Research, CA, USA) as cryoprotectant. Data was 
collected with synchrotron radiation (" = 0.99999 Å) at the PXIII beamline, Swiss Light 
Source, Switzerland. 
 
FimH-CRD-11j co-crystallization. Co-crystals were initially grown in sitting-drop vapor 
diffusion at 20 °C with 0.5 !L of a mixture of FimH-CRD (20 mg/mL) and 11j (5 mM) 
together with 0.5 !L of 0.1 M HEPES pH 7.5, 2 M ammonium sulfate. Plate-like crystals 
formed within two weeks and were used as seeds for subsequent crystallization. Diffraction 
quality crystals were grown by streak-seeding in 0.5 !L of FimH-CRD (10 mg/mL) with 11j 
(2.5 mM) and 0.5 !L of 0.1 M HEPES pH 7.5, 1.25 M ammonium sulfate. The drops were 
covered with perfluoropolyether cryo oil prior to flash cooling to 100 K. Data was collected 
with synchrotron radiation (" = 1.00003 Å) at the PXIII beamline, Swiss Light Source, 
Switzerland. 
 
Structure Determination and Refinement. Data were indexed and integrated with the XDS 
package79 for the FimH-CRD-11e co-crystal structure, and with mosflm807 for the FimH-
CRD-11j co-crystal structure. Scaling was performed with XDS and SCALA included in the 
CCP4 suite, respectively.81 Structures were solved by molecular replacement with PHASER82 
using the FimH-CRD-butyl !-D-mannopyranoside complex  (PDB code 1UWF) as search 
model. The structures were iteratively built using the COOT software83 and refined with the 
PHENIX software.84 Geometric restraints for 11e and 11j were generated with PRODRG.85 
The models were validated using molprobity.86 Residues 113-115 were not modeled in the 
11e structure due to disorder. Furthermore, the ligand was modeled in two possible 
conformations. For both ligands, electron density is reduced on the second aromatic ring due 
to flexibility of the ligand. 
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Table 6. Data Collection and Refinement Statistics for FimH-CRD-11e and FimH-CRD-11j co-crystals. 
 FimH-CRD-11e FimH-CRD-11j 
PDB code 4CSS 4CST 
Space group P 21 21 21 P 21 21 21 
No. of molecules in the asymmetric unit 1 1 
Cell dimensions 
a, b, c (Å) 48.38, 56.23, 61.59  48.84, 55.89, 61.00 
     a, b, c (°)  90, 90, 90 90, 90, 90 
Data Collection 
Beamline Swiss Light Source PXIII Swiss Light Source PXIII 
Resolution range (Å)a 30.0 - 1.07 (1.13 – 1.07) 23.5 – 1.10 (1.12 – 1.10) 
Unique observationsa 72000 (9354) 66470 (2500) 
Average multiplicitya 10.9 (3.7) 5.4 (2.4) 
Completeness (%) 96.1 (78.0) 97.2 (76.5) 
Rmergea 0.056 (0.57) 0.051 (0.305) 
Mean I / !(I)a 21.5 (2.22) 15.5 (2.9) 
Refinement 
Resolution range (Å) 15.7 – 1.07 23.5 – 1.10 
R, Rfree 11.2, 13.2 11.4, 13.0 
Rms deviation from ideal bond length (Å) 0.010 0.010 
Rms deviation from ideal bond angle 
(deg) 
1.170 1.420 
aValues in parentheses are for highest-resolution shell. 
 
Physicochemical and in vitro pharmacokinetic studies. 
 
Materials. Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol, Dulbecco’s Modified 
Eagle’s Medium (DMEM) - high glucose, L-glutamine solution, penicillin-streptomycin 
solution, Dulbecco’s Phosphate Buffered Saline (DPBS), trypsin-EDTA solution, magnesium 
chloride hexahydrate, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
were purchased from Sigma-Aldrich. MEM nonessential amino acid (MEM-NEAA) solution, 
fetal bovine serum (FBS), and DMEM without sodium pyruvate and phenol red were bought 
from Invitrogen (Carlsbad, CA, USA). PRISMA HT universal buffer, GIT-0 Lipid Solution, 
and Acceptor Sink Buffer were ordered from pIon (Woburn, MA, USA). Human plasma was 
bought from Biopredic (Rennes, France) and acetonitrile (MeCN) and methanol (MeOH) 
from Acros Organics (Geel, Belgium). Pooled male rat liver microsomes were purchased 
from BD Bioscience (Franklin Lakes, NJ, USA). Tris(hydroxymethyl)-aminomethane (TRIS) 
was obtained from AppliChem (Darmstadt, Germany). The Caco-2 cells were kindly 
provided by Prof. G. Imanidis, FHNW, Muttenz, and originated from the American Type 
Culture Collection (Rockville, MD, USA).  
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pKa. The pKa values were determined as described elsewhere.87 In brief, the pH of a sample 
solution was gradually changed and the chemical shift of protons adjacent to ionizable 
centers was monitored by 1H nuclear magnetic resonance (NMR) spectroscopy. The shift was 
plotted against the pH of the respective sample, and the pKa was read out from the inflection 
point of the resulting sigmoidal curve. 
 
Log D7.4. The in silico prediction tool ALOGPS88 was used to estimate log P values of the 
compounds. Depending on these values, the compounds were classified into three categories: 
hydrophilic compounds (log P below zero), moderately lipophilic compounds (log P between 
zero and one) and lipophilic compounds (log P above one). For each category, two different 
ratios (volume of 1-octanol to volume of buffer) were defined as experimental parameters 
(Table 7). 
Table 7. Compound classification based on estimated log P values. 
Compound type log P ratio (1-octanol / buffer) 
hydrophilic < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
 
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 !M. For each compound, six determinations, that 
is, three determinations per 1-octanol/buffer ratio, were performed in different wells of a 96-
well plate. The respective volumes of buffer containing analyte (1 !M) were pipetted to the 
wells and covered by saturated 1-octanol according to the chosen volume ratio. The plate was 
sealed with aluminum foil, shaken (1350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 
plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and 
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by LC-MS. 
 
The log D7.4 coefficient was calculated from the 1-octanol/buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 !M), and the concentration of the analyte in buffer 
(cB) with Equation 3: 
  (3) 
 
! 
logD7.4 = log
1µM " cB
cB
#
1
o :b
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Aqueous Solubility. Solubility was determined in a 96-well format using the !SOL Explorer 
solubility analyzer (pIon, version 3.4.0.5). For each compound, measurements were 
performed at pH 3.0 and 7.4 in triplicates. For this purpose, six wells of a deep well plate, 
that is, three wells per pH value, were filled with 300 !L of PRISMA HT universal buffer, 
adjusted to pH 3.0 or 7.4 by adding the requested amount of NaOH (0.5 M). Aliquots (3 !L) 
of a compound stock solution (10-50 mM in DMSO) were added and thoroughly mixed. The 
final sample concentration was 0.1-0.5 mM, the residual DMSO concentration was 1.0% 
(v/v) in the buffer solutions. After 15 h, the solutions were filtrated (0.2 !m 96-well filter 
plates) using a vacuum to collect manifold (Whatman Ltd., Maidstone, UK) to remove the 
precipitates. Equal amounts of filtrate and 1-propanol were mixed and transferred to a 96-
well plate for UV/Vis detection (190 to 500 nm, SpectraMax 190). The amount of material 
dissolved was calculated by comparison with UV/Vis spectra obtained from reference 
samples, which were prepared by dissolving compound stock solution in a 1:1 mixture of 
buffer and 1-propanol (final concentrations 0.017-0.083 mM). 
 
Parallel Artificial Membrane Permeation Assay (PAMPA). Effective permeability (log 
Pe) was determined in a 96-well format with the PAMPA.50 For each compound, 
measurements were performed at pH 5.0 and 7.4 in quadruplicates. Eight wells of a deep well 
plate, that is, four wells per pH-value, were filled with 650 !L of PRISMA HT universal 
buffer adjusted to pH 5.0 or 7.4 by adding the requested amount of NaOH (0.5 M). Samples 
(150 !L) were withdrawn from each well to determine the blank spectra by UV/Vis-
spectroscopy (190 to 500 nm, SpectraMax 190). Then, analyte dissolved in DMSO was 
added to the remaining buffer to yield 50 !M solutions. To exclude precipitation, the optical 
density was measured at 650 nm, with 0.01 being the threshold value. Solutions exceeding 
this threshold were filtrated. Afterwards, samples (150 !L) were withdrawn to determine the 
reference spectra. Further 200 !L were transferred to each well of the donor plate of the 
PAMPA sandwich (pIon, P/N 110163). The filter membranes at the bottom of the acceptor 
plate were infused with 5 !L of GIT-0 Lipid Solution, and 200 !L of Acceptor Sink Buffer 
was filled into each acceptor well. The sandwich was assembled, placed in the GutBoxTM, 
and left undisturbed for 16 h. Then, it was disassembled and samples (150 !L) were 
transferred from each donor and acceptor well to UV-plates for determination of the UV/Vis 
spectra. Effective permeability (log Pe) was calculated from the compound flux deduced from 
the spectra, the filter area, and the initial sample concentration in the donor well with the aid 
of the PAMPA Explorer Software (pIon, version 3.5). 
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Colorectal Adenocarcinoma (Caco-2) Cell Permeation Assay. Caco-2 cells were 
cultivated in tissue culture flasks (BD Biosciences) with DMEM high glucose medium, 
containing L-glutamine (2 mM), nonessential amino acids (0.1 mM), penicillin (100 U/mL), 
streptomycin (100 !g/mL), and fetal bovine serum (10%). The cells were kept at 37 °C in 
humidified air containing 5% CO2, and the medium was changed every second day. When 
approximately 90% confluence was reached, the cells were split in a 1:10 ratio and 
distributed to new tissue culture flasks. At passage numbers between 60 and 65, they were 
seeded at a density of 5.3 ! 105 cells per well to Transwell 6-well plates (Corning Inc.) with 
2.5 mL of culture medium in the basolateral and 1.8 mL in the apical compartment. The 
medium was renewed on alternate days. Permeation experiments were performed between 
days 19 and 21 post seeding. Prior to the experiment, the integrity of the Caco-2 monolayers 
was evaluated by measuring the transepithelial electrical resistance (TEER) with an Endohm 
tissue resistance instrument (World Precision Instruments Inc., Sarasota, FL, USA). Only 
wells with TEER values higher than 250 " cm2 were used. Experiments were performed in 
the apical-to-basolateral (absorptive) and basolateral-to-apical (secretory) directions in 
triplicates. Transport medium (DMEM without sodium pyruvate and phenol red) was 
withdrawn from the donor compartments of three wells and replaced by the same volume of 
compound stock solution (10 mM in DMSO) to reach an initial sample concentration of 62.5 
!M. The Transwell plate was then shaken (600 rpm, 37 °C) on a Heidolph Titramax 1000 
plate-shaker. Samples (40 !L) were withdrawn from the donor and acceptor compartments 
30 min after initiation of the experiment and the compound concentrations were determined 
by LC-MS (see below). Apparent permeability (Papp) was calculated according to Equation 4: 
  (4) 
where dQ/dt is the compound flux (mol s-1), A is the surface area of the monolayer (cm2), and 
c0 is the initial concentration in the donor compartment (mol cm-3).50 After the experiment, 
TEER values were assessed again for each well and results from wells with values below 
250 " cm2 were discarded. 
 
Plasma Protein Binding (PPB). PPB was determined in a 96-well format using a high 
throughput dialysis block (HTD96b; HTDialysis LCC, Gales Ferry, CT, USA). For each 
compound, measurements were performed in triplicate. Dialysis membranes (MWCO 12-14 
K; HTDialysis LCC) were hydrated according to the instructions of the manufacturer and 
placed into the dialysis block. Human plasma was centrifuged (5800 rpm, 5 °C, 10 min), the 
! 
Papp =
dQ
d t "
1
A " c0
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pH of the supernatant (without floating plasma lipids) was adjusted to 7.4 by adding the 
requested amount of HCl (4 M), and analyte was added to yield a final concentration of 10 
!M. Equal volumes (150 !L) of plasma containing the analyte or TRIS-HCl buffer (0.1 M, 
pH 7.4) were transferred to the compartments separated by the dialysis membrane. The block 
was covered with a sealing film and left undisturbed (5 h, 37 °C). Afterwards, samples (90 
!L) were withdrawn from the buffer compartments and diluted with plasma (10 !L). From 
the plasma compartments, samples (10 !L) were withdrawn and diluted with TRIS-HCl 
buffer (90 !L). The solutions were further diluted with ice-cooled MeCN (300 !L) to 
precipitate the proteins and centrifuged (3600 rpm, 4 °C, 10 min). The supernatants (50 !L) 
were retrieved, and the analyte concentrations were determined by LC-MS (see below). The 
fraction bound (fb) was calculated as follows (Equation 5): 
 
! 
fb = 1"
cb
cp
 (5) 
where cb is the concentration of the analyte withdrawn from the buffer compartment before 
dilution and cp is the concentration in the plasma compartment. The values were accepted if 
the recovery of analyte was between 80 and 120% of the initial amount. 
 
Cytochrome P450-mediated metabolism. Incubations consisted of pooled male rat liver 
microsomes (0.5 mg microsomal protein/mL), test compound (2 !M), MgCl2 (2 mM), and 
NADPH (1 mM) in a total volume of 300 !L TRIS-HCl buffer (0.1 M, pH 7.4) and were 
performed in a 96-well plate on a Thermomixer Comfort (Eppendorf). Compounds and 
microsomes were preincubated (37 °C, 700 rpm, 10 min) before NADPH was added. 
Samples (50 !L) at t = 0 min and after an incubation time of 5, 10, 20, and 30 min were 
quenched with 150 !L of ice-cooled MeOH, centrifuged (3600 rpm, 4 °C, 10 min), and 80 
!L of supernatant was transferred to a 96-well plate for LC-MS analysis (see below). The 
metabolic half-life (t1/2) was calculated from the slope of the linear regression from the log 
percentage remaining compound versus incubation time relationship. Control experiments 
without NADPH were performed in parallel. 
 
LC-MS measurements. Analyses were performed using an 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara, 
CA, USA) equipped with electrospray ionization. The system was controlled with the Agilent 
MassHunter Workstation Data Acquisition software (version B.01.04). The column used was 
an Atlantis® T3 C18 column (2.1 x 50 mm) with a 3-!m particle size (Waters Corp., 
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Milford, MA, USA). The mobile phase consisted of eluent A: H2O containing 0.1% formic 
acid (for 11a-f, h-i), or 10 mM ammonium acetate, pH 5.0 in 95:5, H2O/MeCN (for 11g, j); 
and eluent B: MeCN containing 0.1% formic acid. The flow rate was maintained at 0.6 
mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then 
hold at 5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, 
resulting in a total duration of 4 min. MS parameters such as fragmentor voltage, collision 
energy, polarity were optimized individually for each analyte, and the molecular ion was 
followed for each compound in the multiple reaction monitoring mode. The concentrations of 
the analytes were quantified by the Agilent Mass Hunter Quantitative Analysis software 
(version B.01.04). 
 
In Vivo Pharmacokinetic Studies. 
 
Materials. DMSO and PBS were purchased from Sigma-Aldrich. The 96-well plates were 
bought from Agilent Technologies (0.5 mL, polypropylene). The gavage was obtained from 
Fine Science (Heidelberg, Germany) and the syringes (BD Micro Fine, U-100 Insuline, 30 G) 
and needles (BD Microlance 3, 25 G) from Becton Dickinson (USA, Ireland) and Henke Sass 
Wolf in Germany (Soft-Ject, 1 mL syringes). 
 
Animals. Female C3H/HeN mice weighing between 19 and 25 g were obtained from Charles 
River Laboratories (Sulzfeld, Germany) and were housed three or four per cage. The mice 
were kept under specific pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital of Basel, and animal experimentation guidelines according 
to the regulations of the Swiss veterinary law were followed. After 7 d of acclimatization, 9-
10 week old mice were used for the studies. Animals had free access to chow and water at 
any time and were kept in a 12h/12h light/dark cycle. For administration volumes and 
sampling the good practice guidelines were followed.89 
 
Pharmacokinetic studies. The single-dose studies for the first experiment set were 
performed by intravenous application of FimH antagonists at a dosage of 50 mg/kg body 
weight, followed by plasma and urine sampling. Antagonists were diluted in PBS for 
injection into the tail vein. Blood and urine samples (10 !L) were taken at 6 and 30 min, and 
1, 2, 4, 6, and 8 h after injection. For the PK studies with 11j, the antagonist was dissolved in 
PBS with 5 % DMSO and injected into the tail vain (0.625 mg/kg) or given orally (1.25 
mg/kg) using a gavage. Blood and urine were sampled (10 !L) after 7, 13, 20, 30, 45 min, 
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and 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 h. Both, blood and urine samples, were directly diluted 
after sampling with MeOH to precipitate the proteins and centrifuged for 11 min at 13000 
rpm. The supernatants were transferred to a 96-well plate and the analyte concentrations were 
determined by LC-MS (see above). 
 
Infection study. For all infection studies, the drinking water of the mice was replaced by 5% 
glucose (monohydrate from AppliChem, BioChemica) containing water, three days before 
the start of the experiment. 11j was dosed at 1.25 mg/kg (in 5% DMSO and PBS) and 10 
mg/kg (5% DMSO in PBS containing 1% Tween 80) applied orally to 6 and 4 mice, 
respectively, as described in the pharmacokinetic studies, 40 min prior to infection. 
Ciprofloxacin was dosed with 8 mg/kg, which would correspond to a human dose of 400 
mg,70 subcutaneously 10 minutes prior to infection with UTI89 to 4 mice. Control values 
resulted from the infection of 11 mice. Before infection, remaining urine in the bladder was 
expelled by gentle pressure on the abdomen. Mice were anaesthetised in 2.5 vol% 
isoflurane/oxygen mixture (Attane, Minrad Inc, Buffalo, NY, USA) and placed on their back. 
Infection was performed transurethrally using a polyethylene catheter (Intramedic 
polyethylene tubing, inner diameter 0.28 mm, outer diameter 0.61 mm, Beckton Dickinson, 
Allschwil, Switzerland), on a syringe (Hamilton Gastight Syringe 50 !l, removable 30G 
needle, BGB Analytik AG, Boeckten, Switzerland). After gentle insertion of the catheter into 
the bladder, 50 !l of bacterial suspension of UTI89 (5.5x109-2.25x1010 CFU/ml) was slowly 
injected. This corresponded to approximately 107-108 CFU per mouse. Mice were killed by 
CO2 three hours after inoculation and bladder and kidneys were aseptically removed. Organs 
were homogenized in 1 ml PBS using a tissue lyser (Retsch, Haan, Germany). Serial dilutions 
of bladder and kidneys were plated on Levine Eosin Methylene Blue Agar plates (Beckton 
Dickinson, France) and CFU were counted after overnight incubation at 37°C. 
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In the following, an overview of the lectin antagonists synthesized in the course of this thesis 
is given. The formulas are numbered as they appear in the corresponding sections. 
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